

The resurgence of platinum-based cancer chemotherapy

Nature Reviews Cancer

7, 573-584

DOI: [10.1038/nrc2167](https://doi.org/10.1038/nrc2167)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Elemental Tomography of Cancer-Cell Spheroids Reveals Incomplete Uptake of Both Platinum(II) and Platinum(IV) Complexes. <i>Journal of the American Chemical Society</i> , 2007, 129, 13400-13401.	6.6	56
3	Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. <i>Pure and Applied Chemistry</i> , 2007, 79, 2243-2261.	0.9	272
4	Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 621-629.	1.1	20
5	Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 511-520.	1.1	37
6	Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. <i>BMC Gastroenterology</i> , 2008, 8, 33.	0.8	33
7	The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. <i>Mass Spectrometry Reviews</i> , 2008, 27, 67-100.	2.8	82
8	Unique Properties of DNA Interstrand Crosslinks of Antitumor Oxaliplatin and the Effect of Chirality of the Carrier Ligand. <i>Chemistry - A European Journal</i> , 2008, 14, 1330-1341.	1.7	76
9	Similar Biological Activities of Two Isostructural Ruthenium and Osmium Complexes. <i>Chemistry - A European Journal</i> , 2008, 14, 4816-4822.	1.7	85
10	Head-to-Head Right-Handed Crosslinks of the Antitumor Active Bis($\frac{1}{4}$ -N,N'-diethylformamidinato)dirhodium(II,II) Unit with the Dinucleotides d(GpA) and d(ApG). <i>Chemistry - A European Journal</i> , 2008, 14, 9902-9913.		16
11	Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 604-613.	1.5	21
12	Synthesis and characterization of dinuclear pyrazolato bridged platinum(IV) complexes. <i>Polyhedron</i> , 2008, 27, 914-922.	1.0	14
13	Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 2060-2066.	1.5	132
14	Platinum Drug Adduct Formation in the Nucleosome Core Alters Nucleosome Mobility but Not Positioning. <i>Chemistry and Biology</i> , 2008, 15, 1023-1028.	6.2	21
15	Stepwise assembly of platinum-folic acid conjugates. <i>Inorganica Chimica Acta</i> , 2008, 361, 1447-1455.	1.2	24
16	Chromatin - a New, Old Drug Target?. <i>Chemical Biology and Drug Design</i> , 2008, 72, 165-170.	1.5	12
17	Peripheral neurotoxicity of platinum-based chemotherapy. <i>Nature Reviews Cancer</i> , 2008, 8, 72-72.	12.8	25
18	Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. <i>BMC Cancer</i> , 2008, 8, 175.	1.1	96
19	Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. <i>Biochemical Pharmacology</i> , 2008, 76, 19-27.	2.0	120

#	ARTICLE	IF	CITATIONS
20	Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. <i>Molecular Cancer</i> , 2008, 7, 24.	7.9	47
21	NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. <i>Journal of Translational Medicine</i> , 2008, 6, 9.	1.8	51
22	Genetic variants associated with cisplatin-induced ototoxicity. <i>Pharmacogenomics</i> , 2008, 9, 1521-1530.	0.6	23
23	Synthesis, Crystal Structure, Studies in Solution and Cytotoxicity of Two New Fluorescent Platinum(II) Compounds Containing Anthracene Derivatives as a Carrier Ligand. <i>Inorganic Chemistry</i> , 2008, 47, 11171-11179.	1.9	47
24	<i>cis</i> -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8902-8907.	3.3	222
25	Nanoscale Coordination Polymers for Platinum-Based Anticancer Drug Delivery. <i>Journal of the American Chemical Society</i> , 2008, 130, 11584-11585.	6.6	753
26	Hyperbranched polymers for controlled release of cisplatin. <i>Dalton Transactions</i> , 2008, , 5872.	1.6	55
27	Resistance against novel anticancer metal compounds: Differences and similarities. <i>Drug Resistance Updates</i> , 2008, 11, 1-16.	6.5	201
28	Novel cytotoxic drugs: Old challenges, new solutions. <i>Cancer Treatment Reviews</i> , 2008, 34, 81-91.	3.4	83
29	Cancer Stem Cells Contribute to Cisplatin Resistance in <i>Brca1/p53</i> Mediated Mouse Mammary Tumors. <i>Cancer Research</i> , 2008, 68, 3243-3250.	0.4	292
30	Promising particle-based vaccines in cancer therapy. <i>Expert Review of Vaccines</i> , 2008, 7, 1103-1119.	2.0	61
31	Inorganic pharmaceuticals. <i>Annual Reports on the Progress of Chemistry Section A</i> , 2008, 104, 477.	0.8	3
32	Synthesis, Characterization and Stat3 Inhibitory Properties of the Prototypical Platinum(IV) Anticancer Drug, [PtCl ₃ (NO ₂)(NH ₃) ₂] (CPA-7). <i>Inorganic Chemistry</i> , 2008, 47, 2798-2804.	1.9	28
33	Photochemotherapy: Targeted Activation of Metal Anticancer Complexes. <i>Australian Journal of Chemistry</i> , 2008, 61, 669.	0.5	69
34	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin. <i>Clinical Cancer Research</i> , 2008, 14, 3916-3925.	3.2	299
35	Interaction of Metallothionein-2 with Platinum-Modified 5'-Guanosine Monophosphate and DNA. <i>Biochemistry</i> , 2008, 47, 10961-10969.	1.2	24
36	A Non-Cross-Linking Platinum-Acridine Agent with Potent Activity in Non-Small-Cell Lung Cancer. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7574-7580.	2.9	100
37	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17079-17084.	3.3	854

#	ARTICLE	IF	CITATIONS
38	Elevated Glutathione Levels Confer Cellular Sensitization to Cisplatin Toxicity by Up-Regulation of Copper Transporter hCtr1. <i>Molecular Pharmacology</i> , 2008, 74, 697-704.	1.0	63
39	In Vitro Evaluation of a Stable Monomeric Gold(II) Complex with Hematoporphyrin IX: Cytotoxicity against Tumor and Kidney Cells, Cellular Accumulation, and Induction of Apoptosis. <i>Bioinorganic Chemistry and Applications</i> , 2008, 2008, 1-8.	1.8	8
40	Protective role of Pur1± to cisplatin. <i>Cancer Biology and Therapy</i> , 2008, 7, 1926-1935.	1.5	21
41	How do real tumors become resistant to cisplatin?. <i>Cell Cycle</i> , 2008, 7, 1353-1359.	1.3	185
42	MicroRNA Microarray Identifies <i>Let-7i</i> as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2008, 68, 10307-10314.	0.4	343
43	Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib). <i>TJ ETQq1 1 0,784314 pgBT /Over</i>	1.3	57
44	"Platinum on the road": Interactions of antitumoral cisplatin with proteins. <i>Pure and Applied Chemistry</i> , 2008, 80, 2715-2725.	0.9	59
45	Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2299-2306.	1.7	95
46	1±,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3047-3055.	1.9	50
47	Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin. <i>Clinical Cancer Research</i> , 2008, 14, 6478-6486.	3.2	77
48	Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 10-18.	1.9	68
49	Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?. <i>Current Cancer Drug Targets</i> , 2008, 8, 266-274.	0.8	9
50	Drug Resistance Caused by Reversion Mutation. <i>Cancer Research</i> , 2008, 68, 10021-10023.	0.4	88
51	Activity of lipoplatin in tumor and in normal cells in vitro. <i>Anti-Cancer Drugs</i> , 2008, 19, 983-990.	0.7	20
52	Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 253-262.	0.7	41
53	Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. <i>International Journal of Oncology</i> , 2009, 34, 743-55.	1.4	27
54	Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. <i>International Journal of Oncology</i> , 2009, 36, .	1.4	2
55	A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 771-778.	1.9	58

#	ARTICLE	IF	CITATIONS
56	Involvement of High Mobility Group B Proteins in Cisplatin-Induced Cytotoxicity in Squamous Cell Carcinoma of Skin. <i>DNA and Cell Biology</i> , 2009, 28, 311-318.	0.9	14
57	A Ruthenium-Containing Organometallic Compound Reduces Tumor Growth through Induction of the Endoplasmic Reticulum Stress Gene <i>CHOP</i> . <i>Cancer Research</i> , 2009, 69, 5458-5466.	0.4	201
58	Imaging the distribution of individual platinum-based anticancer drug molecules attached to single-wall carbon nanotubes. <i>Nanomedicine</i> , 2009, 4, 763-772.	1.7	24
59	Evaluation of the Effect of Acetyl-L-Carnitine on Experimental Cisplatin Nephrotoxicity. <i>Chemotherapy</i> , 2009, 55, 451-459.	0.8	35
60	In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. <i>Metal-Based Drugs</i> , 2009, 2009, 1-11.	3.8	22
61	The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs. <i>Molecular Pharmacology</i> , 2009, 75, 324-330.	1.0	143
62	Functional Interactions of Cu-ATPase ATP7B with Cisplatin and the Role of ATP7B in the Resistance of Cells to the Drug. <i>Journal of Biological Chemistry</i> , 2009, 284, 7793-7802.	1.6	56
64	Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study. <i>Clinical Cancer Research</i> , 2009, 15, 3866-3871.	3.2	15
65	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. <i>Clinical Cancer Research</i> , 2009, 15, 1417-1427.	3.2	266
66	Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 855-863.	1.9	23
67	Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. <i>Cell Cycle</i> , 2009, 8, 3191-3198.	1.3	49
68	Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. <i>Cell Cycle</i> , 2009, 8, 3043-3054.	1.3	45
69	Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy. <i>Current Drug Therapy</i> , 2009, 4, 19-28.	0.2	9
70	New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1489-1503.	1.1	42
71	The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP. <i>Cancer Biology and Therapy</i> , 2009, 8, 1914-1921.	1.5	12
72	Nanocapsules of platinum anticancer drugs: development towards therapeutic use. <i>Future Medicinal Chemistry</i> , 2009, 1, 1467-1480.	1.1	16
73	Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours. <i>Dalton Transactions</i> , 2009, , 10904.	1.6	35
74	Strategies to Improve the Efficacy of Platinum Compounds. <i>Current Medicinal Chemistry</i> , 2009, 16, 2355-2365.	1.2	54

#	ARTICLE	IF	CITATIONS
75	Circadian regulation of DNA excision repair: Implications for chrono-chemotherapy. <i>Cell Cycle</i> , 2009, 8, 1665-1667.	1.3	77
76	Study of Interactions between Metallothionein and Cisplatin by using Differential Pulse Voltammetry Brdicka's reaction and Quartz Crystal Microbalance. <i>Sensors</i> , 2009, 9, 1355-1369.	2.1	26
77	Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes. <i>Nucleic Acids Research</i> , 2009, 37, 5432-5442.	6.5	14
78	VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo. <i>Endocrine-Related Cancer</i> , 2009, 16, 1185-1195.	1.6	37
79	Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival. <i>Molecular Pharmacology</i> , 2009, 76, 208-214.	1.0	112
80	New-generation platinum agents for solid tumors. <i>Future Oncology</i> , 2009, 5, 33-42.	1.1	101
81	The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA. <i>Nucleic Acids Research</i> , 2009, 37, 2658-2671.	6.5	56
82	Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 115, 430-437.	0.6	28
83	Organometallic compounds in oncology: implications of novel organotin as antitumor agents. <i>Drug Discovery Today</i> , 2009, 14, 500-508.	3.2	216
84	Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. <i>Drug Discovery Today</i> , 2009, 14, 1089-1097.	3.2	542
85	Toxicity of Copper(I)-NHC Complexes Against Human Tumor Cells: Induction of Cell Cycle Arrest, Apoptosis, and DNA Cleavage. <i>Chemistry - A European Journal</i> , 2009, 15, 314-318.	1.7	86
86	Energetics, Conformation, and Recognition of DNA Duplexes Modified by Methylated Analogues of [PtCl(dien)] ⁺ . <i>Chemistry - A European Journal</i> , 2009, 15, 6211-6221.	1.7	20
87	Functional evidence for Eme1 as a marker of cisplatin resistance. <i>International Journal of Cancer</i> , 2009, 124, 2997-3001.	2.3	19
88	Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. <i>International Journal of Cancer</i> , 2009, 124, 2905-2910.	2.3	56
89	Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. <i>International Journal of Cancer</i> , 2009, 125, 2450-2455.	2.3	33
90	Characterizing Pt-Derived Anticancer Drugs from First Principles: The Case of Oxaliplatin in Aqueous Solution. <i>ChemPhysChem</i> , 2009, 10, 1044-1052.	1.0	23
91	Towards Antitumor Active <i>trans</i> -Platinum Compounds. <i>European Journal of Inorganic Chemistry</i> , 2009, 2009, 1293-1302.	1.0	142
92	Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design. <i>European Journal of Inorganic Chemistry</i> , 2009, 2009, 1303-1312.	1.0	316

#	ARTICLE	IF	CITATIONS
93	[Tris(pyrazolyl)methane]ruthenium Complexes Capable of Inhibiting Cancer Cell Growth. <i>European Journal of Inorganic Chemistry</i> , 2009, 2009, 4629-4633.	1.0	14
94	Polymeric drug delivery of platinum-based anticancer agents. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2299-2316.	1.6	114
97	Reversible Cell-Specific Drug Delivery with Aptamer-Functionalized Liposomes. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 6494-6498.	7.2	343
98	Coencapsulation of Arsenic- and Platinum-based Drugs for Targeted Cancer Treatment. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 9295-9299.	7.2	69
99	Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer. <i>Gastric Cancer</i> , 2009, 12, 38-42.	2.7	2
100	Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 123-132.	1.1	12
101	DNA adducts of antitumor cisplatin preclude telomeric sequences from forming G-quadruplexes. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 959-968.	1.1	22
102	Structural consequences of a 3'→5' DNA interstrand cross-link by a trinuclear platinum complex: unique formation of two such cross-links in a 10-mer duplex. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 969-977.	1.1	14
104	Reaction of human metallothionein-3 with cisplatin and transplatin. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 1129-1138.	1.1	36
105	Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 1313-1323.	1.1	74
106	Synthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl ₂ (R-dimepyrr)] (R-dimepyrr=N-dimethyl-2(R)-aminomethylpyrrolidine). <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 2807-2814.	2.6	14
107	Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 361-7.	1.1	16
108	Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. <i>Clinical and Translational Oncology</i> , 2009, 11, 780-786.	1.2	27
109	Role of copper transporters in resistance to platinating agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 133-142.	1.1	34
110	Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 753-761.	1.1	163
111	The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 925-933.	1.1	10
112	Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity. <i>Cancer Cell International</i> , 2009, 9, 4.	1.8	25
113	Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. <i>BMC Medical Genomics</i> , 2009, 2, 34.	0.7	192

#	ARTICLE	IF	CITATIONS
114	Cell cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. <i>Cell Proliferation</i> , 2009, 42, 195-206.	2.4	75
115	Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 467-477.	2.8	35
116	Liver metastases from colorectal cancer: radioembolization with systemic therapy. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 687-697.	12.5	90
117	Synthesis, characterization, and cytotoxicity of trimethylplatinum(IV) complexes with 2-thiocytosine and 1-methyl-2-thiocytosine ligands. <i>Inorganica Chimica Acta</i> , 2009, 362, 189-195.	1.2	31
118	Synthesis and characterization of gold(III) complexes with alkyldiamine ligands. <i>Inorganica Chimica Acta</i> , 2009, 362, 3109-3113.	1.2	14
119	Enantioselectivity and stereoselectivity in the reactions of the enantiomers of the platinum complex [PtCl ₂ (ahaz)] (ahaz=3(R)- or 3(S)-aminohexahydroazepine) with DNA. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 168-173.	1.5	12
120	A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 256-261.	1.5	49
121	Side-on binding of p-sulphonatocalix[4]arene to the dinuclear platinum complex trans-[[PtCl(NH ₃) ₂] ₂ μ ₄ -dpzm] ²⁺ and its implications for anticancer drug delivery. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 448-454.	1.5	41
122	Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 791-796.	1.5	17
123	Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 1039-1044.	1.5	110
124	The DNA sequence selectivity of maltolato-containing cisplatin analogues in purified plasmid DNA and in intact human cells. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 1151-1155.	1.5	10
125	Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: Synthesis, characterizations, DFT calculations, cytotoxic assays and binding to a DNA model base. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 1278-1287.	1.5	21
126	Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 1602-1608.	1.5	14
127	Physical characterization and biological studies of a (streptidine)(PtIICl ₄) compound. <i>Polyhedron</i> , 2009, 28, 3459-3466.	1.0	4
128	Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. <i>Coordination Chemistry Reviews</i> , 2009, 253, 2070-2081.	9.5	251
129	Novel trans-dichloridoplatinum(II) complexes with 3- and 4-acetylpyridine: Synthesis, characterization, DFT calculations and cytotoxicity. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 1921-1925.	2.6	24
130	Metals in anticancer therapy: Copper(II) complexes as inhibitors of the 20S proteasome. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4353-4361.	2.6	98
131	Efficacy of Intracerebral Delivery of Carboplatin in Combination With Photon Irradiation for Treatment of F98 Glioma-Bearing Rats. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 530-536.	0.4	40

#	ARTICLE	IF	CITATIONS
132	Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3423-3425.	1.0	7
133	Targeted Killing of Cancer Cells <i>in Vivo</i> and <i>in Vitro</i> with EGF-Directed Carbon Nanotube-Based Drug Delivery. <i>ACS Nano</i> , 2009, 3, 307-316.	7.3	796
134	Are RAS mutations predictive markers of resistance to standard chemotherapy?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 528-534.	12.5	79
135	Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition. <i>Cancer Research</i> , 2009, 69, 1951-1957.	0.4	497
136	Is Glutathione the Major Cellular Target of Cisplatin? A Study of the Interactions of Cisplatin with Cancer Cell Extracts. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4319-4328.	2.9	125
137	Density Functional Theory Characterization and Descriptive Analysis of Cisplatin and Related Compounds. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 1407-1419.	2.5	14
138	Synthesis of a 1,4-benzodiazepine containing palladacycle with <i>in vitro</i> anticancer and cathepsin B activity. <i>Dalton Transactions</i> , 2009, , 4299.	1.6	43
139	Solution Behavior of Amidine Complexes: An Unexpected <i>cis/trans</i> Isomerization and Formation of Di- and Trinuclear Platinum(III) and Platinum(II) Species. <i>Inorganic Chemistry</i> , 2009, 48, 10800-10810.	1.9	34
140	Coupling CP-MD Simulations and X-ray Absorption Spectroscopy: Exploring the Structure of Oxaliplatin in Aqueous Solution. <i>Journal of Physical Chemistry B</i> , 2009, 113, 12343-12352.	1.2	20
141	Quantitative Profiling of <i>in Vivo</i> Generated Cisplatin-DNA Adducts Using Different Isotope Dilution Strategies. <i>Analytical Chemistry</i> , 2009, 81, 9553-9560.	3.2	25
142	Mechanistic Insight into the Inhibition of Matrix Metalloproteinases by Platinum Substrates. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7847-7855.	2.9	28
143	Gold(I) Analogues of a Platinum-Acridine Antitumor Agent Are Only Moderately Cytotoxic but Show Potent Activity against <i>Mycobacterium tuberculosis</i> . <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6519-6522.	2.9	44
144	Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress. <i>Cancer Research</i> , 2009, 69, 3842-3849.	0.4	133
145	Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 167-174.	3.4	50
146	EXAFS structural study of platinum-based anticancer drugs degradation in presence of sulfur nucleophilic species. <i>Biochimie</i> , 2009, 91, 1301-1306.	1.3	16
147	hCCR4/cNOT6 targets DNA-damage response proteins. <i>Cancer Letters</i> , 2009, 273, 281-291.	3.2	11
148	Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. <i>Cancer Letters</i> , 2009, 279, 57-64.	3.2	22
149	The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinum analogue toxicity in human proximal tubular cell primary cultures. <i>Toxicology in Vitro</i> , 2009, 23, 780-788.	1.1	12

#	ARTICLE	IF	CITATIONS
150	Head and Neck Squamous cell Carcinoma Targeted Chemosensitization. <i>Otolaryngology - Head and Neck Surgery</i> , 2009, 141, 177-183.	1.1	5
151	Platinum Drug Distribution in Cancer Cells and Tumors. <i>Chemical Reviews</i> , 2009, 109, 4911-4920.	23.0	314
152	Inhibition of transcription by platinum antitumor compounds. <i>Metallomics</i> , 2009, 1, 280.	1.0	475
153	Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review. <i>Oncology</i> , 2009, 76, 231-238.	0.9	58
154	Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. <i>Dalton Transactions</i> , 2009, , 10651.	1.6	205
155	Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 643-662.	2.4	39
156	Is Anticancer Drug Development Heading in the Right Direction?. <i>Cancer Research</i> , 2009, 69, 1259-1262.	0.4	145
157	Dumbbell-like Au ³⁺ O ⁴⁻ Nanoparticles for Target-Specific Platin Delivery. <i>Journal of the American Chemical Society</i> , 2009, 131, 4216-4217.	6.6	378
158	Dual anti-angiogenic and cytotoxic properties of ruthenium(iii) complexes containing pyrazolato and/or pyrazole ligands. <i>Dalton Transactions</i> , 2009, , 10712.	1.6	33
159	Synthesis, characterization, in vitro antitumoral investigations and interaction with plasmid pBR322 DNA of R ₂ eddp-platinum(iv) complexes (R = Et, n-Pr). <i>Dalton Transactions</i> , 2009, , 10720.	1.6	28
160	Replacement of a Thiourea-S with an Amidine-NH Donor Group in a Platinum ^{II} Acridine Antitumor Compound Reduces the Metal ^{II} 's Reactivity with Cysteine Sulfur. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3424-3427.	2.9	46
161	Recent Advances in the Development of Polyamine Analogues as Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4551-4573.	2.9	153
162	Mice with Cisplatin and Oxaliplatin-Induced Painful Neuropathy Develop Distinct Early Responses to Thermal Stimuli. <i>Molecular Pain</i> , 2009, 5, 1744-8069-5-9.	1.0	122
164	Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. <i>Advances in Inorganic Chemistry</i> , 2009, 61, 1-62.	0.4	182
165	Identification by NMR Spectroscopy of the Two Stereoisomers of the Platinum Complex [PtCl ₂ (S-ahaz)] (S-ahaz = 3(S)-Aminohexahydroazepine) Bound to a DNA 14-mer Oligonucleotide. NMR Evidence of Structural Alteration of a Platinated AAT-rich 14-mer DNA Duplex. <i>Inorganic Chemistry</i> , 2009, 48, 3047-3056.	1.9	9
166	A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. <i>Chemical Communications</i> , 2009, , 6735.	2.2	99
167	Molecular combo of photodynamic therapeutic agent silicon(iv) phthalocyanine and anticancer drug cisplatin. <i>Chemical Communications</i> , 2009, , 908.	2.2	89
168	Imidazole-based phosphane gold(I) complexes as potential agents for cancer treatment: Synthesis, structural studies and antitumour activity. <i>Dalton Transactions</i> , 2009, , 7741.	1.6	29

#	ARTICLE	IF	CITATIONS
169	Mono- and dinuclear platinum(II) compounds with 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine. Structure, cytotoxic activity and reaction with 5 α -GMP. Dalton Transactions, 2009, , 10736.	1.6	36
170	A novel ruthenium(III) complex with a tridentate dianionic P,O,O-ligand showing high cytotoxic activity. Dalton Transactions, 2009, , 10727.	1.6	9
171	Synthesis of stable platinum complexes containing carborane in a carrier group for potential BNCT agents. Dalton Transactions, 2009, , 4978.	1.6	16
172	The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamate complexes. Dalton Transactions, 2009, , 10670.	1.6	86
173	Binding of [Pt(1C3)(dien)] ²⁺ to the duplex DNA oligonucleotide 5 α -d(TGGCCA)-3 α : the effect of an appended positive charge on the orientation and location of anthraquinone intercalation. Dalton Transactions, 2009, , 932-939.	1.6	15
174	Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action. Metallomics, 2009, 1, 434.	1.0	60
175	DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation. Dalton Transactions, 2009, , 10846.	1.6	44
176	Discrimination between drug-resistant and non-resistant human melanoma cell lines by FTIR spectroscopy. Analyst, The, 2009, 134, 294-300.	1.7	41
177	Fluorescent method for platinum detection in buffers and serums for cancer medicine and occupational hazards. Chemical Communications, 2009, , 83-85.	2.2	48
178	Comparison of Oxaliplatin- and Cisplatin-Induced Painful Peripheral Neuropathy in the Rat. Journal of Pain, 2009, 10, 534-541.	0.7	112
179	Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2009, 10, 549-558.	5.1	67
180	Exclusive platination of loop adenines in the human telomeric G-quadruplex. Organic and Biomolecular Chemistry, 2009, 7, 2864.	1.5	78
181	Identification and characterization of metallodrug binding proteins by (metallo)proteomics. Metallomics, 2009, 1, 25-31.	1.0	74
182	Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Molecular Cancer Therapeutics, 2009, 8, 3162-3170.	1.9	66
183	A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer. Neoplasia, 2009, 11, 552-IN9.	2.3	50
184	Synthesis of Apoptosis-Inducing Iminophosphorane Organogold(III) Complexes and Study of Their Interactions with Biomolecular Targets. Inorganic Chemistry, 2009, 48, 1577-1587.	1.9	79
185	Treatment of Advanced Lung Cancer. Clinical Pulmonary Medicine, 2009, 16, 157-171.	0.3	2
186	Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Anti-Cancer Drugs, 2009, 20, 559-572.	0.7	17

#	ARTICLE	IF	CITATIONS
187	Degradation of platinum based anticancer drugs by methionine: An EXAFS study. <i>Journal of Physics: Conference Series</i> , 2009, 190, 012206.	0.3	5
188	Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. <i>International Journal of Oncology</i> , 2009, , .	1.4	22
189	Synthesis, Characterization and Cytotoxicity of Dihalogeno-platinum(II) Complexes with L-Histidine Ligand. <i>Chemical and Pharmaceutical Bulletin</i> , 2009, 57, 424-427.	0.6	5
190	Telomeres and Telomerase: Potential Targets for Platinum Complexes. , 0, , 209-234.		7
191	Whole-genome approach implicates CD44 in cellular resistance to carboplatin. <i>Human Genomics</i> , 2009, 3, 128.	1.4	23
192	Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 8.	0.6	9
193	Metallothioneins and Cancer. <i>Current Protein and Peptide Science</i> , 2009, 10, 360-375.	0.7	138
194	Novel Metals and Metal Complexes as Platforms for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2010, 16, 1813-1825.	0.9	427
195	A Better Platinum-Based Anticancer Drug Yet to Come?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 293-301.	0.9	93
196	Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer. <i>Current Pharmaceutical Design</i> , 2010, 16, 1863-1876.	0.9	20
197	Role of Epidermal Growth Factor Receptor Degradation in Cisplatin-Induced Cytotoxicity in Head and Neck Cancer. <i>Cancer Research</i> , 2010, 70, 2862-2869.	0.4	62
199	p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma. <i>Oncology Reports</i> , 2010, , .	1.2	0
200	Polymorphisms of OCT2, GGT1, HO1, and DNASE1 genes and nephrotoxicity of cisplatin in ovarian cancer patients. <i>Molecular Genetics, Microbiology and Virology</i> , 2010, 25, 163-166.	0.0	7
201	Design, synthesis, characterisation and chemical reactivity of mixed-ligand platinum(ii) oxadiazoline complexes with potential cytotoxic properties. <i>Dalton Transactions</i> , 2010, 39, 7747.	1.6	18
202	Novel platinum(ii) complexes of 3-(aminomethyl)naphthoquinone Mannich bases: synthesis, crystal structure and cytotoxic activities. <i>Dalton Transactions</i> , 2010, 39, 10203.	1.6	32
203	Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 945-952.	1.1	16
204	Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 3683-3697.	2.4	58
205	Investigation of the interaction of gold(III)â€“alkyldiamine complexes with l-histidine and imidazole ligands by ¹ H and ¹³ C NMR, and UV spectrophotometry. <i>Inorganica Chimica Acta</i> , 2010, 363, 3200-3207.	1.2	9

#	ARTICLE	IF	CITATIONS
206	Cisplatin interaction with phosphatidylserine bilayer studied by solid-state NMR spectroscopy. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 213-223.	1.1	20
207	Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 677-688.	1.1	86
208	Biological activity of enantiomeric complexes [PtCl ₂ L ₂] (L ₂ is aromatic bisphosphanes and aromatic) <i>TJ ETQq0 0 0 rgBT /Overlock 10 T</i>	1.1	25
209	The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1827-1837.	1.2	26
210	Synthesis and In Vitro cytotoxicity of Cis-[Pt(NH ₃)(NH ₂ OH)Cl ₂]. <i>Archives of Pharmacal Research</i> , 2010, 33, 807-811.	2.7	1
211	Adjuvant therapy of triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 285-291.	1.1	54
212	Efficacy of intracerebral delivery of cisplatin in combination with photon irradiation for treatment of brain tumors. <i>Journal of Neuro-Oncology</i> , 2010, 98, 287-295.	1.4	51
213	Exploring the binding of Pt drugs to gold nanoparticles for controlled passive release of cisplatin. <i>Journal of Controlled Release</i> , 2010, 148, e31-e32.	4.8	13
214	Interaction of liposomes with proteins measured by surface plasmon resonance correlates with their in vivo circulation time. <i>Journal of Controlled Release</i> , 2010, 148, e32-e33.	4.8	1
215	Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. <i>BMC Cancer</i> , 2010, 10, 451.	1.1	42
216	Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 53-71.	3.3	292
217	Cisplatin resistance: Preclinical findings and clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 172-182.	3.3	220
218	Conformation and recognition of DNA modified by a new antitumor dinuclear Pt(II) complex resistant to decomposition by sulfur nucleophiles. <i>Biochemical Pharmacology</i> , 2010, 79, 112-121.	2.0	33
219	Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt(II) chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand. <i>Biochemical Pharmacology</i> , 2010, 79, 552-564.	2.0	48
220	Fine tuning chemotherapy to match BRCA1 status. <i>Biochemical Pharmacology</i> , 2010, 80, 647-653.	2.0	14
221	1,25D ₃ Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. <i>Cancer</i> , 2010, 116, 3294-3303.	2.0	74
222	Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells. <i>Head and Neck</i> , 2011, 33, 309-317.	0.9	5
223	Alterations of microRNAs and their targets are associated with acquired resistance of MCF7 breast cancer cells to cisplatin. <i>International Journal of Cancer</i> , 2010, 127, 1785-1794.	2.3	301

#	ARTICLE	IF	CITATIONS
224	Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma. <i>International Journal of Cancer</i> , 2010, 127, 2790-2803.	2.3	75
225	A Photo-Caged Platinum(II) Complex That Increases Cytotoxicity upon Light Activation. <i>European Journal of Inorganic Chemistry</i> , 2010, 2010, 2224-2228.	1.0	51
226	Synthesis and DNA Interaction of Platinum Complex/Peptide Chimera as Potential Drug Candidates. <i>European Journal of Organic Chemistry</i> , 2010, 2010, 6161-6170.	1.2	9
227	Synthesis, Functionalization, and Biomedical Applications of Multifunctional Magnetic Nanoparticles. <i>Advanced Materials</i> , 2010, 22, 2729-2742.	11.1	1,260
228	Translesion Synthesis of 1,3-GTC Cisplatin DNA Lesions. <i>ChemBioChem</i> , 2010, 11, 1521-1524.	1.3	12
229	Stable Anticancer Gold(III)-Porphyrin Complexes: Effects of Porphyrin Structure. <i>Chemistry - A European Journal</i> , 2010, 16, 3097-3113.	1.7	136
230	Mitochondrial Mode of Action of a Thymidine-Based Cisplatin Analogue Breaks Resistance in Cancer Cells. <i>Chemistry - A European Journal</i> , 2010, 16, 14498-14505.	1.7	12
231	Chemo-Genetic Optimization of DNA Recognition by Metallodrugs using a Presenter-Protein Strategy. <i>Chemistry - A European Journal</i> , 2010, 16, 12883-12889.	1.7	12
233	A Potent <i>Trans</i> -Diimine Platinum Anticancer Complex Photoactivated by Visible Light. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 8905-8908.	7.2	261
234	Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. <i>Medicinal Research Reviews</i> , 2010, 30, 550-580.	5.0	431
235	Substituted 9-aminoacridine-4-carboxamides tethered to platinum(II)diamine complexes: Chemistry, cytotoxicity and DNA sequence selectivity. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 815-819.	1.5	12
236	Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH ₃) ₂ } ₂ +d(GpG) cross-link at 1.77Å... resolution. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 902-908.	1.5	101
237	Platinum(II) complexes of 8-quinolylmethylphosphonates: Synthesis, characterization and antitumour activity. <i>Polyhedron</i> , 2010, 29, 2527-2536.	1.0	9
238	Novel palladium(II) and platinum(II) complexes of biocidal benzisothiazolinone (Bit); X-ray crystal structures of co-crystallised Bit/BitO and cis-Pd(en)(Bit~1H) ₂ ·H ₂ O. <i>Inorganica Chimica Acta</i> , 2010, 363, 2333-2337.	1.2	19
239	A detailed theoretical DFT study of the hydrolysis mechanism of orally active anticancer drug ZD0473. <i>Chemical Physics Letters</i> , 2010, 487, 108-115.	1.2	30
240	Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination. <i>Cancer Cell International</i> , 2010, 10, 32.	1.8	20
241	NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner. <i>Journal of Molecular Signaling</i> , 2010, 5, 4.	0.5	4
242	Pharmacogenomics: a systems approach. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2010, 2, 3-22.	6.6	55

#	ARTICLE	IF	CITATIONS
243	Differential transport of platinum compounds by the human organic cation transporter hOCT2 (<i>hSLC22A2</i>). <i>British Journal of Pharmacology</i> , 2010, 159, 898-908.	2.7	108
244	Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. <i>British Journal of Pharmacology</i> , 2010, 159, 1326-1338.	2.7	24
245	Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. <i>Oncogene</i> , 2010, 29, 463-468.	2.6	58
246	Immunogenic death of colon cancer cells treated with oxaliplatin. <i>Oncogene</i> , 2010, 29, 482-491.	2.6	937
247	Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer. <i>British Journal of Cancer</i> , 2010, 103, 1822-1830.	2.9	27
248	Cellular Responses to Cisplatin-Induced DNA Damage. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-16.	0.8	361
249	Renal Organic Cation and Anion Transport: From Physiology to Genes. , 2010, , 23-53.		5
250	Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1058-1069.	1.9	74
251	Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. <i>Endocrine-Related Cancer</i> , 2010, 17, R91-R107.	1.6	63
252	Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs. <i>Nucleic Acids Research</i> , 2010, 38, 7089-7099.	6.5	68
253	FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2010, 8, 24-34.	1.5	172
254	ASNA-1 Activity Modulates Sensitivity to Cisplatin. <i>Cancer Research</i> , 2010, 70, 10321-10328.	0.4	26
255	Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based Chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 811-821.	1.1	42
256	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. <i>Genes and Development</i> , 2010, 24, 837-852.	2.7	174
257	Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs. <i>Molecular Pharmacology</i> , 2010, 77, 887-894.	1.0	287
258	Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. <i>Carcinogenesis</i> , 2010, 31, 984-993.	1.3	66
259	Regulation of Cisplatin Cytotoxicity by Cu Influx Transporters. <i>Metal-Based Drugs</i> , 2010, 2010, 1-9.	3.8	38
260	Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy. <i>Metal-Based Drugs</i> , 2010, 2010, 1-7.	3.8	212

#	ARTICLE	IF	CITATIONS
261	DNA Polymerase $\hat{\Gamma}$, a Key Protein in Translesion Synthesis in Human Cells. <i>Sub-Cellular Biochemistry</i> , 2010, 50, 189-209.	1.0	34
262	Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. <i>Annals of Oncology</i> , 2010, 21, 1786-1793.	0.6	132
263	Chemical, spectroscopic characterization, and in vitro antibacterial studies of a new gold(I) complex with N-acetyl-L-cysteine. <i>Journal of Coordination Chemistry</i> , 2010, 63, 1390-1397.	0.8	24
264	Phosphorylated TP63 Induces Transcription of RPN13, Leading to NOS2 Protein Degradation. <i>Journal of Biological Chemistry</i> , 2010, 285, 41422-41431.	1.6	7
265	DNA binding, cytotoxicity, and apoptotic-inducing activity of ruthenium(II) polypyridyl complex. <i>Acta Biochimica Et Biophysica Sinica</i> , 2010, 42, 440-449.	0.9	32
266	Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17939-17944.	3.3	545
267	Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4890-4895.	3.3	199
268	Differential Roles for DNA Polymerases Eta, Zeta, and REV1 in Lesion Bypass of Intrastrand versus Interstrand DNA Cross-Links. <i>Molecular and Cellular Biology</i> , 2010, 30, 1217-1230.	1.1	115
269	Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine. <i>Bioinorganic Chemistry and Applications</i> , 2010, 2010, 1-6.	1.8	4
270	EVALUATION OF THE UPTAKE OF CDDP-CONTAINING POLYMERIC MICELLES IN SINGLE PANCREATIC CANCER CELLS. <i>International Journal of PIXE</i> , 2010, 20, 37-43.	0.4	2
271	Synthesis, Characterization, and Cytotoxicity of New Types of Binuclear Platinum(II) Complexes. <i>Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry</i> , 2010, 40, 879-882.	0.6	1
272	Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2010, 21, 961-967.	0.6	81
273	Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments. <i>Current Medicinal Chemistry</i> , 2010, 17, 3045-3057.	1.2	80
274	Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. <i>Cell Cycle</i> , 2010, 9, 3804-3815.	1.3	24
275	Fourier Transform Infrared (FTIR) spectroscopy to monitor the cellular impact of newly synthesized platinum derivatives. <i>International Journal of Oncology</i> , 2010, 37, 679-86.	1.4	6
276	Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells. <i>Genes and Cancer</i> , 2010, 1, 803-811.	0.6	32
277	Free Radical-Induced Redox Chemistry of Nedaplatin and Satraplatin under Physiological Conditions. <i>Radiation Research</i> , 2010, 173, 843-848.	0.7	3
278	Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance. <i>Cell Death and Disease</i> , 2010, 1, e78-e78.	2.7	22

#	ARTICLE	IF	CITATIONS
279	Mechanisms of Cytotoxicity of Anticancer Titanocenes. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 302-311.	0.9	52
280	Copper Compounds in Cancer Chemotherapy. <i>Current Medicinal Chemistry</i> , 2010, 17, 3606-3615.	1.2	202
281	Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamate Complexes. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 283-292.	0.9	72
282	Therapeutic targeting of Trk suppresses tumor proliferation and enhances cisplatin activity in HNSCC. <i>Cancer Biology and Therapy</i> , 2010, 10, 644-653.	1.5	35
283	{(1 <i>R</i> ,2 <i>R</i> ,4 <i>R</i>)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7356-7364.	2.9	51
284	N-Heterocyclic Carbene-Amine Pt(II) Complexes, a New Chemical Space for the Development of Platinum-Based Anticancer Drugs. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2146-2154.	2.9	150
285	Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin. <i>Journal of the American Chemical Society</i> , 2010, 132, 4678-4684.	6.6	739
286	Photocytotoxicity and DNA cleavage activity of l-arg and l-lys Schiff base oxovanadium(IV) complexes having phenanthroline bases. <i>Dalton Transactions</i> , 2010, 39, 7104.	1.6	61
287	Gold nanorods for platinum based prodrug delivery. <i>Chemical Communications</i> , 2010, 46, 8424.	2.2	94
288	Transcription Inhibition by Platinum-DNA Cross-Links in Live Mammalian Cells. <i>Journal of the American Chemical Society</i> , 2010, 132, 7429-7435.	6.6	80
289	Circumventing Tumor Resistance to Chemotherapy by Nanotechnology. <i>Methods in Molecular Biology</i> , 2010, 596, 467-488.	0.4	259
290	Synthesis and Characterization of Luminescent Bis-Cyclometalated Platinum(IV) Complexes. <i>Inorganic Chemistry</i> , 2010, 49, 11297-11308.	1.9	53
291	Platinum(II) Complexes with Bioactive Carrier Ligands Having High Affinity for the Translocator Protein. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5144-5154.	2.9	64
292	Ferrocene-Promoted Photoactivated DNA Cleavage and Anticancer Activity of Terpyridyl Copper(II) Phenanthroline Complexes. <i>Organometallics</i> , 2010, 29, 3632-3641.	1.1	106
293	Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. <i>Lung Cancer</i> , 2010, 69, 155-164.	0.9	47
294	Mesoporous Silica Microparticles Enhance the Cytotoxicity of Anticancer Platinum Drugs. <i>ACS Nano</i> , 2010, 4, 789-794.	7.3	133
295	Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. <i>Nanomedicine</i> , 2010, 5, 1535-1546.	1.7	151
296	Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. <i>Pharmacogenomics Journal</i> , 2010, 10, 54-61.	0.9	169

#	ARTICLE	IF	CITATIONS
297	TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. <i>Journal of Translational Medicine</i> , 2010, 8, 15.	1.8	7
298	Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 78.	1.8	74
299	Treatment options for patients with triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2010, 3, 42.	6.9	50
301	Synthesis, Characterization, and Photophysical Properties of Three Platinum(II) Complexes Bearing Fluorescent Analogues of the Di-2-pyridylmethane Ligand. <i>Inorganic Chemistry</i> , 2010, 49, 5303-5315.	1.9	24
302	Unusual Dimeric Chemical Structure for a Carboplatin Analogue as a Potential Anticancer Complex. <i>Inorganic Chemistry</i> , 2010, 49, 5792-5794.	1.9	13
303	Ruthenium Polypyridyl Complexes That Induce Mitochondria-Mediated Apoptosis in Cancer Cells. <i>Inorganic Chemistry</i> , 2010, 49, 6366-6368.	1.9	227
304	Core-Cross-Linked Micelles Synthesized by Clicking Bifunctional Pt(IV) Anticancer Drugs to Isocyanates. <i>Biomacromolecules</i> , 2010, 11, 2290-2299.	2.6	86
305	Basic Coordination Chemistry Relevant to DNA Adducts Formed by the Cisplatin Anticancer Drug. NMR Studies on Compounds with Sterically Crowded Chiral Ligands. <i>Inorganic Chemistry</i> , 2010, 49, 5573-5583.	1.9	28
306	DNA Polymerases and Diseases. , 2010, , 261-279.		0
307	Organometallic Osmium Arene Complexes with Potent Cancer Cell Cytotoxicity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8192-8196.	2.9	118
308	Photocytotoxic trans-Diam(m)ine Platinum(IV) Diazido Complexes More Potent than Their cis Isomers. <i>Chemical Research in Toxicology</i> , 2010, 23, 413-421.	1.7	85
309	New reactions of anticancer-platinum complexes and their intriguing behaviour under various experimental conditions. <i>Dalton Transactions</i> , 2010, 39, 10601.	1.6	22
310	Facile Synthesis of a Platinum Nanoflower Monolayer on a Single-Walled Carbon Nanotube Membrane and Its Application in Glucose Detection. <i>Journal of Physical Chemistry C</i> , 2010, 114, 18121-18125.	1.5	56
311	Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12435-12440.	3.3	121
312	Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. <i>NeuroToxicology</i> , 2010, 31, 188-194.	1.4	23
313	Downregulation of RhoB GTPase confers resistance to cisplatin in human laryngeal carcinoma cells. <i>Cancer Letters</i> , 2010, 295, 182-190.	3.2	15
314	Targeting DNA repair in breast cancer: A clinical and translational update. <i>Cancer Treatment Reviews</i> , 2010, 36, 557-565.	3.4	51
315	Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 600-605.	1.0	126

#	ARTICLE	IF	CITATIONS
316	The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Transactions, 2010, 39, 8113.	1.6	1,398
317	New reduction pathways for $[PtCl_2(CH_3CO)_2(NH_3)(Am)]$ anticancer prodrugs. Chemical Communications, 2010, 46, 1842-1844.	2.2	76
318	The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers. American Journal of Pathology, 2010, 176, 2607-2615.	1.9	89
319	Pinpointing Differences in Cisplatin-induced Apoptosis in Adherent and Non-adherent Cancer Cells. Cellular Physiology and Biochemistry, 2010, 26, 809-820.	1.1	28
320	Genome Stability and Human Diseases. Sub-Cellular Biochemistry, 2010, , .	1.0	5
321	Cisplatin Induces Cytotoxicity through the Mitogen-Activated Protein Kinase Pathways and Activating Transcription Factor 3. Neoplasia, 2010, 12, 527-538.	2.3	74
322	Delivery of carboplatin by carbon-based nanocontainers mediates increased cancer cell death. Nanotechnology, 2010, 21, 335101.	1.3	64
323	Studies on Cellular Accumulation of Satraplatin and Its Major Metabolite JM118 and Their Interactions with Glutathione. Molecular Pharmaceutics, 2010, 7, 2093-2102.	2.3	27
324	Platinum(ii) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity. Chemical Communications, 2010, 46, 1212.	2.2	68
325	Analytical methodologies for metallomics studies of antitumor Pt-containing drugs. Metallomics, 2010, 2, 19-38.	1.0	98
326	Determination of Cisplatin 1,2-Intrastrand Guanine-Guanine DNA Adducts in Human Leukocytes by High-Performance Liquid Chromatography Coupled to Inductively Coupled Plasma Mass Spectrometry. Chemical Research in Toxicology, 2010, 23, 1313-1321.	1.7	48
327	Polymer-Caged Nanobins for Synergistic Cisplatin-Doxorubicin Combination Chemotherapy. Journal of the American Chemical Society, 2010, 132, 17130-17138.	6.6	190
328	Cysteine proteases as targets for metal-based drugs. Metallomics, 2010, 2, 366.	1.0	126
329	Excursions in polynuclear platinum DNA binding. Chemical Communications, 2010, 46, 6640.	2.2	106
330	Identifying drug metallation sites on peptides using electron transfer dissociation (ETD), collision induced dissociation (CID) and ion mobility-mass spectrometry (IM-MS). Chemical Communications, 2010, 46, 5458.	2.2	70
331	Thioether binding mediates monofunctional platinum antitumor reagents to trans configuration in DNA interactions. Chemical Communications, 2010, 46, 6938.	2.2	26
332	On-line fast column switching SEC-IC separation combined with ICP-MS detection for mapping metallo-drug-biomolecule interaction. Journal of Analytical Atomic Spectrometry, 2010, 25, 861.	1.6	22
333	Chiral ruthenium polypyridyl complexes as mitochondria-targeted apoptosis inducers. MedChemComm, 2010, 1, 73-75.	3.5	49

#	ARTICLE	IF	CITATIONS
334	Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. <i>Metallomics</i> , 2011, 3, 591.	1.0	126
335	An anti-cancer trinuclear ruthenium(III) complex with 2-thiosalicylate ligands attenuates Wnt- β -catenin signaling. <i>Chemical Science</i> , 2011, 2, 1788.	3.7	15
336	Pt(II) complexes with bidentate and tridentate pyrazolyl-containing chelators: synthesis, structural characterization and biological studies. <i>Dalton Transactions</i> , 2011, 40, 5781.	1.6	23
337	Photoreaction pathways for the anticancer complex <i>trans,trans,trans</i> -[Pt(N ₃) ₂ (OH) ₂ (NH ₃) ₂]. <i>Dalton Transactions</i> , 2011, 40, 262-268.	1.6	54
338	Quantitative determination of intact free cisplatin in cell models by LC-ICP-MS. <i>Journal of Analytical Atomic Spectrometry</i> , 2011, 26, 109-115.	1.6	21
339	Monofunctional platinum complexes containing a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore: Distribution in tumour cells. <i>Dalton Transactions</i> , 2011, 40, 10376.	1.6	41
340	Molecular transition-metal phosphonates. <i>Dalton Transactions</i> , 2011, 40, 5394.	1.6	78
341	Osmium(VI) complexes as a new class of potential anti-cancer agents. <i>Chemical Communications</i> , 2011, 47, 2140.	2.2	46
342	Novel platinum-N-heterocyclic carbene complex is more cardiotoxic than cisplatin in rats. <i>Human and Experimental Toxicology</i> , 2011, 30, 1342-1349.	1.1	18
343	Silymarin selectively protects human renal cells from cisplatin-induced cell death. <i>Pharmaceutical Biology</i> , 2011, 49, 1082-1090.	1.3	26
344	Synthesis, spectroscopic characterization, and antibacterial assays <i>in vitro</i> of a new platinum(II) complex with methionine sulfoxide. <i>Journal of Coordination Chemistry</i> , 2011, 64, 272-280.	0.8	6
345	Polymeric Micelles with Pendant Dicarboxylate Chelating Ligands Prepared via a Michael Addition for <i>cis</i> -Platinum Drug Delivery. <i>Macromolecules</i> , 2011, 44, 7888-7900.	2.2	65
346	Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents. <i>Chemical Communications</i> , 2011, 47, 5184.	2.2	134
347	Platinum Interference with siRNA Non-seed Regions Fine-Tunes Silencing Capacity. <i>Journal of the American Chemical Society</i> , 2011, 133, 11977-11984.	6.6	20
348	NMR Studies of Models Having the Pt(d(GpC)) 17-Membered Macrocyclic Ring Formed in DNA by Platinum Anticancer Drugs: Pt Complexes with Bulky Chiral Diamine Ligands. <i>Inorganic Chemistry</i> , 2011, 50, 4559-4571.	1.9	23
349	Unusual Reactivity of a Potent Platinum-Acridine Hybrid Antitumor Agent. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 687-691.	1.3	21
350	Current Management of Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2011, 32, 853-863.	0.8	34
351	Advances in the field of β -conjugated 2,2',6',2'-terpyridines. <i>Chemical Society Reviews</i> , 2011, 40, 1459-1517.		452

#	ARTICLE	IF	CITATIONS
352	Role of Drp1, a Key Mitochondrial Fission Protein, in Neuropathic Pain. <i>Journal of Neuroscience</i> , 2011, 31, 11404-11410.	1.7	79
353	Synthesis and Antiproliferative Activity of a C,N-Cycloplatinated(II) Complex with a Potentially Intercalative Anthraquinone Pendant. <i>Inorganic Chemistry</i> , 2011, 50, 2151-2158.	1.9	51
354	Orphan Nuclear Receptors. , 2011, , 2656-2661.		0
355	Multinuclear solid-state NMR of square-planar platinum complexes—Cisplatin and related systems. <i>Canadian Journal of Chemistry</i> , 2011, 89, 919-937.	0.6	65
356	Novel strategies for the treatment of small-cell lung carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 611-619.	12.5	93
357	The anticancer drug cisplatin can cross-link the interdomain zinc site on human albumin. <i>Chemical Communications</i> , 2011, 47, 6006.	2.2	80
358	A Potent Ruthenium(II) Antitumor Complex Bearing a Lipophilic Levonorgestrel Group. <i>Inorganic Chemistry</i> , 2011, 50, 9164-9171.	1.9	74
359	Thiol-ene and Thiol-ene Click-Chemistry as a Tool for a Variety of Platinum Drug Delivery Carriers, from Statistical Copolymers to Crosslinked Micelles. <i>Biomacromolecules</i> , 2011, 12, 1738-1751.	2.6	123
360	Gold Nanostructures as a Platform for Combinational Therapy in Future Cancer Therapeutics. <i>Cancers</i> , 2011, 3, 1081-1110.	1.7	126
361	Novel Dinuclear Platinum(II) Complexes Containing Mixed Nitrogen-Sulfur Donor Ligands. <i>Inorganic Chemistry</i> , 2011, 50, 12747-12761.	1.9	22
362	Organometallic Half-Sandwich Iridium Anticancer Complexes. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3011-3026.	2.9	306
363	Oculodermal Melanocytosis. , 2011, , 2597-2598.		0
364	BIO-RELATED COPPER-MEDIATED OXIDATIVE PROCESSES. <i>Comments on Inorganic Chemistry</i> , 2011, 32, 219-245.	3.0	24
365	Rhenium(iv) compounds inducing apoptosis in cancer cells. <i>Chemical Communications</i> , 2011, 47, 5283.	2.2	35
366	The preparation and characterization of trans-platinum(iv) complexes with unusually high cytotoxicity. <i>Dalton Transactions</i> , 2011, 40, 344-347.	1.6	29
367	Synthesis and evaluation of metallocene containing methylenedene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors. <i>Metallomics</i> , 2011, 3, 600.	1.0	23
368	Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(ii) compounds with sulfur and phosphorus donors. <i>Dalton Transactions</i> , 2011, 40, 2006.	1.6	27
371	TOX4 and its binding partners recognize DNA adducts generated by platinum anticancer drugs. <i>Archives of Biochemistry and Biophysics</i> , 2011, 507, 296-303.	1.4	36

#	ARTICLE	IF	CITATIONS
372	miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. <i>Cancer Letters</i> , 2011, 304, 52-59.	3.2	113
373	A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. <i>Cancer Letters</i> , 2011, 307, 47-52.	3.2	41
374	RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. <i>Cancer Letters</i> , 2011, 311, 48-56.	3.2	40
375	Drug transporters of platinum-based anticancer agents and their clinical significance. <i>Drug Resistance Updates</i> , 2011, 14, 22-34.	6.5	191
376	p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. <i>European Journal of Cancer</i> , 2011, 47, 1585-1594.	1.3	103
377	Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. <i>Biochemical and Biophysical Research Communications</i> , 2011, 405, 333-337.	1.0	73
378	PLC β 3 is required for RhoGDI2-mediated cisplatin resistance in gastric cancer. <i>Biochemical and Biophysical Research Communications</i> , 2011, 414, 575-580.	1.0	19
379	Luminescent cyclometalated platinum(ii) complexes containing N-heterocyclic carbene ligands with potent in vitro and in vivo anti-cancer properties accumulate in cytoplasmic structures of cancer cells. <i>Chemical Science</i> , 2011, 2, 728.	3.7	147
380	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1085-1127.	2.5	420
381	Simultaneous determination of selenomethionine enantiomers in biological fluids by stable isotope dilution gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 3253-3258.	1.2	9
382	Ionic liquids for extraction of metals and metal containing compounds from communal and industrial waste water. <i>Water Research</i> , 2011, 45, 4601-4614.	5.3	142
383	Design, synthesis and biological evaluation of estradiol-PEG-linked platinum(II) hybrid molecules: Comparative molecular modeling study of three distinct families of hybrids. <i>Steroids</i> , 2011, 76, 94-103.	0.8	33
384	Use of Top-Down and Bottom-Up Fourier Transform Ion Cyclotron Resonance Mass Spectrometry for Mapping Calmodulin Sites Modified by Platinum Anticancer Drugs. <i>Analytical Chemistry</i> , 2011, 83, 9507-9515.	3.2	47
385	Replacement of a Thiourea with an Amidine Group in a Monofunctional Platinum β -Acridine Antitumor Agent. Effect on DNA Interactions, DNA Adduct Recognition and Repair. <i>Molecular Pharmaceutics</i> , 2011, 8, 1941-1954.	2.3	33
386	Copper Binding Agents Acting as Copper Ionophores Lead to Caspase Inhibition and Paraptotic Cell Death in Human Cancer Cells. <i>Journal of the American Chemical Society</i> , 2011, 133, 6235-6242.	6.6	240
387	Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay. <i>Journal of Biological Inorganic Chemistry</i> , 2011, 16, 373-380.	1.1	25
388	Thermodynamic and Kinetic Studies on Novel Dinuclear Platinum(II) Complexes Containing Bidentate N-donor ligands. <i>Inorganic Chemistry</i> , 2011, 50, 8984-8996.	1.9	41
389	Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting. <i>Science Translational Medicine</i> , 2011, 3, 64ra2.	5.8	231

#	ARTICLE	IF	CITATIONS
390	Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells. <i>Journal of Experimental Pharmacology</i> , 2011, 3, 43.	1.5	8
391	A DNA Repair Protein BRCA1 as a Potentially Molecular Target for the Anticancer Platinum Drug Cisplatin. , 2011, , .		0
393	Editorial [Hot Topic: Gold Derivatives as Anti-Cancer Agents (Guest Editor: Laura Rodriguez Raurell)]. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 920-920.	0.9	0
394	Uptake of CDDP-containing Polymeric Micelles by Cells Using Particle Induced X-Ray Emission. <i>Journal of Radiation Research</i> , 2011, 52, 193-198.	0.8	2
395	Investigational Approaches for Mesothelioma. <i>Frontiers in Oncology</i> , 2011, 1, 22.	1.3	6
396	Quantitative Proteomic and Interaction Network Analysis of Cisplatin Resistance in HeLa Cells. <i>PLoS ONE</i> , 2011, 6, e19892.	1.1	37
397	Rationale for Heating Oxaliplatin for the Intraperitoneal Treatment of Peritoneal Carcinomatosis. <i>Annals of Surgery</i> , 2011, 254, 138-144.	2.1	70
398	“Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin. <i>Current Cancer Drug Targets</i> , 2011, 11, 226-235.	0.8	63
399	Sensitization of Head and Neck Cancer to Cisplatin Through the Use of a Novel Curcumin Analog. <i>JAMA Otolaryngology</i> , 2011, 137, 499.	1.5	40
400	Pleasure Molecules. , 2011, , 140-167.		0
401	Man-Made Healers. , 2011, , 190-213.		0
402	Emerging treatments for small-cell lung cancer: Phase II and III trials. <i>Clinical Investigation</i> , 2011, 1, 255-263.	0.0	0
403	Comparison of Reproductive Toxicity Caused by Cisplatin and Novel Platinum-N-Heterocyclic Carbene Complex in Male Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 328-333.	1.2	33
404	KISS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2011, 30, 3163-3173.	2.6	31
405	Phospho- \hat{P}^{63} Np63 \hat{I} is a key regulator of the cisplatin-induced microRNAome in cancer cells. <i>Cell Death and Differentiation</i> , 2011, 18, 1220-1230.	5.0	93
406	Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells. <i>Cancer Gene Therapy</i> , 2011, 18, 176-188.	2.2	36
407	Platinum (IV)-coordinate polymers for cancer drug delivery. <i>Journal of Controlled Release</i> , 2011, 152, e108-e109.	4.8	5
408	Functional surface modification of PE film by dopamine- \hat{I}^2 -cyclodextrin conjugate. <i>Journal of Controlled Release</i> , 2011, 152, e109-e111.	4.8	1

#	ARTICLE	IF	CITATIONS
409	Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 1306-1313.	1.5	57
410	Platinum(II) and palladium(II) complexes with (N,N ²) and (C,N,N ²) ⁺ ligands derived from pyrazole as anticancer and antimalarial agents: Synthesis, characterization and in vitro activities. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 1720-1728.	1.5	75
411	Functionalization of microspheres with malonates using Michael Addition as a pathway to create a drug delivery system for platinum drugs for the treatment of liver cancer. <i>Polymer</i> , 2011, 52, 5993-6002.	1.8	10
412	A tumor pH-responsive complex: Carboxyl-modified hyperbranched polyether and cis-dichlorodiammineplatinum(II). <i>Colloids and Surfaces B: Biointerfaces</i> , 2011, 88, 674-681.	2.5	23
413	Inclusion complexes of β -cyclodextrin and the cisplatin analogues oxaliplatin, carboplatin and nedaplatin: A theoretical approach. <i>Chemical Physics Letters</i> , 2011, 515, 127-131.	1.2	19
414	Stereospecific ligands and their complexes. Part VII. Synthesis, characterization and in vitro antitumoral activity of platinum(II) complexes with O,O ² -dialkyl esters of (S,S)-ethylenediamine-N,N ² -di-2-(4-methyl)pentanoic acid. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 4559-4565.	2.6	22
415	Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. <i>European Journal of Pharmacology</i> , 2011, 651, 41-50.	1.7	94
416	A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells. <i>European Journal of Pharmacology</i> , 2011, 669, 38-44.	1.7	18
417	Plasmodium falciparum: DNA sequence specificity of cisplatin and cisplatin analogues. <i>Experimental Parasitology</i> , 2011, 128, 396-400.	0.5	5
418	Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. <i>FEBS Letters</i> , 2011, 585, 881-887.	1.3	25
419	Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery. <i>Biomaterials</i> , 2011, 32, 9136-9143.	5.7	87
420	Pt-rotaxanes as cytotoxic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6880-6883.	1.0	9
421	Adamantane-platinum conjugate hosted in β -cyclodextrin: Enhancing transport and cytotoxicity by noncovalent modification. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7421-7425.	1.0	20
422	Metal binding calixarenes with potential biomimetic and biomedical applications. <i>Coordination Chemistry Reviews</i> , 2011, 255, 2727-2745.	9.5	84
423	Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids. <i>Cancer Cell</i> , 2011, 20, 370-383.	7.7	279
424	Synthesis, Characterization, and Cytotoxicity of Platinum(IV) Carbamate Complexes. <i>Inorganic Chemistry</i> , 2011, 50, 3103-3115.	1.9	102
425	Synthesis, reactions with DNA, and antitumor activity of platinum complexes with aminonitroxyl radicals. <i>Russian Chemical Bulletin</i> , 2011, 60, 1342-1351.	0.4	6
426	Nucleoside-Lipid-Based Nanoparticles for Cisplatin Delivery. <i>ACS Nano</i> , 2011, 5, 8649-8655.	7.3	64

#	ARTICLE	IF	CITATIONS
427	Synergistic antitumor effect of cisplatin and the platinum(IV) nitroxyl complex BC118 and the development of resistance to their combined action. <i>Russian Chemical Bulletin</i> , 2011, 60, 1944-1947.	0.4	6
428	Review on gold nanoparticles and their applications. <i>Toxicology and Environmental Health Sciences</i> , 2011, 3, 193-205.	1.1	179
429	Synthesis, molecular characterisation, and in vivo study of platinum(IV) coordination compounds against B16 mouse melanoma tumours. <i>Chemical Papers</i> , 2011, 65, .	1.0	2
430	Superparamagnetic magnetite nanocrystal clusters as potential magnetic carriers for the delivery of platinum anticancer drugs. <i>Journal of Materials Chemistry</i> , 2011, 21, 11142.	6.7	65
431	Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1340-1351.	6.6	226
432	Anticancer activity and mode of action of titanocene C. <i>Investigational New Drugs</i> , 2011, 29, 607-614.	1.2	24
433	Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line. <i>Investigational New Drugs</i> , 2011, 29, 827-832.	1.2	5
434	Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator. <i>Investigational New Drugs</i> , 2011, 29, 1164-1176.	1.2	41
435	Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 41-50.	1.0	19
436	Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice. <i>Pharmaceutical Research</i> , 2011, 28, 610-625.	1.7	42
437	Molecular Interaction Fields (MIFs) to Predict Lipophilicity and ADME Profile of Antitumor Pt(II) Complexes. <i>Pharmaceutical Research</i> , 2011, 28, 640-646.	1.7	7
438	Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. <i>Molecular and Cellular Biochemistry</i> , 2011, 357, 31-38.	1.4	93
439	Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. <i>Journal of Neuro-Oncology</i> , 2011, 101, 379-390.	1.4	41
440	Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2011, 16, 361-372.	1.1	59
441	A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis. <i>Journal of Biological Inorganic Chemistry</i> , 2011, 16, 715-724.	1.1	42
442	The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence. <i>Journal of Biological Inorganic Chemistry</i> , 2011, 16, 735-743.	1.1	18
443	Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2011, 16, 288-300.	2.2	18
444	A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1247-1256.	1.1	10

#	ARTICLE	IF	CITATIONS
445	Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1389-1400.	1.1	40
446	In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin ϕ). <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1001-1008.	1.1	23
447	Comparative study of the hydrolysis of a third- and a first-generation platinum anticancer complexes. <i>Theoretical Chemistry Accounts</i> , 2011, 128, 627-638.	0.5	36
448	Determination of gallium originated from a gallium-based anticancer drug in human urine using ICP-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 709-714.	1.9	22
449	Grading of intrinsic and acquired cisplatin-resistant human melanoma cell lines: an infrared ATR study. <i>European Biophysics Journal</i> , 2011, 40, 795-804.	1.2	10
450	Recent advances in biosensory and medicinal therapeutic applications of zinc(II) and copper(II) coordination complexes. <i>Coordination Chemistry Reviews</i> , 2011, 255, 459-472.	9.5	130
451	Synthesis, characterization and anti proliferative effect of [Au(en) ₂]Cl ₃ and [Au(N-propyl-en) ₂]Cl ₃ on human cancer cell lines. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2011, 79, 1196-1201.	2.0	21
452	Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin. <i>Molecular Cancer</i> , 2011, 10, 74.	7.9	27
453	Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 94.	1.8	15
454	Transport processes of radiopharmaceuticals and -modulators. <i>Radiation Oncology</i> , 2011, 6, 59.	1.2	11
455	Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. <i>Journal of Molecular Signaling</i> , 2011, 6, 7.	0.5	122
456	An integrative approach to identifying cancer chemoresistance-associated pathways. <i>BMC Medical Genomics</i> , 2011, 4, 23.	0.7	17
457	Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast. <i>BMC Genomics</i> , 2011, 12, 44.	1.2	20
458	Synthesis and Characterization of Platinum(II) Complexes with a Diazenecarboxamide ϕ Appended Picoly ϕ Triazole Ligand. <i>European Journal of Inorganic Chemistry</i> , 2011, 2011, 1921-1929.	1.0	24
459	DNA Reactivity Profile of <i>trans</i> -Platinum Planar Amine Derivatives. <i>ChemMedChem</i> , 2011, 6, 1283-1290.	1.6	15
460	Gold(III) ϕ dithiocarbamate anticancer agents: Activity, toxicology and histopathological studies in rodents. <i>International Journal of Cancer</i> , 2011, 129, 487-496.	2.3	92
461	Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 2837-2849.	1.2	60
463	Polysilsesquioxane Nanoparticles for Targeted Platin ϕ Based Cancer Chemotherapy by Triggered Release. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 10330-10334.	7.2	82

#	ARTICLE	IF	CITATIONS
464	Gel Formulation Containing Mixed Surfactant and Lipids Associating with Carboplatin. <i>Chemistry and Biodiversity</i> , 2011, 8, 2195-2210.	1.0	1
465	Insights into the Acid-Base Properties of Pt ^{IV} -Diazidodiam(m)inedihydroxido Complexes from Multinuclear NMR Spectroscopy. <i>Chemistry - A European Journal</i> , 2011, 17, 12051-12058.	1.7	11
466	A Ruthenium Antimetastasis Agent Forms Specific Histone Protein Adducts in the Nucleosome Core. <i>Chemistry - A European Journal</i> , 2011, 17, 3562-3566.	1.7	160
467	Studies of Glutathione Transferase P1 Bound to a Platinum(IV)-Based Anticancer Compound Reveal the Molecular Basis of Its Activation. <i>Chemistry - A European Journal</i> , 2011, 17, 7806-7816.	1.7	73
468	Probing Platinum Azido Complexes by ¹⁴ N and ¹⁵ N-...NMR Spectroscopy. <i>Chemistry - A European Journal</i> , 2011, 17, 12059-12066.	1.7	23
469	Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1701-1705.	1.0	25
470	Malignant pleural mesothelioma: The standard of care and challenges for future management. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 92-111.	2.0	115
471	In search of patterns over physicochemical properties and pharmacological activities for a set of [MCl ₂ (thiosemicarbazone)] complexes (M=Pt/Pd): Support for multiple mechanisms of antichagasic action excluding DNA-bonding in vivo?. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2639-2651.	2.6	19
472	Organometallic ruthenium-based antitumor compounds with novel modes of action. <i>Journal of Organometallic Chemistry</i> , 2011, 696, 989-998.	0.8	324
473	Synthesis, characterization, structure, molecular modeling studies and biological activity of sterically crowded Pt(II) complexes containing bis(imidazole) ligands. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 400-409.	1.5	17
474	Novel C,N-chelate platinum(II) antitumor complexes bearing a lipophilic ethisterone pendant. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 525-531.	1.5	49
475	Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 793-799.	1.5	42
476	Platinum(IV) coordination compounds containing 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one as nonleaving ligand. Molecular and cytotoxicity in vitro characterization. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2011, 79, 497-501.	2.0	11
477	Synthesis, characterization and tumor cell growth inhibition of new trans platinum complexes with phosphane derivatives. <i>Polyhedron</i> , 2011, 30, 1646-1650.	1.0	23
478	Phospho- ¹²⁵ I-Np63/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure. <i>Cell Cycle</i> , 2011, 10, 3938-3947.	1.3	88
479	Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 921-928.	0.9	84
480	Anticancer Metallotherapeutics in Preclinical Development. <i>Current Medicinal Chemistry</i> , 2011, 18, 4738-4752.	1.2	78
481	Lactogens and estrogens in breast cancer chemoresistance. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 411-422.	1.2	18

#	ARTICLE	IF	CITATIONS
482	Bioanalytical and Biophysical Techniques for the Elucidation of the Mode of Action of Metal-Based Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2632-2646.	1.0	21
483	Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2623-2631.	1.0	67
484	Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease. <i>Cellular and Molecular Immunology</i> , 2011, 8, 289-295.	4.8	8
485	Non-Classical Structures Among Current Platinum Complexes with Potential as Antitumor Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2613-2622.	1.0	18
486	Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2602-2612.	1.0	75
488	Celecoxib Antagonizes the Cytotoxicity of Cisplatin in Human Esophageal Squamous Cell Carcinoma Cells by Reducing Intracellular Cisplatin Accumulation. <i>Molecular Pharmacology</i> , 2011, 79, 608-617.	1.0	24
489	Bim Protein Degradation Contributes to Cisplatin Resistance. <i>Journal of Biological Chemistry</i> , 2011, 286, 22384-22392.	1.6	56
490	A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110 β Isoform in Medulloblastoma Cell Proliferation and Chemoresistance. <i>Molecular Cancer Research</i> , 2011, 9, 925-935.	1.5	56
491	The phosphate clamp: a small and independent motif for nucleic acid backbone recognition. <i>Nucleic Acids Research</i> , 2011, 39, 325-336.	6.5	61
492	Volumetric and Angiogenic Evaluation of Antitumor Effects with Acoustic Liposome and High-Frequency Ultrasound. <i>Cancer Research</i> , 2011, 71, 6957-6964.	0.4	32
493	^{225}Ac Confers Tumor Cell Resistance to Cisplatin through the AKT1 Transcriptional Regulation. <i>Cancer Research</i> , 2011, 71, 1167-1176.	0.4	51
494	Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas?. <i>Neuro-Oncology</i> , 2011, 13, 725-735.	0.6	16
495	Should the Presence of Germline <i>BRCA1/2</i> Mutations Influence Treatment Selection in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3724-3726.	0.8	5
496	c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance. <i>Science Signaling</i> , 2011, 4, ra19.	1.6	88
497	Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. <i>Nanotechnology</i> , 2011, 22, 265101.	1.3	27
498	Synergistic Interactions between Heregulin and Peroxisome Proliferator-activated Receptor- γ (PPAR γ) Agonist in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 20087-20099.	1.6	14
499	Schlafen-3 decreases cancer stem cell marker expression and autocrine/juxtacrine signaling in FOLFOX-resistant colon cancer cells. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G347-G355.	1.6	28
500	Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?. <i>Journal of Thoracic Oncology</i> , 2011, 6, 559-568.	0.5	32

#	ARTICLE	IF	CITATIONS
501	Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation. <i>Clinical Cancer Research</i> , 2011, 17, 6229-6238.	3.2	162
502	Screening for modulators of cisplatin sensitivity: Unbiased screens reveal common themes. <i>Cell Cycle</i> , 2011, 10, 380-386.	1.3	15
504	Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation. <i>Nucleic Acids Research</i> , 2011, 39, 8200-8212.	6.5	31
505	Effect of eIF3a on Response of Lung Cancer Patients to Platinum-Based Chemotherapy by Regulating DNA Repair. <i>Clinical Cancer Research</i> , 2011, 17, 4600-4609.	3.2	74
506	Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 10668-10672.	3.3	57
507	Pomegranate Seed Extract Attenuates Chemotherapy-Induced Acute Nephrotoxicity and Hepatotoxicity in Rats. <i>Journal of Medicinal Food</i> , 2011, 14, 1254-1262.	0.8	48
508	Up-Regulation of Extracellular Signal-Regulated Kinase 1/2-Dependent Thymidylate Synthase and Thymidine Phosphorylase Contributes to Cisplatin Resistance in Human Non-Small-Cell Lung Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 184-194.	1.3	22
509	Functional Genomics Reveals Diverse Cellular Processes That Modulate Tumor Cell Response to Oxaliplatin. <i>Molecular Cancer Research</i> , 2011, 9, 173-182.	1.5	16
510	A Human Head and Neck Squamous Cell Carcinoma Cell Line with Acquired Cisplatin-Resistance Shows Remarkable Upregulation of BRCA1 and Hypersensitivity to Taxane. <i>International Journal of Otolaryngology</i> , 2011, 2011, 1-4.	1.0	11
511	Tumour suppressor genes in chemotherapeutic drug response. <i>Bioscience Reports</i> , 2012, 32, 361-374.	1.1	87
512	The Key to Unlocking the Chemotherapeutic Potential of PPAR γ Ligands: Having the Right Combination. <i>PPAR Research</i> , 2012, 2012, 1-13.	1.1	17
513	Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. <i>Nucleic Acids Research</i> , 2012, 40, 8953-8964.	6.5	142
514	GERM CELL TUMORS. <i>Neuro-Oncology</i> , 2012, 14, i49-i55.	0.6	4
515	Neurological complications of chemotherapy to the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 903-916.	1.0	54
516	Role of Neurofilament Light Polypeptide in Head and Neck Cancer Chemoresistance. <i>Molecular Cancer Research</i> , 2012, 10, 305-315.	1.5	26
517	Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-PtII complexes containing long alkane linkers. <i>Pure and Applied Chemistry</i> , 2012, 85, 343-354.	0.9	5
518	DEVELOPMENT OF PLATINUM(IV) COMPLEXES AS ANTICANCER PRODRUGS: THE STORY SO FAR. <i>Cosmos</i> , 2012, 08, 121-134.	0.4	6
519	Inhibition of the JAK-STAT3 Signaling Pathway by Ganoderic Acid A Enhances Chemosensitivity of HepG2 Cells to Cisplatin. <i>Planta Medica</i> , 2012, 78, 1740-1748.	0.7	54

#	ARTICLE	IF	CITATIONS
520	Global tumor protein p53/p63 interactome. <i>Cell Cycle</i> , 2012, 11, 2367-2379.	1.3	39
521	Independent transcriptional reprogramming and apoptosis induction by cisplatin. <i>Cell Cycle</i> , 2012, 11, 3472-3480.	1.3	32
522	New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy. <i>Current Medicinal Chemistry</i> , 2012, 19, 4678-4687.	1.2	29
523	p53-Aurora A mitotic feedback loop regulates cell cycle progression and genomic stability. <i>Cell Cycle</i> , 2012, 11, 3719-3719.	1.3	5
524	Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes. <i>Cell Cycle</i> , 2012, 11, 3723-3723.	1.3	2
525	Cell-autonomous circadian DNA damage response. <i>Cell Cycle</i> , 2012, 11, 3720-3720.	1.3	2
526	Transcriptional profiling of apoptosis. <i>Cell Cycle</i> , 2012, 11, 3721-3721.	1.3	2
527	Wee1-Hsp90 inhibitor combination treatment. <i>Cell Cycle</i> , 2012, 11, 3722-3722.	1.3	3
528	Autophagy and tumor cell invasion. <i>Cell Cycle</i> , 2012, 11, 3718-3718.	1.3	10
529	Malignant pleural mesothelioma. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 377-385.	0.5	16
530	The antitumor efficiency of combined electrochemotherapy and single dose irradiation on a breast cancer tumor model. <i>Radiology and Oncology</i> , 2012, 46, 226-32.	0.6	15
531	Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2483-2494.	1.9	67
532	Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale. <i>Journal of Clinical Oncology</i> , 2012, 30, 2408-2417.	0.8	298
533	New International Society of Pediatric Oncology Boston Ototoxicity Grading Scale for Pediatric Oncology: Still Room for Improvement. <i>Journal of Clinical Oncology</i> , 2012, 30, 2303-2306.	0.8	12
534	Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11294-11299.	3.3	121
535	Management of Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1420.	3.8	12
536	DNA Polymerase η Is a Major Determinant of Resistance to Platinum-Based Chemotherapeutic Agents. <i>Molecular Pharmacology</i> , 2012, 81, 778-787.	1.0	47
537	Sensitive Marker of the Cisplatin-DNA Interaction: X-Ray Photoelectron Spectroscopy of CL. <i>Bioinorganic Chemistry and Applications</i> , 2012, 2012, 1-10.	1.8	2

#	ARTICLE	IF	CITATIONS
538	ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 663-671.	0.5	58
539	3-Hydroxycarboplatin, a Simple Carboplatin Derivative Endowed with an Improved Toxicological Profile. <i>Platinum Metals Review</i> , 2012, 56, 248-256.	1.5	15
540	Induction of Apoptosis and Sensitization of Head and Neck Squamous Carcinoma Cells to Cisplatin by Targeting Survivin Gene Expression. <i>Current Gene Therapy</i> , 2012, 12, 444-453.	0.9	23
541	Growth Responses Following a Single Intra-Muscular hGH Plasmid Administration Compared to Daily Injections of hGH in Dwarf Mice. <i>Current Gene Therapy</i> , 2012, 12, 437-443.	0.9	7
542	Genomics and Cancer Drug Resistance. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 651-673.	0.9	39
544	Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus. <i>Oncology Reports</i> , 2012, 27, 971-978.	1.2	7
545	Transcription Inhibition by Organometallic Ruthenium - Arene Anticancer Complexes in Live Mammalian Cells. <i>Australian Journal of Chemistry</i> , 2012, 65, 1271.	0.5	9
546	Cellular Response to Antitumor <i>cis</i> -Dichlorido Platinum(II) Complexes of CDK Inhibitor Bohemine and Its Analogues. <i>Chemical Research in Toxicology</i> , 2012, 25, 500-509.	1.7	18
547	Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 786-792.	0.9	45
548	Valuable Insight into the Anticancer Activity of the Platinum-Histone Deacetylase Inhibitor Conjugate, 2012, 9, 1990-1999.	2.3	41
549	[RuII(η -5-C5H5)(bipy)(PPh3)] ⁺ , a promising large spectrum antitumor agent: Cytotoxic activity and interaction with human serum albumin. <i>Journal of Inorganic Biochemistry</i> , 2012, 117, 261-269.	1.5	72
550	Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand As Potential Anticancer Agents. <i>Organometallics</i> , 2012, 31, 5772-5781.	1.1	70
551	Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES). <i>Metallomics</i> , 2012, 4, 568.	1.0	56
552	Structural Determinants of Cisplatin and Transplatin Binding to the Met-Rich Motif of Ctr1: A Computational Spectroscopy Approach. <i>Journal of Chemical Theory and Computation</i> , 2012, 8, 2912-2920.	2.3	27
553	A circular dichroism study uncovers a two-step interaction of antitumor azolato-bridged dinuclear platinum(II) complexes with calf thymus DNA. <i>Metallomics</i> , 2012, 4, 641.	1.0	17
555	Cis-trans isomerism in diphenoxido bridged dicopper complexes: role of crystallized water to stabilize the cis isomer, variation in magnetic properties and conversion of both into a trinuclear species. <i>Dalton Transactions</i> , 2012, 41, 12200.	1.6	27
556	In Vitro Anticancer Activity of <i>cis</i> -Diammineplatinum(II) Complexes with η^2 -Diketonate Leaving Group Ligands. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5326-5336.	2.9	110
557	Melanoma tumor inhibition by tetrachlorido(O, η^2 -dibutyl-ethylenediamine-N,N ϵ^2 -di-3-propionate)platinum(IV) complex: in vitro and in vivo investigations. <i>Metallomics</i> , 2012, 4, 1155.	1.0	15

#	ARTICLE	IF	CITATIONS
558	Mixed ligand palladium(ii) complexes of 6-methoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde 4N-substituted thiosemicarbazones with triphenylphosphine co-ligand: Synthesis, crystal structure and biological properties. Dalton Transactions, 2012, 41, 13308.	1.6	94
559	Clinical and pharmacokinetic evaluation of satraplatin. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 103-111.	1.5	34
560	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Research, 2012, 14, R110.	2.2	179
561	Platinum(ii/iv) complexes containing ethylenediamine-N,Nâ€²-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. Metallomics, 2012, 4, 979.	1.0	35
562	Analysis of the DNA damage produced by a platinumâ€™acridine antitumor agent and its effects in NCI-H460 lung cancer cells. Metallomics, 2012, 4, 645.	1.0	28
563	Synthesis and characterization of new platinum(II) phosphinate complexes. Journal of Coordination Chemistry, 2012, 65, 1093-1106.	0.8	2
564	Thermodynamic and Mechanistic Insights into Translesion DNA Synthesis Catalyzed by Yâ€™Family DNA Polymerase Across a Bulky Doubleâ€™Base Lesion of an Antitumor Platinum Drug. Chemistry - A European Journal, 2012, 18, 15439-15448.	1.7	29
565	Plasmodium falciparum: The potential of the cancer chemotherapeutic agent cisplatin and its analogues as anti-malarials. Experimental Parasitology, 2012, 132, 440-443.	0.5	5
566	Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. International Journal of Pharmaceutics, 2012, 438, 98-106.	2.6	80
567	Ruthenium (II) complexes binding to human serum albumin and inducing apoptosis of tumor cells. Inorganic Chemistry Communication, 2012, 24, 104-109.	1.8	20
568	Using a Build-and-Click Approach for Producing Structural and Functional Diversity in DNA-Targeted Hybrid Anticancer Agents. Journal of Medicinal Chemistry, 2012, 55, 10198-10203.	2.9	46
569	Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology, 2012, 23, 075103.	1.3	23
570	Alterations of Phosphoproteins in NCI-H526 Small Cell Lung Cancer Cells Involved in Cytotoxicity of Cisplatin and Titanocene Y. Neoplasia, 2012, 14, 813-822.	2.3	19
571	Long-term Smoking Mediated Down-regulation of Smad3 Induces Resistance to Carboplatin in Non-Small Cell Lung Cancer. Neoplasia, 2012, 14, 644-IN23.	2.3	19
572	Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA affinity?. Dalton Transactions, 2012, 41, 9417.	1.6	42
573	Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor. Experimental Biology and Medicine, 2012, 237, 973-984.	1.1	19
574	Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells. Metallomics, 2012, 4, 1185.	1.0	60
575	Simple, selective, and sensitive colorimetric and ratiometric fluorescence/phosphorescence probes for platinum(ii) based on Salen-type Schiff bases. RSC Advances, 2012, 2, 10529.	1.7	65

#	ARTICLE	IF	CITATIONS
576	Interactions of DNA with a New Platinum(IV) Azide Dipyridine Complex Activated by UVA and Visible Light: Relationship to Toxicity in Tumor Cells. <i>Chemical Research in Toxicology</i> , 2012, 25, 1099-1111.	1.7	72
577	Role of π -Acceptor Effects in Controlling the Lability of Novel Monofunctional Pt(II) and Pd(II) Complexes: Crystal Structure of [Pt(triipyridinedimethane)Cl]Cl. <i>Inorganic Chemistry</i> , 2012, 51, 1516-1529.	1.9	48
578	Block Copolymer Micelles with Pendant Bifunctional Chelator for Platinum Drugs: Effect of Spacer Length on the Viability of Tumor Cells. <i>Biomacromolecules</i> , 2012, 13, 1010-1023.	2.6	70
579	Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity. <i>Dalton Transactions</i> , 2012, 41, 11330.	1.6	25
580	Photoinduced Ligand Exchange and Covalent DNA Binding by Two New Dirhodium Bis-Amidato Complexes. <i>Inorganic Chemistry</i> , 2012, 51, 11882-11890.	1.9	22
581	Toward the Selective Delivery of Chemotherapeutics into Tumor Cells by Targeting Peptide Transporters: Tailored Gold-Based Anticancer Peptidomimetics. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 2212-2226.	2.9	56
582	Chimeric Platinum-Polyamines and DNA Binding. Kinetics of DNA Interstrand Cross-Link Formation by Dinuclear Platinum Complexes with Polyamine Linkers. <i>Journal of the American Chemical Society</i> , 2012, 134, 7135-7146.	6.6	27
583	Site-Specific Platinum(II) Cross-Linking in a Ribozyme Active Site. <i>Journal of the American Chemical Society</i> , 2012, 134, 256-262.	6.6	19
584	Tuning the Activity of Platinum(IV) Anticancer Complexes through Asymmetric Acylation. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7571-7582.	2.9	92
585	Liposomal quercetin: evaluating drug delivery <i>in vitro</i> and biodistribution <i>in vivo</i> . <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 599-613.	2.4	62
586	Synthesis, Aqueous Reactivity, and Biological Evaluation of Carboxylic Acid Ester-Functionalized Platinum- π -Acridine Hybrid Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7817-7827.	2.9	43
587	Phospho- β -dependent regulation of autophagic signaling through transcription and micro-RNA modulation. <i>Cell Cycle</i> , 2012, 11, 1247-1259.	1.3	105
588	Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK. <i>Tumor Biology</i> , 2012, 33, 1855-1862.	0.8	28
589	A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. <i>MedChemComm</i> , 2012, 3, 1275.	3.5	27
590	Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 757-766.	1.7	92
591	Syntheses, structures, and anticancer activity of novel organometallic ruthenium- π -maltol complexes. <i>Journal of Organometallic Chemistry</i> , 2012, 700, 180-187.	0.8	20
592	Platinum(II) and gold(I) complexes based on 1,1'-bis(diphenylphosphino)metallocene derivatives: Synthesis, characterization and biological activity of the gold complexes. <i>Journal of Organometallic Chemistry</i> , 2012, 720, 52-59.	0.8	29
593	Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 1502-1511.	1.1	16

#	ARTICLE	IF	CITATIONS
594	Enhancement of cisplatin cytotoxicity by benzyl isothiocyanate in HL-60 cells. <i>Food and Chemical Toxicology</i> , 2012, 50, 2397-2406.	1.8	20
595	L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. <i>Cancer Letters</i> , 2012, 316, 70-76.	3.2	27
596	Role of the RAD51 G172T polymorphism in the clinical outcome of cervical cancer patients under concomitant chemoradiotherapy. <i>Gene</i> , 2012, 504, 279-283.	1.0	23
597	The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum. <i>Dalton Transactions</i> , 2012, 41, 13239.	1.6	100
598	Transcriptional Inhibition by DNA Damage as a Trigger for Cell Death. <i>Issues in Toxicology</i> , 2012, , 266-289.	0.2	1
599	How to modify 7-azaindole to form cytotoxic Pt(II) complexes: Highly in vitro anticancer effective cisplatin derivatives involving halogeno-substituted 7-azaindole. <i>Journal of Inorganic Biochemistry</i> , 2012, 115, 57-63.	1.5	46
600	DNA Metalatingâ€“Intercalating Hybrid Agents for the Treatment of Chemoresistant Cancers. <i>Chemistry - A European Journal</i> , 2012, 18, 12926-12934.	1.7	73
601	Ruthenium(II/III)â€“Based Compounds with Encouraging Antiproliferative Activity against Nonâ€“smallâ€“Cell Lung Cancer. <i>Chemistry - A European Journal</i> , 2012, 18, 14464-14472.	1.7	27
602	Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. <i>BMC Cancer</i> , 2012, 12, 200.	1.1	54
603	Evidence for different mechanisms of â€“unhookingâ€“™ for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. <i>BMC Cancer</i> , 2012, 12, 436.	1.1	20
604	Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs. <i>BMC Research Notes</i> , 2012, 5, 207.	0.6	3
605	The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. <i>Nature Reviews Cancer</i> , 2012, 12, 587-598.	12.8	509
606	Mammalian metallothioneins: properties and functions. <i>Metallomics</i> , 2012, 4, 739.	1.0	212
607	Inhibition of autophagy impairs tumor cell invasion in an organotypic model. <i>Cell Cycle</i> , 2012, 11, 2022-2029.	1.3	105
608	Phospho- ¹²⁵ I-Np63/SREBF1 protein interactions: Bridging cell metabolism and cisplatin chemoresistance. <i>Cell Cycle</i> , 2012, 11, 3810-3827.	1.3	22
609	A Zinc(II) Phthalocyanine Conjugated with an Oxaliplatin Derivative for Dual Chemo- and Photodynamic Therapy. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5446-5454.	2.9	99
610	The role of microRNA in the response to cisplatin treatment. <i>Biochemical Society Transactions</i> , 2012, 40, 821-825.	1.6	28
611	Cisplatin-Tethered Gold Nanoparticles That Exhibit Enhanced Reproducibility, Drug Loading, and Stability: a Step Closer to Pharmaceutical Approval?. <i>Inorganic Chemistry</i> , 2012, 51, 3490-3497.	1.9	94

#	ARTICLE	IF	CITATIONS
612	Combined Theoretical and Computational Study of Interstrand DNA Guanine-Guanine Cross-Linking by $\text{trans-[Pt(pyridine)}_2\text{]}$ Derived from the Photoactivated Prodrug $\text{trans,trans,trans-[Pt(N}_3\text{)}_2\text{(OH)}_2\text{(pyridine)}_2\text{]}$. <i>Inorganic Chemistry</i> , 2012, 51, 6830-6841.	1.9	42
613	DNA binding and antiproliferative activity toward human carcinoma cells of copper(II) and zinc(II) complexes of a 2,5-diphenyl[1,3,4]oxadiazole derivative. <i>Dalton Transactions</i> , 2012, 41, 4389.	1.6	51
614	Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. <i>Biochemical Pharmacology</i> , 2012, 84, 1428-1436.	2.0	58
615	The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin. <i>Cancer Epidemiology</i> , 2012, 36, 481-489.	0.8	17
616	Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair. <i>Cancer Letters</i> , 2012, 324, 171-178.	3.2	18
617	Seven-membered cycloplatinated complexes as a new family of anticancer agents. X-ray characterization and preliminary biological studies. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 557-566.	2.6	37
618	Liposomes as vehicles for water insoluble platinum-based potential drug: 2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II). <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 567-572.	2.6	10
619	Synthesis, visible light photocleavage, antiproliferative and cellular uptake properties of ruthenium complex $[\text{Ru(phen)}_2\text{(mitatp)}]^{2+}$. <i>European Journal of Medicinal Chemistry</i> , 2012, 55, 146-154.	2.6	35
620	Photo-induced anticancer activity of polypyridyl platinum(II) complexes. <i>European Journal of Medicinal Chemistry</i> , 2012, 57, 250-258.	2.6	17
621	Structural and anticancer properties of hydrogen bonded diphenyl phosphate adducts of Pt(IV) complexes: The importance of pKa matching. <i>Journal of Inorganic Biochemistry</i> , 2012, 115, 220-225.	1.5	2
622	DNA conformation and repair of polymeric natural DNA damaged by antitumor azolato-bridged dinuclear Pt(II) complex. <i>Journal of Inorganic Biochemistry</i> , 2012, 114, 15-23.	1.5	22
623	Understanding trans platinum complexes as potential antitumor drugs beyond targeting DNA. <i>Journal of Inorganic Biochemistry</i> , 2012, 114, 106-112.	1.5	66
624	Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum-bisphosphonate complexes in the treatment of bone tumors: A mini-review. <i>Journal of Inorganic Biochemistry</i> , 2012, 117, 237-247.	1.5	56
625	Cytotoxic hydrophilic iminophosphorane coordination compounds of d8 metals. Studies of their interactions with DNA and HSA. <i>Journal of Inorganic Biochemistry</i> , 2012, 116, 204-214.	1.5	56
626	Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. <i>Journal of Inorganic Biochemistry</i> , 2012, 116, 1-10.	1.5	67
627	Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2012, 77, 438-442.	0.9	57
628	Potential cytotoxic and amoebicide activity of first row transition metal compounds with 2,9-bis-(2,5-diazahexanyl)-1,10-phenanthroline (L1). <i>Dalton Transactions</i> , 2012, 41, 10164.	1.6	23
629	Ferrocene-Conjugated Copper(II) Complexes of Methionine and Phenanthroline Bases: Synthesis, Structure, and Photocytotoxic Activity. <i>Organometallics</i> , 2012, 31, 3010-3021.	1.1	65

#	ARTICLE	IF	CITATIONS
630	Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. <i>Inorganica Chimica Acta</i> , 2012, 393, 328-333.	1.2	100
631	t-Butylsarcosinedithiocarbamate gold(III)-based anticancer agents: Design, in vitro biological evaluation and interaction with model biomolecules. <i>Inorganica Chimica Acta</i> , 2012, 393, 304-317.	1.2	17
632	Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets. <i>Inorganica Chimica Acta</i> , 2012, 393, 173-181.	1.2	23
633	Photoactive sawhorse-type diruthenium tetracarbonyl complexes. <i>Inorganica Chimica Acta</i> , 2012, 393, 246-251.	1.2	19
634	Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs. <i>Dalton Transactions</i> , 2012, 41, 9689.	1.6	26
635	SKY1 and IXR1 interactions, their effects on cisplatin and spermine resistance in <i>Saccharomyces cerevisiae</i> . <i>Canadian Journal of Microbiology</i> , 2012, 58, 184-188.	0.8	5
636	Theoretical Prediction of the Complexation Behaviors of Antitumor Platinum Drugs with Cucurbiturils. <i>Journal of Physical Chemistry B</i> , 2012, 116, 14029-14039.	1.2	42
637	Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. <i>Nature Cell Biology</i> , 2012, 14, 276-286.	4.6	295
638	Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 891-898.	1.1	31
639	Multifunctional magnetic calcium phosphate nanoparticles for targeted platinum delivery. <i>Dalton Transactions</i> , 2012, 41, 10777.	1.6	35
640	Cellular uptake and remarkable photocytotoxicity of pyrenylter pyridine oxovanadium(IV) complexes of dipyrrophenazine bases. <i>Inorganica Chimica Acta</i> , 2012, 393, 284-293.	1.2	12
641	Interaction of Cisplatin with Human Superoxide Dismutase. <i>Journal of the American Chemical Society</i> , 2012, 134, 7009-7014.	6.6	65
642	Platinum(IV) prodrugs entrapped within multiwalled carbon nanotubes: Selective release by chemical reduction and hydrophobicity reversal. <i>Chemical Science</i> , 2012, 3, 2083.	3.7	84
643	Cisplatin cytotoxicity: a theoretical study of induced mutations. <i>Physical Chemistry Chemical Physics</i> , 2012, 14, 12457.	1.3	37
644	Synthesis, characterization, and biological activity of five new mixed-ligand palladium(II) complexes with ethylenediamine and 4-toluenesulfonyl-L-alanine dianion. <i>Journal of Coordination Chemistry</i> , 2012, 65, 239-250.	0.8	14
645	Harnessing chemoselective imine ligation for tethering bioactive molecules to platinum(IV) prodrugs. <i>Dalton Transactions</i> , 2012, 41, 6104.	1.6	47
646	Acid Degradable Cross-Linked Micelles for the Delivery of Cisplatin: A Comparison with Nondegradable Cross-Linker. <i>Chemistry of Materials</i> , 2012, 24, 3197-3211.	3.2	52
647	Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin. <i>Dalton Transactions</i> , 2012, 41, 3313.	1.6	38

#	ARTICLE	IF	CITATIONS
648	Metallo-drugs in the treatment of malignant pleural mesothelioma. <i>Inorganica Chimica Acta</i> , 2012, 393, 64-74.	1.2	15
649	Thermodynamic and kinetic behaviour of [Pt(2-methylthiomethylpyridine)(OH) ₂] ²⁺ . <i>Dalton Transactions</i> , 2012, 41, 512-522.	1.6	24
650	Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 99.	3.5	41
651	Differential Effects of Lovastatin on Cisplatin Responses in Normal Human Mesothelial Cells versus Cancer Cells: Implication for Therapy. <i>PLoS ONE</i> , 2012, 7, e45354.	1.1	21
652	Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin. <i>PLoS ONE</i> , 2012, 7, e47562.	1.1	86
653	Preparation, Biodistribution and Neurotoxicity of Liposomal Cisplatin following Convection Enhanced Delivery in Normal and F98 Glioma Bearing Rats. <i>PLoS ONE</i> , 2012, 7, e48752.	1.1	53
654	Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice. <i>International Journal of Nanomedicine</i> , 2012, 7, 2557.	3.3	51
655	Platinum Complexes with Bioactive Nitroxyl Radicals: Synthesis and Antitumor Properties. , 0, , .		3
656	Suppression of colorectal cancer metastasis by nigericin through inhibition of epithelial-mesenchymal transition. <i>World Journal of Gastroenterology</i> , 2012, 18, 2640.	1.4	35
657	Theoretical study of inclusion of a dinuclear platinum(II) complex in β , γ , and δ -cyclodextrins. <i>International Journal of Quantum Chemistry</i> , 2012, 112, 3403-3408.	1.0	6
658	The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. <i>Chemical Society Reviews</i> , 2012, 41, 2885.	18.7	974
659	Proteomics-based Strategy to Delineate the Molecular Mechanisms of RhoGDI2-induced Metastasis and Drug Resistance in Gastric Cancer. <i>Journal of Proteome Research</i> , 2012, 11, 2355-2364.	1.8	25
660	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. <i>Molecular Pharmacology</i> , 2012, 81, 719-728.	1.0	54
661	Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry?. <i>Chemical Science</i> , 2012, 3, 3135.	3.7	174
662	Molecular mechanisms of cisplatin resistance. <i>Oncogene</i> , 2012, 31, 1869-1883.	2.6	2,058
663	Multiscale Modeling of Double-Helical DNA and RNA: A Unification through Lie Groups. <i>Journal of Physical Chemistry B</i> , 2012, 116, 8556-8572.	1.2	15
664	Antiproliferative Activity of Pt ^{II} Complexes with Carboxylated Phosphanes in Chelated or Ring-Opened Forms. <i>European Journal of Inorganic Chemistry</i> , 2012, 2012, 3441-3448.	1.0	10
665	Structural basis for cisplatin DNA damage tolerance by human polymerase δ during cancer chemotherapy. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 628-632.	3.6	72

#	ARTICLE	IF	CITATIONS
666	Synthesis of a glycopolymeric Pt(II) carrier and its induction of apoptosis in resistant cancer cells. <i>Chemical Communications</i> , 2012, 48, 6357.	2.2	23
667	Revisiting [PtCl ₂ (cis-1,4-DACH)]: An Underestimated Antitumor Drug with Potential Application to the Treatment of Oxaliplatin-Refractory Colorectal Cancer. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7182-7192.	2.9	65
669	Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 6742-6747.	7.2	199
670	Synthesis and cytostatic activity of Pt(II) complexes of intramolecularly coordinated phosphine and stibine ligands. <i>Applied Organometallic Chemistry</i> , 2012, 26, 237-245.	1.7	20
671	A Computational Approach to Tuning the Photochemistry of Platinum(IV) Anticancer Agents. <i>Chemistry - A European Journal</i> , 2012, 18, 10630-10642.	1.7	16
672	Anticancer Activity of Silver ⁺ -Heterocyclic Carbene Complexes: Caspase-Independent Induction of Apoptosis via Mitochondrial Apoptosis-Inducing Factor (AIF). <i>ChemMedChem</i> , 2012, 7, 805-814.	1.6	116
673	Scandium-Catalyzed Preparation of Cytotoxic 3-Functionalized Quinolin-2-ones: Regioselective Ring Enlargement of Isatins or Imino Isatins. <i>ChemPlusChem</i> , 2012, 77, 563-569.	1.3	24
674	Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect. <i>Metallomics</i> , 2012, 4, 561.	1.0	90
675	Gold Ion ⁺ -Angiotensin Peptide Interaction by Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2012, 23, 942-951.	1.2	15
676	Induction of Cell Cycle Arrest and Apoptosis by Ruthenium Complex cis-(Dichloro)tetramineruthenium(III) Chloride in Human Lung Carcinoma Cells A549. <i>Biological Trace Element Research</i> , 2012, 147, 8-15.	1.9	20
677	Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator. <i>Journal of Chemical Biology</i> , 2012, 5, 51-61.	2.2	20
678	The expression and significance of MRP1, LRP, TOPOII ² , and BCL2 in tongue squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2012, 41, 141-148.	1.4	29
679	PDCD6 additively cooperates with anti-cancer drugs through activation of NF- κ B pathways. <i>Cellular Signalling</i> , 2012, 24, 726-733.	1.7	34
680	Towards a more selective analogue of oxaliplatin: Synthesis of [Pt((1R,2R)-diaminocyclohexane)(3-carboxypredicentrinato)]. <i>Inorganica Chimica Acta</i> , 2012, 384, 255-259.	1.2	9
681	Modulation of ligand fluorescence by the Pt(II)/Pt(IV) redox couple. <i>Inorganica Chimica Acta</i> , 2012, 389, 77-84.	1.2	31
682	A novel Ru(II) complex derived from hydroxydiamine as a potential antitumor agent: Synthesis and Structural Characterization. <i>Inorganic Chemistry Communication</i> , 2012, 20, 252-258.	1.8	21
683	Synthesis, characterization and in vitro antitumour activity of a series of novel platinum(II) complexes bearing Schiff base ligands. <i>European Journal of Medicinal Chemistry</i> , 2012, 53, 168-175.	2.6	46
684	Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. <i>European Journal of Pharmacology</i> , 2012, 674, 143-152.	1.7	21

#	ARTICLE	IF	CITATIONS
685	Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. <i>Biomaterials</i> , 2012, 33, 1455-1461.	5.7	91
686	Cholesterol-based anionic long-circulating cisplatin liposomes with reduced renal toxicity. <i>Biomaterials</i> , 2012, 33, 1596-1606.	5.7	59
687	Ruthenium-based complex nanocarriers for cancer therapy. <i>Biomaterials</i> , 2012, 33, 3770-3782.	5.7	71
688	In vitro biological evaluation of platinum(II) complexes with 1-(methoxy substituted benzyl) azetidene-3,3-dicarboxylate ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 1461-1467.	1.4	5
689	Synthesis and cytotoxicity of diam(m)ineplatinum(II) complexes with 2,2-bis(hydroxymethyl)malonate as the leaving group. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2239-2241.	1.0	7
690	RNAi knockdown of the Akt1 gene increases the chemosensitivity of gastric cancer cells to cisplatin both in vitro and in vivo. <i>Regulatory Peptides</i> , 2012, 176, 13-21.	1.9	13
691	Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. <i>Toxicology</i> , 2012, 291, 1-9.	2.0	283
692	Cytotoxic palladium(II) complexes of 8-aminoquinoline derivatives and the interaction with human serum albumin. <i>Journal of Inorganic Biochemistry</i> , 2012, 106, 46-51.	1.5	52
693	Synthesis, cytotoxicity and structure-activity relationships between ester and amide functionalities in novel acridine-based platinum(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2012, 110, 51-57.	1.5	6
694	Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 124, 575-581.	0.6	79
695	Measuring β -tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. <i>Cancer Science</i> , 2012, 103, 262-268.	1.7	23
696	The interaction of [Pd(N,N-dimethylaminopropylamine)(H ₂ O)] ₂ ⁺ with dicarboxylic acids and inosine: Thermodynamic model for carboplatin drug. <i>Open Chemistry</i> , 2012, 10, 1253-1261.	1.0	1
697	Chiral ruthenium complexes induce apoptosis of tumor cell and interact with bovine serum albumin. <i>Chirality</i> , 2012, 24, 174-180.	1.3	7
698	Cisplatin increases Bcl-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells. <i>International Journal of Cancer</i> , 2012, 130, 1755-1767.	2.3	27
699	Polyethylene glycol-polyethylenimine-tetrachloroplatinum (IV): A novel conjugate with good abilities of antitumor and gene delivery. <i>Journal of Applied Polymer Science</i> , 2012, 123, 1509-1517.	1.3	4
700	Antinociceptive Effect of Salvia Extract on Cisplatin-Induced Hyperalgesia in Mice. <i>Neurophysiology</i> , 2012, 43, 452-458.	0.2	7
701	Thermodynamic stability and energetics of DNA duplexes containing major intrastrand cross-links of second-generation antitumor dinuclear Pt(II) complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 187-196.	1.1	7
702	Antitumor bifunctional dinuclear Pt(II) complex BBR3535 forms interduplex DNA cross-links under molecular crowding conditions. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 239-245.	1.1	17

#	ARTICLE	IF	CITATIONS
703	Synthesis, characterization, and in vitro antitumor properties of gold(III) compounds with the traditional Chinese medicine (TCM) active ingredient liriodenine. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 247-261.	1.1	32
704	Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. <i>World Journal of Surgical Oncology</i> , 2013, 11, 22.	0.8	48
705	Let-7b expression determines response to chemotherapy through the regulation of Cyclin D1 in Glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 41.	3.5	71
706	The Transcription Factor FOXM1 (Forkhead box M1). <i>Advances in Cancer Research</i> , 2013, 118, 97-398.	1.9	135
707	Anticancer metallodrug research analytically painting the “omics” current developments and future trends. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1791-1808.	1.9	57
708	The cytotoxic effect of I^2 -elemene against malignant glioma is enhanced by base-excision repair inhibitor methoxyamine. <i>Journal of Neuro-Oncology</i> , 2013, 113, 375-384.	1.4	12
709	Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation. <i>Inorganic Chemistry</i> , 2013, 52, 12276-12291.	1.9	347
710	DNA-based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complex. <i>Journal of Inorganic Biochemistry</i> , 2013, 128, 124-130.	1.5	12
711	Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation. <i>Cancer Letters</i> , 2013, 329, 189-196.	3.2	22
712	Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis. <i>ACS Chemical Biology</i> , 2013, 8, 1335-1343.	1.6	137
713	Review of current thermal ablation treatment for lung cancer and the potential of electrochemotherapy as a means for treatment of lung tumours. <i>Cancer Treatment Reviews</i> , 2013, 39, 862-871.	3.4	60
714	Circadian Clocks. <i>Handbook of Experimental Pharmacology</i> , 2013, , .	0.9	20
715	Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. <i>NeuroToxicology</i> , 2013, 34, 205-211.	1.4	76
716	Poly(amido)amine (PAMAM) dendrimer-cisplatin complexes for chemotherapy of cisplatin-resistant ovarian cancer cells. <i>Journal of Nanoparticle Research</i> , 2013, 15, 1.	0.8	26
717	The Role of Platinum Compounds for the Treatment of Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013, 5, 11-22.	0.5	1
718	Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. <i>BMC Genomics</i> , 2013, 14, 480.	1.2	25
719	Picazoplatin, an Azide-Containing Platinum(II) Derivative for Target Analysis by Click Chemistry. <i>Journal of the American Chemical Society</i> , 2013, 135, 11680-11683.	6.6	54
720	DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology. <i>Chemistry and Biology</i> , 2013, 20, 648-659.	6.2	465

#	ARTICLE	IF	CITATIONS
721	Gold(III) Complexes of Pyridyl- and Isoquinolylamido Ligands: Structural, Spectroscopic, and Biological Studies of a New Class of Dual Topoisomerase I and II Inhibitors. <i>Inorganic Chemistry</i> , 2013, 52, 7889-7906.	1.9	33
722	Cisplatin influences acquisition of resistance to molecularly targeted agents through epithelial-mesenchymal transition-like changes. <i>Cancer Science</i> , 2013, 104, 904-911.	1.7	48
723	Identification of fluorescent ruthenium complexes containing imidazole derivatives as a new class of apoptosis inducers by living cell real-time imaging. <i>MedChemComm</i> , 2013, 4, 865.	3.5	8
724	Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1839-1857.	0.9	70
725	Novel clioquinol and its analogous platinum complexes: importance, role of the halogen substitution and the hydroxyl group of the ligand. <i>Dalton Transactions</i> , 2013, 42, 13343.	1.6	62
726	Effect of a Monofunctional Phenanthriplatin-DNA Adduct on RNA Polymerase II Transcriptional Fidelity and Translesion Synthesis. <i>Journal of the American Chemical Society</i> , 2013, 135, 13054-13061.	6.6	67
727	Cobalt and Zinc Compounds Bearing 1,10-Phenanthroline-5,6-dione or 1,3,5-Triaza-7-phosphaadamantane Derivatives – Synthesis, Characterization, Cytotoxicity, and Cell Selectivity Studies. <i>European Journal of Inorganic Chemistry</i> , 2013, 2013, 3651-3658.	1.0	39
728	Anticancer Activity and DNA Binding of a Bifunctional Ru(II) Arene Aqua-Complex with the 2,4-Diamino-6-(2-pyridyl)-1,3,5-triazine Ligand. <i>Inorganic Chemistry</i> , 2013, 52, 9962-9974.	1.9	67
729	Synthesis and Characterization of Pt(IV) Fluorescein Conjugates to Investigate Pt(IV) Intracellular Transformations. <i>Bioconjugate Chemistry</i> , 2013, 24, 1733-1740.	1.8	54
730	Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats. <i>Environmental Toxicology and Pharmacology</i> , 2013, 36, 883-890.	2.0	8
731	Robust Structure and Reactivity of Aqueous Arsenous Acid-Platinum(II) Anticancer Complexes. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 10749-10752.	7.2	51
732	Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes. <i>Dalton Transactions</i> , 2013, 42, 15457.	1.6	56
733	Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 35-44.	1.1	13
734	Hydration of Cisplatin Studied by an Effective Ab Initio Pair Potential Including Solute-Solvent Polarization. <i>Journal of Chemical Theory and Computation</i> , 2013, 9, 4562-4573.	2.3	27
735	Gold(III) complexes with esters of cyclohexyl-functionalized ethylenediamine-N,N'-diacetate. <i>Journal of Inorganic Biochemistry</i> , 2013, 128, 146-153.	1.5	19
736	Ruthenium-Arene- ¹² C-carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase-1: Synthesis, Characterization and Anticancer Mechanism Studies. <i>Chemistry - A European Journal</i> , 2013, 19, 12152-12160.	1.7	63
737	Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells. <i>Journal of Biological Inorganic Chemistry</i> , 2013, 18, 579-589.	1.1	24
738	Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand. <i>Journal of Inorganic Biochemistry</i> , 2013, 126, 46-54.	1.5	6

#	ARTICLE	IF	CITATIONS
739	Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment. <i>British Journal of Cancer</i> , 2013, 109, 1223-1229.	2.9	18
740	Cyclopalladated benzophenone imines: Synthesis, cytotoxicity against human breast adenocarcinoma cell lines and DNA interaction. <i>Journal of Organometallic Chemistry</i> , 2013, 724, 289-296.	0.8	32
741	Oxidative reactivity and cytotoxic properties of a platinum(II) complex prepared by outer-sphere amide bond coupling. <i>Polyhedron</i> , 2013, 58, 71-78.	1.0	4
742	DNA polymerase β modulates replication fork progression and DNA damage responses in platinum-treated human cells. <i>Scientific Reports</i> , 2013, 3, 3277.	1.6	23
743	Synthesis, spectroscopic characterization and anti-cancer properties of new gold(III)-alkanediamine complexes against gastric, prostate and ovarian cancer cells; crystal structure of $[\text{Au}_2(\text{pn})_2(\text{Cl})_2]\text{Cl}_2 \cdot \text{H}_2\text{O}$. <i>Polyhedron</i> , 2013, 61, 225-234.	1.0	24
745	A novel platinum complex of the histone deacetylase inhibitor belinostat: Rational design, development and in vitro cytotoxicity. <i>Journal of Inorganic Biochemistry</i> , 2013, 124, 70-77.	1.5	30
746	Synthesis and In Vitro Pharmacological Behavior of Platinum(II) Complexes Containing 1,2-Diamino-1-(4-fluorophenyl)-2-alkanol Ligands. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7951-7964.	2.9	25
747	Bidentate Ligands on Osmium(VI) Nitrido Complexes Control Intracellular Targeting and Cell Death Pathways. <i>Journal of the American Chemical Society</i> , 2013, 135, 14060-14063.	6.6	88
748	Synthesis, characterization, and cytotoxicity of platinum(II)/palladium(II) complexes with 4-toluenesulfonyl-L-amino acid dianion and diimine/diamine. <i>Journal of Coordination Chemistry</i> , 2013, 66, 638-649.	0.8	18
749	Nanocarriers for delivery of platinum anticancer drugs. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1667-1685.	6.6	345
750	cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: Synthesis and cytotoxicity in human cancer cell lines in vitro. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 719-727.	2.6	18
751	Visualizing Inhibition of Nucleosome Mobility and Transcription by Cisplatin-DNA Interstrand Crosslinks in Live Mammalian Cells. <i>Cancer Research</i> , 2013, 73, 4451-4460.	0.4	29
752	On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes. <i>Chemical Communications</i> , 2013, 49, 11533.	2.2	101
753	The Effect of Ligand Lipophilicity on the Nanoparticle Encapsulation of Pt(IV) Prodrugs. <i>Inorganic Chemistry</i> , 2013, 52, 9915-9920.	1.9	50
754	In Vivo Multimodality Imaging and Cancer Therapy by Near-Infrared Light-Triggered <i>trans</i> -Platinum Pro-Drug-Conjugated Upconversion Nanoparticles. <i>Journal of the American Chemical Society</i> , 2013, 135, 18920-18929.	6.6	508
755	An Oxygen-Chelate Complex, Palladium Bis-acetylacetonate, Induces Apoptosis in H460 Cells via Endoplasmic Reticulum Stress Pathway Rather than Interacting with DNA. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9601-9611.	2.9	22
756	Clinicopathological significance of ERCC1 expression in breast cancer. <i>Pathology Research and Practice</i> , 2013, 209, 331-336.	1.0	14
757	A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. <i>Talanta</i> , 2013, 116, 141-148.	2.9	50

#	ARTICLE	IF	CITATIONS
758	Synthesis, characterization and cytotoxicity of the Au(III) complexes with cyclic amine-based dithiocarbamate ligands. <i>Inorganic Chemistry Communication</i> , 2013, 30, 178-181.	1.8	23
759	Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma. <i>Cancer Letters</i> , 2013, 331, 105-114.	3.2	58
760	A Re-Evaluation of the Role of hCTR1, the Human High-Affinity Copper Transporter, in Platinum-Drug Entry into Human Cells. <i>Molecular Pharmacology</i> , 2013, 83, 1237-1246.	1.0	73
761	Destabilization of the MutS \pm protein-protein interface due to binding to the DNA adduct induced by anticancer agent carboplatin via molecular dynamics simulations. <i>Journal of Molecular Modeling</i> , 2013, 19, 4969-4989.	0.8	5
762	Kinetics and mechanism of interaction of some bioactive ligands with cis-diaqua(cis-1,2-diaminocyclohexane)platinum(II) in aqueous medium. <i>Journal of Chemical Sciences</i> , 2013, 125, 1133-1143.	0.7	2
763	RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. <i>BMC Cancer</i> , 2013, 13, 463.	1.1	49
764	Pharmacogenomics of cisplatin-based chemotherapy in ovarian-cancer patients from Yakutia. <i>Molecular Genetics, Microbiology and Virology</i> , 2013, 28, 137-140.	0.0	8
765	Rational Design of Multifunctional Upconversion Nanocrystals/Polymer Nanocomposites for Cisplatin (IV) Delivery and Biomedical Imaging. <i>Advanced Materials</i> , 2013, 25, 4898-4905.	11.1	127
766	DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2013, 14, 689-700.	0.6	19
767	Biological characterization of the antiproliferative potential of Co(II) and Sn(IV) coordination compounds in human cancer cell lines: a comparative proteomic approach. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 167-176.	0.3	38
768	Rhenium Complexes with Visible-Light-Induced Anticancer Activity. <i>ChemMedChem</i> , 2013, 8, 924-927.	1.6	74
769	A Fluorescent Probe for Investigating the Activation of Anticancer Platinum(IV) Prodrugs Based on the Cisplatin Scaffold. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 11785-11789.	7.2	41
770	Metals and Metal Derivatives in Medicine. <i>Mini-Reviews in Medicinal Chemistry</i> , 2013, 13, 211-221.	1.1	4
771	Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 404-415.	2.0	46
772	The development of bis(hydroxymethyl)pyrrole analogs as bifunctional DNA cross-linking agents and their chemotherapeutic potential. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 609-621.	2.6	43
773	Time dependence of cisplatin-induced duplex dissociation of 15-mer RNAs and mature miR-146a. <i>Dalton Transactions</i> , 2013, 42, 14959.	1.6	9
774	Shell crosslinked knedel-like nanoparticles for delivery of cisplatin: effects of crosslinking. <i>Nanoscale</i> , 2013, 5, 3220.	2.8	42
775	A dinuclear cyclometalated gold(III) phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo. <i>Chemical Science</i> , 2013, 4, 1979.	3.7	104

#	ARTICLE	IF	CITATIONS
776	Metallohelices with activity against cisplatin-resistant cancer cells; does the mechanism involve DNA binding?. <i>Chemical Science</i> , 2013, 4, 4407.	3.7	64
777	The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro. <i>Metallomics</i> , 2013, 5, 597.	1.0	63
778	Cisplatin Enhances the Formation of DNA Single- and Double-Strand Breaks by Hydrated Electrons and Hydroxyl Radicals. <i>Radiation Research</i> , 2013, 179, 323-331.	0.7	64
779	Exploring the DNA binding/cleavage, cellular accumulation and topoisomerase inhibition of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases and their platinum(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2013, 119, 54-64.	1.5	55
780	Synthesis, characterization, interaction with DNA and cytotoxicity of Pd(ii) and Pt(ii) complexes containing pyridine carboxylic acid ligands. <i>Dalton Transactions</i> , 2013, 42, 3957.	1.6	32
781	An ytterbium(<i>iii</i>) porphyrin induces endoplasmic reticulum stress and apoptosis in cancer cells: cytotoxicity and transcriptomics studies. <i>Chemical Science</i> , 2013, 4, 747-754.	3.7	37
782	Pyrazinoporphyrazines with Externally Appended Pyridine Rings. 13. Structure, UV-Visible Spectral Features, and Noncovalent Interaction with DNA of a Positively Charged Binuclear (ZnII/PtII) Macrocycle with Multimodal Anticancer Potentialities. <i>Inorganic Chemistry</i> , 2013, 52, 321-328.	1.9	33
783	Oral delivery of anticancer drugs II: the prodrug strategy. <i>Drug Discovery Today</i> , 2013, 18, 93-98.	3.2	18
784	Competitive formation of both long-range 5'â€²â€²5' and short-range antiparallel 3'â€²â€²3' DNA interstrand cross-links by a trinuclear platinum complex on binding to a 10-mer duplex. <i>Dalton Transactions</i> , 2013, 42, 3181-3187.	1.6	9
785	Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. <i>Chemical Society Reviews</i> , 2013, 42, 755-773.	18.7	672
786	Drug Delivery with a Calixpyrrole- <i>trans</i> -Pt(II) Complex. <i>Journal of the American Chemical Society</i> , 2013, 135, 2544-2551.	6.6	62
787	Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: The role of IL-6 signaling and Nrf2/AKR1C axis identification. <i>Biochemical Pharmacology</i> , 2013, 86, 872-887.	2.0	47
788	Dinuclear bridged biphosphinic and mononuclear cyclopalladated complexes of benzylamines: Synthesis, structural characterization and antitumor activity. <i>Polyhedron</i> , 2013, 50, 187-192.	1.0	32
789	The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 451-459.	0.6	39
790	New Insights into the Mechanism Underlying the Synergistic Action of Ionizing Radiation With Platinum Chemotherapeutic Drugs: The Role of Low-Energy Electrons. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 847-853.	0.4	57
791	Detection of Cellular Glutathione and Oxidized Glutathione Using Magnetic-Plasmonic Nanocomposite-Based Turn-Off-Surface Enhanced Raman Scattering. <i>Analytical Chemistry</i> , 2013, 85, 9221-9228.	3.2	127
792	Novel Mixed-Ligand Copper(I) Complexes: Role of Diimine Ligands on Cytotoxicity and Genotoxicity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7416-7430.	2.9	72
793	Some new [(thione) ₂ Au(diamine)]Cl ₃ complexes: Synthesis, spectroscopic characterization, computational and in vitro cytotoxic studies. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2013, 115, 641-647.	2.0	6

#	ARTICLE	IF	CITATIONS
794	New steroidal 7-azaindole platinum(II) antitumor complexes. <i>Journal of Inorganic Biochemistry</i> , 2013, 128, 48-56.	1.5	24
795	The interaction of cisplatin with a human telomeric DNA sequence containing seventeen tandem repeats. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1041-1045.	1.0	12
796	Carboplatin delays mammary cancer 4T1 growth in mice. <i>Pathology Research and Practice</i> , 2013, 209, 24-29.	1.0	20
797	New polydentate Ru(III)-Salan complexes: Synthesis, characterization, anti-tumour activity and interaction with human serum proteins. <i>Inorganica Chimica Acta</i> , 2013, 394, 616-626.	1.2	31
798	Enhancement of cisplatin-induced apoptosis by \hat{I}^2 -elemene in resistant human ovarian cancer cells. <i>Medical Oncology</i> , 2013, 30, 424.	1.2	42
799	miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer. <i>Cancer Investigation</i> , 2013, 31, 17-23.	0.6	56
800	Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. <i>Nanomedicine</i> , 2013, 8, 687-698.	1.7	65
801	Targeting and delivery of platinum-based anticancer drugs. <i>Chemical Society Reviews</i> , 2013, 42, 202-224.	18.7	588
802	Interaction studies of muts and mutl with DNA containing the major cisplatin lesion and its mismatched counterpart under equilibrium and nonequilibrium conditions. <i>Biopolymers</i> , 2013, 99, 636-647.	1.2	5
804	Detecting and delivering platinum anticancer drugs using fluorescent maghemite nanoparticles. <i>Chemical Communications</i> , 2013, 49, 2786.	2.2	21
805	Tris-(2-carboxyethyl) phosphine significantly promotes the reaction of cisplatin with Sp1 zinc finger protein. <i>Chemical Communications</i> , 2013, 49, 1226.	2.2	27
806	In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. <i>Metallomics</i> , 2013, 5, 636.	1.0	33
807	Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism. <i>Dalton Transactions</i> , 2013, 42, 7131.	1.6	83
808	Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. <i>Cancer Gene Therapy</i> , 2013, 20, 251-259.	2.2	49
809	Role of Conventional Chemosensitivity Test and Tissue Biomarker Expression in Predicting Response to Treatment of Peritoneal Carcinomatosis From Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2013, 12, 122-127.	1.0	20
810	Synthesis and cytotoxic activity of metallic complexes of lawsone. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2471-2477.	1.4	44
811	Pharmacological Modulators of the Circadian Clock as Potential Therapeutic Drugs: Focus on Genotoxic/Anticancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2013, , 289-309.	0.9	35
812	A platinum anticancer theranostic agent with magnetic targeting potential derived from maghemite nanoparticles. <i>Chemical Science</i> , 2013, 4, 2605.	3.7	43

#	ARTICLE	IF	CITATIONS
813	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. <i>Cell Cycle</i> , 2013, 12, 877-883.	1.3	57
814	Design and development of polymeric micelles with cleavable links for intracellular drug delivery. <i>Progress in Polymer Science</i> , 2013, 38, 503-535.	11.8	450
815	Photocytotoxic ferrocene-appended (l-tyrosine)copper(II) complexes of phenanthroline bases. <i>Polyhedron</i> , 2013, 52, 1287-1298.	1.0	23
816	EXAFS Debye-Waller factors issued from Car-Parrinello molecular dynamics: Application to the fit of oxaliplatin and derivatives. <i>Journal of Chemical Physics</i> , 2013, 138, 084303.	1.2	9
817	Antitumor <i>trans</i> -N-Heterocyclic Carbene-amine-Pt(II) Complexes: Synthesis of Dinuclear Species and Exploratory Investigations of DNA Binding and Cytotoxicity Mechanisms. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2074-2086.	2.9	72
818	<i>trans</i> -Dichloridopalladium(II) and platinum(II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: Synthesis, structural characterization, DNA binding and <i>in vitro</i> cytotoxicity studies. <i>European Journal of Medicinal Chemistry</i> , 2013, 60, 386-394.	2.6	64
819	Pt(II) complexes with (N,N- η^2) or (C,N,E- η^3) (E=N,S) ligands: Cytotoxic studies, effect on DNA tertiary structure and structure-activity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4210-4217.	1.4	22
820	Platinum(II) complexes with mono-aminophosphonate ester targeting group that induce apoptosis through G1 cell-cycle arrest: Synthesis, crystal structure and antitumour activity. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 76-84.	2.6	36
821	Inhibition of cytoplasmic GSK-3 β increases cisplatin resistance through activation of Wnt/ β -catenin signaling in A549/DDP cells. <i>Cancer Letters</i> , 2013, 336, 231-239.	3.2	64
822	Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on <i>In Vivo</i> Properties. <i>ACS Nano</i> , 2013, 7, 5675-5683.	7.3	89
823	Platinum (IV) Pro-drug Conjugated NaYF ₄ :Yb ³⁺ /Er ³⁺ Nanoparticles for Targeted Drug Delivery and Up-conversion Cell Imaging. <i>Advanced Healthcare Materials</i> , 2013, 2, 562-567.	3.9	45
824	The apoptosis of non-small cell lung cancer induced by cisplatin through modulation of STIM1. <i>Experimental and Toxicologic Pathology</i> , 2013, 65, 1073-1081.	2.1	38
825	The Contrasting Activity of Iodido versus Chlorido Ruthenium and Osmium Arene Azo- and Imino-pyridine Anticancer Complexes: Control of Cell Selectivity, Cross-Resistance, p53 Dependence, and Apoptosis Pathway. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1291-1300.	2.9	199
826	Cleavage Enhancement of Specific Chemical Bonds in DNA by Cisplatin Radiosensitization. <i>Journal of Physical Chemistry B</i> , 2013, 117, 4893-4900.	1.2	34
827	Transporting and Shielding Photosensitisers by Using Water-soluble Organometallic Cages: A New Strategy in Drug Delivery and Photodynamic Therapy. <i>Chemistry - A European Journal</i> , 2013, 19, 8378-8386.	1.7	123
828	<i>S</i> -Propargylthiopyridine Phosphane Derivatives As Anticancer Agents: Characterization and Antitumor Activity. <i>Organometallics</i> , 2013, 32, 3710-3720.	1.1	53
829	Characterisation of Ternary Complex Formation Between [Ru ^{III} (edta)] ⁻ and Various Bidentate Ligands. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2013, 639, 1640-1647.	0.6	1
830	Biomedical and Biochemical Applications of Self-Assembled Metallacycles and Metallacages. <i>Accounts of Chemical Research</i> , 2013, 46, 2464-2474.	7.6	438

#	ARTICLE	IF	CITATIONS
831	Coordination polymer nanoparticles in medicine. <i>Coordination Chemistry Reviews</i> , 2013, 257, 2839-2847.	9.5	153
832	Cellular Uptake Mechanisms of an Antitumor Ruthenium Compound: The Endosomal/Lysosomal System as a Target for Anticancer Metal-Based Drugs. <i>Microscopy and Microanalysis</i> , 2013, 19, 1122-1130.	0.2	35
833	Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2013, 129, 63-68.	0.6	98
834	Potential Anticancer Heterometallic Fe ^{II} -Au and Fe ^{II} -Pd Agents: Initial Mechanistic Insights. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5806-5818.	2.9	86
835	p101. , 2013, , 1623-1623.		0
836	Anticancer Cationic Ruthenium Nanovectors: From Rational Molecular Design to Cellular Uptake and Bioactivity. <i>Biomacromolecules</i> , 2013, 14, 2549-2560.	2.6	53
837	Conformational Determinants for the Recruitment of ERCC1 by XPA in the Nucleotide Excision Repair (NER) Pathway: Structure and Dynamics of the XPA Binding Motif. <i>Biophysical Journal</i> , 2013, 104, 2503-2511.	0.2	12
838	Surface-engineered nanomaterials as X-ray absorbing adjuvant agents for Auger-mediated chemo-radiation. <i>Nanoscale</i> , 2013, 5, 5252.	2.8	22
839	Zinc(ii) complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers that trigger DNA damage-mediated p53 phosphorylation in cancer cells. <i>Dalton Transactions</i> , 2013, 42, 5932.	1.6	78
840	Overcoming cisplatin resistance in chemotherapy by biomineralization. <i>Chemical Communications</i> , 2013, 49, 4932.	2.2	27
841	Monofunctional and Higher-Valent Platinum Anticancer Agents. <i>Inorganic Chemistry</i> , 2013, 52, 12234-12249.	1.9	199
842	The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients. <i>Lung Cancer</i> , 2013, 79, 65-72.	0.9	29
843	Hydrated Electrons React with High Specificity with Cisplatin Bound to Single-Stranded DNA. <i>Journal of Physical Chemistry B</i> , 2013, 117, 15994-15999.	1.2	11
844	Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1381-1390.	1.5	26
845	Tunable Cytotoxicity of Rhodamine 6G via Anion Variations. <i>Journal of the American Chemical Society</i> , 2013, 135, 15873-15879.	6.6	102
846	Custom ² Fit Ruthenium(II) Metallopeptides: A New Twist to DNA Binding With Coordination Compounds. <i>Chemistry - A European Journal</i> , 2013, 19, 13369-13375.	1.7	22
847	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2013, 73, 7222-7231.	0.4	153
848	Novel Organostannanes with Assorted Drugs: Synthesis, Spectral, and Potentiometric Studies. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2013, 188, 1433-1441.	0.8	0

#	ARTICLE	IF	CITATIONS
849	Kinetics, mechanism, and equilibrium studies of the reactions between a ruthenium(II) complex and some nitrogen- and sulfur-donor nucleophiles. <i>Monatshefte für Chemie</i> , 2013, 144, 1489-1498.	0.9	9
850	The Anticancer Ruthenium Complex KP1019 Induces DNA Damage, Leading to Cell Cycle Delay and Cell Death in <i>Saccharomyces cerevisiae</i> . <i>Molecular Pharmacology</i> , 2013, 83, 225-234.	1.0	39
851	Molecular Imaging Reveals a Role for AKT in Resistance to Cisplatin for Ovarian Endometrioid Adenocarcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 158-169.	3.2	18
852	Progress in Synthesis and Antitumor Activities of Estradiol-linked Platinum Complex. <i>Mini-Reviews in Medicinal Chemistry</i> , 2013, 13, 265-272.	1.1	0
853	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , 2013, 12, 647-654.	1.3	16
854	Application of liposomal technologies for delivery of platinum analogs in oncology. <i>International Journal of Nanomedicine</i> , 2013, 8, 3309.	3.3	67
855	Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry. <i>Genes and Development</i> , 2013, 27, 1739-1751.	2.7	44
856	Depletion of the ER chaperone ENPL-1 sensitizes <i>C. elegans</i> to the anticancer drug cisplatin. <i>Worm</i> , 2013, 2, e24059.	1.0	15
857	Differential Regulation of c-Jun Protein Plays an Instrumental Role in Chemoresistance of Cancer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 19321-19329.	1.6	19
858	Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2157-2166.	1.9	43
859	Garcinol, a Polyisoprenylated Benzophenone Modulates Multiple Proinflammatory Signaling Cascades Leading to the Suppression of Growth and Survival of Head and Neck Carcinoma. <i>Cancer Prevention Research</i> , 2013, 6, 843-854.	0.7	166
860	DNA Damage-Specific Control of Cell Death by Cryptochrome in p53-Mutant Ras-Transformed Cells. <i>Cancer Research</i> , 2013, 73, 785-791.	0.4	34
861	Mechanisms in Cancer Pain. , 2013, , 47-70.		4
862	Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. <i>Expert Reviews in Molecular Medicine</i> , 2013, 15, e12.	1.6	46
863	The Arf/p53 Protein Module, Which Induces Apoptosis, Down-regulates Histone H2AX to Allow Normal Cells to Survive in the Presence of Anti-cancer Drugs. <i>Journal of Biological Chemistry</i> , 2013, 288, 13269-13277.	1.6	26
864	Expression of Aryl Hydrocarbon Receptor Nuclear Translocator Enhances Cisplatin Resistance by Upregulating MDR1 Expression in Cancer Cells. <i>Molecular Pharmacology</i> , 2013, 84, 591-602.	1.0	27
865	Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. <i>EMBO Molecular Medicine</i> , 2013, 5, 935-948.	3.3	77
866	Tea phenols in bulk and nanoparticle form modify DNA damage in human lymphocytes from colon cancer patients and healthy individuals treated <i>in vitro</i> with platinum-based chemotherapeutic drugs. <i>Nanomedicine</i> , 2013, 8, 389-401.	1.7	27

#	ARTICLE	IF	CITATIONS
867	Two mixed-NH ₃ /amine platinum (II) anticancer complexes featuring a dichloroacetate moiety in the leaving group. <i>Scientific Reports</i> , 2013, 3, 2464.	1.6	26
868	<i>cis</i> -Pt(II) (1 <i>R</i> ,2 <i>R</i>)- Δ CH(3-acetoxy-1-cyclobutanedicarboxylato)], a Water-Soluble, Oxalate-Free and Stable Analogue of Oxaliplatin: Synthesis, Characterization, and Biological Evaluations. <i>ChemMedChem</i> , 2013, 8, 1465-1467.	1.6	8
870	Ototoxic Model of Oxaliplatin and Protection from Nicotinamide Adenine Dinucleotide. <i>Journal of Otolology</i> , 2013, 8, 63-71.	0.4	8
871	Mapping the protein-binding sites for novel iridium(III) anticancer complexes using electron capture dissociation. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 2028-2032.	0.7	25
872	Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light Form Novel DNA Adducts. <i>Chemistry - A European Journal</i> , 2013, 19, 9578-9591.	1.7	90
873	Evaluation of Platinum Chemotherapy in Combination with HER2-Targeted β -Particle Radiation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 441-449.	0.7	22
874	Higher anti-tumour efficacy of platinum(IV) complex <i>LA</i> 12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells. <i>Cell Proliferation</i> , 2013, 46, 665-676.	2.4	7
875	Mechanistic and Kinetic Investigations on the Interaction of Model Platinum(II) Complex With Ligands of Biological Significance in Reference to the Antitumor Activity. <i>Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry</i> , 2013, 43, 1563-1570.	0.6	5
876	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. <i>Cell Cycle</i> , 2013, 12, 417-421.	1.3	26
877	Photochemistry and DNA photocleavage by a new unsupported dirhodium(II,II) complex. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2013, 371, 20120128.	1.6	12
878	RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. <i>Oncogene</i> , 2013, 32, 3944-3953.	2.6	18
879	miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced injury. <i>Cell Death and Disease</i> , 2013, 4, e899-e899.	2.7	77
880	A novel role for the anti-senescence factor TBX2 in DNA repair and cisplatin resistance. <i>Cell Death and Disease</i> , 2013, 4, e846-e846.	2.7	24
881	Spontaneous Translocation of Antitumor Oxaliplatin, its Enantiomeric Analogue, and Cisplatin from One Strand to Another in Double-Helical DNA. <i>Chemistry - A European Journal</i> , 2013, 19, 11984-11991.	1.7	5
882	miR-153 Supports Colorectal Cancer Progression via Pleiotropic Effects That Enhance Invasion and Chemotherapeutic Resistance. <i>Cancer Research</i> , 2013, 73, 6435-6447.	0.4	132
883	An Updated View of Cisplatin Transport. <i>European Journal of Inorganic Chemistry</i> , 2013, 2013, 2701-2711.	1.0	63
884	Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistant gastric cancer cells to cisplatin. <i>Oncology Reports</i> , 2013, 30, 2288-2296.	1.2	10
885	Repopulation of Ovarian Cancer Cells after Chemotherapy. <i>Cancer Growth and Metastasis</i> , 2013, 6, CGM.S11333.	3.5	19

#	ARTICLE	IF	CITATIONS
886	Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes. <i>Anti-Cancer Drugs</i> , 2013, 24, 131-139.	0.7	7
887	Comparison of Cis- and Oxaliplatin-Induced Destabilization of 15-mer DNA- and RNA Duplexes by Binding to Centrally Located GC- and GNC Sequences. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2013, 639, 1655-1660.	0.6	5
888	Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. <i>Journal of Chemotherapy</i> , 2013, 25, 162-169.	0.7	41
890	Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin. <i>Radiology and Oncology</i> , 2013, 47, 346-357.	0.6	6
891	Persistent Hyperalgesia in the Cisplatin-Treated Mouse as Defined by Threshold Measures, the Conditioned Place Preference Paradigm, and Changes in Dorsal Root Ganglia Activated Transcription Factor 3. <i>Anesthesia and Analgesia</i> , 2013, 116, 224-231.	1.1	68
892	G-Quadruplexes as Potential Therapeutic Targets for Embryonal Tumors. <i>Molecules</i> , 2013, 18, 12500-12537.	1.7	38
893	The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day. <i>Drug Design, Development and Therapy</i> , 2013, 7, 511.	2.0	6
894	DNA Damage, DNA Repair and Cancer. , 0, , .		40
895	Strategies to Improve the Anti-Cancer Properties of Gold(III) Complexes. <i>Modern Chemistry & Applications</i> , 2013, 01, .	0.2	2
896	DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e61555.	1.1	34
897	Molecular Mechanisms of Platinum Resistance in Ovarian Cancer. , 0, , .		26
898	Genome maintenance and transcription integrity in aging and disease. <i>Frontiers in Genetics</i> , 2013, 4, 19.	1.1	53
899	Synthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands. <i>Bioinorganic Chemistry and Applications</i> , 2013, 2013, 1-12.	1.8	6
900	Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor. <i>ISRN Spectroscopy</i> , 2013, 2013, 1-29.	0.9	75
901	Catalytic nanomedicine technology: copper complexes loaded on titania nanomaterials as cytotoxic agents of cancer cell. <i>International Journal of Nanomedicine</i> , 2013, 8, 581.	3.3	16
902	DNA Repair and Resistance to Cancer Therapy. , 0, , .		2
903	Gold(III)-Dithiocarbamate Peptidomimetics in the Forefront of the Targeted Anticancer Therapy: Preclinical Studies against Human Breast Neoplasia. <i>PLoS ONE</i> , 2014, 9, e84248.	1.1	42
904	Pharmacological and Molecular Effects of Platinum(II) Complexes Involving 7-Azaindole Derivatives. <i>PLoS ONE</i> , 2014, 9, e90341.	1.1	27

#	ARTICLE	IF	CITATIONS
905	Methylseleninic Acid Sensitizes Notch3-Activated OVCA429 Ovarian Cancer Cells to Carboplatin. PLoS ONE, 2014, 9, e101664.	1.1	6
906	The Biological Side of Water-Soluble Arene Ruthenium Assemblies. Advances in Chemistry, 2014, 2014, 1-20.	1.1	16
907	Synthesis, Characterization and in Vitro Antitumor Activity of Platinum(II) Oxalato Complexes Involving 7-Azaindole Derivatives as Coligands. Molecules, 2014, 19, 10832-10844.	1.7	27
908	Stepwise encapsulation and controlled two-stage release system for cis-Diamminediiodoplatinum. International Journal of Nanomedicine, 2014, 9, 3175.	3.3	5
909	Synthesis Characterization and Antimicrobial Activities of Azithromycin Metal Complexes. Modern Chemistry & Applications, 2014, 02, .	0.2	8
910	A Systems Biology Approach to Understanding the Mechanisms of Action of an Alternative Anticancer Compound in Comparison to Cisplatin. Proteomes, 2014, 2, 501-526.	1.7	3
911	E3 Ubiquitin Ligase HOIP Attenuates Apoptotic Cell Death Induced by Cisplatin. Cancer Research, 2014, 74, 2246-2257.	0.4	61
912	Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro. Tumor Biology, 2014, 35, 10879-10890.	0.8	9
913	Activation of the MAPK11/12/13/14 (p38 MAPK) pathway regulates the transcription of autophagy genes in response to oxidative stress induced by a novel copper complex in HeLa cells. Autophagy, 2014, 10, 1285-1300.	4.3	82
914	Kinetics and mechanism of reactions of some essential amino acids with cis-diaqua(1,3-diaminopropane)-platinum(II) ion: a potent anticancer agent. Monatshefte für Chemie, 2014, 145, 1727-1735.	0.9	3
915	JWA reverses cisplatin resistance via the CK2- α -XRCC1 pathway in human gastric cancer cells. Cell Death and Disease, 2014, 5, e1551-e1551.	2.7	52
916	Microwave functionalized single-walled carbon nanotube as nanocarrier for the delivery of anticancer drug cisplatin: in vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology, 2014, 24, 572-578.	1.4	14
917	EGCG Enhances the Efficacy of Cisplatin by Downregulating hsa-miR-98-5p in NSCLC A549 Cells. Nutrition and Cancer, 2014, 66, 636-644.	0.9	78
918	Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts. International Journal of Molecular Sciences, 2014, 15, 19265-19280.	1.8	9
919	Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells. International Journal of Molecular Sciences, 2014, 15, 3403-3431.	1.8	155
920	Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?. Frontiers in Genetics, 2014, 5, 391.	1.1	26
921	Anticancer activities and mechanism of action of 2 novel metal complexes, C ₁₆ H ₃₄ N ₈ O ₅ Ag ₂ Cd and C ₁₁ H ₁₆ N ₇ O ₂ Ag ₃ Ni. Turkish Journal of Biology, 2014, 38, 948-955.	2.1	14
922	MRP1 and GSTp1 expression in non-small cell lung cancer does not correlate with clinicopathological parameters: A Slovakian population study. Acta Histochemica, 2014, 116, 1390-1398.	0.9	2

#	ARTICLE	IF	CITATIONS
923	FANCD2 is a target for caspase 3 during DNA damage-induced apoptosis. <i>FEBS Letters</i> , 2014, 588, 3778-3785.	1.3	13
924	β^2 -diketone-cobalt complexes inhibit DNA synthesis and induce S-phase arrest in rat C6 glioma cells. <i>Oncology Letters</i> , 2014, 7, 881-885.	0.8	10
925	Hypersensitivity reactions associated with oxaliplatin and their clinical management. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1545-1554.	1.0	8
926	Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems. <i>Frontiers in Oncology</i> , 2014, 4, 81.	1.3	12
927	Platinum Anticancer Drugs and Photochemotherapeutic Agents: Recent Advances and Future Developments. <i>Science Progress</i> , 2014, 97, 20-40.	1.0	68
929	Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 403-414.	1.5	17
930	Metal-based Drugs. <i>Science Progress</i> , 2014, 97, 1-19.	1.0	37
932	Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. <i>Cell Death and Disease</i> , 2014, 5, e1505-e1505.	2.7	106
933	Platinum Compounds for High-Resolution In Vivo Cancer Imaging. <i>ChemMedChem</i> , 2014, 9, 1131-1135.	1.6	49
934	A Light-Activated Metal Complex Targets both DNA and RNA in a Fluorescent in Vitro Transcription and Translation Assay. <i>ChemBioChem</i> , 2014, 15, 507-511.	1.3	16
935	Down-regulation of Ras-related Protein Rab 5C-dependent Endocytosis and Glycolysis in Cisplatin-resistant Ovarian Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3138-3151.	2.5	36
936	Nanoparticle mediated delivery of a GST inhibitor ethacrynic acid for sensitizing platinum based chemotherapy. <i>RSC Advances</i> , 2014, 4, 61124-61132.	1.7	17
937	<i>In vivo</i> anti-tumor activity of the organometallic ruthenium(II)-arene complex $[\text{Ru}(\text{f}^6\text{-p-cymene})\text{Cl}_2(\text{pta})]$ (RAPTA-C) in human ovarian and colorectal carcinomas. <i>Chemical Science</i> , 2014, 5, 4742-4748.	3.7	224
938	A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, $[\text{Pt}(\text{BDI}^{\text{QQ}})\text{Cl}]$. <i>Metallomics</i> , 2014, 6, 437-443.	1.0	36
939	DNA synthesis inhibitors for the treatment of gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2361-2372.	0.9	4
940	Modulation of ATR-mediated DNA damage checkpoint response by cryptochrome 1. <i>Nucleic Acids Research</i> , 2014, 42, 4427-4434.	6.5	65
941	Organotin(IV)-Loaded Mesoporous Silica as a Biocompatible Strategy in Cancer Treatment. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 5982-5987.	7.2	82
942	Optimizing the Electronic Properties of Photoactive Anticancer Oxypyridine-Bridged Dirhodium(II,II) Complexes. <i>Journal of the American Chemical Society</i> , 2014, 136, 17058-17070.	6.6	37

#	ARTICLE	IF	CITATIONS
943	Potent Anticancer Activity and Possible Low Toxicity of Platinum(II) Complexes with Functionalized 1,1â€¢Cyclobutanedicarboxylate as a Leaving Ligand. <i>Chemistry - A European Journal</i> , 2014, 20, 15216-15225.	1.7	34
944	Redesigning the DNAâ€¢Targeted Chromophore in Platinumâ€¢Acridine Anticancer Agents: A Structureâ€¢Activity Relationship Study. <i>Chemistry - A European Journal</i> , 2014, 20, 16174-16187.	1.7	43
945	Cisplatin exposure damages resident stem cells of the mammalian inner Ear. <i>Developmental Dynamics</i> , 2014, 243, 1328-1337.	0.8	24
946	Different affinity of nuclear factorâ€¢kappa B proteins to <scp>DNA</scp> modified by antitumor cisplatin and its clinically ineffective <i>trans</i> isomer. <i>FEBS Journal</i> , 2014, 281, 1393-1408.	2.2	16
947	Rational Design of Polyion Complex Nanoparticles to Overcome Cisplatin Resistance in Cancer Therapy. <i>Advanced Materials</i> , 2014, 26, 931-936.	11.1	134
948	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 415-422.	0.6	38
949	Response to: â€¢Deceptive argumentation against diagnostic microdosing of anticancer drugsâ€¢ by Dirk Theile and Gerd Mikus (Letter dated February 13, 2014). <i>International Journal of Cancer</i> , 2014, 135, 1751-1752.	2.3	0
950	Synthesis and <i>in vitro</i> activity of platinum containing 2-oxazoline-based glycopolymers. <i>Journal of Polymer Science Part A</i> , 2014, 52, 2703-2714.	2.5	12
951	Photoinduced Reduction of PtIV within an Anti-Proliferative PtIV-Texaphyrin Conjugate. <i>Chemistry - A European Journal</i> , 2014, 20, n/a-n/a.	1.7	17
952	Structural Biology of Cisplatin Complexes with Cellular Targets: The Adduct with Human Copper Chaperone Atox1 in Aqueous Solution. <i>Chemistry - A European Journal</i> , 2014, 20, 11719-11725.	1.7	14
953	Organometallic Titanoceneâ€¢Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties. <i>Organometallics</i> , 2014, 33, 6669-6681.	1.1	63
954	Efficacy of Different Sequences of Radioâ€¢and Chemotherapy in Experimental Models of Human Melanoma. <i>Journal of Cellular Physiology</i> , 2014, 229, 1548-1556.	2.0	8
955	Clinical translational challenges in nanomedicine. <i>MRS Bulletin</i> , 2014, 39, 259-264.	1.7	16
956	Synergistic Therapeutic Effect of Cisplatin and Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Cancer Growth and Metastasis of Brca1 Mutant Tumors. <i>Journal of Biological Chemistry</i> , 2014, 289, 24202-24214.	1.6	21
957	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. <i>Oncolmmunology</i> , 2014, 3, e955685.	2.1	16
958	Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [18F] FDG PET-CT. <i>Oncology Reports</i> , 2014, 31, 2007-2014.	1.2	4
959	Palladium(II) Complexes Containing Mixed Nitrogen-Sulphur Donor Ligands: Interaction of [Pd(Methionine Methyl Ester)(H2O)2]2+ with Biorelevant Ligands. <i>Bioinorganic Chemistry and Applications</i> , 2014, 2014, 1-8.	1.8	4
960	Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors. <i>Nanomedicine</i> , 2014, 9, 1939-1955.	1.7	43

#	ARTICLE	IF	CITATIONS
961	Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and Desensitization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 40-45.	2.0	65
962	Prognostic significance of the estrogen receptor beta (ER β) isoforms ER β 1, ER β 2, and ER β 5 in advanced serous ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 351-359.	0.6	55
963	A Small Molecule Screen Identifies an Inhibitor of DNA Repair Inducing the Degradation of TFIID and the Chemosensitization of Tumor Cells to Platinum. <i>Chemistry and Biology</i> , 2014, 21, 398-407.	6.2	72
964	Synthesis and in vitro characterization of platinum(II) anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method for new compound discovery. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3527-3536.	1.4	11
965	Gelatin-encapsulated iron oxide nanoparticles for platinum (IV) prodrug delivery, enzyme-stimulated release and MRI. <i>Biomaterials</i> , 2014, 35, 6359-6368.	5.7	111
966	Assessing the intracellular concentration of platinum in medulloblastoma cell lines after Cisplatin incubation. <i>Journal of Trace Elements in Medicine and Biology</i> , 2014, 28, 166-172.	1.5	9
967	Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo. <i>Cancer Letters</i> , 2014, 343, 200-209.	3.2	27
968	Pharmacological Modulation of Cytotoxicity and Cellular Uptake of Anti-cancer Drugs by PDE5 Inhibitors in Lung Cancer Cells. <i>Pharmaceutical Research</i> , 2014, 31, 86-96.	1.7	30
969	Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. <i>Journal of Biological Inorganic Chemistry</i> , 2014, 19, 17-27.	1.1	21
970	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 295-307.	2.7	5
971	Thiosemicarbazone Cu(II) and Zn(II) complexes as potential anticancer agents: Syntheses, crystal structure, DNA cleavage, cytotoxicity and apoptosis induction activity. <i>Journal of Inorganic Biochemistry</i> , 2014, 136, 13-23.	1.5	76
972	4-Aminobenzoic Acid-Coated Maghemite Nanoparticles as Potential Anticancer Drug Magnetic Carriers: A Case Study on Highly Cytotoxic Cisplatin-Like Complexes Involving 7-Azaindoles. <i>Molecules</i> , 2014, 19, 1622-1634.	1.7	10
973	Conjugation of vitamin E analog α -TOS to Pt(IV) complexes for dual-targeting anticancer therapy. <i>Chemical Communications</i> , 2014, 50, 2465.	2.2	94
974	Square Planar Platinum(II) Complexes with N,S-Donor Ligands: Synthesis, Characterisation, DNA Interaction and Cytotoxic Activity. <i>Applied Biochemistry and Biotechnology</i> , 2014, 172, 1846-1858.	1.4	7
975	Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors. <i>Radiation Oncology</i> , 2014, 9, 25.	1.2	26
976	Metal-based anticancer chemotherapeutic agents. <i>Current Opinion in Chemical Biology</i> , 2014, 19, 144-153.	2.8	438
977	The Potent Oxidant Anticancer Activity of Organoiridium Catalysts. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 3941-3946.	7.2	283
978	Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: Synthesis, characterisation and preliminary evaluation of biological activity. <i>European Journal of Medicinal Chemistry</i> , 2014, 77, 110-120.	2.6	21

#	ARTICLE	IF	CITATIONS
979	InÂvitro cytotoxicity studies of palladacyclic complexes containing the symmetric diphosphine bridging ligand. Studies of their interactions with DNA and BSA. <i>European Journal of Medicinal Chemistry</i> , 2014, 73, 8-17.	2.6	69
980	Zinc (II) complex with a cationic Schiff base ligand: Synthesis, characterization, and biological studies. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2014, 121, 101-108.	2.0	17
981	Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine. <i>European Journal of Medicinal Chemistry</i> , 2014, 78, 54-64.	2.6	10
982	Biological evaluation of bismuth non-steroidal anti-inflammatory drugs (BiNSAIDs): Stability, toxicity and uptake in HCT-8 colon cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2014, 135, 28-39.	1.5	16
983	DNA fastening and ripping actions of novel Knoevenagel condensed dicarboxylic acid complexes in antitumor journey. <i>European Journal of Medicinal Chemistry</i> , 2014, 80, 57-70.	2.6	25
984	Synthesis, characterization of ruthenium(II) complex of 1,3,8-trihydroxy-6-methyl-anthraquinone (emodin) and its binding behavior with c-myc G-quadruplex. <i>Inorganica Chimica Acta</i> , 2014, 418, 23-29.	1.2	9
985	Selenium partially prevents cisplatin-induced neurotoxicity: A preliminary study. <i>NeuroToxicology</i> , 2014, 42, 71-75.	1.4	21
986	Nanotube-mediated efficiency of cisplatin anticancer therapy. <i>Carbon</i> , 2014, 70, 46-58.	5.4	22
987	Synthesis, crystal structure and antiproliferative activity of Cu(II) nalidixic acidâ€“DACH conjugate: Comparative inÂvitro DNA/RNA binding profile, cleavage activity and molecular docking studies. <i>European Journal of Medicinal Chemistry</i> , 2014, 81, 76-88.	2.6	55
990	Evaluation of DNA Binding, Protein Interaction, and Cytotoxic Activity of a Mononuclear Copper(II) Complex. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2014, 640, 1506-1513.	0.6	8
991	Palladium(II) and platinum(II) oxamate complexes as potential anticancer agents: Structural characterization and cytotoxic activity. <i>Polyhedron</i> , 2014, 76, 16-21.	1.0	30
992	Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes. <i>Cancer Research</i> , 2014, 74, 3913-3922.	0.4	277
993	Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. <i>Clinical Cancer Research</i> , 2014, 20, 2831-2837.	3.2	349
994	Ligand substitutions between rutheniumâ€“cymene compounds can control protein versus DNA targeting and anticancer activity. <i>Nature Communications</i> , 2014, 5, 3462.	5.8	257
995	Copper compounds in nuclear medicine and oncology. <i>Journal of Coordination Chemistry</i> , 2014, 67, 1493-1519.	0.8	37
996	Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. <i>Pharmacogenomics</i> , 2014, 15, 329-337.	0.6	49
997	Phenanthroline ligands are biologically more active than their corresponding ruthenium(II) arene complexes. <i>Dalton Transactions</i> , 2014, 43, 2629-2645.	1.6	34
998	Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin. <i>Metallomics</i> , 2014, 6, 126-131.	1.0	20

#	ARTICLE	IF	CITATIONS
999	The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer. <i>Pharmacological Reviews</i> , 2014, 66, 222-307.	7.1	418
1000	Guanidine platinum(II) complexes: synthesis, in vitro antitumor activity, and DNA interactions. <i>Journal of Inorganic Biochemistry</i> , 2014, 133, 33-39.	1.5	32
1001	Predicting distant metastasis and chemoresistance using plasma miRNAs. <i>Medical Oncology</i> , 2014, 31, 799.	1.2	62
1002	2,3-Dihydroimidazo[1,2-b]ferroceno[d]pyridazines and a 3,4-dihydro-2H-pyrimido[1,2-b]ferroceno[d]pyridazine: Synthesis, structure and in vitro antiproliferation activity on selected human cancer cell lines. <i>Journal of Organometallic Chemistry</i> , 2014, 750, 41-48.	0.8	17
1003	Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells. <i>Lasers in Medical Science</i> , 2014, 29, 995-1007.	1.0	13
1004	Ligation of anti-cancer drugs to self-assembling ultrashort peptides by click chemistry for localized therapy. <i>Chemical Science</i> , 2014, 5, 625-630.	3.7	54
1005	Photo-Inducible Crosslinked Nanoassemblies for pH-Controlled Drug Release. <i>Pharmaceutical Research</i> , 2014, 31, 1254-1263.	1.7	8
1006	Synthesis, Structure, and Antiproliferative Activity of Ruthenium(II) Arene Complexes with N,O-Chelating Pyrazolone-Based β^2 -Ketoamine Ligands. <i>Inorganic Chemistry</i> , 2014, 53, 13105-13111.	1.9	50
1007	The role of DNA repair pathways in cisplatin resistant lung cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 1161-1170.	3.4	114
1008	Design, synthesis and comparative cytotoxic investigation of platinum(II) complexes with some derivatives of 5-methyl-5-(4-pyridyl)hydantoin. <i>Inorganica Chimica Acta</i> , 2014, 423, 46-51.	1.2	7
1009	Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. <i>International Journal of Cancer</i> , 2014, 134, 1796-1809.	2.3	28
1010	Characterization of the antiproliferative potential and biological targets of a trans ketoimine platinum complex. <i>Inorganica Chimica Acta</i> , 2014, 423, 156-167.	1.2	10
1011	A mitochondrion-targeting copper complex exhibits potent cytotoxicity against cisplatin-resistant tumor cells through multiple mechanisms of action. <i>Chemical Science</i> , 2014, 5, 2761-2770.	3.7	108
1012	Enhanced drug toxicity by conjugation of platinum drugs to polymers with guanidine containing zwitterionic functional groups that mimic cell-penetrating peptides. <i>Polymer Chemistry</i> , 2014, 5, 6600-6610.	1.9	15
1013	A site-selective, irreversible inhibitor of the DNA replication auxiliary factor proliferating cell nuclear antigen (PCNA). <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6333-6343.	1.4	19
1014	Dinuclear zinc complexes containing (benzimidazol-2-yl)benzene that overcome drug resistance in hepatocellular carcinoma cells through induction of mitochondria fragmentation. <i>Dalton Transactions</i> , 2014, 43, 6973-6976.	1.6	16
1015	Enzyme-triggered supramolecular self-assembly of platinum prodrug with enhanced tumor-selective accumulation and reduced systemic toxicity. <i>Journal of Materials Chemistry B</i> , 2014, 2, 8303-8309.	2.9	40
1016	Platination of the copper transporter ATP7A involved in anticancer drug resistance. <i>Dalton Transactions</i> , 2014, 43, 12085.	1.6	29

#	ARTICLE	IF	CITATIONS
1017	Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents. <i>Inorganic Chemistry Frontiers</i> , 2014, 1, 231-241.	3.0	41
1018	Systems biology of cisplatin resistance: past, present and future. <i>Cell Death and Disease</i> , 2014, 5, e1257-e1257.	2.7	625
1019	Synthesis and characterization of two novel dicyanidoargentate(Ag^{I}) complexes containing N-(2-hydroxyethyl)ethylenediamine exhibiting significant biological activity. <i>New Journal of Chemistry</i> , 2014, 38, 4760-4773.	1.4	25
1020	Undecylprodigiosin conjugated monodisperse gold nanoparticles efficiently cause apoptosis in colon cancer cells in vitro. <i>Journal of Materials Chemistry B</i> , 2014, 2, 3271-3281.	2.9	10
1021	Synthesis of novel platinum complex core as a selective $\text{Ag}^{\text{+}}$ sensor and its H-bonded tetrads self-assembled with triarylamine dendrimers for electron/energy transfers. <i>Journal of Materials Chemistry A</i> , 2014, 2, 17463-17476.	5.2	17
1022	Kinetic and mechanistic studies of 1,3-bis(2-pyridylimino)isoindolate Pt^{II} derivatives. Experimental and new computational approach. <i>Dalton Transactions</i> , 2014, 43, 2549-2558.	1.6	25
1023	Ligand substitution reaction on a platinum(Pt^{II}) complex with bio-relevant thiols: kinetics, mechanism and bioactivity in aqueous medium. <i>RSC Advances</i> , 2014, 4, 43516-43524.	1.7	17
1024	The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme. <i>Chemical Communications</i> , 2014, 50, 8360.	2.2	40
1025	Design and Biological Evaluation of New Platinum(II) Complexes Bearing Ligands with DNA-Targeting Ability. <i>Inorganic Chemistry</i> , 2014, 53, 12627-12634.	1.9	25
1026	Metabolic Markers of MG-63 Osteosarcoma Cell Line Response to Doxorubicin and Methotrexate Treatment: Comparison to Cisplatin. <i>Journal of Proteome Research</i> , 2014, 13, 6033-6045.	1.8	33
1027	Synthesis, characterization and biological evaluation of cationic hydrazone copper complexes with diverse diimine co-ligands. <i>RSC Advances</i> , 2014, 4, 61232-61247.	1.7	26
1028	Monofunctional Platinum(II) Complexes with Potent Tumor Cell Growth Inhibitory Activity: The Effect of a Hydrogen-Bond Donor/Acceptor N^{H} -Heterocyclic Ligand. <i>ChemMedChem</i> , 2014, 9, 1161-1168.	1.6	17
1029	Formation of glutathione sulfenate and sulfinate complexes by an organoiridium(Ir^{III}) anticancer complex. <i>Inorganic Chemistry Frontiers</i> , 2014, 1, 668-672.	3.0	13
1030	Cisplatin-induced duplex dissociation of complementary and destabilized short GG-containing duplex RNAs. <i>Dalton Transactions</i> , 2014, 43, 11941-11949.	1.6	13
1031	Coordination-triggered NO release from a dinitrosyl iron complex leads to anti-inflammatory activity. <i>Chemical Science</i> , 2014, 5, 2374-2378.	3.7	25
1032	Gold(III) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 gene. <i>Chemical Science</i> , 2014, 5, 1579.	3.7	61
1033	Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 17163-17173.	1.6	214
1034	Complementarity of MALDI and LA ICP mass spectrometry for platinum anticancer imaging in human tumor. <i>Metallomics</i> , 2014, 6, 1382-1386.	1.0	63

#	ARTICLE	IF	CITATIONS
1035	Selenium substitution endows cystine with radiosensitization activity against cervical cancer cells. RSC Advances, 2014, 4, 34210-34216.	1.7	17
1036	pH dependent catalytic activities of platinum nanoparticles with respect to the decomposition of hydrogen peroxide and scavenging of superoxide and singlet oxygen. Nanoscale, 2014, 6, 11904-11910.	2.8	171
1037	Transition metal complexes with oligopeptides: single crystals and crystal structures. Dalton Transactions, 2014, 43, 9821-9833.	1.6	17
1038	Potential of Cycloaddition Reactions To Generate Cytotoxic Metal Drugs In Vitro. Inorganic Chemistry, 2014, 53, 9315-9321.	1.9	19
1039	Novel in situ methodology to observe the interactions of chemotherapeutic Pt drugs with DNA under physiological conditions. Dalton Transactions, 2014, 43, 13839-13844.	1.6	18
1040	Subcellular Localization and Transport Kinetics of Ruthenium Organometallic Anticancer Compounds in Living Cells: A Dose-Dependent Role for Amino Acid and Iron Transporters. Inorganic Chemistry, 2014, 53, 5150-5158.	1.9	45
1041	Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro. Metallomics, 2014, 6, 2034-2041.	1.0	23
1042	Effects of Monofunctional Platinum Agents on Bacterial Growth: A Retrospective Study. Journal of the American Chemical Society, 2014, 136, 116-118.	6.6	80
1043	Nano Regulation of Cisplatin Chemotherapeutic Behaviors by Biomineralization Controls. Small, 2014, 10, 3644-3649.	5.2	21
1044	Investigation of diorganotin(IV) complexes: Synthesis, characterization, in vitro DNA binding studies and cytotoxicity assessment of di-n-butyltin(IV) complex. Inorganica Chimica Acta, 2014, 423, 204-214.	1.2	18
1045	Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery. Molecular Therapy, 2014, 22, 964-973.	3.7	52
1046	Nanoscale Metal-Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells. Journal of the American Chemical Society, 2014, 136, 5181-5184.	6.6	759
1047	Raman and Infrared Spectroscopy, DFT Calculations, and Vibrational Assignment of the Anticancer Agent Picoplatin: Performance of Long-Range Corrected/Hybrid Functionals for a Platinum(II) Complex. Journal of Physical Chemistry A, 2014, 118, 6922-6934.	1.1	25
1048	Inhibition of Na ⁺ /K ⁺ -ATPase and cytotoxicity of a few selected gold(III) complexes. Journal of Inorganic Biochemistry, 2014, 140, 228-235.	1.5	11
1049	A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells. Biomedicine and Pharmacotherapy, 2014, 68, 1049-1056.	2.5	12
1050	Phosphate Diester Cleavage, DNA Interaction and Cytotoxic Activity of a Bimetallic Bis(1,4,7-triazacyclononane) Zinc Complex. European Journal of Inorganic Chemistry, 2014, 2014, 4084-4092.	1.0	19
1052	PEGylated dendritic diaminocyclohexyl-platinum (II) conjugates as pH-responsive drug delivery vehicles with enhanced tumor accumulation and antitumor efficacy. Biomaterials, 2014, 35, 10080-10092.	5.7	81
1053	Synthesis and crystal structure determination of copper(II)-complex: In vitro DNA and HSA binding, pBR322 plasmid cleavage, cell imaging and cytotoxic studies. European Journal of Medicinal Chemistry, 2014, 83, 141-154.	2.6	56

#	ARTICLE	IF	CITATIONS
1054	Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. <i>Journal of Inorganic Biochemistry</i> , 2014, 141, 79-82.	1.5	27
1055	Synthesis and Evaluation of Glycopolymeric Decorated Gold Nanoparticles Functionalized with Gold-Triphenyl Phosphine as Anti-Cancer Agents. <i>Biomacromolecules</i> , 2014, 15, 3802-3810.	2.6	48
1056	Labelling Herceptin with a novel oxaliplatin derivative: a computational approach towards the selective drug delivery. <i>Journal of Molecular Modeling</i> , 2014, 20, 2401.	0.8	24
1058	Synthesis, spectroscopic characterization, X-ray structure and electrochemistry of new bis(1,2-diaminocyclohexane)gold(III) chloride compounds and their anticancer activities against PC3 and SGC7901 cancer cell lines. <i>New Journal of Chemistry</i> , 2014, 38, 3199-3211.	1.4	15
1059	Synthesis, spectroscopic characterization and density functional studies of a bis-benzimidazole derivative and of its complexes with palladium(II) halides. <i>Comptes Rendus Chimie</i> , 2014, 17, 905-912.	0.2	9
1060	Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamate complexes. <i>International Journal of Pharmaceutics</i> , 2014, 473, 194-202.	2.6	28
1061	Synthesis and properties of a new micellar polyphosphazene-platinum(II) conjugate drug. <i>Journal of Inorganic Biochemistry</i> , 2014, 140, 45-52.	1.5	19
1062	Exploration of glycosylated-organotin(IV) complexes as anticancer drug candidates. <i>Inorganica Chimica Acta</i> , 2014, 423, 38-45.	1.2	15
1063	Synthesis and antiproliferative activity of (1 <i>R</i> ,2 <i>R</i>)- <i>N</i> ¹ -(2-butyl)-1,2-cyclohexanediamine platinum(II) complexes with malonate derivatives. <i>Journal of Coordination Chemistry</i> , 2014, 67, 2858-2866.	0.8	13
1064	Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma. <i>Nanoscale</i> , 2014, 6, 10865-10873.	2.8	111
1065	Platinum-RNA Modifications Following Drug Treatment in <i>S. cerevisiae</i> Identified by Click Chemistry and Enzymatic Mapping. <i>ACS Chemical Biology</i> , 2014, 9, 2404-2411.	1.6	49
1066	Preparation, characterisation and bioactivity evaluation of the inclusion complex formed between picoplatin and β -cyclodextrin. <i>Carbohydrate Research</i> , 2014, 396, 54-61.	1.1	17
1067	The Chiral Potential of Phenanthriplatin and Its Influence on Guanine Binding. <i>Journal of the American Chemical Society</i> , 2014, 136, 2126-2134.	6.6	66
1068	Cisplatin in cancer therapy: Molecular mechanisms of action. <i>European Journal of Pharmacology</i> , 2014, 740, 364-378.	1.7	3,667
1069	Antitumor platinum(II) complexes of N-monoalkyl 1 <i>R</i> ,2 <i>R</i> -diamino-cyclohexanes with 3-(nitrooxy)cyclobutane-1,1-dicarboxylate as a leaving group. <i>European Journal of Medicinal Chemistry</i> , 2014, 85, 408-417.	2.6	11
1070	Synthesis, anticancer activity and toxicity of a water-soluble 4 <i>S</i> ,5 <i>S</i> -derivative of heptaplatin, cis-[Pt(II)[(4 <i>S</i> ,5 <i>S</i>)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]·(3-hydroxyl-cyclobutane-1,1-dicarboxylate)}. <i>Journal of Inorganic Biochemistry</i> , 2014, 140, 126-130.	1.5	11
1071	Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C ^N -Chelated and Pyridine Ligands. <i>Organometallics</i> , 2014, 33, 5324-5333.	1.1	109
1072	Metallomics insights into the programmed cell death induced by metal-based anticancer compounds. <i>Metallomics</i> , 2014, 6, 978.	1.0	95

#	ARTICLE	IF	CITATIONS
1073	Potential apoptosis inducing agents based on a new benzimidazole schiff base ligand and its dicopper(II) complex. RSC Advances, 2014, 4, 41228-41236.	1.7	38
1074	A Breast Cancer Stem Cell-Selective, Mammospheres-Potent Osmium(VI) Nitrido Complex. Journal of the American Chemical Society, 2014, 136, 14413-14416.	6.6	88
1075	3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction. BMC Cancer, 2014, 14, 562.	1.1	7
1076	Methylene bridge regulated geometrical preferences of ligands in cobalt(III) coordination chemistry and phenoxazinone synthase mimicking activity. Dalton Transactions, 2014, 43, 5443.	1.6	90
1077	Mixed ligand copper(II) complexes of 2,9-dimethyl-1,10-phenanthroline: Tridentate 3N primary ligands determine DNA binding and cleavage and cytotoxicity. Journal of Inorganic Biochemistry, 2014, 140, 202-212.	1.5	74
1078	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. Journal of Medicinal Chemistry, 2014, 57, 6751-6764.	2.9	49
1080	Young Researcher Presentations. Journal of Biological Inorganic Chemistry, 2014, 19, 765-772.	1.1	3
1081	Substitution Reaction of the Hydroxopentaquaquarhodium(III) Ion with L-Glutamine, Glycine and L-Histidine in Aqueous Medium: A Kinetic and Mechanistic Approach. Journal of Solution Chemistry, 2014, 43, 1205-1217.	0.6	0
1082	Strategy to enhance the anticancer efficacy of X-ray radiotherapy in melanoma cells by platinum complexes, the role of ROS-mediated signaling pathways. Cancer Letters, 2014, 354, 58-67.	3.2	38
1083	Dinuclear Cu ^I complexes of pyridyl-diazadiphosphetidines and aminobis(phosphonite) ligands: synthesis, structural studies and antiproliferative activity towards human cervical, colon carcinoma and breast cancer cells. Dalton Transactions, 2014, 43, 11339-11351.	1.6	23
1084	Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration. Experimental Brain Research, 2014, 232, 2685-2697.	0.7	14
1085	Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemotherapy and Pharmacology, 2014, 73, 1021-1029.	1.1	14
1086	Characterising the atypical 5'-CG DNA sequence specificity of 9-aminoacridine carboxamide Pt complexes. Journal of Biological Inorganic Chemistry, 2014, 19, 997-1007.	1.1	10
1087	The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549). BioMetals, 2014, 27, 459-469.	1.8	14
1088	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Investigational New Drugs, 2014, 32, 465-472.	1.2	31
1089	Caprylate-Conjugated Cisplatin for the Development of Novel Liposomal Formulation. AAPS PharmSciTech, 2014, 15, 845-857.	1.5	34
1090	Emission solvatochromic behavior of a pentacoordinated Zn(II) complex: A viable tool for studying the metaldrug-protein interaction. Journal of Luminescence, 2014, 151, 138-142.	1.5	9
1091	Neuropilin-1-Targeted Gold Nanoparticles Enhance Therapeutic Efficacy of Platinum(IV) Drug for Prostate Cancer Treatment. ACS Nano, 2014, 8, 4205-4220.	7.3	146

#	ARTICLE	IF	CITATIONS
1092	A comprehensive biological insight of trinuclear copper(Cu_3)-tin(Sn) chemotherapeutic anticancer drug entity: in vitro cytotoxicity and in vivo systemic toxicity studies. <i>Metallomics</i> , 2014, 6, 1469.	1.0	21
1093	Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 408-415.	0.9	26
1094	Targeted Theranostic Platinum(IV) Prodrug with a Built-In Aggregation-Induced Emission Light-Up Apoptosis Sensor for Noninvasive Early Evaluation of Its Therapeutic Responses in Situ. <i>Journal of the American Chemical Society</i> , 2014, 136, 2546-2554.	6.6	439
1095	Guanidine Complexes of Platinum: A Theoretical Study. <i>Journal of Physical Chemistry A</i> , 2014, 118, 5540-5547.	1.1	4
1096	Structural and mechanistic studies of polymerase γ bypass of phenanthriplatin DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9133-9138.	3.3	55
1097	Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery. <i>Journal of the American Chemical Society</i> , 2014, 136, 8790-8798.	6.6	362
1098	A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. <i>Nature Chemical Biology</i> , 2014, 10, 298-304.	3.9	211
1099	Genetic markers for prediction of treatment outcomes in ovarian cancer. <i>Pharmacogenomics Journal</i> , 2014, 14, 401-410.	0.9	16
1100	Discovery and Investigation of Anticancer Ruthenium-Arene Schiff-Base Complexes via Water-Promoted Combinatorial Three-Component Assembly. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6043-6059.	2.9	126
1101	Detailed mechanistic study on ligand substitution reactions in dinuclear platinum(II) complexes: effect of alkanediamine linker. <i>Transition Metal Chemistry</i> , 2014, 39, 407-420.	0.7	11
1102	The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. <i>Tumor Biology</i> , 2014, 35, 8259-8265.	0.8	18
1103	Mass Spectrometric Strategies to Improve the Identification of Pt(II)-Modification Sites on Peptides and Proteins. <i>Journal of the American Society for Mass Spectrometry</i> , 2014, 25, 1217-1227.	1.2	32
1104	Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(Pt) prodrugs. <i>Chemical Science</i> , 2014, 5, 2265-2270.	3.7	70
1105	Photophysical properties and in vitro cytotoxicity studies of new Ru(Ru) carbonyl complexes and mixed geometrical Ru(Ru)-Ni(Ni) complex in HS-DNA/BSA protein and human lung (A549) and liver (HepG2) cells. <i>RSC Advances</i> , 2014, 4, 51850-51864.	1.7	22
1106	Cytotoxicity Studies of Cyclometallated Ruthenium(II) Compounds: New Applications for Ruthenium Dyes. <i>Organometallics</i> , 2014, 33, 1100-1103.	1.1	93
1107	Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. <i>Metallomics</i> , 2014, 6, 1324-1335.	1.0	170
1108	Cisplatin Intrastrand Adducts Sensitize DNA to Base Damage by Hydrated Electrons. <i>Journal of Physical Chemistry B</i> , 2014, 118, 4803-4808.	1.2	24
1109	Nuclease activity and protein-binding properties of a novel tetranuclear thiosemicarbazide Pt(Pt) complex. <i>Dalton Transactions</i> , 2014, 43, 1663-1671.	1.6	21

#	ARTICLE	IF	CITATIONS
1110	Anticancer Ruthenium(η^6 -p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives. <i>Organometallics</i> , 2014, 33, 5546-5553.	1.1	82
1111	PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2014, 111, 1757-1764.	2.9	53
1112	Interaction of electrons with cisplatin and the subsequent effect on DNA damage: a density functional theory study. <i>Physical Chemistry Chemical Physics</i> , 2014, 16, 19290.	1.3	14
1113	Near-Infrared Light-Mediated Photoactivation of a Platinum Antitumor Prodrug and Simultaneous Cellular Apoptosis Imaging by Upconversion Luminescent Nanoparticles. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 1012-1016.	7.2	274
1114	Synthesis, Characterization, and in vitro Antiproliferative Activity of [Salophene]platinum(II) Complexes. <i>ChemMedChem</i> , 2014, 9, 1176-1187.	1.6	14
1115	Encapsulation in Nanoparticles Improves Anti-cancer Efficacy of Carboplatin. <i>AAPS PharmSciTech</i> , 2014, 15, 1029-1038.	1.5	39
1116	A new platinum complex with tryptophan: Synthesis, structural characterization, DFT studies and biological assays in vitro over human tumorigenic cells. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2014, 122, 209-215.	2.0	10
1117	The crystal structure of oxaliplatin: A case of overlooked pseudo symmetry. <i>Polyhedron</i> , 2014, 67, 429-435.	1.0	21
1118	TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 752-757.	0.6	32
1119	Cisplatin-induced alterations in the functional spermatogonial stem cell pool and niche in C57/BL/6 mice following a clinically relevant multi-cycle exposure. <i>Toxicology Letters</i> , 2014, 227, 99-112.	0.4	22
1120	Non-DSB clustered DNA lesions induced by ionizing radiation are largely responsible for the loss of plasmid DNA functionality in the presence of cisplatin. <i>Chemico-Biological Interactions</i> , 2014, 217, 9-18.	1.7	16
1121	Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. <i>Free Radical Biology and Medicine</i> , 2014, 70, 68-77.	1.3	62
1122	Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc. <i>Journal of Proteomics</i> , 2014, 103, 103-120.	1.2	37
1123	Synthesis, characterization and cytotoxicity of novel Pt(II) η^2 -O ₂ O ₂ -acetylacetonate complexes with nitrogen ligands. <i>Inorganica Chimica Acta</i> , 2014, 412, 88-93.	1.2	5
1124	Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 97-104.	0.4	245
1125	Assessment of new DFT methods for predicting vibrational spectra and structure of cisplatin: Which density functional should we choose for studying platinum(II) complexes?. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2014, 125, 431-439.	2.0	38
1126	Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 6752-6756.	7.2	104
1127	Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. <i>Nature Communications</i> , 2014, 5, 4182.	5.8	205

#	ARTICLE	IF	CITATIONS
1128	Development of anticancer agents: wizardry with osmium. <i>Drug Discovery Today</i> , 2014, 19, 1640-1648.	3.2	139
1129	Cytotoxicity and enzyme inhibition studies of polyoxometalates and their chitosan nanoassemblies. <i>Toxicology Reports</i> , 2014, 1, 341-352.	1.6	61
1130	Ruthenium(II) polypyridyl complexes: Cellular uptake, cell image and apoptosis of HeLa cancer cells induced by double targets. <i>European Journal of Medicinal Chemistry</i> , 2014, 82, 82-95.	2.6	55
1132	Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment. <i>Progress in Polymer Science</i> , 2014, 39, 1614-1643.	11.8	97
1133	Synthesis, characterization and in vitro antitumor activity of new palladium(II) complexes with (S,S)-R2edda-type esters. <i>Polyhedron</i> , 2014, 80, 106-111.	1.0	17
1134	KIN enhances stem cell-like properties to promote chemoresistance in colorectal carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2014, 448, 63-69.	1.0	4
1135	Fe ²⁺ -salphen complexes from intracellular pH-triggered degradation of Fe ₃ O ₄ @Salphen-InIII CPPs for selectively killing cancer cells. <i>Biomaterials</i> , 2014, 35, 1676-1685.	5.7	28
1136	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. <i>Oncogene</i> , 2014, 33, 378-386.	2.6	188
1137	Non-specificity and synergy at the binding site of the carboplatin-induced DNA adduct via molecular dynamics simulations of the MutS α -DNA recognition complex. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 969-992.	2.0	15
1138	p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. <i>International Journal of Oncology</i> , 2014, 45, 2341-2348.	1.4	63
1140	Curcuma Longa (Curcumin) Decreases In Vivo Cisplatin-Induced Ototoxicity Through Heme Oxygenase-1 Induction. <i>Otology and Neurotology</i> , 2014, 35, e169-e177.	0.7	54
1141	The effects of MOTILIPERM on cisplatin induced testicular toxicity in Sprague-Dawley rats. <i>Cancer Cell International</i> , 2015, 15, 121.	1.8	30
1142	Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms. <i>Molecular Medicine Reports</i> , 2015, 12, 7374-7388.	1.1	16
1143	The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line. <i>Oncology Letters</i> , 2015, 10, 3081-3086.	0.8	7
1144	Platinum-based anticancer therapeutics and their mechanistic aspects: An overview. , 2015, , 419-432.		0
1145	Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P ₂ -based anti-cancer drugs. <i>EMBO Journal</i> , 2015, 34, 2993-3008.	3.5	209
1146	Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. <i>Scientific Reports</i> , 2014, 4, 6370.	1.6	103
1147	VRAC s swallow platinum drugs. <i>EMBO Journal</i> , 2015, 34, 2985-2987.	3.5	8

#	ARTICLE	IF	CITATIONS
1148	Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 41-49.	4.9	21
1149	The conformation effect of the diamine bridge on the stability of dinuclear platinum(II) complexes and their hydrolysis. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 61, 290-296.	1.3	6
1150	Conditions Favoring the Formation of Monomeric Pt ^{III} Derivatives in the Electrochemical Oxidation of <i>trans</i> -[Pt ^{II} {(p) <i>trans</i> -BrC ₆ F ₄)}NCH ₂ CH ₂ NEt ₂]O. <i>ChemElectroChem</i> , 2015, 2, 1048-1061.	1.7	7
1151	A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin. <i>Chemistry - A European Journal</i> , 2015, 21, 18474-18486.	1.7	27
1152	Combination of two-dimensional gel electrophoresis and a fluorescent carboxyfluorescein diacetate labeled cisplatin analogue allows the identification of intracellular cisplatin-protein adducts. <i>Electrophoresis</i> , 2015, 36, 2811-2819.	1.3	13
1153	Synthesis and Analysis of the Structure, Diffusion and Cytotoxicity of Heterocyclic Platinum(IV) Complexes. <i>Chemistry - A European Journal</i> , 2015, 21, 16990-17001.	1.7	28
1154	Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin. <i>Chemistry - A European Journal</i> , 2015, 21, 16547-16554.	1.7	50
1155	Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidin-Platinum(II) Complex. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 7550-7556.	1.2	6
1156	Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy. <i>Medicinal Research Reviews</i> , 2015, 35, 1268-1299.	5.0	84
1157	Consolidation of proteomics data in the Cancer Proteomics database. <i>Proteomics</i> , 2015, 15, 3765-3771.	1.3	16
1158	Novel antitumor dinuclear platinum (II) complexes with a new chiral tetradentate ligand as the carrier group. <i>Applied Organometallic Chemistry</i> , 2015, 29, 481-486.	1.7	5
1159	Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents. <i>Journal of Cancer Science & Therapy</i> , 2015, 07, 121-126.	1.7	9
1160	Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model. <i>International Journal of Nanomedicine</i> , 2015, 10, 2847.	3.3	12
1161	Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2887.	2.0	20
1162	FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway. <i>Neoplasia</i> , 2015, 62, 61-71.	0.7	24
1163	Cell death in cancer therapy of lung adenocarcinoma. <i>International Journal of Developmental Biology</i> , 2015, 59, 119-129.	0.3	21
1164	Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 13255-13268.	0.8	48
1165	Prediction of Protein-Ligand Binding Sites for Cisplatin and Transplatin based on Hydrogen Bonds. <i>Journal of Proteomics and Bioinformatics</i> , 2015, 8, .	0.4	0

#	ARTICLE	IF	CITATIONS
1166	Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity. <i>Molecules</i> , 2015, 20, 18526-18538.	1.7	21
1167	Synthesis of Cu(II) complex with schiff bases derived from aryl-S-benzylidithiocarbamate: Antimicrobial activity and in silico biological properties evaluations. <i>African Journal of Pharmacy and Pharmacology</i> , 2015, 9, 1009-1019.	0.2	7
1168	Characterization of regulatory sequences in alternative promoters of hypermethylated genes associated with tumor resistance to cisplatin. <i>Molecular and Clinical Oncology</i> , 2015, 3, 408-414.	0.4	1
1169	PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	1.4	8
1170	Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity. <i>Toxics</i> , 2015, 3, 304-321.	1.6	44
1171	Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19836-19850.	1.8	23
1172	Improved Chemotherapeutic Activity by <i>Morus alba</i> Fruits through Immune Response of Toll-Like Receptor 4. <i>International Journal of Molecular Sciences</i> , 2015, 16, 24139-24158.	1.8	24
1173	PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines. <i>PLoS ONE</i> , 2015, 10, e0123830.	1.1	29
1174	Highly and Broad-Spectrum In Vitro Antitumor Active cis-Dichloridoplatinum(II) Complexes with 7-Azaindoles. <i>PLoS ONE</i> , 2015, 10, e0136338.	1.1	14
1175	DNA Damage Response Checkpoint Activation Drives KP1019 Dependent Pre-Anaphase Cell Cycle Delay in <i>S. cerevisiae</i> . <i>PLoS ONE</i> , 2015, 10, e0138085.	1.1	8
1176	Membrane Transition Temperature Determines Cisplatin Response. <i>PLoS ONE</i> , 2015, 10, e0140925.	1.1	13
1177	Organometallic Half-Sandwich Dichloridoruthenium(II) Complexes with 7-Azaindoles: Synthesis, Characterization and Elucidation of Their Anticancer Inactivity against A2780 Cell Line. <i>PLoS ONE</i> , 2015, 10, e0143871.	1.1	6
1178	The Preventive Effect of Oxytocin to Cisplatin-Induced Neurotoxicity: An Experimental Rat Model. <i>BioMed Research International</i> , 2015, 2015, 1-5.	0.9	55
1179	The Flavonoid Apigenin Ameliorates Cisplatin-Induced Nephrotoxicity through Reduction of p53 Activation and Promotion of PI3K/Akt Pathway in Human Renal Proximal Tubular Epithelial Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-9.	0.5	49
1180	Etoposide Incorporated into Camel Milk Phospholipids Liposomes Shows Increased Activity against Fibrosarcoma in a Mouse Model. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	16
1181	Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity. <i>Bioinorganic Chemistry and Applications</i> , 2015, 2015, 1-7.	1.8	26
1182	The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 31593-31603.	0.8	39
1183	Convenient detection of metal-DNA, metal-RNA, and metal-protein adducts with a click-modified Pt(II) complex. <i>Dalton Transactions</i> , 2015, 44, 3536-3539.	1.6	21

#	ARTICLE	IF	CITATIONS
1184	Cationic liposomes as efficient nanocarriers for the drug delivery of an anticancer cholesterol-based ruthenium complex. <i>Journal of Materials Chemistry B</i> , 2015, 3, 3011-3023.	2.9	52
1185	Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1307-1317.	1.5	36
1186	UCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress. <i>Free Radical Biology and Medicine</i> , 2015, 86, 67-77.	1.3	78
1187	DNA repair mechanisms in cancer development and therapy. <i>Frontiers in Genetics</i> , 2015, 6, 157.	1.1	240
1188	Prioritizing therapeutic targets using patient-derived xenograft models. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 223-234.	3.3	29
1189	A ruthenium(II) complex inhibits tumor growth in vivo with fewer side-effects compared with cisplatin. <i>Journal of Inorganic Biochemistry</i> , 2015, 146, 89-96.	1.5	49
1190	Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation. <i>Metallomics</i> , 2015, 7, 837-846.	1.0	16
1191	Elemental and molecular mass spectrometric strategies for probing interactions between DNA and new Ru(II) complexes containing phosphane ligands and either a tris(pyrazol-1-yl)borate or a pyridine bis(oxazoline) ligand. <i>Journal of Analytical Atomic Spectrometry</i> , 2015, 30, 172-179.	1.6	2
1192	Fluorescence imaging of a new monofunctional platinum(II) complex containing a thioflavin-T (ThT)-based fluorophore. <i>New Journal of Chemistry</i> , 2015, 39, 1592-1596.	1.4	10
1193	Structures and antitumor activities of planar chiral cyclopalladated ferrocene derivatives. <i>Inorganic Chemistry Communication</i> , 2015, 58, 57-59.	1.8	13
1194	Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy. <i>Scientific Reports</i> , 2015, 5, 10414.	1.6	30
1195	The use of Resonant X-ray Emission Spectroscopy (RXES) for the electronic analysis of metal complexes and their interactions with biomolecules. <i>Drug Discovery Today: Technologies</i> , 2015, 16, 1-6.	4.0	2
1196	Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents. <i>Nucleic Acids Research</i> , 2015, 43, 5284-5296.	6.5	21
1197	Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery. <i>Journal of Clinical Oncology</i> , 2015, 33, 4219-4226.	0.8	141
1198	Computational metallomics of the anticancer drug cisplatin. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 231-238.	1.5	20
1199	Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 1081-1095.	1.1	14
1200	Synthesis, characterization and anticancer activity of gold(III) complexes with (1R,2R)-(λ^2)-1,2-diaminocyclohexane. <i>Polyhedron</i> , 2015, 102, 773-781.	1.0	16
1201	Highly efficient uptake into cisplatin-resistant cells and the isomerization upon coordinative DNA binding of anticancer tetrazolato-bridged dinuclear platinum(II) complexes. <i>Metallomics</i> , 2015, 7, 1488-1496.	1.0	15

#	ARTICLE	IF	CITATIONS
1202	Electrophilic Activation of Oxidized Sulfur Ligands and Implications for the Biological Activity of Ruthenium(II) Arene Anticancer Complexes. <i>Inorganic Chemistry</i> , 2015, 54, 11574-11580.	1.9	8
1203	Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes. <i>Molecular Medicine Reports</i> , 2015, 12, 2503-2510.	1.1	7
1204	Dense diamond nanoneedle arrays for enhanced intracellular delivery of drug molecules to cell lines. <i>Journal of Materials Science</i> , 2015, 50, 7800-7807.	1.7	17
1205	Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function. <i>International Journal of Oncology</i> , 2015, 47, 1890-1900.	1.4	26
1206	Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 353-360.	1.4	34
1207	REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. <i>Oncology Reports</i> , 2015, 34, 1460-1468.	1.2	28
1208	Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin. <i>Oncology Reports</i> , 2015, 33, 1791-1798.	1.2	11
1209	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 89-99.	1.1	47
1210	In Vivo Evaluation of Folate Decorated Cross-Linked Micelles for the Delivery of Platinum Anticancer Drugs. <i>Biomacromolecules</i> , 2015, 16, 515-523.	2.6	52
1211	Interaction of cisplatin and two potential antitumoral platinum(IV) complexes with a model lipid membrane: a combined NMR and MD study. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 1458-1468.	1.3	16
1212	New application of carbon nanotubes in haemostatic dressing filled with anticancer substance. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 349-354.	2.5	10
1213	The X-ray structure of the primary adducts formed in the reaction between cisplatin and cytochrome c. <i>Chemical Communications</i> , 2015, 51, 2559-2561.	2.2	31
1214	A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma. <i>International Journal of Pharmaceutics</i> , 2015, 483, 89-100.	2.6	38
1215	Design, synthesis and anticancer activity of diam(m)ine platinum(II) complexes bearing a small-molecular cell apoptosis inducer dichloroacetate. <i>Journal of Inorganic Biochemistry</i> , 2015, 146, 14-18.	1.5	26
1216	Rational Design of a Cytotoxic Dinuclear Cu ₂ Complex That Binds by Molecular Recognition at Two Neighboring Phosphates of the DNA Backbone. <i>Inorganic Chemistry</i> , 2015, 54, 2679-2690.	1.9	47
1217	A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug. <i>Biomaterials</i> , 2015, 51, 12-21.	5.7	109
1218	Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: Implications for diagnostic microdosing. <i>International Journal of Cancer</i> , 2015, 136, 1485-1493.	2.3	10
1219	A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance. <i>Cancer Research</i> , 2015, 75, 628-634.	0.4	104

#	ARTICLE	IF	CITATIONS
1220	Synthesis and anticancer activity of a new water-soluble derivative of heptaplatin, cis-[Pt(II)][(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane](3-acetoxy-cyclobutane-1,1-dicarboxylato)}. Research on Chemical Intermediates, 2015, 41, 6149-6155.	1.3	2
1221	The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treatment Reviews, 2015, 41, 160-169.	3.4	83
1222	Synthesis and anticancer activity of diam(m)ine platinum(II) complexes with 3-oxo-cyclobutane-1,1-dicarboxylate as the leaving group. Research on Chemical Intermediates, 2015, 41, 8725-8733.	1.3	7
1223	Redox-active and DNA-binding coordination complexes of clotrimazole. Dalton Transactions, 2015, 44, 3673-3685.	1.6	23
1224	RhoGTPases – A novel link between cytoskeleton organization and cisplatin resistance. Drug Resistance Updates, 2015, 19, 22-32.	6.5	52
1225	Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Tumor Cell Apoptosis by Organoplatinum(II) Complexes with Oxoisoaporphine. Journal of Medicinal Chemistry, 2015, 58, 2159-2179.	2.9	147
1226	Tuning the Structural and Photophysical Properties of Cationic Pt(II) Complexes Bearing Neutral Bis(triazolyl)pyridine Ligands. Inorganic Chemistry, 2015, 54, 1588-1596.	1.9	37
1227	Platinum Diolefin Complexes – Synthesis, Structures, and Cytotoxicity. European Journal of Inorganic Chemistry, 2015, 2015, 226-239.	1.0	23
1228	Glycopolymer Self-Assemblies with Gold(I) Complexed to the Core as a Delivery System for Auranofin. Macromolecules, 2015, 48, 1065-1076.	2.2	17
1229	Chalcoptatin, a dual-targeting and p53 activator-containing anticancer platinum (<sc>iv</sc>) prodrug with unique mode of action. Chemical Communications, 2015, 51, 6301-6304.	2.2	90
1230	Germline oncopharmacogenetics, a promising field in cancer therapy. Cellular Oncology (Dordrecht), 2015, 38, 65-89.	2.1	11
1231	Synthesis and Evaluation of Series of Diazine-Bridged Dinuclear Platinum(II) Complexes through in Vitro Toxicity and Molecular Modeling: Correlation between Structure and Activity of Pt(II) Complexes. Journal of Medicinal Chemistry, 2015, 58, 1442-1451.	2.9	39
1232	Revealing DNA Interactions with Exogenous Agents by Surface-Enhanced Raman Scattering. Journal of the American Chemical Society, 2015, 137, 469-476.	6.6	88
1233	Cisplatin-induced testicular dysfunction and its amelioration by <i>Launaea taraxacifolia</i> leaf extract. Andrologia, 2015, 47, 553-559.	1.0	22
1234	Gold(III) – pyrrolidinedithiocarbamate Derivatives as Antineoplastic Agents. ChemistryOpen, 2015, 4, 183-191.	0.9	21
1235	TGF- β 2 Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma. Cell, 2015, 160, 963-976.	13.5	401
1236	Association of structural modifications with bioactivity in three new copper(II) complexes of Schiff base ligands derived from 5-chlorosalicylaldehyde and amino acids. Journal of Inorganic Biochemistry, 2015, 146, 52-60.	1.5	29
1237	Computational evidence for structural consequences of kiteplatin damage on DNA. Journal of Biological Inorganic Chemistry, 2015, 20, 35-48.	1.1	12

#	ARTICLE	IF	CITATIONS
1238	Necroptosis-Inducing Rhenium(V) Oxo Complexes. <i>Journal of the American Chemical Society</i> , 2015, 137, 2967-2974.	6.6	85
1239	Photoswitching the Cytotoxic Properties of Platinum(II) Compounds. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 4561-4565.	7.2	67
1240	Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 856-861.	1.0	14
1241	Speciation of cisplatin in environmental water samples by hydrophilic interaction liquid chromatography coupled to inductively coupled plasma mass spectrometry. <i>Talanta</i> , 2015, 138, 1-7.	2.9	30
1242	miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma. <i>Clinical Lung Cancer</i> , 2015, 16, e121-e129.	1.1	25
1244	Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides. <i>Dalton Transactions</i> , 2015, 44, 202-212.	1.6	67
1245	XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. <i>Mutagenesis</i> , 2015, 30, 441-449.	1.0	28
1246	Enhanced cancer cell killing of a Pt(IV) prodrug promoted by outer-sphere coordination with polyethyleneimines. <i>Dalton Transactions</i> , 2015, 44, 7135-7138.	1.6	5
1247	Kinetics of cisplatin binding to short r(GG) containing miRNA mimics: influence of Na ⁺ versus K ⁺ , temperature and hydrophobicity on reactivity. <i>Dalton Transactions</i> , 2015, 44, 12623-12632.	1.6	3
1248	Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor. <i>Molecular Medicine Reports</i> , 2015, 12, 2417-2424.	1.1	45
1249	Image-guided combination chemotherapy and photodynamic therapy using a mitochondria-targeted molecular probe with aggregation-induced emission characteristics. <i>Chemical Science</i> , 2015, 6, 4580-4586.	3.7	182
1250	Platinum trimethyl bipyridyl thiolates: new, tunable, red- to near IR emitting luminophores for bioimaging applications. <i>Chemical Communications</i> , 2015, 51, 11441-11444.	2.2	13
1251	Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance. <i>Chemical Communications</i> , 2015, 51, 11587-11590.	2.2	79
1252	Erdosteine protects HEI-OC1 auditory cells from cisplatin toxicity through suppression of inflammatory cytokines and induction of Nrf2 target proteins. <i>Toxicology and Applied Pharmacology</i> , 2015, 288, 192-202.	1.3	25
1253	Synthetic Modeling Chemistry of Iron-Sulfur Clusters in Nitric Oxide Signaling. <i>Accounts of Chemical Research</i> , 2015, 48, 2453-2461.	7.6	67
1254	Real-time in situ monitoring via europium emission of the photo-release of antitumor cisplatin from a Eu-Pt complex. <i>Chemical Communications</i> , 2015, 51, 14022-14025.	2.2	44
1255	Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. <i>Journal of Inorganic Biochemistry</i> , 2015, 149, 45-48.	1.5	10
1256	Mass Spectrometric and Computational Investigation of the Protonated Carnosine-Carboplatin Complex Fragmentation. <i>Inorganic Chemistry</i> , 2015, 54, 7885-7897.	1.9	5

#	ARTICLE	IF	CITATIONS
1258	Investigation of thermodynamic and structural properties of drug delivery system based on carbon nanotubes as a carboplatin drug carrier by molecular dynamics simulations. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2015, 83, 131-140.	0.9	13
1259	Relevant Cancer Diagnoses, Commonly Used Chemotherapy Agents and Their Biochemical Mechanisms of Action. , 2015, , 21-33.		4
1260	The ameliorating effect of <i>Filipendula hexapetala</i> extracts on hepatorenal toxicity of cisplatin. <i>Journal of Functional Foods</i> , 2015, 18, 198-212.	1.6	13
1261	Radiosensitization of DNA by Cisplatin Adducts Results from an Increase in the Rate Constant for the Reaction with Hydrated Electrons and Formation of Pt ^I . <i>Journal of Physical Chemistry B</i> , 2015, 119, 9496-9500.	1.2	17
1262	cis-Pt I ₂ (NH ₃) ₂ : a reappraisal. <i>Dalton Transactions</i> , 2015, 44, 14896-14905.	1.6	45
1263	The effect of potential supramolecular-bond promoters on the DNA-interacting abilities of copper ^{II} -terpyridine compounds. <i>Dalton Transactions</i> , 2015, 44, 16061-16072.	1.6	26
1264	APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. <i>Cell Death and Disease</i> , 2015, 6, e1794-e1794.	2.7	151
1265	Efficient Synthesis of a Maghemite/Gold Hybrid Nanoparticle System as a Magnetic Carrier for the Transport of Platinum-Based Metallotherapeutics. <i>International Journal of Molecular Sciences</i> , 2015, 16, 2034-2051.	1.8	16
1266	Heterometallic titanium ^{II} -gold complexes inhibit renal cancer cells in vitro and in vivo. <i>Chemical Science</i> , 2015, 6, 5269-5283.	3.7	100
1267	A polymer ^{II} (multifunctional single-drug) conjugate for combination therapy. <i>Journal of Materials Chemistry B</i> , 2015, 3, 4913-4921.	2.9	20
1268	Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery. <i>Biomedicine and Pharmacotherapy</i> , 2015, 73, 116-122.	2.5	12
1269	Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems. <i>Dalton Transactions</i> , 2015, 44, 13914-13925.	1.6	42
1270	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
1271	Anti-growth effect of a novel trans-dichloridobis[2-(2-hydroxyethyl)pyridine]platinum (II) complex via induction of apoptosis on breast cancer cell lines. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4303-4310.	1.4	14
1272	New platinum(II) complexes of cycloalkanespiro-5-(2-thiohydantoin)s. Synthesis and quantum chemical investigation. <i>Acta Chimica Slovenica</i> , 2015, 62, 225-32.	0.2	4
1273	Glucose conjugated platinum(II) complex: Antitumor superiority to oxaliplatin, combination effect and mechanism of action. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 400-408.	2.6	39
1274	Theoretical study of the interaction between carbon nanotubes and carboplatin anticancer molecules. <i>Analytical Methods</i> , 2015, 7, 10145-10150.	1.3	21
1275	New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants. <i>Drug Resistance Updates</i> , 2015, 20, 1-11.	6.5	47

#	ARTICLE	IF	CITATIONS
1276	Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5825-5841.	2.9	88
1277	Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. <i>International Immunology</i> , 2015, 27, 621-632.	1.8	30
1278	DNA Alkylating Agents. , 2015, , 197-241.		6
1279	Clinical Translation of Nanomedicine. <i>Chemical Reviews</i> , 2015, 115, 11147-11190.	23.0	619
1280	DNA fragment conformations in adducts with Kiteplatin. <i>Dalton Transactions</i> , 2015, 44, 3544-3556.	1.6	10
1281	Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2941-2951.	3.2	90
1282	Inorganic nanocarriers for platinum drug delivery. <i>Materials Today</i> , 2015, 18, 554-564.	8.3	122
1283	Advances in cobalt complexes as anticancer agents. <i>Dalton Transactions</i> , 2015, 44, 13796-13808.	1.6	219
1284	Polymeric biomaterials for the delivery of platinum-based anticancer drugs. <i>Biomaterials Science</i> , 2015, 3, 1002-1017.	2.6	77
1285	Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2538-2547.	1.4	21
1286	Improved in vitro antitumor potential of (O,O'-Diisobutyl-ethylenediamine-N,N'-di-3-propionate)tetrachloridoplatinum(IV) complex under normoxic and hypoxic conditions. <i>European Journal of Pharmacology</i> , 2015, 760, 136-144.	1.7	7
1287	Synthesis of four binuclear copper(II) complexes: Structure, anticancer properties and anticancer mechanism. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 360-368.	2.6	61
1288	Synthesis and DNA-Damaging Properties of Cisplatin-Mustard Conjugates. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 2654-2660.	1.2	7
1289	New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells. <i>Biochemical Pharmacology</i> , 2015, 95, 133-144.	2.0	78
1290	A novel cisplatin mediated apoptosis pathway is associated with Acid sphingomyelinase and FAS proapoptotic protein activation in ovarian cancer. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015, 20, 960-974.	2.2	31
1291	Convection-enhancement delivery of platinum-based drugs and Lipoplatin TM to optimize the concomitant effect with radiotherapy in F98 glioma rat model. <i>Investigational New Drugs</i> , 2015, 33, 555-563.	1.2	24
1292	Curcumin reverses cisplatin resistance in cisplatin-resistant lung cancer cells by inhibiting FA/BRCA pathway. <i>Tumor Biology</i> , 2015, 36, 3591-3599.	0.8	70
1293	Mixed Quantum Mechanical/Molecular Mechanical Molecular Dynamics Simulations of Biological Systems in Ground and Electronically Excited States. <i>Chemical Reviews</i> , 2015, 115, 6217-6263.	23.0	352

#	ARTICLE	IF	CITATIONS
1294	A molecular view of cisplatin's mode of action: interplay with DNA bases and acquired resistance. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 5155-5171.	1.3	39
1295	Nucleotides with Altered Hydrogen Bonding Capacities Impede Human DNA Polymerase β by Reducing Synthesis in the Presence of the Major Cisplatin DNA Adduct. <i>Journal of the American Chemical Society</i> , 2015, 137, 4728-4734.	6.6	9
1296	Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme. <i>Dalton Transactions</i> , 2015, 44, 10392-10398.	1.6	47
1297	HMGB1 bound to cisplatin-DNA adducts undergoes extensive acetylation and phosphorylation in vivo. <i>Chemical Science</i> , 2015, 6, 2074-2078.	3.7	26
1298	Synthesis, characterization and <i>in vitro</i> biological evaluation of [Ru(η -6-arene)(N,N)Cl]PF ₆ compounds using the natural products arenes methylisoeugenol and anethole. <i>Journal of Organometallic Chemistry</i> , 2015, 782, 131-137.	0.8	10
1299	A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S ₂ Phase by Up-regulating p27 ^{KIP1} . <i>Chemistry - A European Journal</i> , 2015, 21, 9185-9197.	1.7	49
1300	Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets. <i>Chemical Society Reviews</i> , 2015, 44, 8773-8785.	18.7	174
1301	Cancer Therapy and Replication Stress. <i>Advances in Clinical Chemistry</i> , 2015, 69, 91-138.	1.8	23
1302	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents. <i>Metallomics</i> , 2015, 7, 1256-1264.	1.0	42
1303	Human Transport Protein Carrier for Controlled Photoactivation of Antitumor Prodrug and Real-Time Intracellular Tumor Imaging. <i>Bioconjugate Chemistry</i> , 2015, 26, 955-961.	1.8	47
1304	Hydration of Two Cisplatin Aqua-Derivatives Studied by Quantum Mechanics and Molecular Dynamics Simulations. <i>Journal of Chemical Theory and Computation</i> , 2015, 11, 1735-1744.	2.3	28
1305	An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects. <i>Advanced Healthcare Materials</i> , 2015, 4, 1034-1042.	3.9	38
1306	New salen-type manganese(III) Schiff base complexes derived from <i>meso</i> -1,2-diphenyl-1,2-ethylenediamine: <i>in vitro</i> anticancer activity, mechanism of action, and molecular docking studies. <i>Journal of Coordination Chemistry</i> , 2015, 68, 1500-1513.	0.8	20
1307	Fluorescent sensing of monofunctional platinum species. <i>Chemical Communications</i> , 2015, 51, 6312-6314.	2.2	24
1308	Analysis of Platinum and Trace Metals in Treated Glioma Rat Cells by X-Ray Fluorescence Emission. <i>Biological Trace Element Research</i> , 2015, 163, 177-183.	1.9	10
1309	Antitumor properties of platinum(IV) prodrug-loaded silk fibroin nanoparticles. <i>Dalton Transactions</i> , 2015, 44, 13513-13521.	1.6	38
1310	Coordination compounds in cancer: Past, present and perspectives. <i>Journal of Applied Biomedicine</i> , 2015, 13, 79-103.	0.6	113
1311	Cisplatin binding to human serum albumin: a structural study. <i>Chemical Communications</i> , 2015, 51, 9436-9439.	2.2	115

#	ARTICLE	IF	CITATIONS
1312	Polymer-Albumin Conjugate for the Facilitated Delivery of Macromolecular Platinum Drugs. <i>Macromolecular Rapid Communications</i> , 2015, 36, 890-897.	2.0	32
1313	Speciation studies of mono- and binuclear Pd(II) complexes involving mixed nitrogen-sulfur donor ligand and 4,4'-bipyridine as a linker. <i>Journal of Coordination Chemistry</i> , 2015, 68, 3135-3147.	0.8	2
1314	Core-shell polymer nanoparticles for prevention of GSH drug detoxification and cisplatin delivery to breast cancer cells. <i>Nanoscale</i> , 2015, 7, 17964-17979.	2.8	81
1315	Empirical force field for cisplatin based on quantum dynamics data: case study of new parameterization scheme for coordination compounds. <i>Journal of Molecular Modeling</i> , 2015, 21, 268.	0.8	20
1316	Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. <i>Nature Communications</i> , 2015, 6, 8692.	5.8	353
1317	Theoretical demonstration of the potentiality of boron nitride nanotubes to encapsulate anticancer molecule. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 30057-30064.	1.3	25
1318	Synthesis, DNA binding, cellular DNA lesion and cytotoxicity of a series of new benzimidazole-based Schiff base copper(II) complexes. <i>Dalton Transactions</i> , 2015, 44, 19983-19996.	1.6	60
1319	A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. <i>Cancer Cell</i> , 2015, 28, 623-637.	7.7	68
1320	DFT Investigation of the Mechanism of Action of Organoiridium(III) Complexes As Anticancer Agents. <i>Inorganic Chemistry</i> , 2015, 54, 10801-10810.	1.9	30
1321	Reduced toxicological manifestations of cisplatin following encapsulation in folate grafted albumin nanoparticles. <i>Life Sciences</i> , 2015, 142, 76-85.	2.0	19
1322	Chronic-Leptin Attenuates Cisplatin Cytotoxicity in MCF-7 Breast Cancer Cell Line. <i>Cellular Physiology and Biochemistry</i> , 2015, 36, 221-232.	1.1	17
1323	Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex. <i>Journal of Controlled Release</i> , 2015, 215, 82-90.	4.8	23
1324	Cellular Recognition and Repair of Monofunctional Intercalative Platinum-DNA Adducts. <i>Chemical Research in Toxicology</i> , 2015, 28, 2170-2178.	1.7	34
1325	Presentation and Diagnosis of Hypersensitivity to Platinum Drugs. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 15.	2.4	60
1326	Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. <i>British Journal of Cancer</i> , 2015, 113, 1434-1444.	2.9	93
1327	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. <i>Cancer Discovery</i> , 2015, 5, 1137-1154.	7.7	657
1328	Absence of Activation of DNA Repair Genes and Excellent Efficacy of Phosphaplatins against Human Ovarian Cancers: Implications To Treat Resistant Cancers. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8387-8401.	2.9	18
1329	Design, synthesis and DNA interactions of a chimera between a platinum complex and an IHF mimicking peptide. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 11704-11713.	1.5	2

#	ARTICLE	IF	CITATIONS
1330	Palladium Complexes with Tridentate N-Heterocyclic Carbene Ligands: Selective "Normal" and "Abnormal" Bindings and Their Anticancer Activities. <i>Organometallics</i> , 2015, 34, 4359-4368.	1.1	59
1331	Synthesis, characterization and theoretical calculations of (1,2-diaminocyclohexane)(1,3-diaminopropane)gold(III) chloride complexes: in vitro cytotoxic evaluations against human cancer cell lines. <i>BioMetals</i> , 2015, 28, 827-844.	1.8	16
1332	The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2332-2342.	1.9	27
1333	Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer. <i>Cancer Research</i> , 2015, 75, 3543-3553.	0.4	30
1334	RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells. <i>Gynecologic Oncology</i> , 2015, 138, 647-655.	0.6	29
1335	Sugar-boronate ester scaffold tethered pyridyl-imine palladium(II) complexes: synthesis and their in vitro anticancer evaluation. <i>Dalton Transactions</i> , 2015, 44, 17600-17616.	1.6	23
1336	Nanoparticle-based cisplatin therapy for cancer. <i>Therapeutic Delivery</i> , 2015, 6, 115-119.	1.2	12
1337	Synthesis, structure, and <i>in vitro</i> cytotoxicity of organoplatinum(II) complexes containing aryl olefins and quinolines. <i>Journal of Coordination Chemistry</i> , 2015, 68, 3525-3536.	0.8	19
1338	Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative Activity, and Crystallographic Evidence of Protein Binding. <i>Inorganic Chemistry</i> , 2015, 54, 8560-8570.	1.9	37
1339	Nanomedicine Applications of Hybrid Nanomaterials Built from Metal-Ligand Coordination Bonds: Nanoscale Metal-Organic Frameworks and Nanoscale Coordination Polymers. <i>Chemical Reviews</i> , 2015, 115, 11079-11108.	23.0	839
1340	Anticancer Activity and Autophagy Involvement of Self-Assembled Arene-Ruthenium Metallacycles. <i>Organometallics</i> , 2015, 34, 4507-4514.	1.1	36
1341	Target-selective delivery and activation of platinum-based anticancer agents. <i>Future Medicinal Chemistry</i> , 2015, 7, 911-927.	1.1	15
1342	Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain. <i>Molecular Pharmaceutics</i> , 2015, 12, 3597-3609.	2.3	58
1343	Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460. <i>Journal of Radiation Research</i> , 2015, 56, 229-238.	0.8	28
1344	In vitro antiproliferative and apoptosis-inducing properties of a mononuclear copper(II) complex with dppz ligand, in two genotypically different breast cancer cell lines. <i>BioMetals</i> , 2015, 28, 929-943.	1.8	34
1345	Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7310-7327.	2.9	118
1346	Novel self-micellizing anticancer lipid nanoparticles induce cell death of colorectal cancer cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 135, 793-801.	2.5	17
1347	Electrochemical Formation of Reactive Oxygen Species at Pt (111)-A Density Functional Theory Study. <i>ACS Catalysis</i> , 2015, 5, 6090-6098.	5.5	29

#	ARTICLE	IF	CITATIONS
1348	Photoactivatable platinum(II) compounds: in search of novel anticancer drugs. <i>Theoretical Chemistry Accounts</i> , 2015, 134, 1.	0.5	6
1349	Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014 . <i>European Urology</i> , 2015, 68, e33-e34.	0.9	6
1350	Increasing DNA reactivity and in vitro antitumor activity of trans diiodido Pt(II) complexes with UVA light. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 211-218.	1.5	15
1351	Effects of antitumor derivatives of ineffective transplatin on bacterial cells: Is DNA a pharmacological target?. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 206-210.	1.5	9
1352	Antitumor platinum(II) complexes of N-cyclobutyl-1R,2R-diaminocyclohexane with dicarboxylates as leaving groups. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 221-224.	1.0	12
1353	Synthesis, Crystal Structure, Luminescent Property and Anti-esophageal Tumor Activity of Dinuclear Zinc Complex Based on meso-1,2,3,4-Tetra(1H-benzo[d]imidazol-2-yl)butane. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2015, 641, 627-630.	0.6	6
1354	Novel Antitumor Cisplatin and Transplatin Derivatives Containing 1-Methyl-7-Azaindole: Synthesis, Characterization, and Cellular Responses. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 847-859.	2.9	50
1355	Fluorinated Fe(III) Salophene Complexes: Optimization of Tumor Cell Specific Activity and Utilization of Fluorine Labeling for in Vitro Analysis. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 588-597.	2.9	24
1356	Supramolecular self-assembled nanoparticles for chemo-photodynamic dual therapy against cisplatin resistant cancer cells. <i>Chemical Communications</i> , 2015, 51, 1807-1810.	2.2	63
1357	Thermogelling Polymer-Platinum(IV) Conjugates for Long-Term Delivery of Cisplatin. <i>Biomacromolecules</i> , 2015, 16, 105-115.	2.6	97
1358	Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. <i>Nature</i> , 2015, 517, 209-213.	13.7	500
1359	Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. <i>Journal of Neurophysiology</i> , 2015, 113, 1501-1510.	0.9	31
1360	Anti-proliferative activity of the combination of salan Ti($\text{Ti}(\text{salan})_2$) complexes with other organic and inorganic anticancer drugs against HT-29 and NCI-H1229 cells: synergism with cisplatin. <i>RSC Advances</i> , 2015, 5, 7874-7879.	1.7	11
1361	Degradable cross-linked polymer vesicles for the efficient delivery of platinum drugs. <i>Polymer Chemistry</i> , 2015, 6, 35-43.	1.9	25
1362	In vitro anticancer activity of gold(III) complexes with some esters of (S,S)-ethylenediamine-N,N'-di-2-propanoic acid. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 766-774.	2.6	30
1363	Structural and theoretical studies on rhodium and iridium complexes with 5-nitrosopyrimidines. Effects on the proteolytic regulatory enzymes of the renin-angiotensin system in human tumoral brain cells. <i>Journal of Inorganic Biochemistry</i> , 2015, 143, 20-33.	1.5	12
1364	The frequency of poly(G) tracts in the human genome and their use as a sensor of DNA damage. <i>Computational Biology and Chemistry</i> , 2015, 54, 13-17.	1.1	5
1365	Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 419-429.	1.2	35

#	ARTICLE	IF	CITATIONS
1366	Analytical approaches to investigating metal-containing drugs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 106, 210-217.	1.4	13
1367	Epithelialâ€mesenchymal status renders differential responses to cisplatin in ovarian cancer. <i>Oncogene</i> , 2015, 34, 1899-1907.	2.6	108
1368	A monofunctional platinum(II)-based anticancer agent from a salicylanilide derivative: Synthesis, antiproliferative activity, and transcription inhibition. <i>Journal of Inorganic Biochemistry</i> , 2015, 142, 118-125.	1.5	16
1369	Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 31-38.	1.7	71
1370	Metallomic and metalloproteomic strategies in elucidating the molecular mechanisms of metallodrugs. <i>Dalton Transactions</i> , 2015, 44, 437-447.	1.6	40
1371	Targeted delivery of photoactive diazido Pt^{IV} complexes conjugated with fluorescent carbon dots. <i>New Journal of Chemistry</i> , 2015, 39, 800-804.	1.4	32
1372	Silencing of highâ€mobility group box 2 (HMGB2) modulates cisplatin and 5â€fluorouracil sensitivity in head and neck squamous cell carcinoma. <i>Proteomics</i> , 2015, 15, 383-393.	1.3	30
1373	Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer. <i>Biomaterials</i> , 2015, 36, 124-133.	5.7	112
1374	A platinum(IV)-based metallointercalator: synthesis, cytotoxicity, and redox reactions with thiol-containing compounds. <i>Transition Metal Chemistry</i> , 2015, 40, 31-37.	0.7	10
1375	Effect of chirality in platinum drugs. <i>Coordination Chemistry Reviews</i> , 2015, 284, 286-297.	9.5	50
1376	Singleâ€cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry. <i>International Journal of Cancer</i> , 2015, 136, 1202-1209.	2.3	31
1377	Efficacy of Piroxicam Plus Cisplatin-Loaded PLGA Nanoparticles in Inducing Apoptosis in Mesothelioma Cells. <i>Pharmaceutical Research</i> , 2015, 32, 362-374.	1.7	9
1378	Constitutively Active ErbB2 Regulates Cisplatin-Induced Cell Death in Breast Cancer Cells via Pro- and Antiapoptotic Mechanisms. <i>Molecular Cancer Research</i> , 2015, 13, 63-77.	1.5	20
1379	Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. <i>Oncogene</i> , 2015, 34, 3053-3062.	2.6	67
1380	Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer. <i>Biomaterials Science</i> , 2015, 3, 163-174.	2.6	129
1381	ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. <i>Oncotarget</i> , 2016, 7, 1947-1959.	0.8	24
1382	Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. <i>OncoTargets and Therapy</i> , 2016, 9, 2769.	1.0	16
1383	Ruthenium Complexes Induce HepG2 Human Hepatocellular Carcinoma Cell Apoptosis and Inhibit Cell Migration and Invasion through Regulation of the Nrf2 Pathway. <i>International Journal of Molecular Sciences</i> , 2016, 17, 775.	1.8	31

#	ARTICLE	IF	CITATIONS
1384	Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. <i>Oncotarget</i> , 2016, 7, 33111-33124.	0.8	27
1386	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 738-749.	0.6	14
1387	Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. <i>Biomarker Insights</i> , 2016, 11, BMI.S39445.	1.0	52
1388	Hybrid Nanomaterials Based on Iron Oxide Nanoparticles and Mesoporous Silica Nanoparticles: Overcoming Challenges in Current Cancer Treatments. <i>Journal of Chemistry</i> , 2016, 2016, 1-15.	0.9	27
1389	Evaluation of Apoptosis rate of Pegylated nanoliposomal oxaliplatin in Breast Cancer MCF-7 and MDA-MB-231 cells. <i>Oriental Journal of Chemistry</i> , 2016, 32, 2915-2919.	0.1	0
1390	Novel Zinc(II) Complexes [Zn(atc-Et) ₂] and [Zn(atc-Ph) ₂]: In Vitro and in Vivo Antiproliferative Studies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 781.	1.8	21
1391	Novel Improved Synthesis of HSP70 Inhibitor, Pifithrin-1/4. In Vitro Synergy Quantification of Pifithrin-1/4 Combined with Pt Drugs in Prostate and Colorectal Cancer Cells. <i>Molecules</i> , 2016, 21, 949.	1.7	35
1392	Recent Advances in Stimuli-Responsive Release Function Drug Delivery Systems for Tumor Treatment. <i>Molecules</i> , 2016, 21, 1715.	1.7	110
1393	Global Proteome Changes in Liver Tissue 6 Weeks after FOLFOX Treatment of Colorectal Cancer Liver Metastases. <i>Proteomes</i> , 2016, 4, 30.	1.7	1
1394	Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 27.	1.3	51
1395	5-Hydroxy-7-Methoxyflavone Triggers Mitochondrial-Associated Cell Death via Reactive Oxygen Species Signaling in Human Colon Carcinoma Cells. <i>PLoS ONE</i> , 2016, 11, e0154525.	1.1	34
1396	The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model. <i>PLoS ONE</i> , 2016, 11, e0168389.	1.1	35
1397	Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 3655-3675.	3.3	80
1398	Design of a novel theranostic nanomedicine: synthesis and physicochemical properties of a biocompatible polyphosphazene–platinum(II) conjugate. <i>International Journal of Nanomedicine</i> , 2016, 11, 837.	3.3	10
1399	In Vitro Antitumor Active Gold(I) Triphenylphosphane Complexes Containing 7-Azaindoles. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2084.	1.8	8
1400	MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. <i>International Journal of Biological Sciences</i> , 2016, 12, 1437-1447.	2.6	60
1401	Dose-dependent effects of cisplatin on the severity of testicular injury in Sprague Dawley rats: reactive oxygen species and endoplasmic reticulum stress. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3959-3968.	2.0	63
1402	Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines. <i>Journal of Inorganic Biochemistry</i> , 2016, 162, 109-116.	1.5	10

#	ARTICLE	IF	CITATIONS
1403	Hydroxyapatite nanocrystals as a smart, pH sensitive, delivery system for kiteplatin. Dalton Transactions, 2016, 45, 13187-13195.	1.6	28
1404	Synergistic Effects of Metals in a Promising Ru ^{II} Pt ^{II} Assembly for a Combined Anticancer Approach: Theoretical Exploration of the Photophysical Properties. Chemistry - A European Journal, 2016, 22, 9162-9168.	1.7	34
1405	Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. Laryngoscope, 2016, 126, E184-90.	1.1	12
1406	Labile Pd-sulphur and Pt-sulphur bonds in organometallic palladium and platinum complexes [(COD)M(alkyl)(S-ligand)] _n —A speciation study. Journal of Inorganic Biochemistry, 2016, 165, 119-127.	1.5	13
1407	Anticancer potential of a photoactivated transplatin derivative containing the methylzaindole ligand mediated by ROS generation and DNA cleavage. Dalton Transactions, 2016, 45, 13179-13186.	1.6	14
1408	Platinum-conjugated antibodies for application in mass cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 292-300.	1.1	98
1409	Glycosylated platinum(IV) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects. Dalton Transactions, 2016, 45, 11830-11838.	1.6	40
1410	Enhancing Tumor Cell Response to Chemotherapy through the Targeted Delivery of Platinum Drugs Mediated by Highly Stable, Multifunctional Carboxymethylcellulose-Coated Magnetic Nanoparticles. Chemistry - A European Journal, 2016, 22, 9750-9759.	1.7	14
1411	An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance. Dalton Transactions, 2016, 45, 13052-13060.	1.6	58
1412	A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells. Angewandte Chemie - International Edition, 2016, 55, 2550-2554.	7.2	137
1413	Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry. Electrophoresis, 2016, 37, 959-972.	1.3	23
1414	Propagation on Molecular Interaction Networks: Prediction of Effective Drug Combinations and Biomarkers in Cancer Treatment. Current Pharmaceutical Design, 2016, 22, 1-1.	0.9	2
1415	Mechanisms of reactions of Ru(III)-based drug NAMI-A and its aquated products with DNA purine bases: a DFT study. RSC Advances, 2016, 6, 113620-113629.	1.7	8
1416	Cisplatin-induced regulation of signal transduction pathways and transcription factors in p53-mutated subclone variants of hepatoma cells: Potential application for therapeutic targeting. Oncology Letters, 2016, 12, 3723-3730.	0.8	2
1417	The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Scientific Reports, 2016, 6, 39217.	1.6	3
1418	Role of Wnt/β ² -catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca ²⁺ pathways in cisplatin-induced chemoresistance in ovarian cancer. Experimental and Therapeutic Medicine, 2016, 12, 3851-3858.	0.8	29
1419	Gefitinib enhances oxaliplatin-induced apoptosis mediated by Src and PKC-modulated gap junction function. Oncology Reports, 2016, 36, 3251-3258.	1.2	14
1420	Characterization, luminescent properties, and crystal structure determination of [Pt(Ph ₂ bipy)Cl ₂]. Journal of Structural Chemistry, 2016, 57, 1675-1679.	0.3	5

#	ARTICLE	IF	CITATIONS
1421	Cdk2 phosphorylation of Bcl-xL after stress converts it to a pro-apoptotic protein mimicking Bax/Bak. <i>Cell Death Discovery</i> , 2016, 2, .	2.0	22
1422	Chemical Imaging of Platinum-Based Drugs and their Metabolites. <i>Scientific Reports</i> , 2016, 6, 38507.	1.6	46
1423	β -elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. <i>Scientific Reports</i> , 2016, 6, 21010.	1.6	64
1424	Platinum Complexes with Edda (Ethylenediamine -N, N - Diacetate) Ligands as Potential Anticancer Agents. <i>Serbian Journal of Experimental and Clinical Research</i> , 2016, 17, 285-296.	0.2	7
1425	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. <i>Scientific Reports</i> , 2016, 6, 19552.	1.6	26
1426	Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 657-666.	1.4	20
1427	EPR spectroscopic characterization of a monomeric Pt III species produced via electrochemical oxidation of the anticancer compound trans -[Pt II {(p-HC 6 F 4)NCH 2 CH 2 NEt 2 }Cl(py)]. <i>Journal of Inorganic Biochemistry</i> , 2016, 162, 194-200.	1.5	13
1428	Chemotherapeutic response to cisplatin-like drugs in human breast cancer cells probed by vibrational microspectroscopy. <i>Faraday Discussions</i> , 2016, 187, 273-298.	1.6	65
1429	A comparative study on the interactions of human copper chaperone Cox17 with anticancer organoruthenium(II) complexes and cisplatin by mass spectrometry. <i>Journal of Inorganic Biochemistry</i> , 2016, 161, 99-106.	1.5	4
1430	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1219-1238.	1.0	52
1431	How to assess the role of Pt and Zn in the nephrotoxicity of Pt anti-cancer drugs?: An investigation combining ^{14}XRF and statistical analysis. Part II: Clinical application. <i>Comptes Rendus Chimie</i> , 2016, 19, 1586-1589.	0.2	13
1432	Intracellular delivery of chemical probes using a glutathione-responsive traceless tag. <i>Chemical Communications</i> , 2016, 52, 7715-7718.	2.2	14
1433	Linker design for the modular assembly of multifunctional and targeted platinum(II)-containing anticancer agents. <i>Dalton Transactions</i> , 2016, 45, 13104-13113.	1.6	8
1434	In-vitro and in-vivo evaluation of the anticancer activity of diruthenium-2, a new trithiolato arene ruthenium complex $[(\eta^6\text{-p-MeC}_6\text{H}_4\text{Pr i})_2\text{Ru}_2(\eta^4\text{-S-p-C}_6\text{H}_4\text{OH})_3]\text{Cl}$. <i>Anti-Cancer Drugs</i> , 2016, 27, 643-650.	0.7	9
1435	Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. <i>Inorganica Chimica Acta</i> , 2016, 450, 124-130.	1.2	14
1436	Improved efficacy of cisplatin in combination with a nano-formulation of pentacyclic triterpenediol. <i>Materials Science and Engineering C</i> , 2016, 68, 109-116.	3.8	19
1437	Anticancer activity of a chelating nitrogen mustard bearing tetrachloridoplatinum(II) complex: better stability yet equipotent to the Pt(II) analogue. <i>Dalton Transactions</i> , 2016, 45, 11710-11722.	1.6	21
1438	Deciphering the effect of an oxovanadium(IV) complex with the flavonoid chrysin (VOChrys) on intracellular cell signalling pathways in an osteosarcoma cell line. <i>Metallomics</i> , 2016, 8, 739-749.	1.0	40

#	ARTICLE	IF	CITATIONS
1439	Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair. <i>DNA Repair</i> , 2016, 44, 33-41.	1.3	56
1440	Time-programmed DCA and oxaliplatin release by multilayered nanofiber mats in prevention of local cancer recurrence following surgery. <i>Journal of Controlled Release</i> , 2016, 235, 125-133.	4.8	63
1441	Cytotoxic trans-platinum(II) complex with 3-hydroxymethylpyridine: Synthesis, X-ray structure and biological activity evaluation. <i>Journal of Inorganic Biochemistry</i> , 2016, 161, 40-51.	1.5	6
1442	Co-Delivery of Cisplatin Prodrug and Chlorin e6 by Mesoporous Silica Nanoparticles for Chemo-Photodynamic Combination Therapy to Combat Drug Resistance. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 13332-13340.	4.0	167
1443	Design, synthesis and biological evaluation of a novel series of glycosylated platinum(IV) complexes as antitumor agents. <i>Dalton Transactions</i> , 2016, 45, 10366-10374.	1.6	52
1444	Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. <i>Journal of Controlled Release</i> , 2016, 231, 94-102.	4.8	54
1445	Anticancer activity of large metalla-assemblies built from half-sandwich complexes. <i>CrystEngComm</i> , 2016, 18, 4952-4957.	1.3	27
1446	Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain. <i>Molecular Pharmaceutics</i> , 2016, 13, 1501-1507.	2.3	62
1447	Encapsulation of lipophilic kiteplatin Pt(IV) prodrugs in PLGA-PEG micelles. <i>Dalton Transactions</i> , 2016, 45, 13070-13081.	1.6	27
1448	Boron nitride nanotube as a delivery system for platinum drugs: Drug encapsulation and diffusion coefficient prediction. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 88, 291-297.	1.9	49
1449	Asplatin enhances drug efficacy by altering the cellular response. <i>Metallomics</i> , 2016, 8, 672-678.	1.0	38
1450	Hydrolytic behaviour of mono- and dithiolato-bridged dinuclear arene ruthenium complexes and their interactions with biological ligands. <i>RSC Advances</i> , 2016, 6, 38332-38341.	1.7	8
1451	Protein phosphatase 2A-B55 γ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 67.	3.5	31
1452	Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer. <i>Journal of the American Chemical Society</i> , 2016, 138, 6010-6019.	6.6	108
1453	Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles. <i>Biomaterials</i> , 2016, 94, 9-19.	5.7	47
1454	Knockdown of retinoblastoma protein may sensitize glioma cells to cisplatin through inhibition of autophagy. <i>Neuroscience Letters</i> , 2016, 620, 137-142.	1.0	20
1455	Coumarin-appended phosphorescent cyclometalated iridium(III) complexes as mitochondria-targeted theranostic anticancer agents. <i>Dalton Transactions</i> , 2016, 45, 13042-13051.	1.6	77
1456	Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing. <i>Cell</i> , 2016, 165, 631-642.	13.5	253

#	ARTICLE	IF	CITATIONS
1457	The water soluble ruthenium(II) organometallic compound [Ru(<i>p</i> -cymene)(bis(3,5)-Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 747 Td (dimet tumor infiltration of regulatory T cells. <i>Pharmacological Research</i> , 2016, 107, 282-290.	3.1	60
1458	The Fanconi anaemia pathway: new players and new functions. <i>Nature Reviews Molecular Cell Biology</i> , 2016, 17, 337-349.	16.1	562
1459	Oxidative Stressâ€“Induced Protein Damage Inhibits DNA Repair and Determines Mutation Risk and Therapeutic Efficacy. <i>Molecular Cancer Research</i> , 2016, 14, 612-622.	1.5	70
1460	Determination of Liposomal Cisplatin by High-Performance Liquid Chromatography and Its Application in Pharmacokinetic Studies. <i>Journal of Chromatographic Science</i> , 2016, 54, 1016-1021.	0.7	25
1461	Complexes of biogenic amines in their role in living systems. <i>ChemistrySelect</i> , 2016, 1, .	0.7	4
1462	Co(III) complex with (E)-2-(2-(pyridine-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole: structure and activity against 2-D and 3-D cancer cell models. <i>Journal of Coordination Chemistry</i> , 2016, 69, 3354-3366.	0.8	17
1463	Synthesis and Structures of 9-Oxabispidine Analogues of Cisplatin, Carboplatin, and Oxaliplatin. <i>Inorganic Chemistry</i> , 2016, 55, 9424-9435.	1.9	11
1464	Antimetastatic activity of novel ruthenium (<sc>III</sc>) pyridine complexes. <i>Cancer Medicine</i> , 2016, 5, 2850-2860.	1.3	23
1465	Synthesis and biological evaluation of new imidazo[2,1-b]thiazole derivatives as anticancer agents. <i>Medicinal Chemistry Research</i> , 2016, 25, 2471-2484.	1.1	10
1466	Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology. <i>Chemical Research in Toxicology</i> , 2016, 29, 1976-1986.	1.7	13
1468	Tuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy. <i>Metallomics</i> , 2016, 8, 1170-1176.	1.0	27
1469	Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 1398-1407.	2.2	52
1470	Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression. <i>Biochemical Pharmacology</i> , 2016, 122, 90-98.	2.0	10
1471	AI-Egens for Drug Delivery Applications. <i>ACS Symposium Series</i> , 2016, , 271-283.	0.5	0
1472	Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11507-11512.	3.3	149
1473	Rational design of multi-targeting ruthenium- and platinum-based anticancer complexes. <i>Science China Chemistry</i> , 2016, 59, 1240-1249.	4.2	14
1474	Functionalized nonporous silica nanoparticles as carriers for Pt(<sc>IV</sc>) anticancer prodrugs. <i>Dalton Transactions</i> , 2016, 45, 17233-17240.	1.6	14
1475	Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients. <i>Oncology Letters</i> , 2016, 12, 2590-2598.	0.8	6

#	ARTICLE	IF	CITATIONS
1476	Roles of RAD18 in DNA Replication and Postreplication Repair. , 2016, , 257-273.		1
1477	Hydrolysis mechanism of anticancer drug lobaplatin in aqueous medium under neutral and acidic conditions: A DFT study. Chemical Physics Letters, 2016, 663, 115-122.	1.2	16
1478	Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells. Neoplasia, 2016, 18, 525-535.	2.3	25
1479	Selective anticancer activity of the novel thiobenzanilide 63T against human lung adenocarcinoma cells. Toxicology in Vitro, 2016, 37, 148-161.	1.1	4
1480	VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells. Molecular Pharmaceutics, 2016, 13, 3712-3723.	2.3	47
1481	A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways. Tumor Biology, 2016, 37, 14863-14872.	0.8	16
1482	Insights into the anti-angiogenic properties of phosphaplatins. Journal of Inorganic Biochemistry, 2016, 164, 5-16.	1.5	10
1483	New Insights into the Reactivity of Cisplatin with Free and Restrained Nucleophiles: Microsolvation Effects and Base Selectivity in Cisplatin-DNA Interactions. ChemPhysChem, 2016, 17, 3932-3947.	1.0	10
1484	Half-sandwich iridium(III) complexes with pyrazole-substituted heterocyclic frameworks and their biological applications. New Journal of Chemistry, 2016, 40, 9968-9980.	1.4	16
1485	MiR-182-5p protects inner ear hair cells from cisplatin-induced apoptosis by inhibiting FOXO3a. Cell Death and Disease, 2016, 7, e2362-e2362.	2.7	36
1486	Heterodinuclear Pt(IV)-Ru(II) anticancer prodrugs to combat both drug resistance and tumor metastasis. Chemical Communications, 2016, 52, 10735-10738.	2.2	70
1487	$\text{[Pt}^{\text{II}}\text{N}^{\text{III}}\text{]}^{\text{+}}$ heterocyclic thiosemicarbazone Fe(III) complex: Characterization of its antitumor activity and identification of anticancer mechanism. European Journal of Medicinal Chemistry, 2016, 123, 354-364.	2.6	67
1488	Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. Journal of Inorganic Biochemistry, 2016, 165, 170-180.	1.5	15
1489	N-Heterocyclic Carbene-Polyethylenimine Platinum Complexes with Potent in Vitro and in Vivo Antitumor Efficacy. Bioconjugate Chemistry, 2016, 27, 1942-1948.	1.8	34
1490	Biological evaluation of dimethylpyridine-platinum complexes with potent antiproliferative activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 150-165.	2.5	20
1491	Endoplasmic Reticulum-Localized Iridium(III) Complexes as Efficient Photodynamic Therapy Agents via Protein Modifications. Journal of the American Chemical Society, 2016, 138, 10968-10977.	6.6	330
1492	Investigation of antitumor mechanism of the chiral ruthenium complex $\text{[Ru(phen)}_2\text{p-MOPIP]}^{2+}$ in human gastric cancer MGC-803 cells. Inorganic Chemistry Communication, 2016, 72, 1-6.	1.8	5
1493	Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action. Bioconjugate Chemistry, 2016, 27, 2132-2148.	1.8	60

#	ARTICLE	IF	CITATIONS
1494	Interactions between proteins and Ru compounds of medicinal interest: A structural perspective. <i>Coordination Chemistry Reviews</i> , 2016, 326, 111-134.	9.5	101
1495	Interstitial Release of Cisplatin from Triggerable Liposomes Enhances Efficacy against Triple Negative Breast Cancer Solid Tumor Analogues. <i>Molecular Pharmaceutics</i> , 2016, 13, 3224-3233.	2.3	17
1496	Benzimidazole based Pt(II) complexes with better normal cell viability than cisplatin: synthesis, substitution behavior, cytotoxicity, DNA binding and DFT study. <i>RSC Advances</i> , 2016, 6, 76600-76613.	1.7	65
1497	Platinum(II) O,S complexes as potential metallodrugs against Cisplatin resistance. <i>Dalton Transactions</i> , 2016, 45, 18876-18891.	1.6	15
1498	Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. <i>Macromolecular Bioscience</i> , 2016, 16, 1239-1249.	2.1	27
1499	Bioactive gold(I) complexes with 4-mercaptoproline derivatives. <i>Dalton Transactions</i> , 2016, 45, 13483-13490.	1.6	17
1500	Nanoparticles in the clinic. <i>Bioengineering and Translational Medicine</i> , 2016, 1, 10-29.	3.9	1,003
1501	Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies. <i>ChemMedChem</i> , 2016, 11, 1199-1210.	1.6	104
1502	Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer. <i>Pharmaceutical Research</i> , 2016, 33, 2943-2953.	1.7	25
1503	Novel cis-[(NHC) ¹ (NHC) ² (L)Cl]platinum(II) complexes – synthesis, structures, and anticancer activities. <i>Dalton Transactions</i> , 2016, 45, 15390-15398.	1.6	31
1504	Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. <i>Annals of Oncology</i> , 2016, 27, 2004-2016.	0.6	93
1505	CpG methylation increases the DNA binding of 9-aminoacridine carboxamide Pt analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4701-4710.	1.4	8
1506	Mathematical models of breast and ovarian cancers. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2016, 8, 337-362.	6.6	19
1507	Solvent-Triggered Cis/Trans Isomerism in Cobalt Dioxolene Chemistry: Distinguishing Effects of Packing on Valence Tautomerism. <i>Inorganic Chemistry</i> , 2016, 55, 8331-8340.	1.9	29
1508	Peptide-Mediated Delivery of Chemical Probes and Therapeutics to Mitochondria. <i>Accounts of Chemical Research</i> , 2016, 49, 1893-1902.	7.6	188
1509	Diastereomeric bactericidal effect of Ru(phenanthroline) ₂ dipyridophenazine. <i>Chirality</i> , 2016, 28, 713-720.	1.3	11
1510	Organic cation transporter 6 directly confers resistance to anticancer platinum drugs. <i>Biomedical Reports</i> , 2016, 5, 639-643.	0.9	15
1511	Identification of binding sites of cisplatin to human copper chaperone protein Cox17 by high-resolution FT-ICR-MS. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 168-172.	0.7	6

#	ARTICLE	IF	CITATIONS
1512	Carvedilol alleviates testicular and spermatological damage induced by cisplatin in rats via modulation of oxidative stress and inflammation. <i>Archives of Pharmacal Research</i> , 2016, 39, 1693-1702.	2.7	36
1513	A theoretical study on electrons attachment to the trans-[Pt(P)NH ₃ Cl ₂] (P=3-picoline or pyridine) and the subsequent interacting with ribose moiety or thymine(T). <i>Computational and Theoretical Chemistry</i> , 2016, 1094, 47-54.	1.1	1
1514	Ru(II) complexes bearing guanidinium ligands as potent anticancer agents. <i>Journal of Inorganic Biochemistry</i> , 2016, 164, 91-98.	1.5	22
1515	Cu(II), Ni(II) complexes derived from chiral Schiff-base ligands: Synthesis, characterization, cytotoxicity, protein and DNA binding properties. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 163, 403-412.	1.7	44
1516	COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. <i>Oncology Reports</i> , 2016, 36, 877-885.	1.2	73
1517	Exploring Intein Inhibition by Platinum Compounds as an Antimicrobial Strategy. <i>Journal of Biological Chemistry</i> , 2016, 291, 22661-22670.	1.6	32
1518	Ruthenium(II) arene complexes containing benzhydrazone ligands: synthesis, structure and antiproliferative activity. <i>Inorganic Chemistry Frontiers</i> , 2016, 3, 1245-1255.	3.0	158
1519	New water-soluble palladium(II) complexes of lidocaine and phenylcyanamide derivative ligands: cytotoxicity and cellular response mechanisms. <i>Investigational New Drugs</i> , 2016, 34, 723-732.	1.2	11
1520	A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9035-9046.	2.9	59
1521	Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells. <i>Cancer Letters</i> , 2016, 380, 485-493.	3.2	70
1522	Simultaneously Photo-cleavable and Activatable Prodrug-Backboned Block Copolymer Micelles for Precise Anticancer Drug Delivery. <i>Advanced Healthcare Materials</i> , 2016, 5, 2493-2499.	3.9	50
1523	Tunable Design of Gold(III)-Doxorubicin Complex-PEGylated Nanocarrier. <i>The Golden Doxorubicin for Oncological Applications. ACS Applied Materials & Interfaces</i> , 2016, 8, 19946-19957.	4.0	49
1524	Synthesis, crystal structure of nickel(II) complexes of 4-nitro phenylcyanamide: Comparative in vitro evaluations of biological perspectives. <i>Inorganica Chimica Acta</i> , 2016, 450, 402-410.	1.2	17
1525	Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. <i>Scientific Reports</i> , 2016, 6, 29367.	1.6	56
1526	Tetraphenylethene-based highly emissive metallacage as a component of theranostic supramolecular nanoparticles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13720-13725.	3.3	161
1527	Axially-modified paddlewheel diruthenium(II,III)-ibuprofenato metallodrugs and the influence of the structural modification on U87MG and A172 human glioma cell proliferation, apoptosis, mitosis and migration. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 181-191.	1.5	29
1528	Highly potent extranuclear-targeted luminescent iridium(III) antitumor agents containing benzimidazole-based ligands with a handle for functionalization. <i>Chemical Communications</i> , 2016, 52, 14165-14168.	2.2	48
1529	Triple Block Nanocarrier Platform for Synergistic Cancer Therapy of Antagonistic Drugs. <i>Biomacromolecules</i> , 2016, 17, 4075-4085.	2.6	32

#	ARTICLE	IF	CITATIONS
1530	Bypass of DNA-Protein Cross-links Conjugated to the 7-Deazaguanine Position of DNA by Translesion Synthesis Polymerases. <i>Journal of Biological Chemistry</i> , 2016, 291, 23589-23603.	1.6	33
1531	Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXCR4-Chemokine/NF- κ B signalling pathway. <i>Scientific Reports</i> , 2016, 6, 24675.	1.6	103
1532	Heteroleptic mononuclear compounds of ruthenium(II): synthesis, structural analyses, in vitro antitumor activity and in vivo toxicity on zebrafish embryos. <i>Dalton Transactions</i> , 2016, 45, 19127-19140.	1.6	45
1533	The induction of apoptosis in SGC-7901 cells through the ROS-mediated mitochondrial dysfunction pathway by a Ir(III) complex. <i>Journal of Biological Inorganic Chemistry</i> , 2016, 21, 1047-1060.	1.1	23
1534	Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 457-474.	1.1	13
1535	Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines. <i>Scientific Reports</i> , 2016, 6, 33078.	1.6	18
1536	Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes. <i>Scientific Reports</i> , 2016, 6, 28474.	1.6	5
1537	Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. <i>Science Translational Medicine</i> , 2016, 8, 348ra97.	5.8	82
1538	Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells. <i>BioMetals</i> , 2016, 29, 1075-1083.	1.8	6
1539	Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes. <i>Scientific Reports</i> , 2016, 6, 20596.	1.6	52
1540	Examining the protective effects of acetyl-L-carnitine on cisplatin-induced uterine tube toxicity. <i>Journal of Obstetrics and Gynaecology</i> , 2016, 36, 1086-1092.	0.4	5
1542	Ru(II) carbazole thiosemicarbazone complexes with four membered chelate ring: Synthesis, molecular structures and evaluation of biological activities. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 165, 310-327.	1.7	11
1543	A Multifunctional Platform for Tumor Angiogenesis-Targeted Chemo-Thermal Therapy Using Polydopamine-Coated Gold Nanorods. <i>ACS Nano</i> , 2016, 10, 10404-10417.	7.3	183
1544	Platinum complexes as light promoted anticancer agents: a redefined strategy for controlled activation. <i>Dalton Transactions</i> , 2016, 45, 19157-19171.	1.6	42
1545	Synthesis and molecular structure of arene ruthenium(II) benzhydrazone complexes: impact of substitution at the chelating ligand and arene moiety on antiproliferative activity. <i>New Journal of Chemistry</i> , 2016, 40, 9813-9823.	1.4	130
1547	Magnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approach. <i>JRSM Open</i> , 2016, 7, 205427041666093.	0.2	2
1548	Electron transfer processes occurring on platinum neural stimulating electrodes: pulsing experiments for cathodic-first/charge-balanced/biphasic pulses for 0.566 μ s \times 2.3 in oxygenated and deoxygenated sulfuric acid. <i>Journal of Neural Engineering</i> , 2016, 13, 056001.	1.8	11
1549	Optoelectronic method for determining platinum in biological products. , 2016, , .		1

#	ARTICLE	IF	CITATIONS
1550	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. <i>Biomarkers in Cancer</i> , 2016, 8s1, BIC.S34417.	3.6	27
1551	A Triple-€ Collaborative Strategy for High-€ Performance Tumor Therapy by Multifunctional Mesoporous Silica-€ Coated Gold Nanorods. <i>Advanced Functional Materials</i> , 2016, 26, 4339-4350.	7.8	150
1552	A kinetic analysis of oxidation of the antioxidant N-acetyl-L-cysteine (NAC) by Pt(IV) complexes. <i>Transition Metal Chemistry</i> , 2016, 41, 295-304.	0.7	3
1553	Insights into anticancer activity and mechanism of action of a ruthenium(II) complex in human esophageal squamous carcinoma EC109 cells. <i>European Journal of Pharmacology</i> , 2016, 786, 60-71.	1.7	19
1554	The length of the bridging chain in ansa-metallocenes influences their antiproliferative activity against triple negative breast cancer cells (TNBC). <i>Dalton Transactions</i> , 2016, 45, 13126-13134.	1.6	8
1555	Single-Cell-Arrayed Agarose Chip for <i>in Situ</i> Analysis of Cytotoxicity and Genotoxicity of DNA Cross-Linking Agents. <i>Analytical Chemistry</i> , 2016, 88, 6734-6742.	3.2	24
1556	Bio-inspired cisplatin nanocarriers for osteosarcoma treatment. <i>Biomaterials Science</i> , 2016, 4, 1212-1218.	2.6	13
1557	Unusual mode of protein binding by a cytotoxic π -arene ruthenium(II) piano-stool compound containing an O,S-chelating ligand. <i>Dalton Transactions</i> , 2016, 45, 12283-12287.	1.6	31
1558	Geometry matters: inverse cytotoxic relationship for cis/trans-Ru(II) polypyridyl complexes from cis/trans-[PtCl ₂ (NH ₃) ₂]. <i>Chemical Communications</i> , 2016, 52, 10121-10124.	2.2	32
1559	Comprehensive Vibrational Spectroscopic Investigation of <i>trans,trans,trans</i> -[Pt(N ₃) ₂ (OH) ₂ (py) ₂], a Pt(IV) Diazo Anticancer Prodrug Candidate. <i>Inorganic Chemistry</i> , 2016, 55, 5983-5992.	1.9	22
1560	Synthesis, characterization and biological evaluation of labile intercalative ruthenium(II) complexes for anticancer drug screening. <i>Dalton Transactions</i> , 2016, 45, 13135-13145.	1.6	42
1561	Role of the XPA protein in the NER pathway: A perspective on the function of structural disorder in macromolecular assembly. <i>Computational and Structural Biotechnology Journal</i> , 2016, 14, 78-85.	1.9	38
1562	Anticancer activity assessment of two novel binuclear platinum (II) complexes. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 161, 345-354.	1.7	27
1563	How to assess the role of Pt and Zn in the nephrotoxicity of Pt anti-cancer drugs? An investigation combining ¹¹⁹ XRF and statistical analysis: Part I: On mice. <i>Comptes Rendus Chimie</i> , 2016, 19, 1580-1585.	0.2	14
1564	Kiteplatin: Differential binding between GSH and GMP. <i>Inorganica Chimica Acta</i> , 2016, 452, 130-136.	1.2	3
1565	Mechanistic studies of the anticancer activity of an octahedral hexanuclear Pt(II) cage. <i>Inorganica Chimica Acta</i> , 2016, 452, 125-129.	1.2	25
1566	Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 815-820.	0.8	6
1567	Systemic Delivery and Biodistribution of Cisplatin <i>in Vivo</i> . <i>Molecular Pharmaceutics</i> , 2016, 13, 2677-2682.	2.3	31

#	ARTICLE	IF	CITATIONS
1568	Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome. <i>Nucleic Acids Research</i> , 2016, 44, 4978-4987.	6.5	69
1569	Supramolecular nanofibers of self-assembling peptides and DDP to inhibit cancer cell growth. <i>RSC Advances</i> , 2016, 6, 56903-56906.	1.7	4
1570	A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells. <i>Angewandte Chemie</i> , 2016, 128, 2596-2600.	1.6	31
1571	Design, Synthesis of Novel Platinum(II) Glycoconjugates, and Evaluation of Their Antitumor Effects. <i>Chemical Biology and Drug Design</i> , 2016, 87, 867-877.	1.5	14
1572	Gender differences in a mouse model of chemotherapy-induced neuropathic pain. <i>Laboratory Animals</i> , 2016, 50, 15-20.	0.5	46
1573	Atypical presentation of fever as hypersensitivity reaction to oxaliplatin. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 319-324.	0.5	5
1574	Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death. <i>Cell Death and Differentiation</i> , 2016, 23, 64-75.	5.0	39
1575	DNA Binding and Photocleavage Properties, Cellular Uptake and Localization, and in-Vitro Cytotoxicity of Dinuclear Ruthenium(II) Complexes with Varying Lengths in Bridging Alkyl Linkers. <i>Inorganic Chemistry</i> , 2016, 55, 1412-1422.	1.9	45
1576	Binding interaction, conformational change, and molecular docking study of N-(pyridin-2-ylmethylene)aniline derivatives and carbazole Ru(II) complexes with human serum albumins. <i>Polyhedron</i> , 2016, 107, 124-135.	1.0	32
1577	Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 545-553.	0.8	16
1578	Nonsteroidal Anti-inflammatory-Organometallic Anticancer Compounds. <i>Inorganic Chemistry</i> , 2016, 55, 1788-1808.	1.9	65
1579	Current and future potential of metallo drugs: Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action. <i>Inorganica Chimica Acta</i> , 2016, 444, 1-22.	1.2	79
1580	Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 156-165.	1.5	39
1581	Resonant X-ray emission spectroscopy of platinum(II) anticancer complexes. <i>Analyst</i> , The, 2016, 141, 1226-1232.	1.7	6
1582	Palladium(II) and platinum(II) complexes of derivatives of 2-(4-aminophenyl)benzothiazole as potential anticancer agents. <i>Inorganica Chimica Acta</i> , 2016, 444, 63-75.	1.2	36
1583	Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs. <i>Toxicology Letters</i> , 2016, 242, 47-52.	0.4	6
1584	Modulating the cellular uptake of platinum drugs with glycopolymers. <i>Polymer Chemistry</i> , 2016, 7, 1031-1036.	1.9	31
1585	Cytotoxic properties of a new organometallic platinum-gold heterobimetallic derivatives. <i>Dalton Transactions</i> , 2016, 45, 579-590.	1.6	47

#	ARTICLE	IF	CITATIONS
1586	Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. <i>Tumor Biology</i> , 2016, 37, 6389-6402.	0.8	16
1587	Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. <i>Drug Resistance Updates</i> , 2016, 24, 34-54.	6.5	124
1588	miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 382-387.	1.0	35
1589	The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 264-274.	1.5	40
1590	Smart Nanopreparations for Cancer. , 2016, , 449-478.		0
1591	Environmentally Benign CO ₂ -Based Copolymers: Degradable Polycarbonates Derived from Dihydroxybutyric Acid and Their Platinum Polymer Conjugates. <i>Journal of the American Chemical Society</i> , 2016, 138, 4626-4633.	6.6	49
1592	Targeting of DNA molecules, BSA/c-Met tyrosine kinase receptors and anti-proliferative activity of bis(terpyridine)copper(II) complexes. <i>Dalton Transactions</i> , 2016, 45, 7794-7814.	1.6	81
1593	Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2016, 14, 59.	0.8	31
1594	Inhibition of cancer cell growth by ruthenium complexes. <i>Journal of Translational Medicine</i> , 2016, 14, 48.	1.8	29
1595	Synthesis of α,β -Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3549-3561.	2.9	74
1596	New heteroleptic palladium(II) dithiocarbamates: synthesis, characterization, packing and anticancer activity against five different cancer cell lines. <i>Applied Organometallic Chemistry</i> , 2016, 30, 392-398.	1.7	38
1597	Platinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect. <i>Free Radical Biology and Medicine</i> , 2016, 95, 216-229.	1.3	50
1598	Metal Complexes with Very Large Dipole Moments: the Anionic Carborane Nitriles 12-NCâ€“(X =) Tj ETQq0 0 0 rgBT /Overlo	1.9	22
1599	Rational design of dinuclear complexes binding at two neighboring phosphate esters of DNA. <i>Inorganica Chimica Acta</i> , 2016, 452, 62-72.	1.2	15
1600	Behavior of platinum(IV) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. <i>Metallomics</i> , 2016, 8, 422-433.	1.0	39
1601	Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 42-50.	3.4	296
1602	Cisplatin encapsulation within a ferritin nanocage: a high-resolution crystallographic study. <i>Chemical Communications</i> , 2016, 52, 4136-4139.	2.2	57
1603	Platinum(IV) prodrug conjugated Pd@Au nanoplates for chemotherapy and photothermal therapy. <i>Nanoscale</i> , 2016, 8, 5706-5713.	2.8	61

#	ARTICLE	IF	CITATIONS
1604	The dual-role of Pt(IV) complexes as active drug and crosslinker for micelles based on β -cyclodextrin grafted polymer. <i>Journal of Materials Chemistry B</i> , 2016, 4, 2114-2123.	2.9	19
1605	Spin-Orbit Coupling Effects in Au I Pt III Clusters ($\text{Au}^{\text{I}}\text{Pt}^{\text{III}}$) <i>TJ ETQq1 1,0,784314,11,fgBT/O</i>	1.1	11
1606	Platinum-based drugs: past, present and future. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1103-1124.	1.1	646
1607	Multi-scale imaging of anticancer platinum(IV) compounds in murine tumor and kidney. <i>Chemical Science</i> , 2016, 7, 3052-3061.	3.7	36
1608	Effect of cisplatin containing liposomes formulated by unsaturated chain-containing lipids on gynecological tumor cells. <i>Journal of Liposome Research</i> , 2016, 26, 307-312.	1.5	4
1609	In vitro evaluation of the cyto-genotoxic potential of Ruthenium(II) SCAR complexes: a promising class of antituberculosis agents. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2016, 798-799, 11-18.	0.9	11
1610	Hydrosulfide Adducts of Organo-Iridium Anticancer Complexes. <i>Inorganic Chemistry</i> , 2016, 55, 2324-2331.	1.9	26
1611	The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. <i>Chemical Reviews</i> , 2016, 116, 3436-3486.	23.0	1,895
1612	Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: <i>In Vitro</i> Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers. <i>Molecular Pharmaceutics</i> , 2016, 13, 1058-1072.	2.3	43
1613	Recent achievements in colorectal cancer diagnostic and therapy by the use of nanoparticles. <i>Drug Metabolism Reviews</i> , 2016, 48, 27-46.	1.5	8
1614	Metal-containing and related polymers for biomedical applications. <i>Chemical Society Reviews</i> , 2016, 45, 5232-5263.	18.7	230
1615	Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 84, 103-115.	1.9	29
1616	Synthesis, characterization, antiproliferative and molecular docking study of new half sandwich Ir(III), Rh(III) and Ru(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2016, 159, 50-61.	1.5	39
1617	Characterization of the interaction between a platinum(II) complex and human serum albumin: spectroscopic analysis and molecular docking. <i>Journal of the Iranian Chemical Society</i> , 2016, 13, 723-731.	1.2	38
1618	Evaluation of the ability of bone marrow derived cells to engraft the kidney and promote renal tubular regeneration in mice following exposure to cisplatin. <i>Renal Failure</i> , 2016, 38, 521-529.	0.8	5
1619	Antitumor and biological investigation of doubly cyclometalated ruthenium(II) organometallics derived from benzimidazolyl derivatives. <i>Dalton Transactions</i> , 2016, 45, 6667-6673.	1.6	25
1620	Novel mononuclear ruthenium(II) complexes as potent and low-toxicity antitumour agents: synthesis, characterization, biological evaluation and mechanism of action. <i>RSC Advances</i> , 2016, 6, 29963-29976.	1.7	15
1621	4-Azidobenzyl ferrocenylcarbamate as an anticancer prodrug activated under reductive conditions. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 218-224.	1.5	17

#	ARTICLE	IF	CITATIONS
1622	DNA binding, topoisomerase inhibition and cytotoxicity of palladium(II) complexes with 1,10-phenanthroline and thioureas. <i>Inorganica Chimica Acta</i> , 2016, 446, 54-60.	1.2	50
1623	Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(II) complexes. <i>Dalton Transactions</i> , 2016, 45, 7049-7066.	1.6	65
1624	Targeting DNA mismatches with rhodium metalloinsertors. <i>Inorganica Chimica Acta</i> , 2016, 452, 3-11.	1.2	33
1625	Understanding the ring-opening, chelation and non-chelation reactions between nedaplatin and thiosulfate: a DFT study based on NBO, ETS-NOCV and QTAIM. <i>Theoretical Chemistry Accounts</i> , 2016, 135, 1.	0.5	5
1626	Mass spectrometric studies on the interaction of cisplatin and insulin. <i>Amino Acids</i> , 2016, 48, 1033-1043.	1.2	11
1627	Copper(II), palladium(II) and platinum(II) complexes with 2,2-thiophen-yl-imidazole: Synthesis, spectroscopic characterization, X-ray crystallographic studies and interactions with calf-thymus DNA. <i>Inorganica Chimica Acta</i> , 2016, 443, 304-315.	1.2	13
1628	Phenyl-guanidine derivatives as potential therapeutic agents for glioblastoma multiforme: catalytic syntheses, cytotoxic effects and DNA affinity. <i>RSC Advances</i> , 2016, 6, 8267-8276.	1.7	9
1629	Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis. <i>Supportive Care in Cancer</i> , 2016, 24, 2635-2642.	1.0	17
1630	Anticancer activity of a cis-dichloridoplatinum(II) complex of a chelating nitrogen mustard: insight into unusual guanine binding mode and low deactivation by glutathione. <i>Dalton Transactions</i> , 2016, 45, 3599-3615.	1.6	22
1631	Nanomedicine for Treatment of Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 137-147.	0.8	55
1632	Reactive oxygen species mediate oxaliplatin-induced epithelial-mesenchymal transition and invasive potential in colon cancer. <i>Tumor Biology</i> , 2016, 37, 8413-8423.	0.8	34
1633	Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 85-93.	1.5	18
1634	Prediction of logP for Pt(II) and Pt(IV) complexes: Comparison of statistical and quantum-chemistry based approaches. <i>Journal of Inorganic Biochemistry</i> , 2016, 156, 1-13.	1.5	45
1635	Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, 158, 71-90.		166
1637	Highly Effective and Hydrolytically Stable Vanadium(V) Amino Phenolato Antitumor Agents. <i>Inorganic Chemistry</i> , 2016, 55, 610-618.	1.9	45
1638	Competing Actions of Type 1 Angiotensin II Receptors Expressed on T Lymphocytes and Kidney Epithelium during Cisplatin-Induced AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2257-2264.	3.0	51
1639	Synthesis, structure and in vitro cytostatic activity of ferrocene-Cinchona hybrids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 946-949.	1.0	20
1640	[Cu(II)-phthalate(phenanthroline)] Exhibits Unique Superoxide-Mediated NCI-60 Chemotherapeutic Action through Genomic DNA Damage and Mitochondrial Dysfunction. <i>ACS Chemical Biology</i> , 2016, 11, 159-171.	1.6	40

#	ARTICLE	IF	CITATIONS
1641	CRISPR-Cas9-based target validation for p53-reactivating model compounds. <i>Nature Chemical Biology</i> , 2016, 12, 22-28.	3.9	74
1642	Synthesis, characterization and in vitro drug release of cisplatin loaded Cassava starch acetate-PEG/gelatin nanocomposites. <i>Journal of the Association of Arab Universities for Basic and Applied Sciences</i> , 2016, 21, 10-16.	1.0	22
1643	Recent advances of cocktail chemotherapy by combination drug delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 19-34.	6.6	496
1644	A luminescent europium(III)-platinum(II) heterometallic complex as a theranostic agent: a proof-of-concept study. <i>Dalton Transactions</i> , 2016, 45, 494-497.	1.6	53
1645	Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer. <i>Metallomics</i> , 2016, 8, 43-60.	1.0	48
1646	High-affinity sequence-selective DNA binding by iridium(III) polypyridyl organometallopeptides. <i>Chemical Communications</i> , 2016, 52, 1234-1237.	2.2	20
1647	Synthesis, characterization, and anticancer activities of lipophilic pyridinecarboxaldimine platinum(II) complexes. <i>Polyhedron</i> , 2016, 108, 23-29.	1.0	14
1648	Extremely low frequency electromagnetic field sensitizes cisplatin-resistant human ovarian adenocarcinoma cells via P53 activation. <i>Cytotechnology</i> , 2016, 68, 1403-1413.	0.7	27
1649	FTIR spectral signature of anticancer drugs. Can drug mode of action be identified?. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016, 1864, 85-101.	1.1	45
1650	Preparation, characterisation and antitumour activity of β -, γ - and HP- β -cyclodextrin inclusion complexes of oxaliplatin. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2016, 152, 501-508.	2.0	39
1651	Impact of apurinic/pyrimidinic endonuclease 1/redox factor-1 on treatment response and survival in oral squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 550-559.	0.9	9
1652	Raloxifene Inhibits NF- κ B Pathway and Potentiates Anti-Tumour Activity of Cisplatin with Simultaneous Reduction in its Nephrotoxicity. <i>Pathology and Oncology Research</i> , 2016, 22, 145-153.	0.9	12
1653	Cationic Ru(II), Rh(III) and Ir(III) complexes containing cyclic -perimeter and 2-aminophenyl benzimidazole ligands: Synthesis, molecular structure, DNA and protein binding, cytotoxicity and anticancer activity. <i>Journal of Organometallic Chemistry</i> , 2016, 801, 68-79.	0.8	60
1654	Coordination chemistry with phosphorus dendrimers. Applications as catalysts, for materials, and in biology. <i>Coordination Chemistry Reviews</i> , 2016, 308, 478-497.	9.5	85
1655	Synthesis, physico-chemical characterization and bacteriostatic study of Pt complexes with substituted amine ligands. <i>Journal of Thermal Analysis and Calorimetry</i> , 2017, 127, 1733-1741.	2.0	3
1656	Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 65-73.	2.4	80
1657	Multifunctional platinum-based nanoparticles for biomedical applications. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1410.	3.3	50
1658	<i>In vitro</i> effects of simultaneous exposure to platinum and cadmium on the activity of antioxidant enzymes and DNA damage and potential protective effects of selenium and zinc. <i>Drug and Chemical Toxicology</i> , 2017, 40, 228-234.	1.2	14

#	ARTICLE	IF	CITATIONS
1659	Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. <i>British Journal of Cancer</i> , 2017, 116, 489-500.	2.9	14
1660	Solid lipid nanoparticles for the delivery of 1,3,5-triaza-7-phosphaadamantane (PTA) platinum (II) carboxylates. <i>Materials Science and Engineering C</i> , 2017, 74, 357-364.	3.8	6
1661	Synthesis, spectral characterization of novel Pd(II), Pt(II) π -coordination compounds based on N-allylthioureas. Cytotoxic properties and DNA binding ability. <i>Journal of Inorganic Biochemistry</i> , 2017, 168, 98-106.	1.5	20
1662	Design, synthesis and biological evaluation of six dinuclear platinum(II) complexes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 963-966.	1.0	6
1663	Injectable doxorubicin-loaded hydrogels based on dendron-like β -cyclodextrin-poly(ethylene glycol) conjugates. <i>Polymer Chemistry</i> , 2017, 8, 1680-1688.	1.9	31
1664	Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species. <i>Nano Letters</i> , 2017, 17, 928-937.	4.5	548
1665	Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in <i>in vitro</i> and <i>in vivo</i> . <i>European Journal of Medicinal Chemistry</i> , 2017, 128, 45-55.	2.6	50
1666	Synthesis, characterization and <i>in vitro</i> biological assays of a silver(I) complex with 5-fluorouracil: A strategy to overcome multidrug resistant tumor cells. <i>Journal of Fluorine Chemistry</i> , 2017, 195, 93-101.	0.9	32
1667	Novel 5-arylthio-5H-chromenopyridines as a new class of anti-fibrotic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1129-1135.	1.0	17
1668	Vitamin B ₁₂ -Metal Conjugates for Targeted Chemotherapy and Diagnosis: Current Status and Future Prospects. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1625-1638.	1.0	34
1669	Heteroleptic tris-chelate ruthenium(II) complexes of N,N-disubstituted-N ² -acylthioureas: Synthesis, structural studies, cytotoxic activity and confocal microscopy studies. <i>Polyhedron</i> , 2017, 126, 33-41.	1.0	20
1670	A platinum blue complex exerts its cytotoxic activity via DNA damage and induces apoptosis in cancer cells. <i>Chemical Biology and Drug Design</i> , 2017, 90, 210-224.	1.5	3
1671	Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management. <i>Journal of Controlled Release</i> , 2017, 249, 42-52.	4.8	10
1672	Antileukemic action of novel diamine Pt(II) halogenido complexes: Comparison of the representative novel Pt(II) with corresponding Pt(IV) complex. <i>Chemical Biology and Drug Design</i> , 2017, 90, 262-271.	1.5	12
1673	Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin-evoked peripheral neuropathy. <i>Journal of Pineal Research</i> , 2017, 62, e12393.	3.4	97
1674	Cisplatin Preferentially Binds to Zinc Finger Proteins Containing C3H1 or C4 Motifs. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1778-1784.	1.0	16
1675	Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity. <i>Journal of Organometallic Chemistry</i> , 2017, 839, 31-37.	0.8	23
1676	Nonconventional trans-Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytotoxicity Studies. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1835-1840.	1.0	10

#	ARTICLE	IF	CITATIONS
1677	Synthesis, Structural and Biological Studies of Some Half-Sandwich η^6 -Metal Complexes with Pyrimidine-Based Ligands. <i>ChemistrySelect</i> , 2017, 2, 2065-2076.	0.7	10
1678	Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: Syntheses, characterization, and in vitro cytotoxicity studies. <i>Inorganic Chemistry Communication</i> , 2017, 78, 17-20.	1.8	5
1679	New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. <i>Autophagy</i> , 2017, 13, 781-819.	4.3	117
1680	Synthesis, characterization, and cytotoxicity of Pt(IV) complexes containing 1,10-phenanthroline and 2,2'-bipyridine and diaminocyclohexane ligands. <i>Transition Metal Chemistry</i> , 2017, 42, 219-228.	0.7	9
1681	Combination of ruthenium(II)-arene complex [Ru(η^6 -p-cymene)Cl ₂ (pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. <i>Scientific Reports</i> , 2017, 7, 43005.	1.6	97
1682	Molecular dynamics study on DNA nanotubes as drug delivery vehicle for anticancer drugs. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 153, 168-173.	2.5	44
1683	New palladium(II) formamidine complexes: Preparation, characterization, theoretical calculations and cytotoxic activity. <i>Journal of Molecular Structure</i> , 2017, 1137, 453-460.	1.8	4
1684	Exploring the Influence of the Aromaticity on the Anticancer and Antivascular Activities of Organoplatinum(II) Complexes. <i>Chemistry - A European Journal</i> , 2017, 23, 5614-5625.	1.7	26
1685	Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester as a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance. <i>Bioconjugate Chemistry</i> , 2017, 28, 1305-1323.	1.8	38
1686	Redox-Active Metal Complexes for Anticancer Therapy. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1541-1548.	1.0	182
1687	A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. <i>Nature Medicine</i> , 2017, 23, 461-471.	15.2	379
1688	X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 433-437.	1.3	21
1689	Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models. <i>Metallomics</i> , 2017, 9, 309-322.	1.0	60
1690	Direct Determination of Metal Complexes TM Interaction with DNA by Atomic Telemetry and Multiscale Molecular Dynamics. <i>Journal of Physical Chemistry Letters</i> , 2017, 8, 805-811.	2.1	21
1691	Synthesis, characterization and <i>in vitro</i> cytotoxicity of platinum(II) complexes of selenones [Pt(selenone) ₂ Cl ₂]. <i>Journal of Coordination Chemistry</i> , 2017, 70, 1020-1031.	0.8	12
1692	One-pot synthesis of a new 2-substituted 1,2,3-triazole 1-oxide derivative from dipyriddy ketone and isonitrosoacetophenone hydrazone: Nickel(II) complex, DNA binding and cleavage properties. <i>Bioorganic Chemistry</i> , 2017, 71, 325-334.	2.0	19
1693	Synthesis, spectroscopic and DNA binding ability of Co II, Ni II, Cu II and Zn II complexes of Schiff base ligand (E)-1-(((1H-benzo[d]imidazol-2-yl)methylimino)methyl)naphthalen-2-ol. X-ray crystal structure determination of cobalt (II) complex. <i>Materials Science and Engineering C</i> , 2017, 75, 1059-1067.	3.8	44
1694	A strategy for photothermal conversion of polymeric nanoparticles by polyaniline for smart control of targeted drug delivery. <i>Nanotechnology</i> , 2017, 28, 165102.	1.3	28

#	ARTICLE	IF	CITATIONS
1695	Phosphatase-triggered cell-selective release of a Pt(IV)-backboned prodrug-like polymer for an improved therapeutic index. <i>Biomaterials Science</i> , 2017, 5, 1558-1566.	2.6	11
1696	New Pt-NNSO core anticancer agents: Structural optimization and investigation of their anticancer activity. <i>Journal of Inorganic Biochemistry</i> , 2017, 170, 34-45.	1.5	5
1697	New Acridine Thiourea Gold(I) Anticancer Agents: Targeting the Nucleus and Inhibiting Vasculogenic Mimicry. <i>ACS Chemical Biology</i> , 2017, 12, 1524-1537.	1.6	48
1698	RGD-mediated delivery of small-molecule drugs. <i>Future Medicinal Chemistry</i> , 2017, 9, 579-604.	1.1	61
1699	Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy. <i>Journal of Controlled Release</i> , 2017, 255, 81-93.	4.8	99
1700	Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin. <i>Journal of Inorganic Biochemistry</i> , 2017, 172, 1-8.	1.5	13
1701	Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 1974-1991.	2.6	65
1702	Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells. <i>Biochemical Pharmacology</i> , 2017, 136, 40-50.	2.0	16
1703	The microbiome in anti-cancer therapy. <i>Seminars in Immunology</i> , 2017, 32, 74-81.	2.7	61
1704	A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2017, 141, 604-613.	2.3	9
1705	Oxoaporphine Metal Complexes (CoII, NiII, ZnII) with High Antitumor Activity by Inducing Mitochondria-Mediated Apoptosis and S-phase Arrest in HepG2. <i>Scientific Reports</i> , 2017, 7, 46056.	1.6	56
1706	Near-infrared light stimuli-responsive synergistic therapy nanoplatforms based on the coordination of tellurium-containing block polymer and cisplatin for cancer treatment. <i>Biomaterials</i> , 2017, 133, 208-218.	5.7	124
1707	Novel mononuclear Cu (II) terpyridine complexes: Impact of fused ring thiophene and thiazole head groups towards DNA/BSA interaction, cleavage and antiproliferative activity on HepG2 and triple negative CAL-51 cell line. <i>European Journal of Medicinal Chemistry</i> , 2017, 135, 434-446.	2.6	48
1708	In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells. <i>Journal of Biological Inorganic Chemistry</i> , 2017, 22, 807-817.	1.1	19
1709	Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 313-320.	0.6	8
1710	Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. <i>Journal of Biological Chemistry</i> , 2017, 292, 10347-10363.	1.6	38
1711	Complexes of polyamines and their derivatives as living system active compounds. <i>Coordination Chemistry Reviews</i> , 2017, 351, 32-44.	9.5	25
1712	Mechanisms of DNA damage, repair, and mutagenesis. <i>Environmental and Molecular Mutagenesis</i> , 2017, 58, 235-263.	0.9	1,129

#	ARTICLE	IF	CITATIONS
1713	Enhanced Cytotoxicity and Reactivity of a Novel Platinum(IV) Family with DNA-Targeting Naphthalimide Ligands. <i>Inorganic Chemistry</i> , 2017, 56, 6175-6183.	1.9	18
1714	High BIM mRNA levels are associated with longer survival in advanced gastric cancer. <i>Oncology Letters</i> , 2017, 13, 1826-1834.	0.8	10
1715	Ruthenium(II) complexes of saccharin with dipyridoquinoxaline and dipyridophenazine: Structures, biological interactions and photoinduced DNA damage activity. <i>European Journal of Medicinal Chemistry</i> , 2017, 136, 52-62.	2.6	36
1717	<i>cis</i> -Platinum Complex Encapsulated in Self-Assembling Cyclic Peptide Dimers. <i>Organic Letters</i> , 2017, 19, 2560-2563.	2.4	16
1718	New opportunities for drug delivery carrier of natural allophane nanoparticles on human lung cancer A549 cells. <i>Applied Clay Science</i> , 2017, 143, 422-429.	2.6	8
1719	Hydrolysis theory based on density functional studies for cytotoxic Pt(II) and Pd(II) complexes with benzimidazole derivative. <i>Chemical Physics Letters</i> , 2017, 678, 250-258.	1.2	5
1720	An effective peptide cargo carrier for the delivery of cisplatin in ovarian cancer cells. <i>Dyes and Pigments</i> , 2017, 143, 342-347.	2.0	9
1721	Pyrazine based Pt(II) bisalkynyl organometallic complexes: Synthesis, characterization, and cytotoxic effect on A549 human lung carcinoma cells. <i>Applied Organometallic Chemistry</i> , 2017, 31, e3824.	1.7	10
1722	Hydrolysis in Acidic Environment and Degradation of Satraplatin: A Joint Experimental and Theoretical Investigation. <i>Inorganic Chemistry</i> , 2017, 56, 6013-6026.	1.9	20
1723	The synthesis, structure-toxicity relationship of cisplatin derivatives for the mechanism research of cisplatin-induced nephrotoxicity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3591-3594.	1.0	13
1724	Ruthenium(II)-Arene Metallacycles: Crystal Structures, Interaction with DNA, and Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1792-1799.	1.0	16
1725	Intracellular water – an overlooked drug target? Cisplatin impact in cancer cells probed by neutrons. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 2702-2713.	1.3	36
1726	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	3.2	122
1727	Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 376-387.	1.9	23
1728	Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 63-74.	5.1	159
1729	A species-specific double isotope dilution strategy for the accurate quantification of platinum-DNA adducts in lung cells exposed to carboplatin. <i>Journal of Analytical Atomic Spectrometry</i> , 2017, 32, 1320-1330.	1.6	5
1730	Recent development of transition metal complexes with in vivo antitumor activity. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 276-286.	1.5	79
1731	Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes. <i>Journal of Inorganic Biochemistry</i> , 2017, 174, 119-129.	1.5	25

#	ARTICLE	IF	CITATIONS
1732	Half-sandwich Schiff-base Ir(III) complexes as anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 72-82.	2.6	36
1733	Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates. <i>Scientific Reports</i> , 2017, 7, 3751.	1.6	38
1734	Harnessing Phosphato-Platinum Bonding Induced Supramolecular Assembly for Systemic Cisplatin Delivery. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 17757-17768.	4.0	15
1735	A micellar cisplatin prodrug simultaneously eliminates both cancer cells and cancer stem cells in lung cancer. <i>Biomaterials Science</i> , 2017, 5, 1612-1621.	2.6	24
1736	Three Pt(II) complexes based on thiosemicarbazone: synthesis, HSA interaction, cytotoxicity, apoptosis and cell cycle arrest. <i>RSC Advances</i> , 2017, 7, 26478-26486.	1.7	11
1737	Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. <i>Journal of Biological Inorganic Chemistry</i> , 2017, 22, 765-774.	1.1	35
1738	New comprehensive studies of a gold(III) Dithiocarbamate complex with proven anticancer properties: Aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 115-127.	2.6	22
1739	The Exploitation of Low-Energy Electrons in Cancer Treatment. <i>Radiation Research</i> , 2017, 188, 123-143.	0.7	42
1740	Electrospray ionization mass spectrometry for the hydrolysis complexes of cisplatin: implications for the hydrolysis process of platinum complexes. <i>Journal of Mass Spectrometry</i> , 2017, 52, 434-441.	0.7	9
1741	Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma. <i>Talanta</i> , 2017, 174, 171-178.	2.9	16
1742	Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancer. <i>Scientific Reports</i> , 2017, 7, 41103.	1.6	15
1743	Enhanced anti-cancer efficacy to cancer cells by a novel monofunctional mononuclear platinum(II) complex containing a mixed S,N,S-donor ligand. <i>New Journal of Chemistry</i> , 2017, 41, 6760-6768.	1.4	8
1744	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 889-898.	1.3	26
1745	Conformational transition of DNA by dinuclear Pt(II) complexes causes cooperative inhibition of gene expression. <i>Chemical Physics Letters</i> , 2017, 678, 123-129.	1.2	8
1746	Synthesis, Photophysical Properties, and Living Cell Imaging of Theranostic Half-Sandwich Iridium(III)-4,4-Difluoro-4-bora-3,4-diaza-1-indacene (BODIPY) Dyads. <i>Organometallics</i> , 2017, 36, 3435-3442.	1.1	29
1747	An investigation on the DNA/protein binding, DNA cleavage and in vitro anticancer properties of SNO pincer type palladium(II) complexes with N-substituted isatin thiosemicarbazone ligands. <i>Inorganica Chimica Acta</i> , 2017, 466, 61-70.	1.2	53
1749	Synthesis and anticancer evaluation of mono- and trinuclear half-sandwich rhodium(III) and iridium(III) complexes based on N,O-salicylaldiminato-sulfonated scaffolds. <i>Journal of Organometallic Chemistry</i> , 2017, 846, 100-104.	0.8	10
1750	Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction. <i>ACS Chemical Biology</i> , 2017, 12, 1903-1912.	1.6	44

#	ARTICLE	IF	CITATIONS
1751	Effect of cisplatin on the transport activity of P_{II}-type ATPases. <i>Metallomics</i> , 2017, 9, 960-968.	1.0	12
1752	Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node?. <i>European Journal of Pharmacology</i> , 2017, 811, 125-128.	1.7	37
1753	Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5736-5748.	2.9	87
1754	Reduction- and pH-Sensitive Hyaluronan Nanoparticles for Delivery of Iridium(III) Anticancer Drugs. <i>Biomacromolecules</i> , 2017, 18, 2102-2117.	2.6	48
1755	Synthesis, X-ray crystal structure, DNA/BSA binding, DNA cleavage and cytotoxicity studies of phenanthroline based copper(II)/zinc(II) complexes. <i>BioMetals</i> , 2017, 30, 575-587.	1.8	16
1756	Cytotoxic Vanadium Complexes of Branched [ONNO]-Type Diamine Bis(phenolato) Ligands. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1807-1811.	1.0	5
1757	Design, synthesis and biological evaluation of demethylcantharidate-linked platinum(II) complexes of N-monoalkyl-1R,2R-diaminocyclohexane derivatives. <i>Inorganica Chimica Acta</i> , 2017, 462, 188-194.	1.2	4
1758	In vitro antitumor activity, metal uptake and reactivity with ascorbic acid and BSA of some gold(III) complexes with N,N-ethylenediamine bidentate ester ligands. <i>Journal of Inorganic Biochemistry</i> , 2017, 172, 55-66.	1.5	12
1759	Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer. <i>Biomaterials Science</i> , 2017, 5, 1522-1525.	2.6	16
1760	Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity. <i>Oncology Reports</i> , 2017, 37, 2025-2032.	1.2	40
1761	Role of Knoevenagel condensate pyrazolone derivative Schiff base ligated transition metal complexes in biological assay and cytotoxic efficacy. <i>Applied Organometallic Chemistry</i> , 2017, 31, e3792.	1.7	10
1762	Cisplatin-directed coordination-crosslinking nanogels with thermo/pH-sensitive triblock polymers: improvement on chemotherapeutic efficacy via sustained release and drug retention. <i>Nanoscale</i> , 2017, 9, 5859-5871.	2.8	48
1763	Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells. <i>Cancer Investigation</i> , 2017, 35, 289-300.	0.6	14
1764	Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1. <i>Biochemical and Biophysical Research Communications</i> , 2017, 487, 34-40.	1.0	27
1765	Metal complexes targeting the Translocator Protein 18 kDa (TSPO). <i>Coordination Chemistry Reviews</i> , 2017, 341, 1-18.	9.5	23
1766	MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression. <i>Oncology Letters</i> , 2017, 13, 722-730.	0.8	12
1767	Heteroleptic silver(I) complexes with 2,2',6',2''-terpyridines and naproxen: DNA interaction, EGFR/VEGFR2 kinase, growth inhibition and cell cycle arrest studies. <i>Materials Science and Engineering C</i> , 2017, 76, 601-615.	3.8	39
1768	An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties. <i>European Journal of Medicinal Chemistry</i> , 2017, 131, 196-206.	2.6	37

#	ARTICLE	IF	CITATIONS
1769	Synthesis, structural characterization and cytotoxicity evaluation of platinum(II) complexes of heterocyclic selenones. <i>Polyhedron</i> , 2017, 128, 2-8.	1.0	14
1770	Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters. <i>Science Bulletin</i> , 2017, 62, 589-596.	4.3	44
1771	Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1423-1438.	2.4	47
1772	Cancer-specific, Intracellular, Reductive Activation of Anticancer Pt ^{IV} Prodrugs. <i>Chemistry - A European Journal</i> , 2017, 23, 5678-5681.	1.7	41
1773	Human topoisomerase inhibition and DNA/BSA binding of Ru(II)-SCAR complexes as potential anticancer candidates for oral application. <i>BioMetals</i> , 2017, 30, 321-334.	1.8	26
1774	New compounds based on a benzimidazole nucleus: synthesis, characterization and cytotoxic activity against breast and colon cancer cell lines. <i>Journal of Organometallic Chemistry</i> , 2017, 839, 98-107.	0.8	53
1775	Crystal structure and antimicrobial activity of a transplatin adduct of N,N ² -dimethylthiourea, trans-[Pt(NH ₃) ₂ (dmtu) ₂]Cl ₂ . <i>Monatshefte für Chemie</i> , 2017, 148, 669-674.	0.9	4
1776	Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase I ² and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma. <i>Cancer</i> , 2017, 123, 849-860.	2.0	18
1777	Anisotropic noble metal nanoparticles: Synthesis, surface functionalization and applications in biosensing, bioimaging, drug delivery and theranostics. <i>Acta Biomaterialia</i> , 2017, 49, 45-65.	4.1	79
1778	Ru ^{III} Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 1100-1119.	1.2	39
1779	Synthesis, characterization, DNA interactions and antiproliferative activity on glioblastoma of iminopyridine platinum(II) chelate complexes. <i>Journal of Inorganic Biochemistry</i> , 2017, 168, 46-54.	1.5	9
1780	Imidazolium and benzimidazolium-containing compounds: from simple toxic salts to highly bioactive drugs. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 1051-1071.	1.5	43
1781	Synchrotron X-ray Fluorescence Nanoprobe Reveals Target Sites for Organo-Osmium Complex in Human Ovarian Cancer Cells. <i>Chemistry - A European Journal</i> , 2017, 23, 2512-2516.	1.7	67
1782	Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs. <i>ChemMedChem</i> , 2017, 12, 300-311.	1.6	46
1783	Cytotoxicity and cellular response mechanisms of water-soluble platinum(II) complexes of lidocaine and phenylcyanamide derivatives. <i>BioMetals</i> , 2017, 30, 59-70.	1.8	9
1784	Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. <i>Cancer Letters</i> , 2017, 389, 33-40.	3.2	8
1785	Synthesis, reactivity and characterization of Pt(II) complexes with N,N ² chelating ligands; structure and dimethylsulfoxide reactivity relationship. <i>Dalton Transactions</i> , 2017, 46, 1467-1480.	1.6	8
1786	Mass Spectrometry-Based Tools to Characterize DNA-Protein Cross-Linking by Bis-Electrophiles. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 63-77.	1.2	19

#	ARTICLE	IF	CITATIONS
1787	Bifunctional bisphosphonate derivatives and platinum complexes with high affinity for bone hydroxyapatite. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1070-1075.	1.0	11
1788	Innocent But Deadly: Nontoxic Organoiridium Catalysts Promote Selective Cancer Cell Death. <i>ChemMedChem</i> , 2017, 12, 292-299.	1.6	22
1789	Four mononuclear platinum(II) complexes: synthesis, DNA/BSA binding, DNA cleavage and cytotoxicity. <i>BioMetals</i> , 2017, 30, 17-26.	1.8	16
1790	The role of arsenic in the hydrolysis and DNA metalation processes in an arsenous acidâ€“platinum(II) anticancer complex. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 1328-1334.	1.3	12
1791	Platinum(IV) Prodrugs â€“ A Step Closer to Ehrlich's Vision?. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1596-1612.	1.0	139
1792	Synthesis and cytotoxicity of N,Nâ€“2-dibisphosphonate ethylenediamine derivatives and platinum(II) complexes with high binding property to hydroxyapatite. <i>Inorganica Chimica Acta</i> , 2017, 457, 46-52.	1.2	5
1793	Studies on the mechanism of action of antitumor bis(aminophenolate) ruthenium(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2017, 168, 27-37.	1.5	23
1794	DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. <i>Chemical Research in Toxicology</i> , 2017, 30, 388-409.	1.7	45
1795	Lysosomeâ€“associated protein transmembrane4âˆ² is involved in multidrug resistance processes of colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 5229-5234.	0.8	1
1796	Dual-target cancer theranostic for glutathione S-transferase and hypoxia-inducible factor-1Î± inhibition. <i>Chemical Communications</i> , 2017, 53, 12406-12409.	2.2	11
1797	Aminophosphine ligands as a privileged platform for development of antitumoral ruthenium(II) arene complexes. <i>Dalton Transactions</i> , 2017, 46, 16113-16125.	1.6	27
1798	Kinetic aspects of platinum anticancer agents. <i>Polyhedron</i> , 2017, 138, 109-124.	1.0	47
1799	Bifunctional Platinum(II) Complexes with Bisphosphonates Substituted Diamine Derivatives: Synthesis and <i>In vitro</i> Cytotoxicity. <i>Chemistry and Biodiversity</i> , 2017, 14, e1700348.	1.0	11
1800	Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. <i>Scientific Reports</i> , 2017, 7, 13936.	1.6	45
1801	A (salicylaldiminato)Pt(II) complex with dimethylpropylene linkage: Synthesis, structural characterization and antineoplastic activity. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 176, 150-156.	1.7	13
1802	Synthesis, spectroscopic characterization and <i>in vitro</i> anticancer activity of new platinum(II) complexes with some thione ligands in the presence of triethylphosphine. <i>BioMetals</i> , 2017, 30, 787-795.	1.8	5
1803	Substitution of aqua ligands from cis-platinum(II) complexes bearing 2-(phenylthiomethyl)pyridine spectator ligands. <i>Transition Metal Chemistry</i> , 2017, 42, 739-751.	0.7	4
1804	The flavonoid 6-methoxyflavone allays cisplatin-induced neuropathic allodynia and hypoalgesia. <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 1725-1733.	2.5	38

#	ARTICLE	IF	CITATIONS
1805	Platinum(<i>iv</i>) oxaliplatinâ€‘peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells. <i>Chemical Communications</i> , 2017, 53, 11318-11321.	2.2	28
1806	High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer. <i>Oncology Letters</i> , 2017, 14, 4995-5003.	0.8	5
1807	Research progress in modern structure of platinum complexes. <i>European Journal of Medicinal Chemistry</i> , 2017, 140, 349-382.	2.6	84
1808	Quantitative Evaluation of Cisplatin Uptake in Sensitive and Resistant Individual Cells by Single-Cell ICP-MS (SC-ICP-MS). <i>Analytical Chemistry</i> , 2017, 89, 11491-11497.	3.2	105
1809	The renaissance of antiâ€‘neoplastic immunity from tumor cell demise. <i>Immunological Reviews</i> , 2017, 280, 194-206.	2.8	53
1810	Monoâ€‘and Diâ€‘Alkylation Processes of DNA Bases by Nitrogen Mustard Mechlorethamine. <i>ChemPhysChem</i> , 2017, 18, 3390-3401.	1.0	4
1811	Control of Carbon Nanotube Solvatochromic Response to Chemotherapeutic Agents. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 37947-37953.	4.0	21
1812	Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 717-736.	2.7	96
1813	Toxic Effects of Metallopharmaceuticals. <i>Serbian Journal of Experimental and Clinical Research</i> , 2017, 18, 191-194.	0.2	4
1814	Synthesis, crystal structure, antibacterial, cytotoxic, and anticancer activities of new Pd(II) complexes of tri-p-tolyl phosphine with thiones. <i>Russian Journal of General Chemistry</i> , 2017, 87, 2073-2082.	0.3	6
1815	Nucleotide Excision Repair: From Neurodegeneration to Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1007, 17-39.	0.8	20
1816	Biotinylated platinum(IV) complexes designed to target cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2017, 176, 175-180.	1.5	38
1817	Novel ruthenium azo-quinoline complexes with enhanced photonuclease activity in human cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 1016-1029.	2.6	27
1818	A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells. <i>Molecular BioSystems</i> , 2017, 13, 2268-2276.	2.9	28
1819	Catalysis of a 1,3-dipolar reaction by distorted DNA incorporating a heterobimetallic platinum(<i>ii</i>) and copper(<i>ii</i>) complex. <i>Chemical Science</i> , 2017, 8, 7038-7046.	3.7	6
1820	Fattigation-platform nanoparticles using apo-transferrin stearic acid as a core for receptor-oriented cancer targeting. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 159, 571-579.	2.5	21
1821	Drug Delivery Strategies for Platinum-Based Chemotherapy. <i>ACS Nano</i> , 2017, 11, 8560-8578.	7.3	172
1822	Synthesis, characterisation and in vitro cytotoxicity of mixed ligand Pt(<i>ii</i>) oxadiazoline complexes with hexamethylenetetramine and 7-nitro-1,3,5-triazaadamantane. <i>Dalton Transactions</i> , 2017, 46, 12226-12238.	1.6	6

#	ARTICLE	IF	CITATIONS
1823	Synergistic Effects in Pt ^{II} Porphyrinoid Dyes as Candidates for a Dual-Action Anticancer Therapy: A Theoretical Exploration. <i>Chemistry - A European Journal</i> , 2017, 23, 15124-15132.	1.7	24
1824	X-ray microfluorescence for biodistribution studies of nanomedicines. <i>International Journal of Pharmaceutics</i> , 2017, 531, 343-349.	2.6	2
1825	Effect of Taurine on iNOS-Mediated DNA Damage in Drug-Induced Renal Injury. <i>Advances in Experimental Medicine and Biology</i> , 2017, 975 Pt 2, 717-727.	0.8	7
1826	Anticancer kiteplatin pyrophosphate derivatives show unexpected target selectivity for DNA. <i>Dalton Transactions</i> , 2017, 46, 14139-14148.	1.6	11
1827	Organoruthenium Complexes with C ^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action. <i>Chemistry - A European Journal</i> , 2017, 23, 15294-15299.	1.7	29
1828	Sugar-incorporated N-heterocyclic carbene-containing Gold(I) Complexes: Synthesis, Characterization, and Cytotoxic Evaluation. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 4955-4961.	1.0	19
1829	Substance P Mediated DGLs Complexing with DACHPt for Targeting Therapy of Glioma. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 34603-34617.	4.0	15
1830	Platinum Binds Proteins in the Endoplasmic Reticulum of <i>S. cerevisiae</i> and Induces Endoplasmic Reticulum Stress. <i>ACS Chemical Biology</i> , 2017, 12, 2737-2745.	1.6	39
1831	Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy. <i>Journal of Proteome Research</i> , 2017, 16, 4227-4236.	1.8	3
1832	Synthesis, crystal structures, molecular docking and in vitro cytotoxicity studies of two new copper(II) complexes: special emphasis on their binding to HSA. <i>New Journal of Chemistry</i> , 2017, 41, 12429-12441.	1.4	36
1833	Isoliquiritigenin pretreatment attenuates cisplatin induced proximal tubular cells (LLC-PK1) death and enhances the toxicity induced by this drug in bladder cancer T24 cell line. <i>Food and Chemical Toxicology</i> , 2017, 109, 143-154.	1.8	23
1834	Synthesis, characterization and DNA binding studies of platinum(II) complexes with benzimidazole derivative ligands. <i>Bioorganic Chemistry</i> , 2017, 74, 272-283.	2.0	13
1835	Anticancer Ru(Î6-p-cymene) complexes of 2-pyridinecarbothioamides: A structure-activity relationship study. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 395-401.	1.5	28
1836	Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) Î ² -carboline complexes. <i>European Journal of Medicinal Chemistry</i> , 2017, 140, 104-117.	2.6	47
1837	Application of Metallomics and Metalloproteomics for Understanding the Molecular Mechanisms of Action of Metal-Based Drugs. <i>Molecular and Integrative Toxicology</i> , 2017, , 199-222.	0.5	0
1838	Tuning the Optical Properties of Phenanthriplatin: Towards New Photoactivatable Analogues. <i>ChemPhotoChem</i> , 2017, 1, 504-512.	1.5	5
1839	<i>GSTP1</i> c.313A>G, <i>XPD</i> c.934G>A, <i>XPF</i> c.2505T>C and <i>CASP9</i> c.1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 520-525.	1.2	11
1840	Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status. <i>Investigational New Drugs</i> , 2017, 35, 682-690.	1.2	27

#	ARTICLE	IF	CITATIONS
1841	Essential and Non-essential Metals. <i>Molecular and Integrative Toxicology</i> , 2017, , .	0.5	5
1842	N-(R)ethanolamine dithiocarbamate ligands and their Ni(II) and Pt(II) complexes. Evaluation of the in vitro anticancer activity of the Pt(II) derivatives. <i>Inorganica Chimica Acta</i> , 2017, 466, 584-590.	1.2	9
1843	Engineering gold-based radiosensitizers for cancer radiotherapy. <i>Materials Horizons</i> , 2017, 4, 817-831.	6.4	173
1844	Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 815-825.	1.1	15
1845	The evolution of chemotherapy for the treatment of prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 2658-2669.	0.6	57
1846	Synthesis and Evaluation of the Antitumor Properties of a Small Collection of Pt ^{II} Complexes with 7-Deazaadenosine as Scaffold. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 4935-4947.	1.2	10
1847	<i>Fusobacterium nucleatum</i> Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. <i>Cell</i> , 2017, 170, 548-563.e16.	13.5	1,377
1848	Synthesis, solvatochromism and crystal structure of trans-[Cu(Et ₂ NCH ₂ CH ₂ NH ₂) ₂ .H ₂ O](NO ₃) ₂ complex: Experimental with DFT combination. <i>Journal of Molecular Structure</i> , 2017, 1148, 328-338.	1.8	22
1849	Chemoradiation Cancer Therapy: Molecular Mechanisms of Cisplatin Radiosensitization. <i>Journal of Physical Chemistry C</i> , 2017, 121, 17505-17513.	1.5	20
1850	Synthesis and Characterization of Pt(II) Complexes with Pyridyl Ligands: Elongated Octahedral Ion Pairs and Other Factors Influencing ¹ H NMR Spectra. <i>Inorganic Chemistry</i> , 2017, 56, 9781-9793.	1.9	8
1851	Cytotoxic (salen)ruthenium(III) anticancer complexes exhibit different modes of cell death directed by axial ligands. <i>Chemical Science</i> , 2017, 8, 6865-6870.	3.7	46
1852	Water soluble Ru(II)-arene complexes of the antidiabetic drug metformin: DNA and protein binding, molecular docking, cytotoxicity and apoptosis-inducing activity. <i>RSC Advances</i> , 2017, 7, 37706-37719.	1.7	37
1853	Gold-stabilized carboxymethyl dextran nanoparticles for image-guided photodynamic therapy of cancer. <i>Journal of Materials Chemistry B</i> , 2017, 5, 7319-7327.	2.9	19
1854	Reprogramming to developmental plasticity in cancer stem cells. <i>Developmental Biology</i> , 2017, 430, 266-274.	0.9	38
1855	The influence of the ethane-1,2-diamine ligand on the activity of a monofunctional platinum complex. <i>Journal of Inorganic Biochemistry</i> , 2017, 177, 328-334.	1.5	10
1856	Synthesis and electro-catalytic activity of Pt-Co nanoflowers. <i>Journal of Nanoparticle Research</i> , 2017, 19, 1.	0.8	2
1857	CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. <i>EMBO Molecular Medicine</i> , 2017, 9, 1415-1433.	3.3	61
1858	Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 92, 164-172.	1.2	19

#	ARTICLE	IF	CITATIONS
1859	Vibrational and conformational studies of 1,3-diaminopropane and its N-deuterated and N-ionised derivatives. <i>New Journal of Chemistry</i> , 2017, 41, 10132-10147.	1.4	6
1860	Synthesis and analysis of the anticancer activity of Ru(II) complexes incorporating 2-hydroxymethylidene-indene-1,3-dione ligands. <i>New Journal of Chemistry</i> , 2017, 41, 10438-10446.	1.4	4
1861	Melatonin Attenuates Pain Hypersensitivity and Decreases Astrocyte-Mediated Spinal Neuroinflammation in a Rat Model of Oxaliplatin-Induced Pain. <i>Inflammation</i> , 2017, 40, 2052-2061.	1.7	38
1862	Electron transfer processes occurring on platinum neural stimulating electrodes: pulsing experiments for cathodic-first, charge-balanced, biphasic pulses for 0.566% \pm 0.1% \pm 0.1% \pm 0.1% subcutaneous tissues. <i>Journal of Neural Engineering</i> , 2017, 14, 056003.	1.7	6
1863	Tunable Signal-Off and Signal-On Electrochemical Cisplatin Sensor. <i>Analytical Chemistry</i> , 2017, 89, 9984-9989.	3.2	24
1864	para -Sulfonatocalix[4]arene and polyamidoamine dendrimer nanocomplexes as delivery vehicles for a novel platinum anticancer agent. <i>Journal of Inorganic Biochemistry</i> , 2017, 176, 1-7.	1.5	8
1865	Interactions of cisplatin analogues with lysozyme: a comparative analysis. <i>BioMetals</i> , 2017, 30, 733-746.	1.8	13
1866	Synthesis, Spectral Characterization, In Vitro Antibacterial Evaluation and POM Analyses of Palladium(II) Thiocyanate Complexes of Thioamides. <i>Pharmaceutical Chemistry Journal</i> , 2017, 51, 793-799.	0.3	5
1868	Cyanocobalamin conjugates of cisplatin and diaminocyclohexane-platinum(ii): matrix-assisted laser desorption ionization mass spectrometry characterization using 4-chloro-L-cyanocinnamic acid as the matrix. <i>RSC Advances</i> , 2017, 7, 53658-53666.	1.7	10
1869	Injectable Thermosensitive Polypeptide-Based CDDP-Complexed Hydrogel for Improving Localized Antitumor Efficacy. <i>Biomacromolecules</i> , 2017, 18, 4341-4348.	2.6	33
1870	Ferroquine, the next generation antimalarial drug, has antitumor activity. <i>Scientific Reports</i> , 2017, 7, 15896.	1.6	72
1871	Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin. <i>Oncology Letters</i> , 2017, 14, 5819-5824.	0.8	6
1872	Mononuclear palladium(II) and platinum(II) complexes of P,C-donor ligands: synthesis, crystal structures, cytotoxicity, and mechanistic studies of a highly stereoselective Mizoroki-Heck reaction. <i>Inorganic Chemistry Frontiers</i> , 2017, 4, 2107-2118.	3.0	16
1873	On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent. <i>Metallomics</i> , 2017, 9, 1786-1795.	1.0	20
1874	Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells. <i>Neoplasia</i> , 2017, 19, 1003-1011.	2.3	28
1875	Characterization of Hydrophilic Gold(I) N-Heterocyclic Carbene (NHC) Complexes as Potent TrxR Inhibitors Using Biochemical and Mass Spectrometric Approaches. <i>Inorganic Chemistry</i> , 2017, 56, 14237-14250.	1.9	76
1876	Targeting DNA repair and replication stress in the treatment of ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 619-628.	1.0	66
1877	Molecular, cellular and pharmacological effects of platinum(II) diiodido complexes containing 9-deazahypoxanthine derivatives: A group of broad-spectrum anticancer active agents. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 173, 423-433.	1.7	6

#	ARTICLE	IF	CITATIONS
1878	p62/RIP1-NF- κ B pathway in human ovarian cancer cells. <i>Cancer Science</i> , 2017, 108, 1405-1413.	1.7	48
1879	Improve the anticancer potency of the platinum(II) complexes through functionalized leaving group. <i>Journal of Inorganic Biochemistry</i> , 2017, 175, 20-28.	1.5	12
1880	Platinum nanoparticles in nanobiomedicine. <i>Chemical Society Reviews</i> , 2017, 46, 4951-4975.	18.7	314
1881	Coordination self-assembly of platinum-bisphosphonate polymer-metal complex nanoparticles for cisplatin delivery and effective cancer therapy. <i>Nanoscale</i> , 2017, 9, 10002-10019.	2.8	32
1882	A Perspective " can copper complexes be developed as a novel class of therapeutics?. <i>Dalton Transactions</i> , 2017, 46, 10758-10773.	1.6	140
1883	Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as pro-oxidants and sensitize human cancer cell lines to paclitaxel. <i>Metallomics</i> , 2017, 9, 1132-1141.	1.0	35
1884	Morphological and in vitro evaluation of programmed cell death in MCF-7 cells by new organoruthenium(II) complexes. <i>New Journal of Chemistry</i> , 2017, 41, 8620-8636.	1.4	11
1885	Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. <i>Journal of Materials Chemistry B</i> , 2017, 5, 6049-6057.	2.9	53
1886	MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance. <i>Oncogene</i> , 2017, 36, 5939-5947.	2.6	21
1887	On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging. <i>Chemical Communications</i> , 2017, 53, 8249-8260.	2.2	64
1888	Insights into the mevalonate pathway in the anticancer effect of a platinum complex on human gastric cancer cells. <i>European Journal of Pharmacology</i> , 2017, 810, 120-127.	1.7	9
1889	Anti-cancer gold(I) phosphine complexes: Cyclic trimers and tetramers containing the P-Au-P moiety. <i>Journal of Inorganic Biochemistry</i> , 2017, 175, 1-8.	1.5	28
1890	Dinuclear Ru(II)(bipy) ₂ Derivatives: Structural, Biological, and in Vivo Zebrafish Toxicity Evaluation. <i>Inorganic Chemistry</i> , 2017, 56, 7127-7144.	1.9	40
1891	A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response. <i>Cancer Letters</i> , 2017, 385, 168-178.	3.2	42
1892	Halogenated Pt(IV) Complexes from N-Halosuccinimide Oxidation of Pt(II) Antitumor Drugs: Synthesis, Mechanistic Investigation, and Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1706-1712.	1.0	13
1893	Platinum complexes containing adenine-based ligands: An overview of selected structural features. <i>Coordination Chemistry Reviews</i> , 2017, 332, 1-29.	9.5	17
1894	Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. <i>Cell Death and Differentiation</i> , 2017, 24, 300-316.	5.0	16
1895	Anionic chlorido(triphenyl)tin(IV) bearing <i>N</i> -phthaloylglycinato or 1,2,4-benzenetricarboxylato 1,2-anhydride ligands: potential cytotoxic and apoptosis-inducing agents against several types of cancer. <i>Chemical Biology and Drug Design</i> , 2017, 89, 628-633.	1.5	8

#	ARTICLE	IF	CITATIONS
1896	Low-Generation Polyamidoamine Dendrimers as Drug Carriers for Platinum(IV) Complexes. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1713-1720.	1.0	20
1897	Reprint of: Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. <i>Inorganica Chimica Acta</i> , 2017, 454, 247-253.	1.2	2
1898	New orally active DNA minor groove binding small molecule CT-1 acts against breast cancer by targeting tumor DNA damage leading to p53-dependent apoptosis. <i>Molecular Carcinogenesis</i> , 2017, 56, 1266-1280.	1.3	13
1899	Synthesis and structure of a new trinuclear nickel(II) complex bridged by $\text{N}(\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2)_3$ and $\text{N}(\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2)_2$ ligands: in vitro anticancer activities and reactivities toward DNA and protein. <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, 1-11.	1.4	5
1900	Synthesis and crystal structures of cobalt(II), cadmium(II), and zinc(II) complexes of 4-nitro phenylcyanamide: enhancing the biological properties through bound to human serum albumin. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 2055-2065.	2.0	11
1901	Fasting boosts sensitivity of human skin melanoma to cisplatin-induced cell death. <i>Biochemical and Biophysical Research Communications</i> , 2017, 485, 16-22.	1.0	19
1902	Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. <i>Oncogene</i> , 2017, 36, 585-592.	2.6	15
1903	SIRT3 Silencing Sensitizes Breast Cancer Cells to Cytotoxic Treatments Through an Increment in ROS Production. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 397-406.	1.2	53
1904	Metal-Containing Pharmacophores in Molecularly Targeted Anticancer Therapies and Diagnostics. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1561-1572.	1.0	15
1905	Plant flavonoids in cancer chemoprevention: role in genome stability. <i>Journal of Nutritional Biochemistry</i> , 2017, 45, 1-14.	1.9	284
1906	Cisplatin-Stitched Polysaccharide Vesicles for Synergistic Cancer Therapy of Triple Antagonistic Drugs. <i>Biomacromolecules</i> , 2017, 18, 113-126.	2.6	46
1907	Metal drugs become targeted. <i>ESMO Open</i> , 2017, 2, e000239.	2.0	14
1909	Crystal structures of two platinum(II) complexes containing ethyl eugenoxycetate and 2-aminopyridine. <i>Acta Crystallographica Section E: Crystallographic Communications</i> , 2017, 73, 573-578.	0.2	3
1910	Selective Ru(II)/lawsone complexes inhibiting tumor cell growth by apoptosis. <i>Journal of Inorganic Biochemistry</i> , 2017, 176, 66-76.	1.5	41
1911	Mononuclear copper(II) and binuclear cobalt(II) complexes with halides and tetradentate nitrogen coordinate ligand: Synthesis, structures and bioactivities. <i>Inorganica Chimica Acta</i> , 2017, 466, 219-227.	1.2	20
1912	Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells. <i>Oncology Letters</i> , 2018, 15, 3313-3320.	0.8	12
1913	Evaluation of cisplatin efficiency as a chemotherapeutic drug based on neural networks optimized by genetic algorithm. , 2017, , .		7
1914	Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells. <i>Oncology Letters</i> , 2017, 15, 2871-2880.	0.8	8

#	ARTICLE	IF	CITATIONS
1915	ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy. <i>Medicine (United States)</i> , 2017, 96, e9402.	0.4	16
1917	Thermo-Sensitive TRP Channels: Novel Targets for Treating Chemotherapy-Induced Peripheral Pain. <i>Frontiers in Physiology</i> , 2017, 8, 1040.	1.3	90
1918	Bioactive Nanocomposites for Tissue Repair and Regeneration: A Review. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 66.	1.2	77
1919	Particular gene upregulation and p53 heterogeneous expression in TP53-mutated maxillary carcinoma. <i>Oncology Letters</i> , 2017, 14, 4633-4640.	0.8	9
1920	STAT3/NF- κ B-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer. <i>Theranostics</i> , 2017, 7, 647-663.	4.6	70
1921	G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2344.	1.8	61
1922	Under-Reported Aspects of Platinum Drug Pharmacology. <i>Molecules</i> , 2017, 22, 382.	1.7	15
1923	Ni(II) Complexes with Schiff Base Ligands: Preparation, Characterization, DNA/Protein Interaction and Cytotoxicity Studies. <i>Molecules</i> , 2017, 22, 1772.	1.7	31
1924	Effects of 1,25(OH) ₂ D ₃ on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents. <i>Nutrients</i> , 2017, 9, 87.	1.7	17
1925	Platinum-Based Drugs Differentially Affect the Ultrastructure of Breast Cancer Cell Types. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	14
1926	Cisplatin, Oxaliplatin, and Kiteplatin Subcellular Effects Compared in a Plant Model. <i>International Journal of Molecular Sciences</i> , 2017, 18, 306.	1.8	5
1927	The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1869.	1.8	25
1928	Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling. <i>International Journal of Molecular Sciences</i> , 2017, 18, 916.	1.8	10
1929	Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin. <i>Journal of Nanomaterials</i> , 2017, 2017, 1-11.	1.5	37
1930	Cytoprotective Effects of Cell-Permeable Bifunctional Antioxidant Enzyme, GST-TAT-SOD, against Cisplatin-Induced Cell Damage. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-7.	1.9	4
1931	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-18.	0.9	40
1932	Multivariant Crystallization of Tetraplatin Precursors from Solutions Containing 1,2-C ₆ H ₁₀ (NH ₃) ₂ CS ₂ ²⁺ and [PtCl ₆] ²⁻ Ions. <i>Journal of Chemistry</i> , 2017, 2017, 1-12.	0.9	0
1933	Melatonin potentiates "inside-out" nano-thermotherapy in human breast cancer cells: a potential cancer target multimodality treatment based on melatonin-loaded nanocomposite particles. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7351-7363.	3.3	15

#	ARTICLE	IF	CITATIONS
1934	Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1517-1533.	2.0	94
1935	Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 3856-3861.	1.2	39
1936	Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition. <i>Journal of Cancer</i> , 2017, 8, 1425-1432.	1.2	11
1937	Long noncoding RNA <i>CRNDE</i> functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 205-216.	1.0	74
1938	The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy. <i>Future Oncology</i> , 2017, 13, 2691-2696.	1.1	7
1939	A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression. <i>Virology Journal</i> , 2017, 14, 149.	1.4	6
1940	ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 166.	3.5	79
1941	New perspectives of cobalt tris(bipyridine) system: anti-cancer effect and its collateral sensitivity towards multidrug-resistant (MDR) cancers. <i>Oncotarget</i> , 2017, 8, 55003-55021.	0.8	27
1942	Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 35-52.	1.0	51
1943	Phosphorylation of eIF2 α suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in human renal proximal tubular cells. <i>International Journal of Molecular Medicine</i> , 2017, 40, 1957-1964.	1.8	6
1944	Arsenic Trioxide Induces Apoptosis via Specific Signaling Pathways in HT-29 Colon Cancer Cells. <i>Journal of Cancer Science & Therapy</i> , 2017, 09, .	1.7	24
1945	Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPT-AEA1. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 212-220.	0.9	27
1946	NO Exchange for a Water Molecule Favorably Changes Ionophoretic Release of Ruthenium Complexes to the Skin. <i>Molecules</i> , 2017, 22, 104.	1.7	5
1947	Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts. <i>Journal of Cancer</i> , 2017, 8, 2614-2625.	1.2	3
1948	<i>C</i> ₃ -symmetric opioid scaffolds are pH-responsive DNA condensation agents. <i>Nucleic Acids Research</i> , 2017, 45, 527-540.	6.5	11
1949	Long non-coding RNA MEG3 contributes to cisplatin-induced apoptosis via inhibition of autophagy in human glioma cells. <i>Molecular Medicine Reports</i> , 2017, 16, 2946-2952.	1.1	50
1950	A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. <i>Oncotarget</i> , 2017, 8, 2568-2584.	0.8	44
1951	Nafion [®] -Containing Solid Lipid Nanoparticles as a Tool for Anticancer Pt Delivery: Preliminary Studies. <i>Journal of Chemistry</i> , 2017, 2017, 1-6.	0.9	4

#	ARTICLE	IF	CITATIONS
1952	Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation. <i>Food and Chemical Toxicology</i> , 2018, 114, 227-236.	1.8	78
1953	Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 303-307.	0.6	21
1954	Bioactive ruthenium(II)-arene complexes containing modified 18 β -glycyrrhetic acid ligands. <i>Journal of Inorganic Biochemistry</i> , 2018, 182, 194-199.	1.5	19
1955	The Physico-Chemical Basis of DNA Radiosensitization: Implications for Cancer Radiation Therapy. <i>Chemistry - A European Journal</i> , 2018, 24, 10271-10279.	1.7	53
1956	Synthesis, cytotoxicity and anti-metastatic properties of new pyridyl-thiazole arene ruthenium(II) complexes. <i>Applied Organometallic Chemistry</i> , 2018, 32, e4311.	1.7	5
1957	<i>In vitro</i> biological properties and predicted DNA-BSA interaction of three new dicyanidoargentate($\text{Ag}(\text{CN})_2^-$)-based complexes: synthesis and characterization. <i>New Journal of Chemistry</i> , 2018, 42, 4679-4692.	1.4	9
1958	Multi-State VALBOND for Atomistic Simulations of H_2O and H_2O_2 Molecules, Metal Complexes, and Reactions. <i>Journal of Chemical Theory and Computation</i> , 2018, 14, 3565-3578.	2.3	9
1959	Supramolecular polymeric chemotherapy based on cucurbit[7]uril-PEG copolymer. <i>Biomaterials</i> , 2018, 178, 697-705.	5.7	74
1960	Development of a novel carboplatin like cytoplasmic trackable near infrared fluorophore conjugate via strain-promoted azide alkyne cycloaddition. <i>Journal of Inorganic Biochemistry</i> , 2018, 182, 150-157.	1.5	11
1961	Interaction between carboplatin and cucurbit[7]uril studied by means of multinuclear NMR spectroscopy and DFT calculations. <i>Journal of Molecular Structure</i> , 2018, 1163, 68-76.	1.8	6
1962	Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	18
1963	Di-copper metallodrugs promote NCI-60 chemotherapy via singlet oxygen and superoxide production with tandem TA/TA and AT/AT oligonucleotide discrimination. <i>Nucleic Acids Research</i> , 2018, 46, 2733-2750.	6.5	41
1964	Update on Cancer Treatment in Exotics. <i>Veterinary Clinics of North America - Exotic Animal Practice</i> , 2018, 21, 465-509.	0.4	15
1965	Suppression of Akt-mediated HDAC3 expression and CDK2 T39 phosphorylation by a bichalcone analog contributes to S phase retardation of cancer cells. <i>European Journal of Pharmacology</i> , 2018, 829, 141-150.	1.7	4
1966	Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis. <i>Cell Cycle</i> , 2018, 17, 833-843.	1.3	32
1967	Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4588-4601.	3.2	11
1968	Anticancer diamino-tris(phenolato) vanadium(V) complexes: Ligand-metal interplay. <i>Journal of Coordination Chemistry</i> , 2018, 71, 2003-2011.	0.8	21
1969	Medicinal Applications of Gold(I/III)-Based Complexes Bearing N-Heterocyclic Carbene and Phosphine Ligands. <i>Journal of Organometallic Chemistry</i> , 2018, 866, 153-164.	0.8	72

#	ARTICLE	IF	CITATIONS
1970	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. <i>Oncogene</i> , 2018, 37, 3981-3997.	2.6	31
1971	Synthesis, structural characterization, biological evaluation and molecular docking studies of new platinum(II) complexes containing isocyanides. <i>New Journal of Chemistry</i> , 2018, 42, 8681-8692.	1.4	13
1972	A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers. <i>Journal of the American Chemical Society</i> , 2018, 140, 5612-5624.	6.6	56
1973	Significant effects of counteranions on the anticancer activity of iridium(III) complexes. <i>Chemical Communications</i> , 2018, 54, 4421-4424.	2.2	80
1974	Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. <i>ChemMedChem</i> , 2018, 13, 1131-1145.	1.6	23
1975	A potential method to improve the in vitro cytotoxicity of half-sandwich Os(II) complexes against A2780 cells. <i>Dalton Transactions</i> , 2018, 47, 5714-5724.	1.6	10
1976	Ruthenium carbonyl containing 4-pyrones as potent anticancer agents. <i>Journal of Organometallic Chemistry</i> , 2018, 872, 135-143.	0.8	3
1977	Emerging Therapies in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2018, 20, 46.	1.8	22
1978	BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. <i>Cancer Letters</i> , 2018, 428, 117-126.	3.2	69
1979	In vitro combinations of inert phenolato Ti(IV) complexes with clinically employed anticancer chemotherapy: synergy with oxaliplatin on colon cells. <i>RSC Advances</i> , 2018, 8, 5822-5827.	1.7	7
1980	Evaluation of novel platinum(II) based AIE compound-encapsulated mesoporous silica nanoparticles for cancer theranostic application. <i>Dalton Transactions</i> , 2018, 47, 4613-4624.	1.6	22
1981	Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells. <i>DNA Repair</i> , 2018, 63, 1-9.	1.3	35
1982	Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy. <i>Coordination Chemistry Reviews</i> , 2018, 360, 34-76.	9.5	214
1983	7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS. , 2018, 18, 199-218.		82
1984	A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 3426-3430.	7.2	97
1985	Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 435-450.	2.6	27
1986	Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues. <i>European Journal of Medicinal Chemistry</i> , 2018, 148, 1-25.	2.6	28
1987	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. <i>Inorganic Chemistry</i> , 2018, 57, 2851-2864.	1.9	45

#	ARTICLE	IF	CITATIONS
1988	A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)â€Ru(II) Anticancer Prodrug. <i>Inorganic Chemistry</i> , 2018, 57, 2917-2924.	1.9	56
1989	13. Antitumor Metallo drugs that Target Proteins. , 2018, 18, 351-386.		7
1990	Modulation of thiol-dependent redox system by metal ions<i>via</i>thioredoxin and glutaredoxin systems. <i>Metallomics</i> , 2018, 10, 218-228.	1.0	83
1991	Anticancer Activity of Bifunctional Organometallic Ru(II) Arene Complexes Containing a 7-Hydroxycoumarin Group. <i>Organometallics</i> , 2018, 37, 441-447.	1.1	47
1992	Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery. <i>British Journal of Surgery</i> , 2018, 105, e131-e141.	0.1	120
1993	Chirality in metal-based anticancer agents. <i>Dalton Transactions</i> , 2018, 47, 4017-4026.	1.6	43
1994	Carbonâ€Dotâ€Mediated Coâ€Administration of Chemotherapeutic Agents for Reversing Cisplatin Resistance in Cancer Therapy. <i>ChemNanoMat</i> , 2018, 4, 801-806.	1.5	8
1995	Lupeol alters ER stressâ€signaling pathway by downregulating ABCG2 expression to induce Oxaliplatinâ€resistant LoVo colorectal cancer cell apoptosis. <i>Environmental Toxicology</i> , 2018, 33, 587-593.	2.1	35
1996	In vitro inhibited effect of gap junction composed of Cx43 in the invasion and metastasis of testicular cancer resisted to cisplatin. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 826-833.	2.5	13
1997	Traceable platinum(II) complexes with alkylene diamine-derived ligands: synthesis, characterization and in vitro studies. <i>Journal of Coordination Chemistry</i> , 2018, 71, 243-257.	0.8	3
1998	Exploring the Effect of Polypyridyl Ligands on the Anticancer Activity of Phosphorescent Iridium(III) Complexes: From Proteosynthesis Inhibitors to Photodynamic Therapy Agents. <i>Chemistry - A European Journal</i> , 2018, 24, 4607-4619.	1.7	55
1999	Nutritional shortage augments cisplatin-effects on murine melanoma cells. <i>Chemico-Biological Interactions</i> , 2018, 281, 89-97.	1.7	7
2000	A Low-Toxicity DNA-Alkylating N-Mustard-Quinoline Conjugate with Preferential Sequence Specificity Exerts Potent Antitumor Activity Against Colorectal Cancer. <i>Neoplasia</i> , 2018, 20, 119-130.	2.3	8
2001	Triphenylstannyl((arylimino)methyl)benzoates with selective potency that induce G1 and G2/M cell cycle arrest and trigger apoptosis <i>via</i> ROS in human cervical cancer cells. <i>Dalton Transactions</i> , 2018, 47, 1993-2008.	1.6	26
2002	Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex. <i>Journal of Biological Inorganic Chemistry</i> , 2018, 23, 261-275.	1.1	28
2003	Synthesis, characterization and anticancer evaluation of transplatin derivatives with heterocyclic thiones. <i>Polyhedron</i> , 2018, 141, 360-368.	1.0	14
2004	Delivery of [Ru(Î-6-p-cymene)Cl2{Ph2P(CH2)3SPh-ÎP}] using unfunctionalized and mercapto functionalized SBA-15 mesoporous silica: Preparation, characterization and in vitro study. <i>Journal of Inorganic Biochemistry</i> , 2018, 180, 155-162.	1.5	14
2005	Automated contour analysis of multi-cellular spheroids spreading through high content imaging. <i>Physical Biology</i> , 2018, 15, 026006.	0.8	2

#	ARTICLE	IF	CITATIONS
2006	Heteroleptic Palladium(II) dithiocarbamates: Synthesis, characterization and <i>in vitro</i> biological screening. <i>Journal of Molecular Structure</i> , 2018, 1156, 564-570.	1.8	10
2007	Novel platinum compounds and nanoparticles as anticancer agents. <i>Pharmaceutical Patent Analyst</i> , 2018, 7, 33-46.	0.4	18
2008	Effects of Banxia Xiexin Decoction (半夏泻心汤) on Cisplatin-Induced Apoptosis of Human A549 Lung Cancer Cells. <i>Chinese Journal of Integrative Medicine</i> , 2018, 24, 436-441.	0.7	7
2009	Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and <i>in vivo</i> mouse models. <i>Cancer Letters</i> , 2018, 416, 138-148.	3.2	29
2010	Synthesis, characterization and cytotoxicity of arene- π -ruthenium(ii) complexes with acylpyrazolones functionalized with aromatic groups in the acyl moiety. <i>Dalton Transactions</i> , 2018, 47, 868-878.	1.6	25
2011	FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells <i>in vivo</i> and <i>in vitro</i> . <i>Cancer Letters</i> , 2018, 418, 27-40.	3.2	34
2012	Making organoruthenium complexes of 8-hydroxyquinolines more hydrophilic: impact of a novel α -phenylalanine-derived arene ligand on the biological activity. <i>Dalton Transactions</i> , 2018, 47, 2192-2201.	1.6	31
2013	Cell-based studies of the first π -sandwich Ir(III) complex containing histone deacetylase inhibitor 4-phenylbutyrate. <i>Applied Organometallic Chemistry</i> , 2018, 32, e4246.	1.7	9
2014	Synthesis and antiproliferative activity of a series of new platinum and palladium diphosphane complexes. <i>Dalton Transactions</i> , 2018, 47, 1918-1932.	1.6	33
2015	Design, synthesis, pharmacological evaluation and DNA interaction studies of binuclear Pt(II) complexes with pyrazolo[1,5-a]pyrimidine scaffold. <i>Applied Organometallic Chemistry</i> , 2018, 32, e4222.	1.7	10
2016	Anticancer platinum-based complexes with non-classical structures. <i>Applied Organometallic Chemistry</i> , 2018, 32, e4228.	1.7	31
2017	Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy. <i>Journal of Proteomics</i> , 2018, 188, 119-138.	1.2	4
2018	An investigation on 3-acetyl-7-methoxy-coumarin Schiff bases and their Ru(II) metallates with potent antiproliferative activity and enhanced LDH and NO release. <i>RSC Advances</i> , 2018, 8, 1539-1561.	1.7	28
2019	MEGF6 Promotes the Epithelial-to-Mesenchymal Transition via the TGF β ² /SMAD Signaling Pathway in Colorectal Cancer Metastasis. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 1895-1906.	1.1	40
2020	Oncosis-inducing cyclometalated iridium(III) complexes. <i>Chemical Science</i> , 2018, 9, 5183-5190.	3.7	95
2021	Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 1971-1984.	1.1	19
2022	DUOX1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. <i>Cancer Letters</i> , 2018, 428, 104-116.	3.2	60
2023	Hyaluronic acid-coated cisplatin conjugated gold nanoparticles for combined cancer treatment. <i>Journal of Industrial and Engineering Chemistry</i> , 2018, 65, 236-243.	2.9	35

#	ARTICLE	IF	CITATIONS
2024	Epigenetics and testicular germ cell tumors. <i>Gene</i> , 2018, 661, 22-33.	1.0	35
2025	Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models. <i>Biomaterials</i> , 2018, 169, 1-10.	5.7	65
2026	Organometallic Gold(III) Complexes Similar to Tetrahydroisoquinoline Induce ER-Stress-Mediated Apoptosis and Pro-Death Autophagy in A549 Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3478-3490.	2.9	90
2027	Synergic highly effective photothermal-chemotherapy with platinum prodrug linked melanin-like nanoparticles. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 356-363.	1.9	12
2028	Synthesis, characterization, and cytotoxic properties of mono- and di-nuclear cobalt(<i>II</i>)-polypyridyl complexes. <i>Dalton Transactions</i> , 2018, 47, 5755-5763.	1.6	20
2029	A supramolecular approach to the examination of the structures of some anticancer organoamidoplatinum(II) complexes. <i>Supramolecular Chemistry</i> , 2018, 30, 418-424.	1.5	7
2030	Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 911-921.	1.1	8
2031	Screening organometallic thiophene containing thiosemicarbazone ruthenium (II/III) complexes as potential anti-tumour agents. <i>Journal of Biological Inorganic Chemistry</i> , 2018, 23, 425-435.	1.1	11
2032	Planar Chiral Ferrocene Cyclopalladated Derivatives Induce Caspase-Dependent Apoptosis and Antimetastasis in Cancer Cells. <i>Organometallics</i> , 2018, 37, 1103-1113.	1.1	19
2033	Strategies against methicillin-resistant <i>Staphylococcus aureus</i> persists. <i>Future Medicinal Chemistry</i> , 2018, 10, 779-794.	1.1	31
2034	Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus. <i>Journal of the American Chemical Society</i> , 2018, 140, 4279-4287.	6.6	28
2035	A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy. <i>Angewandte Chemie</i> , 2018, 130, 3484-3488.	1.6	15
2036	Design, synthesis, MTT assay, DNA interaction studies of platinum(II) complexes. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 14-31.	2.0	7
2037	Preparation, characterization and biological evaluation of two chiral binuclear copper(II) complexes. <i>Applied Organometallic Chemistry</i> , 2018, 32, e3911.	1.7	3
2038	Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug. <i>Inorganica Chimica Acta</i> , 2018, 472, 221-228.	1.2	31
2039	Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. <i>Cancer Biology and Therapy</i> , 2018, 19, 63-75.	1.5	56
2040	Synthesis, crystal structure and anticancer activity of tetrakis(N-isopropylimidazolidine-2-selenone)platinum(II) chloride. <i>Journal of Molecular Structure</i> , 2018, 1152, 232-236.	1.8	8
2041	A new class of platinum(<i>II</i>) complexes with the phosphine ligand pta which show potent anticancer activity. <i>Inorganic Chemistry Frontiers</i> , 2018, 5, 39-53.	3.0	44

#	ARTICLE	IF	CITATIONS
2042	Coordination-Driven Self-Assembly of Ionic Irregular Hexagonal Metallamacrocycles via an Organometallic Clip and Their Cytotoxicity Potency. <i>Inorganic Chemistry</i> , 2018, 57, 3615-3625.	1.9	27
2043	Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. <i>Muscle and Nerve</i> , 2018, 57, 650-658.	1.0	22
2044	Molecular structure, X-ray crystallography, spectroscopic characterization, solvent effect, NLO, NBO, FMO analysis of [Cu(bpabza)] complex. <i>Journal of Molecular Liquids</i> , 2018, 249, 281-293.	2.3	23
2045	Controlling with light the interaction between <i>trans</i> -tetrapyrrolyl ruthenium complexes and an oligonucleotide. <i>Dalton Transactions</i> , 2018, 47, 507-516.	1.6	8
2046	A saccharinate-bridged palladacyclic dimer with a Pd-Pd bond: experimental and molecular docking studies of the interaction with DNA and BSA and <i>in vitro</i> cytotoxicity against human cancer cell lines. <i>New Journal of Chemistry</i> , 2018, 42, 574-586.	1.4	23
2047	Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 17-24.	1.5	30
2048	Modulating Anticancer Potential by Modifying the Structural Properties of a Family of Zinc Metal-Organic Chains Based on 4-Nitro-1H-pyrazole. <i>Crystal Growth and Design</i> , 2018, 18, 969-978.	1.4	32
2049	Acidity-triggered TAT-presenting nanocarriers augment tumor retention and nuclear translocation of drugs. <i>Nano Research</i> , 2018, 11, 5716-5734.	5.8	27
2050	Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. <i>Journal of Cellular Physiology</i> , 2018, 233, 5458-5467.	2.0	119
2051	Platinum coordination compounds with potent anticancer activity. <i>Coordination Chemistry Reviews</i> , 2018, 375, 148-163.	9.5	142
2052	Single X-ray crystal structure, DFT studies and topoisomerase I inhibition activity of a tailored ionic Ag(<i>in situ</i>) naldixic acid-piperazinium drug entity specific for pancreatic cancer cells. <i>New Journal of Chemistry</i> , 2018, 42, 506-519.	1.4	20
2053	Cycloplatinated (<i>in situ</i>) complexes bearing 1,1'-bis(diphenylphosphino)ferrocene ligand: biological evaluation and molecular docking studies. <i>New Journal of Chemistry</i> , 2018, 42, 2385-2392.	1.4	22
2054	Photoactive platinum(II) complexes of nonsteroidal anti-inflammatory drug naproxen: Interaction with biological targets, antioxidant activity and cytotoxicity. <i>European Journal of Medicinal Chemistry</i> , 2018, 144, 243-254.	2.6	32
2055	New Ru(II) complexes containing tris(2-pyridylmethyl)amine. Synthesis, structural, CT-DNA/albumin interaction, anti-oxidant and cytotoxicity studies. <i>Inorganica Chimica Acta</i> , 2018, 471, 724-734.	1.2	12
2056	Chloro(triphenylphosphine)gold(I) a forefront reagent in gold chemistry as apoptotic agent for cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2018, 179, 107-120.	1.5	38
2057	Surface Modification of Cisplatin-Complexed Gold Nanoparticles and Its Influence on Colloidal Stability, Drug Loading, and Drug Release. <i>Langmuir</i> , 2018, 34, 154-163.	1.6	27
2058	Synthesis, Structural Characterization and Anti-proliferative Activity of (I ⁺) ₂ (C ₂ S) ₂ Pt ^{II} Complexes Bearing Thioether-functionalized N-heterocyclic Carbenes. <i>European Journal of Inorganic Chemistry</i> , 2018, 2018, 159-166.	1.0	16
2059	A new animal model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin. <i>Journal of Visceral Surgery</i> , 2018, 155, 183-189.	0.4	11

#	ARTICLE	IF	CITATIONS
2060	Synthesis, crystal structure, vibrational profiling, DFT studies and molecular docking of N-(4-chloro-2-[[2-(1H-indol-2-ylcarbonyl)hydrazinyl](oxo)acetyl]phenyl)acetamide.DMSO: A new antiproliferative agent. <i>Journal of Molecular Structure</i> , 2018, 1155, 457-468.	1.8	10
2061	Self-assembly of flexible [2â€ ⁺ +â€ ⁻ 2] ionic metallamacrocycles and their cytotoxicity potency. <i>Inorganica Chimica Acta</i> , 2018, 471, 223-227.	1.2	10
2062	Non-covalent DNA binding, protein interaction, DNA cleavage and cytotoxicity of [Cu(quamol)Cl]Â•H ₂ O. <i>International Journal of Biological Macromolecules</i> , 2018, 107, 2501-2511.	3.6	25
2063	RecBCD (Exonuclease V) is inhibited by DNA adducts produced by cisplatin and ultraviolet light. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 666-671.	1.0	1
2064	Improving the safety of metal-based drugs by tuning their metabolism with chemoprotective agents. <i>Journal of Inorganic Biochemistry</i> , 2018, 179, 154-157.	1.5	9
2065	Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy. <i>Journal Des Mathematiques Pures Et Appliquees</i> , 2018, 116, 268-308.	0.8	54
2066	Co-delivery of cisplatin and CJM-126 via photothermal conversion nanoparticles for enhanced synergistic antitumor efficacy. <i>Nanotechnology</i> , 2018, 29, 015601.	1.3	14
2067	Is TFIIH the new Achilles heel of cancer cells?. <i>Transcription</i> , 2018, 9, 47-51.	1.7	16
2068	Identification of cisplatin sensitizers through high-throughput combinatorial screening. <i>International Journal of Oncology</i> , 2018, 53, 1237-1246.	1.4	5
2069	A Molecular Study on Drug Delivery System Based on Carbon Nanotube Compared to Silicon Carbide Nanotube for Encapsulation of Platinum-Based Anticancer Drug. <i>Advanced Pharmaceutical Bulletin</i> , 2018, 8, 163-167.	0.6	26
2070	DNA Damage Repair Pathways and Repair of Cisplatin-Induced DNA Damage. , 2018, , .		3
2071	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. <i>Translational Lung Cancer Research</i> , 2018, 7, 50-68.	1.3	96
2072	Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. <i>Oncotarget</i> , 2018, 9, 28456-28473.	0.8	16
2073	Platinum-Based Antitumor Drugs and Their Liposomal Formulations in Clinical Trials. <i>Russian Journal of Bioorganic Chemistry</i> , 2018, 44, 619-630.	0.3	5
2074	Low Pressure Plasma Processing of Collagen Membranes for Anti-Cancer Drug Delivery. <i>Journal of Material Science & Engineering</i> , 2018, 07, .	0.2	1
2075	Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice. <i>Oncotarget</i> , 2018, 9, 35581-35597.	0.8	55
2076	Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(II) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(II) complexes in relation to the complex structure. <i>Dalton Transactions</i> , 2018, 47, 15091-15102.	1.6	19
2077	A Pt(IV)-mediated polymer architecture for facile and stimuli-responsive intracellular gene silencing with chemotherapy. <i>Biomaterials Science</i> , 2018, 6, 3345-3355.	2.6	6

#	ARTICLE	IF	CITATIONS
2078	Quantification of Cisplatin Using a Modified 3-Material Decomposition Algorithm at Third-Generation Dual-Source Dual-Energy Computed Tomography. <i>Investigative Radiology</i> , 2018, 53, 673-680.	3.5	13
2079	Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells. <i>Nutrients</i> , 2018, 10, 1644.	1.7	44
2081	Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands. <i>Inorganic Chemistry</i> , 2018, 57, 14786-14797.	1.9	28
2082	A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies. <i>ChemMedChem</i> , 2018, 14, 182-188.	1.6	35
2083	Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway. <i>International Journal of Biological Sciences</i> , 2018, 14, 1859-1872.	2.6	8
2084	Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. <i>Nature Communications</i> , 2018, 9, 4931.	5.8	134
2085	Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 983-996.	0.9	94
2086	Mechanism of H ₂ O ₂ cell apoptosis induced by carboplatin: Combination of mitochondrial pathway associated with Ca ²⁺ and the nucleus pathways. <i>Molecular Medicine Reports</i> , 2018, 18, 4978-4986.	1.1	6
2087	miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. <i>Oncology Letters</i> , 2018, 17, 1453-1460.	0.8	34
2088	The interactions of novel mononuclear platinum-based complexes with DNA. <i>BMC Cancer</i> , 2018, 18, 1284.	1.1	15
2089	Palladacyclic Conjugate Group Promotes Hybridization of Short Oligonucleotides. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1588.	1.8	12
2090	Organometallic Gold-Based Anticancer Therapeutics. , 2018, , .		1
2091	The induction of apoptosis in BEL-7402 cells by an iridium(III) complex through lysosome-mitochondria pathway. <i>Polyhedron</i> , 2018, 156, 320-331.	1.0	5
2092	Mitochondrial transfer from mesenchymal stem cells to neural stem cells protects against the neurotoxic effects of cisplatin. <i>Acta Neuropathologica Communications</i> , 2018, 6, 139.	2.4	93
2093	Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3/NF- κ B feedback loop. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 321.	3.5	36
2094	Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. <i>Head and Neck</i> , 2019, 41, 185-197.	0.9	37
2095	Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. <i>Cancers</i> , 2018, 10, 481.	1.7	135
2096	Squaramide-Based Pt(II) Complexes as Potential Oxygen-Regulated Light-Triggered Photocages. <i>Inorganic Chemistry</i> , 2018, 57, 15517-15525.	1.9	7

#	ARTICLE	IF	CITATIONS
2097	Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 525-532.	0.6	7
2098	New Platinum(II) agent induces bimodal death of apoptosis and autophagy against A549 cancer cell. <i>Free Radical Biology and Medicine</i> , 2018, 129, 418-429.	1.3	18
2099	Ruthenium(II)-Polypyridyl Compounds with π -Extended Nitrogen Donor Ligands Induce Apoptosis in Human Lung Adenocarcinoma (A549) Cells by Triggering Caspase-3/7 Pathway. <i>Inorganic Chemistry</i> , 2018, 57, 12777-12786.	1.9	20
2100	Pt-induced crosslinks promote target enrichment and protection from serum nucleases. <i>Journal of Inorganic Biochemistry</i> , 2018, 189, 124-133.	1.5	6
2101	Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors. <i>Current Oncology Reports</i> , 2018, 20, 88.	1.8	28
2102	PARP inhibition in platinum-based chemotherapy: Chemopotential and neuroprotection. <i>Pharmacological Research</i> , 2018, 137, 104-113.	3.1	38
2103	Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery. <i>Anticancer Research</i> , 2018, 38, 5599-5606.	0.5	28
2104	Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity. <i>Biochemistry</i> , 2018, 57, 6500-6513.	1.2	11
2105	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 555-561.	0.6	29
2106	Protected and De-protected Platinum(IV) Glycoconjugates With GLUT1 and OCT2-Mediated Selective Cancer Targeting: Demonstrated Enhanced Transporter-Mediated Cytotoxic Properties in vitro and in vivo. <i>Frontiers in Chemistry</i> , 2018, 6, 386.	1.8	21
2107	Carbonyl- π -heterobimetallic Ru(II)/Fe(II)- π -complexes containing polypyridyl ligands: Synthesis, characterization, cellular viability assays and interactions with biomolecules. <i>Archives of Biochemistry and Biophysics</i> , 2018, 660, 156-167.	1.4	8
2108	Parallel Guanine Duplex and Cytosine Duplex DNA with Uninterrupted Spines of Ag ^I -Mediated Base Pairs. <i>Journal of Physical Chemistry Letters</i> , 2018, 9, 6605-6610.	2.1	29
2109	S1PR1 predicts patient survival and promotes chemotherapy drug resistance in gastric cancer cells through STAT3 constitutive activation. <i>EBioMedicine</i> , 2018, 37, 168-176.	2.7	25
2110	Vestibulotoxicity Associated With Platinum-Based Chemotherapy in Survivors of Cancer: A Scoping Review. <i>Frontiers in Oncology</i> , 2018, 8, 363.	1.3	33
2111	Fenton-Reaction-Acceleratable Magnetic Nanoparticles for Ferroptosis Therapy of Orthotopic Brain Tumors. <i>ACS Nano</i> , 2018, 12, 11355-11365.	7.3	449
2112	Ru ^{II} (<i>p</i> -cymene) Compounds as Effective and Selective Anticancer Candidates with No Toxicity in Vivo. <i>Inorganic Chemistry</i> , 2018, 57, 13150-13166.	1.9	52
2113	Structural Elucidation of Cisplatin and Hydrated <i>cis</i> -Diammineplatinum(II) Complex Conjugated with Cyanocobalamin by Liquid Chromatography with Electrospray Ionization- π Mass Spectrometry and Multistage Mass Spectrometry. <i>ACS Omega</i> , 2018, 3, 12914-12922.	1.6	6
2114	Role of Dicer in regulating oxaliplatin resistance of colon cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 87-93.	1.0	15

#	ARTICLE	IF	CITATIONS
2115	In Vitro Cytotoxic Activities of Platinum(II) Complex with 1-Methyl-2-(3'-hydroxypropyl)benzimidazole and 2-(3'-Hydroxypropyl)benzimidazolium Hexa- and Tetrachloroplatinate Salts. <i>Letters in Drug Design and Discovery</i> , 2018, 15, 65-69.	0.4	3
2116	Naphthalimide Platinum(IV) Compounds as Antitumor Agents with Dual DNA Damage Mechanism to Overcome Cisplatin Resistance. <i>European Journal of Inorganic Chemistry</i> , 2018, 2018, 4442-4451.	1.0	13
2117	Extracts of Clove (<i>Syzygium aromaticum</i>) Potentiate FMSP-Nanoparticles Induced Cell Death in MCF-7 Cells. <i>International Journal of Biomaterials</i> , 2018, 2018, 1-10.	1.1	27
2118	Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2711.	1.8	43
2119	Ferrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure-Activity Relationships. <i>Molecules</i> , 2018, 23, 2248.	1.7	11
2120	Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress. <i>Molecular Pharmaceutics</i> , 2018, 15, 5058-5071.	2.3	22
2121	Electronic effects on reactivity and anticancer activity by half-sandwich N,N-chelated iridium(III) complexes. <i>New Journal of Chemistry</i> , 2018, 42, 16183-16192.	1.4	42
2122	Photoactivated platinum-based anticancer drugs. <i>Coordination Chemistry Reviews</i> , 2018, 376, 405-429.	9.5	85
2123	Development and validation of an ICP-MS method for quantification of total carbon and platinum in cell samples and comparison of open-vessel and microwave-assisted acid digestion methods. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 158, 144-150.	1.4	25
2124	Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer. <i>Cancer Research</i> , 2018, 78, 4036-4044.	0.4	31
2125	Patterns of platinum drug use in an acute care setting: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1561-1568.	1.2	22
2126	Microfocus x-ray fluorescence mapping of tumour penetration by an organo-osmium anticancer complex. <i>Journal of Inorganic Biochemistry</i> , 2018, 185, 26-29.	1.5	14
2127	Palladium complexes of bidentate pyridine N-heterocyclic carbenes: Optical resolution, antimicrobial and cytotoxicity studies. <i>Applied Organometallic Chemistry</i> , 2018, 32, e4377.	1.7	19
2128	The trans-[Ru(PPh ₃) ₂ (N,N-dimethyl-N ² -thiophenylthiourea-κ ² O,S)(bipy)]PF ₆ complex has pro-apoptotic effects on triple negative breast cancer cells and presents low toxicity in vivo. <i>Journal of Inorganic Biochemistry</i> , 2018, 186, 70-84.	1.5	17
2129	A mitochondria-targeting hetero-binuclear Ir(III)-Pt(II) complex induces necrosis in cisplatin-resistant tumor cells. <i>Chemical Communications</i> , 2018, 54, 6268-6271.	2.2	51
2130	The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications (Review). <i>Oncology Letters</i> , 2018, 15, 6799-6805.	0.8	51
2131	Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser ¹⁰¹⁵ in non-small cell lung cancer cells. <i>Oncology Letters</i> , 2018, 15, 9251-9256.	0.8	10
2132	Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition. <i>Future Medicinal Chemistry</i> , 2018, 10, 1349-1360.	1.1	18

#	ARTICLE	IF	CITATIONS
2133	Nanomaterial-Based Organelles Protect Normal Cells against Chemotherapy-Induced Cytotoxicity. <i>Advanced Materials</i> , 2018, 30, e1801304.	11.1	49
2134	A novel biocompatible Ni(II) tethered moiety as a glucose uptake agent and a hit against methicillin-resistant <i>Staphylococcus aureus</i> . <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 335-349.	1.9	10
2135	Hierarchically stimuli-responsive nanovectors for improved tumor penetration and programmed tumor therapy. <i>Nanoscale</i> , 2018, 10, 13737-13750.	2.8	34
2136	Metal-ligand interactions in drug design. <i>Nature Reviews Chemistry</i> , 2018, 2, 100-112.	13.8	124
2137	Synthesis and biological evaluation of redox/NIR dual stimulus-responsive polymeric nanoparticles for targeted delivery of cisplatin. <i>Materials Science and Engineering C</i> , 2018, 92, 453-462.	3.8	25
2138	Hypoxia-Targeting Organometallic Ru(II)-Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer Cells. <i>Inorganic Chemistry</i> , 2018, 57, 8396-8403.	1.9	35
2139	Mitochondria-targeted platinum(II) complexes induce apoptosis-dependent autophagic cell death mediated by ER-stress in A549 cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 639-650.	2.6	61
2140	Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. <i>Scientific Reports</i> , 2018, 8, 9513.	1.6	52
2141	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 600-611.	1.2	18
2142	Mitochondria-targeted half-sandwich ruthenium(II) diimine complexes: anticancer and antimetastasis via ROS-mediated signalling. <i>Inorganic Chemistry Frontiers</i> , 2018, 5, 2100-2105.	3.0	72
2143	Redox-responsive cisplatin nanogels for anticancer drug delivery. <i>Chemical Communications</i> , 2018, 54, 8367-8370.	2.2	35
2144	Metal- and metalloid-containing drugs for the treatment of trypanosomatid diseases. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 954-966.	3.0	11
2145	Silver Atomic Quantum Clusters of Three Atoms for Cancer Therapy: Targeting Chromatin Compaction to Increase the Therapeutic Index of Chemotherapy. <i>Advanced Materials</i> , 2018, 30, e1801317.	11.1	20
2146	Synthesis, characterization, DNA binding, topoisomerase I inhibition, and antiproliferation activities of (di-tert-butylbipyridine) platinum(II) complexes. <i>Transition Metal Chemistry</i> , 2018, 43, 657-664.	0.7	0
2148	A Bioactive L-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action. <i>Inorganic Chemistry</i> , 2018, 57, 8521-8529.	1.9	26
2149	Synthesis, Characterization, and Inducing Tumor Cell Apoptosis of Two Ru(II) Complexes Containing Guanidinium as Ligands. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 110-120.	0.9	5
2150	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 4839-4845.	0.5	5
2151	A cytotoxic tantalum(V) half-sandwich complex: a new challenge for metal-based anticancer agents. <i>Chemical Communications</i> , 2018, 54, 9533-9536.	2.2	15

#	ARTICLE	IF	CITATIONS
2152	Exploring diversity in platinum(IV) N-heterocyclic carbene complexes: synthesis, characterization, reactivity and biological evaluation. Dalton Transactions, 2018, 47, 11491-11502.	1.6	22
2153	Cysteine boosts the evolutionary adaptation to CoCl ₂ mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer. BMC Evolutionary Biology, 2018, 18, 97.	3.2	21
2154	Synthesis and characterization of triruthenium carbonyl incorporating 4-pyridones as potential antitumor agents. Journal of Organometallic Chemistry, 2018, 872, 102-109.	0.8	4
2155	Immobilization of Platinum(II) and Platinum(IV) Complexes on Oxidized Nanoporous Carbon Material and Evaluation of the Enthalpy of Adsorption. Russian Journal of Inorganic Chemistry, 2018, 63, 923-929.	0.3	2
2156	Small molecule scaffolds that disrupt the Rev1-CT/RIR protein-protein interaction. Bioorganic and Medicinal Chemistry, 2018, 26, 4301-4309.	1.4	9
2157	Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. Pharmacology, 2018, 102, 161-168.	0.9	8
2158	Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 2184.	1.8	15
2159	Lipid imaging for visualizing cilastatin amelioration of cisplatin-induced nephrotoxicity. Journal of Lipid Research, 2018, 59, 1561-1574.	2.0	21
2160	Third-Order Kinetics for Interaction of Glutathione with a Dinuclear Pd(II) Complex and Their Mechanism, DNA Binding and DFT Study. Journal of Solution Chemistry, 2018, 47, 1139-1156.	0.6	1
2161	Reprogramming axial ligands facilitates the self-assembly of a platinum(IV) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin. Chemical Communications, 2018, 54, 9167-9170.	2.2	29
2162	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine, 2018, 10, .	5.8	32
2163	Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy. Frontiers in Microbiology, 2018, 9, 1607.	1.5	103
2164	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene, 2018, 37, 6463-6476.	2.6	15
2165	The Important Role of the Nuclearity, Rigidity, and Solubility of Phosphane Ligands in the Biological Activity of Gold(I) Complexes. Chemistry - A European Journal, 2018, 24, 14654-14667.	1.7	31
2166	Transcriptional Regulation of Emergency Granulopoiesis in Leukemia. Frontiers in Immunology, 2018, 9, 481.	2.2	14
2167	Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. European Journal of Medicinal Chemistry, 2018, 156, 666-679.	2.6	30
2168	Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin. Current Medicinal Chemistry, 2018, 25, 462-477.	1.2	15
2169	Melatonin Promotes Apoptosis of Colorectal Cancer Cells <i>via</i> Superoxide-mediated ER Stress by Inhibiting Cellular Prion Protein Expression. Anticancer Research, 2018, 38, 3951-3960.	0.5	29

#	ARTICLE	IF	CITATIONS
2170	Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2018, 19, 590.	1.8	29
2171	Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1486.	1.8	37
2172	Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1690.	1.8	111
2173	Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1818.	1.8	10
2174	Pt(IV)/Re(I) Chitosan Conjugates as a Flexible Platform for the Transport of Therapeutic and/or Diagnostic Anticancer Agents. <i>Inorganics</i> , 2018, 6, 4.	1.2	6
2175	Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand. <i>Molecules</i> , 2018, 23, 420.	1.7	20
2176	DNA-Induced Novel Optical Features of Ethyl Viologen-Tethered Perylene-3,4,9,10-tetracarboxylic Diimide Triad. <i>Journal of Physical Chemistry C</i> , 2018, 122, 18061-18069.	1.5	8
2177	Two novel Zn(II)-Li(I)-based and In(III)-based coordination polymers: crystal structures and anti-lung cancer activity. <i>Main Group Metal Chemistry</i> , 2018, 41, 115-120.	0.6	1
2178	Platinum drugs, copper transporters and copper chelators. <i>Coordination Chemistry Reviews</i> , 2018, 374, 254-260.	9.5	31
2179	Hybrid Gd ³⁺ /cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines. <i>Biomaterials Science</i> , 2018, 6, 2386-2409.	2.6	28
2180	Phenanthriplatin(^{iv}) conjugated multifunctional up-converting nanoparticles for drug delivery and biomedical imaging. <i>Journal of Materials Chemistry B</i> , 2018, 6, 5059-5068.	2.9	36
2181	Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 161.	3.5	24
2182	Self-Assembly of a [1 + 1] Ionic Hexagonal Macrocyclic and Its Antiproliferative Activity. <i>Frontiers in Chemistry</i> , 2018, 6, 87.	1.8	8
2183	Synthesis, characterization and anticancer activity of two Ru(II) polypyridyl complexes [Ru(dpq)2L](PF6)2 (L = maip, paip). <i>Inorganica Chimica Acta</i> , 2018, 480, 62-69.	1.2	3
2184	Genetic and cellular sensitivity of <i>Caenorhabditis elegans</i> to the chemotherapeutic agent cisplatin. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	13
2185	SHP-2 restricts apoptosis induced by chemotherapeutic agents via Parkin-dependent autophagy in cervical cancer. <i>Cancer Cell International</i> , 2018, 18, 8.	1.8	12
2186	Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. <i>Journal of Translational Medicine</i> , 2018, 16, 96.	1.8	133
2187	Probing the potency of triazole tethered Schiff base complexes and the effect of substituents on their biological attributes. <i>International Journal of Biological Macromolecules</i> , 2018, 116, 194-207.	3.6	13

#	ARTICLE	IF	CITATIONS
2188	Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4777-E4785.	3.3	65
2189	Quantitative Bioimaging of Platinum via Online Isotope Dilution-Laser Ablation-Inductively Coupled Plasma Mass Spectrometry. <i>Analytical Chemistry</i> , 2018, 90, 7033-7039.	3.2	23
2190	Synthesis, structures and mechanistic pathways of anticancer activity of palladium(<i>II</i>) complexes with indole-3-carbaldehyde thiosemicarbazones. <i>New Journal of Chemistry</i> , 2018, 42, 10818-10832.	1.4	53
2191	Hsp70 and gamma-Semino protein as possible prognostic marker of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1987-2000.	3.0	13
2192	Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation. <i>Theranostics</i> , 2018, 8, 1312-1326.	4.6	46
2193	Ammonium Bisphosphonate Polymeric Magnetic Nanocomplexes for Platinum Anticancer Drug Delivery and Imaging with Potential Hyperthermia and Temperature-Dependent Drug Release. <i>Journal of Nanomaterials</i> , 2018, 2018, 1-14.	1.5	1
2194	Imine- <i>N</i> -Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) <i>p</i> -Cymene Anticancer Complexes: A Structure-Activity Relationship Study. <i>Chemistry - an Asian Journal</i> , 2018, 13, 2923-2933.	1.7	43
2195	miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 846.	1.6	27
2196	Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage. <i>Nucleic Acids Research</i> , 2018, 46, 9537-9549.	6.5	75
2197	Acute toxic effects of ruthenium (II)/amino acid/diphosphine complexes on Swiss mice and zebrafish embryos. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 1082-1092.	2.5	33
2198	A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells. <i>Life Sciences</i> , 2018, 210, 166-176.	2.0	15
2199	A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 777-785.	1.1	21
2200	Tumor necrosis factor α -induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy. <i>Human Pathology</i> , 2018, 82, 239-248.	1.1	8
2201	Half-Sandwich Ir(III) Complex of N1-Pyridyl-7-azaindole Exceeds Cytotoxicity of Cisplatin at Various Human Cancer Cells and 3D Multicellular Tumor Spheroids. <i>Organometallics</i> , 2018, 37, 2749-2759.	1.1	18
2202	The Next Generation of Anticancer Metallopharmaceuticals: Cancer Stem Cell-Active Inorganics. <i>ChemBioChem</i> , 2018, 19, 2246-2253.	1.3	46
2203	BODIPY-based Ru(II) and Ir(III) organometallic complexes of avobenzone, a sunscreen material: Potent anticancer agents. <i>Journal of Inorganic Biochemistry</i> , 2018, 189, 17-29.	1.5	44
2204	Emerging role of long non-coding RNAs in cisplatin resistance. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3185-3194.	1.0	69
2205	Half-sandwich Ir(III) and Rh(III) 2,2'-dipyridylamine complexes: Synthesis, characterization and <i>in vitro</i> cytotoxicity against the ovarian carcinoma cells. <i>Journal of Organometallic Chemistry</i> , 2018, 872, 114-122.	0.8	11

#	ARTICLE	IF	CITATIONS
2206	New bio-sensitive and biologically active single crystal of pyrimidine scaffold ligand and its gold and platinum complexes: DFT, antimicrobial, antioxidant, DNA interaction, molecular docking with DNA/BSA and anticancer studies. <i>Bioorganic Chemistry</i> , 2018, 81, 144-156.	2.0	45
2207	Molecular analysis of gastric cancer identifies genomic markers of drug sensitivity in Asian gastric cancer. <i>Journal of Cancer</i> , 2018, 9, 2973-2980.	1.2	10
2208	Dimetallic Ru(II) arene complexes appended on bis-salicylaldehyde induce cancer cell death and suppress invasion via p53-dependent signaling. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1480-1490.	2.6	30
2209	Analysis of single, cisplatin-induced DNA bends by atomic force microscopy and simulations. <i>Journal of Molecular Recognition</i> , 2018, 31, e2731.	1.1	17
2210	Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2018, 29, 1497-1508.	0.6	305
2211	Metabolic vulnerability of cisplatin-resistant cancers. <i>EMBO Journal</i> , 2018, 37, .	3.5	84
2212	nonleaving ligands toward thiourea nucleophiles. <i>International Journal of Chemical Kinetics</i> , 2018, 50, 531-543.	1.0	2
2213	Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer. <i>Journal of Pathology</i> , 2018, 246, 115-126.	2.1	21
2214	Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin. <i>Journal of Biological Inorganic Chemistry</i> , 2018, 23, 833-848.	1.1	10
2215	Non-coordination planer cis-and trans-configuration of cis-[Pt(II)(mixed-NH ₃ /RNH ₂)(3-OH-cyclobutane-1,1-dicarboxylate)]: separation, characterization, and anticancer activity. <i>Research on Chemical Intermediates</i> , 2018, 44, 6479-6487.	1.3	2
2216	Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. <i>Nano Letters</i> , 2018, 18, 4618-4625.	4.5	173
2217	Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches. <i>Current Medicinal Chemistry</i> , 2018, 24, 4753-4778.	1.2	18
2218	Bacterial Cytological Profiling Reveals the Mechanism of Action of Anticancer Metal Complexes. <i>Molecular Pharmaceutics</i> , 2018, 15, 3404-3416.	2.3	19
2219	Picoplatin-based complexes with the bioactive orotate and 5-fluoroorotate ligands: Synthesis, DFT calculations, structure, spectroscopic characterization and in vitro cytotoxicity. <i>Journal of Molecular Structure</i> , 2018, 1171, 155-167.	1.8	3
2220	New Ru(II) half sandwich complexes bearing the N,N'-bidentate 9-ethyl-N-(pyridin-2-ylmethylene)9H-carbazole-3-amine ligand: Effects of halogen (Cl ⁻ , Br ⁻ and I ⁻) leaving groups versus in vitro activity on HepG2 cancer cells, cell cycle, fluorescence study, cellular accumulation and DFT study. <i>Polyhedron</i> , 2018, 152, 37-48.	1.0	3
2222	Cisplatin-Encapsulated Polymeric Nanoparticles with Molecular Geometry-Regulated Colloidal Properties and Controlled Drug Release. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 23617-23629.	4.0	26
2223	Mangiferin attenuates cisplatin-induced acute kidney injury in rats mediating modulation of MAPK pathway. <i>Molecular and Cellular Biochemistry</i> , 2019, 452, 141-152.	1.4	31
2224	Effect of orexin-A in the arcuate nucleus on cisplatin-induced gastric side effects in rats. <i>Neuroscience Research</i> , 2019, 143, 53-60.	1.0	13

#	ARTICLE	IF	CITATIONS
2225	Synthesis and preliminary biological evaluation for the anticancer activity of organochalcogen (S/se) tethered chrysin-based organometallic Ru ^{II} (I ⁶ -p-cymene) complexes. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 3337-3353.	2.0	11
2226	IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. <i>Tumori</i> , 2019, 105, 84-91.	0.6	29
2227	Photoactivated Lysosomal Escape of a Monofunctional Pt II Complex Pt ^{II} BDPA for Nucleus Access. <i>Angewandte Chemie</i> , 2019, 131, 12791-12796.	1.6	13
2228	The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 836.	1.6	17
2229	Platinum(IV) dihydroxido diazido N-(heterocyclic)imine complexes are potently photocytotoxic when irradiated with visible light. <i>Chemical Science</i> , 2019, 10, 8610-8617.	3.7	25
2230	Identification of a novel S6K1 inhibitor, rosmarinic acid methyl ester, for treating cisplatin-resistant cervical cancer. <i>BMC Cancer</i> , 2019, 19, 773.	1.1	21
2231	Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. <i>Molecules</i> , 2019, 24, 2861.	1.7	15
2232	trans-Platinum(II) Thionate Complexes: Synthesis, Structural Characterization, and in vitro Biological Assessment as Potent Anticancer Agents. <i>ChemPlusChem</i> , 2019, 84, 1525-1535.	1.3	9
2233	Screening and Preliminary Biochemical and Biological Studies of [RuCl(<i>p</i> -cymene)(N,N-bis(diphenylphosphino)-isopropylamine)] ⁺ BF ₄ ⁻ in Breast Cancer Models. <i>ACS Omega</i> , 2019, 4, 13005-13014.	1.6	7
2234	Studies of the anticancer activities of ruthenium(II) polypyridyl complexes toward human hepatocellular carcinoma BEL-7402 cells. <i>Transition Metal Chemistry</i> , 2019, 44, 585-594.	0.7	2
2235	Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661986609.	1.0	28
2236	Platinum(II) complexes showing high cytotoxicity toward A2780 ovarian carcinoma cells. <i>Dalton Transactions</i> , 2019, 48, 13081-13093.	1.6	19
2237	Clustered DNA Damages induced by 0.5 to 30 eV Electrons. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3749.	1.8	20
2238	Nitrogen-doped fluorescent carbon dots used for the imaging and tracing of different cancer cells. <i>RSC Advances</i> , 2019, 9, 24852-24857.	1.7	7
2239	Copper(II) complexes with 2,2',6',6'-terpyridine, 2,6-di(thiazol-2-yl)pyridine and 2,6-di(pyrazin-2-yl)pyridine substituted with quinolines. Synthesis, structure, antiproliferative activity, and catalytic activity in the oxidation of alkanes and alcohols with peroxides. <i>Dalton Transactions</i> , 2019, 48, 12656-12673.	1.6	44
2240	Glyconanoparticles for Targeted Tumor Therapy of Platinum Anticancer Drug. <i>Biomacromolecules</i> , 2019, 20, 2962-2972.	2.6	25
2241	Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer. <i>Cell Death and Disease</i> , 2019, 10, 550.	2.7	15
2242	Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy. <i>Chemical Communications</i> , 2019, 55, 9904-9914.	2.2	100

#	ARTICLE	IF	CITATIONS
2243	Comparative study of electronic-structure methods for platinum-containing molecules: bond lengths and bond dissociation energies. <i>European Physical Journal D</i> , 2019, 73, 1.	0.6	3
2244	Role of Retinoic Acid Receptor- β in DNA Damage-Induced Necroptosis. <i>IScience</i> , 2019, 17, 74-86.	1.9	21
2245	Metalloproteomics for Unveiling the Mechanism of Action of Metallodrugs. <i>Inorganic Chemistry</i> , 2019, 58, 13673-13685.	1.9	32
2246	Construction of Well-Defined Discrete Metallacycles and Their Biological Applications. , 2019, , 1-27.		0
2247	Mitochondrial Involvement in Cisplatin Resistance. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3384.	1.8	88
2248	Synthesis, structure and biological evaluation of mixed ligand oxidovanadium(^{IV}) complexes incorporating 2-(aryloxy)phenolates. <i>New Journal of Chemistry</i> , 2019, 43, 17711-17725.	1.4	21
2249	ERK Regulates HIF1 α -Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5947-5960.	3.2	37
2250	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1640-1650.	0.5	64
2251	Modulation of ruthenium anticancer drugs analogs with tolfenamic acid: Reactivity, biological interactions and growth inhibition of yeast cell. <i>Journal of Inorganic Biochemistry</i> , 2019, 199, 110769.	1.5	13
2252	Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. <i>Cancers</i> , 2019, 11, 1014.	1.7	25
2253	Identification of Catechol-Type Diphenylbutadiene as a Tyrosinase-Activated Pro-oxidative Chemosensitizer against Melanoma A375 Cells via Glutathione <i>S</i> -Transferase Inhibition. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 9060-9069.	2.4	17
2254	Dual-action organoplatinum polymeric nanoparticles overcoming drug resistance in ovarian cancer. <i>Dalton Transactions</i> , 2019, 48, 12451-12458.	1.6	12
2255	Nanocarrier systems assembled from PEGylated hyperbranched poly(arylene oxindole). <i>European Polymer Journal</i> , 2019, 119, 247-259.	2.6	7
2256	Advances in Toxicological Research of the Anticancer Drug Cisplatin. <i>Chemical Research in Toxicology</i> , 2019, 32, 1469-1486.	1.7	215
2257	<p>Synergistic effect of meta-tetra(hydroxyphenyl)chlorin-based photodynamic therapy followed by cisplatin on malignant Hep-2 cells</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5525-5536.	1.0	6
2258	Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activityâ€”An Isobolographic Analysis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3663.	1.8	23
2259	Palladacycles as Potential Anticancer Agents. , 2019, , 343-370.		3
2260	Synthesis and characterisation of platinum(IV) polypyridyl complexes with halide axial ligands. <i>Inorganica Chimica Acta</i> , 2019, 495, 118964.	1.2	9

#	ARTICLE	IF	CITATIONS
2261	Studies on Pd(1,4-bis(2-hydroxyethyl)piperazine)-dicarboxylic acid complexes as models for carboplatin with structural features enhancing the interaction with DNA. <i>Journal of Coordination Chemistry</i> , 2019, 72, 2035-2049.	0.8	5
2262	The modulatory effect of green tea catechin on drug resistance in human ovarian cancer cells. <i>Medicinal Chemistry Research</i> , 2019, 28, 657-667.	1.1	19
2263	A new insight into the reversal of multidrug resistance in cancer by nanodrugs. <i>Biomaterials Science</i> , 2019, 7, 3489-3496.	2.6	11
2264	Solution and solid behavior of mono and binuclear zinc(II) and nickel(II) complexes with dithiocarbazates: X-ray analysis, mass spectrometry and cytotoxicity against cancer cell lines. <i>New Journal of Chemistry</i> , 2019, 43, 11209-11221.	1.4	29
2265	Cytomembrane-Mediated Transport of Metal Ions with Biological Specificity. <i>Advanced Science</i> , 2019, 6, 1900835.	5.6	22
2266	Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. <i>Clinical Lung Cancer</i> , 2019, 20, 391-396.	1.1	36
2267	ATR inhibition sensitizes HPV ⁻ and HPV ⁺ head and neck squamous cell carcinoma to cisplatin. <i>Oral Oncology</i> , 2019, 95, 35-42.	0.8	34
2268	Partially Solvated Dinuclear Ruthenium Compounds Bridged by Quinoxaline-Functionalized Ligands as Ru(II) Photocage Architectures for Low-Energy Light Absorption. <i>Inorganic Chemistry</i> , 2019, 58, 14568-14576.	1.9	8
2269	ROS-mediated cell death induced by mixed ligand copper(II) complexes of l-proline and diimine: effect of co-ligand. <i>Journal of Coordination Chemistry</i> , 2019, 72, 3102-3127.	0.8	12
2270	IL-7-Mediated IL-7R α /JAK3/STAT5 signalling pathway contributes to chemotherapeutic sensitivity in non-small cell lung cancer. <i>Cell Proliferation</i> , 2019, 52, e12699.	2.4	8
2271	Mono and dinuclear platinum and palladium complexes containing adamantane-azole ligands: DNA and BSA interaction and cytotoxicity. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 1087-1103.	1.1	12
2272	Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1570.	1.7	12
2273	Targeting of copper-trafficking chaperones causes gene-specific systemic pathology in <i>Drosophila melanogaster</i> : prospective expansion of mutational landscapes that regulate tumor resistance to cisplatin. <i>Biology Open</i> , 2019, 8, .	0.6	6
2274	ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. <i>Cell Death and Disease</i> , 2019, 10, 757.	2.7	86
2275	Impact of Chemotherapy on Extracellular Vesicles: Understanding the Chemo-EVs. <i>Frontiers in Oncology</i> , 2019, 9, 1113.	1.3	36
2276	Ovarian damage from chemotherapy and current approaches to its protection. <i>Human Reproduction Update</i> , 2019, 25, 673-693.	5.2	309
2277	Multifunctional MoS ₂ nanosheets with Au NPs grown in situ for synergistic chemo-photothermal therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 184, 110551.	2.5	25
2278	End of performance prediction of lithium-ion batteries. <i>Journal of Quality Technology</i> , 2019, 51, 198-213.	1.8	13

#	ARTICLE	IF	CITATIONS
2279	Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management. <i>Advanced Materials</i> , 2020, 32, e1904337.	11.1	130
2280	<p>Fusobacterium nucleatum prevents apoptosis in colorectal cancer cells via the ANO1 pathway</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9057-9066.	0.9	13
2281	Silicon Nanotubes as Potential Therapeutic Platforms. <i>Pharmaceutics</i> , 2019, 11, 571.	2.0	8
2282	Influence of steric and electronic effect of carrier ligand on kinetics & mechanism of Pt(II) complexes with L-cysteine and its substituted derivatives: Their experimental and DFT-based theoretical study. <i>Inorganica Chimica Acta</i> , 2019, 498, 119117.	1.2	7
2283	CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling. <i>BMC Cancer</i> , 2019, 19, 1042.	1.1	4
2284	Disruption of mitochondrial homeostasis with artemisinin unravels anti-angiogenesis effects via auto-paracrine mechanisms. <i>Theranostics</i> , 2019, 9, 6631-6645.	4.6	29
2285	Sulforaphane Mediates Glutathione Depletion via Polymeric Nanoparticles to Restore Cisplatin Chemosensitivity. <i>ACS Nano</i> , 2019, 13, 13445-13455.	7.3	106
2286	Nucleolar Stress Induction by Oxaliplatin and Derivatives. <i>Journal of the American Chemical Society</i> , 2019, 141, 18411-18415.	6.6	43
2287	Structure characterization and antitumor activity of palladium pseudo halide complexes with 4-acetylpyridine. <i>Journal of Coordination Chemistry</i> , 2019, 72, 3088-3101.	0.8	11
2288	Anti-Cancer Activity of a 5-Aminopyrazole Derivative Lead Compound (BC-7) and Potential Synergistic Cytotoxicity with Cisplatin against Human Cervical Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5559.	1.8	14
2289	Synthesis and Structure of Î±-Aminophosphate and Its Interaction with DNA/BSA. <i>Journal of Applied Spectroscopy</i> , 2019, 86, 955-960.	0.3	1
2290	Novel Quinoline-based Ir(III) Complexes Exhibit High Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i> . <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1614-1619.	1.3	16
2291	Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. <i>British Journal of Cancer</i> , 2019, 121, 1027-1038.	2.9	36
2292	PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target. <i>PLoS ONE</i> , 2019, 14, e0224085.	1.1	2
2293	Towards Identification of Essential Structural Elements of Organoruthenium(II)â€Pyrrithionato Complexes for Anticancer Activity. <i>Chemistry - A European Journal</i> , 2019, 25, 14169-14182.	1.7	22
2294	Element 78 â€“ Platinum. <i>Australian Journal of Chemistry</i> , 2019, 72, 649.	0.5	0
2295	Platinumâ€induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S26-S39.	1.4	74
2296	Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells. <i>Cancers</i> , 2019, 11, 1224.	1.7	34

#	ARTICLE	IF	CITATIONS
2297	The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer. <i>ChemMedChem</i> , 2019, 14, 1810-1827.	1.6	5
2298	Design of Surface-Modified Electrodes for the Electrochemical Adsorption of Platinum-Based Anticancer Drugs. <i>Chemistry of Materials</i> , 2019, 31, 8012-8018.	3.2	0
2299	Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. <i>Metallomics</i> , 2019, 11, 1716-1728.	1.0	21
2300	Curcumin Acts as a Chemosensitizer for Leiomyosarcoma Cells In Vitro But Fails to Mediate Antioxidant Enzyme Activity in Cisplatin-Induced Experimental Nephrotoxicity in Rats. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541987281.	0.8	4
2301	Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma. <i>Journal of Receptor and Signal Transduction Research</i> , 2019, 39, 208-214.	1.3	57
2302	Monofunctional platinum(II) compounds and nucleolar stress: is phenanthriplatin unique?. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 899-908.	1.1	15
2303	Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance. <i>Bioorganic Chemistry</i> , 2019, 92, 103236.	2.0	24
2304	Metal-Based Molecular Compounds: Structure, Analytical Properties, dsDNA Binding Studies and In Vitro Antiproliferative Activity on Selected Cancer Cell Lines. <i>Pharmaceutical Chemistry Journal</i> , 2019, 53, 392-410.	0.3	5
2305	Targeted Delivery of Cisplatin-Derived Nanoprecursors via a Biomimetic Yeast Microcapsule for Tumor Therapy by the Oral Route. <i>Theranostics</i> , 2019, 9, 6568-6586.	4.6	35
2306	Rad5 dysregulation drives hyperactive recombination at replication forks resulting in cisplatin sensitivity and genome instability. <i>Nucleic Acids Research</i> , 2019, 47, 9144-9159.	6.5	17
2307	Synthesis and characterization of mixed-ligand Zn(II) and Cu(II) complexes including polyamines and dicyano-dithiolate(2-): In vitro cytotoxic activity of Cu(II) compounds. <i>Inorganica Chimica Acta</i> , 2019, 498, 119098.	1.2	21
2308	High in vitro and in vivo antitumor activities of luminescent platinum(II) complexes with jatrorrhizine derivatives. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111727.	2.6	35
2309	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. <i>Targeted Oncology</i> , 2019, 14, 505-525.	1.7	40
2310	FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression. <i>Oncology Reports</i> , 2019, 42, 1404-1412.	1.2	12
2311	Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 116, 105610.	1.2	26
2312	Novel Pt(II) complexes with modified aroyl-hydrazone Schiff-base ligands: synthesis, cytotoxicity and action mechanism. <i>Metallomics</i> , 2019, 11, 1847-1863.	1.0	15
2313	Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity. <i>Pharmaceuticals</i> , 2019, 12, 146.	1.7	60
2314	Optimization of a low pressure plasma process for fabrication of a Drug Delivery System (DDS) for cancer treatment. <i>Materials Science and Engineering C</i> , 2019, 105, 110089.	3.8	3

#	ARTICLE	IF	CITATIONS
2315	The CK2 inhibitor CX4945 reverses cisplatin resistance in the A549/DDP human lung adenocarcinoma cell line. <i>Oncology Letters</i> , 2019, 18, 3845-3856.	0.8	18
2316	Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light. <i>CheM</i> , 2019, 5, 3151-3165.	5.8	107
2317	Strong in vitro and in vivo cytotoxicity of novel organoplatinum(II) complexes with quinoline-coumarin derivatives. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111751.	2.6	54
2318	Design, Synthesis, Characterization and Antiproliferative Activities of Ru(II) Complexes of Substituted Benzimidazoles. <i>Asian Journal of Chemistry</i> , 2019, 31, 2311-2318.	0.1	0
2319	Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review. <i>International Journal of Audiology</i> , 2019, 58, 685-695.	0.9	26
2320	Coumarin-substituted 1,2,4-triazole-derived silver(ⁱ) and gold(ⁱ) complexes: synthesis, characterization and anticancer studies. <i>New Journal of Chemistry</i> , 2019, 43, 1216-1229.	1.4	52
2321	Carboplatin prodrug conjugated Fe ₃ O ₄ nanoparticles for magnetically targeted drug delivery in ovarian cancer cells. <i>Journal of Materials Chemistry B</i> , 2019, 7, 433-442.	2.9	25
2322	Deciphering the Molecular Profile of Lung Cancer: New Strategies for the Early Detection and Prognostic Stratification. <i>Journal of Clinical Medicine</i> , 2019, 8, 108.	1.0	6
2323	In vitro and in vivo anticancer effects of two quinoline- ⁱⁱ platinum(II) complexes on human osteosarcoma models. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 681-692.	1.1	28
2324	DNA cleavage, DNA/HSA binding study, and antiproliferative activity of a phenolate-bridged binuclear copper(II) complex. <i>BioMetals</i> , 2019, 32, 227-240.	1.8	10
2325	Drugs and Drug-Related Topics. , 2019, , 173-195.		0
2326	Selective adsorption and recovery of precious metal ions from water and metallurgical slag by polymer brush graphene- ⁱⁱ polyurethane composite. <i>Reactive and Functional Polymers</i> , 2019, 136, 138-152.	2.0	25
2327	A safe and efficacious Pt(ⁱⁱ) anticancer prodrug: design, synthesis, <i>in vitro</i> efficacy, the role of carrier ligands and <i>in vivo</i> tumour growth inhibition. <i>Chemical Communications</i> , 2019, 55, 1718-1721.	2.2	9
2328	Computational insight into the interaction of oxaliplatin with insulin. <i>Metallomics</i> , 2019, 11, 765-773.	1.0	10
2329	Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy. <i>Biomaterials Science</i> , 2019, 7, 262-271.	2.6	22
2330	Colloidal hydroxyethyl starch for tumor-targeted platinum delivery. <i>Nanoscale Advances</i> , 2019, 1, 1002-1012.	2.2	17
2331	Selectivity of Terpyridine Platinum Anticancer Drugs for G-quadruplex DNA. <i>Molecules</i> , 2019, 24, 404.	1.7	30
2332	A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer. <i>Journal of Inorganic Biochemistry</i> , 2019, 193, 133-142.	1.5	26

#	ARTICLE	IF	CITATIONS
2333	Tumor Microenvironment-Triggered Aggregated Magnetic Nanoparticles for Reinforced Image-Guided Immunogenic Chemotherapy. <i>Advanced Science</i> , 2019, 6, 1802134.	5.6	90
2334	Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis. <i>PLoS ONE</i> , 2019, 14, e0211268.	1.1	25
2335	Palladium(II) complexes of 5-substituted isatin thiosemicarbazones: Synthesis, spectroscopic characterization, biological evaluation and <i>in silico</i> docking studies. <i>Synthetic Communications</i> , 2019, 49, 146-158.	1.1	19
2336	Tandem mass spectrometry characterization of a conjugate between oleuropein and hydrated <i>cis</i> -diammineplatinum(II). <i>Rapid Communications in Mass Spectrometry</i> , 2019, 33, 657-666.	0.7	5
2337	Emerging platinum(<i>iv</i>) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment. <i>Dalton Transactions</i> , 2019, 48, 2536-2544.	1.6	115
2338	Preparation and evaluation of highly biocompatible nanogels with pH-sensitive charge-convertible capability based on doxorubicin prodrug. <i>Materials Science and Engineering C</i> , 2019, 98, 161-176.	3.8	8
2339	PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2303-2313.	1.6	103
2340	Contribution of Base Damages to the Molecular Radiosensitization Mechanism of Platinum Chemotherapeutic Drugs. <i>ChemistrySelect</i> , 2019, 4, 1084-1091.	0.7	3
2341	2,4-Dihydroxy-5-[(5-mercapto-1 <i>H</i> -1,2,4-triazole-3-yl)diazenyl]benzaldehyde acetato, chloro and nitrate Cu(II) complexes: Synthesis, structural characterization, DNA binding and anticancer and antimicrobial activity. <i>Applied Organometallic Chemistry</i> , 2019, 33, e4707.	1.7	45
2342	Studies on the synthesis, characterization, cytotoxic activities and plasmid DNA binding of platinum(II) complexes having 2-substituted benzimidazole ligands. <i>Polyhedron</i> , 2019, 161, 298-308.	1.0	12
2343	Design and <i>In Vitro</i> Biological Evaluation of a Novel Organotin(IV) Complex with 1-(4-Carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione. <i>Journal of Chemistry</i> , 2019, 2019, 1-8.	0.9	18
2344	Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs. <i>Nature Communications</i> , 2019, 10, 309.	5.8	131
2345	Modulation of the reactivity of nitrogen mustards by metal complexation: approaches to modify their therapeutic properties. <i>Dalton Transactions</i> , 2019, 48, 1144-1160.	1.6	13
2346	Anticancer drug impact on DNA "a study by neutron spectroscopy coupled with synchrotron-based FTIR and EXAFS. <i>Physical Chemistry Chemical Physics</i> , 2019, 21, 4162-4175.	1.3	27
2347	Molecular dynamics simulation of anticancer drug delivery from carbon nanotube using metal nanowires. <i>Journal of Computational Chemistry</i> , 2019, 40, 2179-2190.	1.5	8
2348	Chlorambucil targets <i>BRCA</i> 1/2-deficient tumours and counteracts <i>PARP</i> inhibitor resistance. <i>EMBO Molecular Medicine</i> , 2019, 11, e9982.	3.3	26
2349	Organometallic binuclear Pd(II) complex: Synthesis, crystal structure and in-vitro antitumor activity study. <i>Inorganic Chemistry Communication</i> , 2019, 105, 199-202.	1.8	6
2350	Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it. <i>Drug Metabolism Reviews</i> , 2019, 51, 196-223.	1.5	33

#	ARTICLE	IF	CITATIONS
2351	A Triangular Platinum(II) Multinuclear Complex with Cytotoxicity Towards Breast Cancer Stem Cells. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 12059-12064.	7.2	48
2352	A Triangular Platinum(II) Multinuclear Complex with Cytotoxicity Towards Breast Cancer Stem Cells. <i>Angewandte Chemie</i> , 2019, 131, 12187-12192.	1.6	10
2353	Thermosensitive Nanogels with Cross-Linked Pd(II) Ions for Improving Therapeutic Effects on Platinum-Resistant Cancers via Intratumoral Formation of Hydrogels. <i>Chemistry of Materials</i> , 2019, 31, 5089-5103.	3.2	24
2354	Synthesis, DNA and BSA binding, <i>in vitro</i> anti-proliferative and <i>in vivo</i> anti-angiogenic properties of some cobalt(III) Schiff base complexes. <i>New Journal of Chemistry</i> , 2019, 43, 11391-11407.	1.4	30
2355	Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 487-497.	1.5	32
2356	Synthesis, characterisation and <i>in vitro</i> antitumour potential of novel Pt(II) estrogen linked complexes. <i>Inorganica Chimica Acta</i> , 2019, 495, 118944.	1.2	10
2357	A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13943-13951.	3.3	76
2358	Cisplatin protects mice from challenge of <i>Cryptococcus neoformans</i> by targeting the Prp8 intein. <i>Emerging Microbes and Infections</i> , 2019, 8, 895-908.	3.0	20
2359	Black phosphorus nanosheets-based stable drug delivery system via drug-self-stabilization for combined photothermal and chemo cancer therapy. <i>Chemical Engineering Journal</i> , 2019, 375, 121917.	6.6	91
2360	Involvement of Endothelin Receptors in Peripheral Sensory Neuropathy Induced by Oxaliplatin in Mice. <i>Neurotoxicity Research</i> , 2019, 36, 688-699.	1.3	3
2361	Synthesis and in-depth studies on the anticancer activity of novel palladacyclopentadienyl complexes stabilized by N-Heterocyclic carbene ligands. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 325-334.	2.6	28
2362	Guanidine-modified cyclometalated iridium(III) complexes for mitochondria-targeted imaging and photodynamic therapy. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 26-37.	2.6	48
2363	Hyposalivation due to chemotherapy exacerbates oral ulcerative mucositis and delays its healing. <i>Archives of Oral Biology</i> , 2019, 105, 20-26.	0.8	8
2364	Natural products for treating colorectal cancer: A mechanistic review. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109142.	2.5	116
2365	Long-term, genome-wide kinetic analysis of the effect of the circadian clock and transcription on the repair of cisplatin-DNA adducts in the mouse liver. <i>Journal of Biological Chemistry</i> , 2019, 294, 11960-11968.	1.6	20
2366	Photoactivated Lysosomal Escape of a Monofunctional Pt ^{II} Complex Pt@BDPA for Nucleus Access. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 12661-12666.	7.2	89
2367	GMDTC Chelating Agent Attenuates Cisplatin-Induced Systemic Toxicity without Affecting Antitumor Efficacy. <i>Chemical Research in Toxicology</i> , 2019, 32, 1572-1582.	1.7	9
2368	The <i>in vitro</i> and <i>in vivo</i> antitumor effects of <i>Dracaena cinnabari</i> resin extract on oral cancer. <i>Archives of Oral Biology</i> , 2019, 104, 77-89.	0.8	7

#	ARTICLE	IF	CITATIONS
2369	Graphene oxide nanocells for impairing topoisomerase and DNA in cancer cells. <i>Journal of Materials Chemistry B</i> , 2019, 7, 4191-4197.	2.9	7
2370	Enhanced cellular uptake and photochemotherapeutic potential of a lipophilic strained Ru(II) polypyridyl complex. <i>RSC Advances</i> , 2019, 9, 17254-17265.	1.7	29
2371	Reactivity of lithium and platinum at elevated densities. <i>Physical Review B</i> , 2019, 99, .	1.1	4
2372	Absolute cross sections for chemoradiation therapy: Damages to cisplatin-DNA complexes induced by 10 eV electrons. <i>Journal of Chemical Physics</i> , 2019, 150, 195101.	1.2	5
2373	A glycine spacer improved peptidyl-nuclear-localized efficiency for fluorescent imaging nuclear H ₂ O ₂ . <i>Sensors and Actuators B: Chemical</i> , 2019, 296, 126624.	4.0	15
2374	Diazido platinum(IV) complexes for photoactivated anticancer chemotherapy. <i>Inorganic Chemistry Frontiers</i> , 2019, 6, 1623-1638.	3.0	84
2375	Nanofocused synchrotron X-ray absorption studies of the intracellular redox state of an organometallic complex in cancer cells. <i>Chemical Communications</i> , 2019, 55, 7065-7068.	2.2	17
2376	Construing the Biochemical and Molecular Mechanism Underlying the <i>In Vivo</i> and <i>In Vitro</i> Chemotherapeutic Efficacy of Ruthenium-Baicalein Complex in Colon Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 1052-1071.	2.6	21
2377	Mechanistic Study of TTF-1 Modulation of Cellular Sensitivity to Cisplatin. <i>Scientific Reports</i> , 2019, 9, 7990.	1.6	3
2378	Remarkably Intricate Raman Spectra of Platinum(II) Ligand Skeletal Modes in Diamminedihalido Complexes. <i>Journal of Physical Chemistry A</i> , 2019, 123, 5574-5579.	1.1	7
2379	Ruthenium(II) carbonyl complexes containing thiourea ligand: Enhancing the biological assets through biomolecules interaction and enzyme mimetic activities. <i>Monatshefte für Chemie</i> , 2019, 150, 1059-1071.	0.9	4
2380	NF- κ B hijacking theranostic Pt(II) complex in cancer therapy. <i>Theranostics</i> , 2019, 9, 2158-2166.	4.6	17
2381	Theoretical exploration of the reduction reaction of monofunctional phenanthriplatin Pt(IV) prodrugs. <i>Inorganica Chimica Acta</i> , 2019, 495, 118951.	1.2	2
2382	ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. <i>Cell Death and Disease</i> , 2019, 10, 459.	2.7	46
2383	Non-platinum complexes containing releasable biologically active ligands. <i>Coordination Chemistry Reviews</i> , 2019, 395, 130-145.	9.5	80
2384	Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1405-1417.	1.9	18
2385	Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas. <i>G3: Genes, Genomes, Genetics</i> , 2019, 9, 2267-2276.	0.8	6
2386	New Organometallic Tetraphenylethylene...Iridium(III) Complexes with Antineoplastic Activity. <i>ChemBioChem</i> , 2019, 20, 2767-2776.	1.3	12

#	ARTICLE	IF	CITATIONS
2387	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. , 2019, 201, 94-102.		106
2388	<p>lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway</p>. OncoTargets and Therapy, 2019, Volume 12, 2649-2660.	1.0	101
2389	Surface Coordination of Black Phosphorus with Modified Cisplatin. Bioconjugate Chemistry, 2019, 30, 1658-1664.	1.8	25
2390	New platinum(II)-based DNA intercalator: Synthesis, characterization and anticancer activity. Inorganic Chemistry Communication, 2019, 105, 182-187.	1.8	8
2391	pH and redox dual responsive carrier-free anticancer drug nanoparticles for targeted delivery and synergistic therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102008.	1.7	24
2392	Wogonin pre-treatment attenuates cisplatin-induced nephrotoxicity in rats: Impact on PPAR- β , inflammation, apoptosis and Wnt/ β -catenin pathway. Chemico-Biological Interactions, 2019, 308, 137-146.	1.7	39
2393	In vitro and in vivo activity of novel platinum(ii) complexes with naphthalene imide derivatives inhibiting human non-small cell lung cancer cells. New Journal of Chemistry, 2019, 43, 8146-8152.	1.4	8
2394	Chemotherapy-Induced Peripheral Neuropathy and Changes in Cytoskeleton. International Journal of Molecular Sciences, 2019, 20, 2287.	1.8	30
2395	PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells. Frontiers in Physiology, 2019, 10, 538.	1.3	16
2396	Addition of Platinum Derivatives to Fluoropyrimidine-Based Neoadjuvant Chemoradiotherapy for Stage II/III Rectal Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 887-902.	3.0	22
2397	Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. Toxics, 2019, 7, 27.	1.6	7
2398	The role of thioredoxin system in cancer: strategy for cancer therapy. Cancer Chemotherapy and Pharmacology, 2019, 84, 453-470.	1.1	101
2399	Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma. Epigenetics, 2019, 14, 791-803.	1.3	30
2400	Transporter and protease mediated delivery of platinum complexes for precision oncology. Journal of Biological Inorganic Chemistry, 2019, 24, 457-466.	1.1	17
2401	Discovery of Cisplatin Binding to Thymine and Cytosine on a Single-Stranded Oligodeoxynucleotide by High Resolution FT-ICR Mass Spectrometry. Molecules, 2019, 24, 1852.	1.7	20
2402	The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and Fanconi's syndrome: A comprehensive review. Toxicology, 2019, 423, 1-31.	2.0	40
2403	Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research. Clinical Pharmacology and Therapeutics, 2019, 106, 350-359.	2.3	24
2404	Orally delivered nanoparticle drug-delivery systems for dental applications and their systemic toxicity. , 2019, , 595-616.		0

#	ARTICLE	IF	CITATIONS
2405	Quantitative imaging of platinum-based antitumor complexes in bone tissue samples using LA-ICP-MS. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 54, 98-102.	1.5	15
2406	Cytotoxic ruthenium(II) polypyridyl complexes with naproxen as NSAID: Synthesis, biological interactions and antioxidant activity. <i>Polyhedron</i> , 2019, 172, 132-140.	1.0	10
2407	New ternary palladium(II) complexes: Synthesis, characterization, in vitro anticancer and antioxidant activities. <i>Inorganic Chemistry Communication</i> , 2019, 105, 140-146.	1.8	16
2408	Cytotoxicity and ROS production of novel Pt(IV) oxaliplatin derivatives with indole propionic acid. <i>Inorganica Chimica Acta</i> , 2019, 492, 262-267.	1.2	9
2409	Fuplatin: An Efficient and Low-Toxic Dual-Prodrug. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4543-4554.	2.9	47
2410	Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 206.	1.6	8
2411	CACNA2D3 Enhances the Chemosensitivity of Esophageal Squamous Cell Carcinoma to Cisplatin via Inducing Ca ²⁺ -Mediated Apoptosis and Suppressing PI3K/Akt Pathways. <i>Frontiers in Oncology</i> , 2019, 9, 185.	1.3	20
2412	Platinum(II) complexes containing hydrazide-based aminophosphine ligands: Synthesis, molecular structures, computational investigation and evaluation as antitumour agents. <i>Applied Organometallic Chemistry</i> , 2019, 33, e4873.	1.7	4
2413	Roles of volume-regulatory anion channels, VSOR and Maxi-Cl, in apoptosis, cisplatin resistance, necrosis, ischemic cell death, stroke and myocardial infarction. <i>Current Topics in Membranes</i> , 2019, 83, 205-283.	0.5	34
2414	Induction of a Four-Way Junction Structure in the DNA Palindromic Hexanucleotide 5'-d(CGTACG)-3' by a Mononuclear Platinum Complex. <i>Angewandte Chemie</i> , 2019, 131, 9478-9482.	1.6	4
2415	A Versatile Carbon Monoxide Nanogenerator for Enhanced Tumor Therapy and Anti-Inflammation. <i>ACS Nano</i> , 2019, 13, 5523-5532.	7.3	89
2416	NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer. <i>EBioMedicine</i> , 2019, 43, 238-252.	2.7	34
2417	Phosphine-copper(I) complexes as anticancer agents: design, synthesis, and physicochemical characterization. Part I. , 2019, , 61-82.		6
2418	A highly efficient and selective antitumor agent based on a glucoconjugated carbene platinum(II) complex. <i>Dalton Transactions</i> , 2019, 48, 7794-7800.	1.6	28
2419	Unexpected therapeutic effects of cisplatin. <i>Metallomics</i> , 2019, 11, 1182-1199.	1.0	67
2420	Modulating the Chemical and Biological Properties of Cancer Stem Cell-Potent Copper(II)-Nonsteroidal Anti-Inflammatory Drug Complexes. <i>Molecules</i> , 2019, 24, 1677.	1.7	10
2421	Induction of a Four-Way Junction Structure in the DNA Palindromic Hexanucleotide 5'-d(CGTACG)-3' by a Mononuclear Platinum Complex. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 9378-9382.	7.2	24
2422	A view on multi-action Pt(IV) antitumor prodrugs. <i>Inorganica Chimica Acta</i> , 2019, 492, 32-47.	1.2	71

#	ARTICLE	IF	CITATIONS
2423	Proteomic Strategy for Identification of Proteins Responding to Cisplatin-Damaged DNA. <i>Analytical Chemistry</i> , 2019, 91, 6035-6042.	3.2	14
2424	Efficacy of a Selective Binder of $\alpha_5\beta_1$ Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models. <i>Cancers</i> , 2019, 11, 531.	1.7	18
2425	Nrf2-miRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21. <i>FASEB Journal</i> , 2019, 33, 7953-7969.	0.2	25
2426	Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress. <i>Scientific Reports</i> , 2019, 9, 4954.	1.6	29
2427	Low Cross-Reactivity Between Cisplatin and Other Platinum Salts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1894-1900.	2.0	24
2428	The two isomers of a cyclometallated palladium sensitizer show different photodynamic properties in cancer cells. <i>Chemical Communications</i> , 2019, 55, 4695-4698.	2.2	18
2429	Hybrid cis-stilbene Molecules: Novel Anticancer Agents. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1300.	1.8	31
2430	Host-guest complexation-mediated codelivery of anticancer drug and photosensitizer for cancer photochemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6618-6623.	3.3	111
2431	The State of the Art of Investigational and Approved Nanomedicine Products for Nucleic Acid Delivery. , 2019, , 421-456.		7
2432	Reductions of the cisplatin-based platinum(IV) prodrug cis,cis,trans-[Pt(NH ₃) ₂ Cl ₂ Br ₂] by predominant biological thiols: kinetic and mechanistic studies. <i>Transition Metal Chemistry</i> , 2019, 44, 535-544.	0.7	3
2433	Glucose-conjugated platinum(IV) complexes as tumor-targeting agents: design, synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1639-1645.	1.4	17
2434	Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase. <i>European Journal of Medicinal Chemistry</i> , 2019, 169, 29-41.	2.6	25
2435	Role of epigenetic mechanisms in cisplatin-induced toxicity. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 131-142.	2.0	24
2436	NIR-II light-modulated thermosensitive hydrogel for light-triggered cisplatin release and repeatable chemo-photothermal therapy. <i>Chemical Science</i> , 2019, 10, 4699-4706.	3.7	90
2437	Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line. <i>Biological Research</i> , 2019, 52, 13.	1.5	16
2438	Pyridine Ruthenium(III) complexes entrapped in liposomes with enhanced cytotoxic properties in PC-3 prostate cancer cells. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 51, 552-558.	1.4	11
2439	An iron(III) complex selectively mediated cancer cell death: crystal structure, DNA targeting and <i>in vitro</i> antitumor activities. <i>Inorganic Chemistry Frontiers</i> , 2019, 6, 1040-1049.	3.0	10
2440	Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 18180-18191.	2.0	31

#	ARTICLE	IF	CITATIONS
2441	Protective role of N-acetylcysteine (NAC) on human sperm exposed to etoposide. <i>Basic and Clinical Andrology</i> , 2019, 29, 3.	0.8	6
2442	GE11-PDA-Pt@USPIOs nano-formulation for relief of tumor hypoxia and MRI/PAI-guided tumor radio-chemotherapy. <i>Biomaterials Science</i> , 2019, 7, 2076-2090.	2.6	34
2443	Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells. <i>Cells</i> , 2019, 8, 235.	1.8	13
2444	Differential effects of ginkgol C17:1 on cisplatin-induced cytotoxicity: Protecting human normal L02 hepatocytes versus sensitizing human hepatoma HepG2 cells. <i>Oncology Letters</i> , 2019, 17, 3181-3190.	0.8	8
2445	Synthesis, characterization, DNA binding propensity, nuclease efficacy, antioxidant and antimicrobial activities of Cu(II), Co(II) and Ni(II) complexes derived from 4-(trifluoromethoxy)aniline Schiff bases. <i>Chemical Data Collections</i> , 2019, 20, 100213.	1.1	20
2446	Design and investigation of photoactivatable platinum(II) prodrug complexes of cisplatin. <i>Dalton Transactions</i> , 2019, 48, 7388-7393.	1.6	18
2447	Preparation of platinum(II) complexes with naphthalene imide derivatives and exploration of their in vitro cytotoxic activities. <i>Inorganic Chemistry Communication</i> , 2019, 104, 124-128.	1.8	3
2448	The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward. <i>Neuropharmacology</i> , 2019, 158, 107598.	2.0	14
2449	Rethinking Alkylating(-Like) Agents for Solid Tumor Management. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 342-357.	4.0	31
2450	Cisplatin: The first metal based anticancer drug. <i>Bioorganic Chemistry</i> , 2019, 88, 102925.	2.0	961
2451	Isomeric platinum organometallics derived from pyrimidine, pyridazine or pyrazine and their potential as antitumor drugs. <i>Inorganica Chimica Acta</i> , 2019, 493, 112-117.	1.2	7
2452	Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance. <i>Nano Letters</i> , 2019, 19, 2968-2978.	4.5	81
2453	Protective effect of mirtazapine versus ginger against cisplatin-induced testicular damage in adult male albino rats. <i>Ultrastructural Pathology</i> , 2019, 43, 66-79.	0.4	8
2454	Single cell analysis for elucidating cellular uptake and transport of cobalt curcumin complex with detection by time-resolved ICPMS. <i>Analytica Chimica Acta</i> , 2019, 1066, 13-20.	2.6	21
2455	Effects of cisplatin on photosensitizer-mediated photodynamic therapy in breast tumor-bearing nude mice. <i>Obstetrics and Gynecology Science</i> , 2019, 62, 112.	0.6	6
2456	Dinuclear platinum(II) complexes of imidazophenanthroline-based bridging ligands as potential anticancer agents: synthesis, characterization, and in vitro cytotoxicity studies. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 405-418.	1.1	10
2457	The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model. <i>Scientific Reports</i> , 2019, 9, 5632.	1.6	25
2458	MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 5668.	1.6	74

#	ARTICLE	IF	CITATIONS
2459	Accurate quantification of carboplatin adducts with serum proteins by monolithic chromatography coupled to ICPMS with isotope dilution analysis. <i>Journal of Analytical Atomic Spectrometry</i> , 2019, 34, 729-740.	1.6	12
2460	Anticancer activity and mechanism of bis-pyrimidine based dimetallic Ru(II)(η^6 -p-cymene) complex in human non-small cell lung cancer via p53-dependent pathway. <i>Journal of Inorganic Biochemistry</i> , 2019, 194, 52-64.	1.5	15
2461	Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 751-761.	1.9	14
2462	Cytotoxicity, cellular uptake, and subcellular localization of a nitrogen oxide and aminopropyl- β -lactose derivative ruthenium complex used as nitric oxide delivery agent. <i>Nitric Oxide - Biology and Chemistry</i> , 2019, 86, 38-47.	1.2	10
2463	Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase β . <i>Biochemical Journal</i> , 2019, 476, 747-758.	1.7	14
2464	Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 63.	3.5	43
2465	Design and synthesis of a dual imageable theranostic platinum prodrug for efficient cancer therapy. <i>Polymer Chemistry</i> , 2019, 10, 3066-3078.	1.9	8
2466	Antimicrobial Activity of Organometal Compounds. , 2019, , 173-192.		8
2467	Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. <i>Journal of Proteomics</i> , 2019, 196, 106-119.	1.2	18
2468	Zwitterionic and cationic half-sandwich iridium(κ^3) ruthenium(κ^2) complexes bearing sulfonate groups: synthesis, characterization and their different biological activities. <i>Dalton Transactions</i> , 2019, 48, 3193-3197.	1.6	22
2469	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 667.	1.8	19
2470	Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles. <i>Theranostics</i> , 2019, 9, 778-795.	4.6	82
2471	Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy. <i>Journal of Controlled Release</i> , 2019, 300, 73-80.	4.8	30
2472	Targeting the CINful genome: Strategies to overcome tumor heterogeneity. <i>Progress in Biophysics and Molecular Biology</i> , 2019, 147, 77-91.	1.4	14
2473	In vitro anticancer active cis-Pt(II)-diiodido complexes containing 4-azaindoles. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 257-269.	1.1	10
2474	Conversion mechanism and isomeric preferences of the cis and trans isomers of anti-cancer medicine carmustine; A double hybrid DFT calculation. <i>Chemical Physics</i> , 2019, 522, 39-43.	0.9	6
2475	Nanoparticles of Metal-Organic Cages Overcoming Drug Resistance in Ovarian Cancer. <i>Frontiers in Chemistry</i> , 2019, 7, 39.	1.8	8
2476	A novel Trans-Pt(II) complex bearing 2-acetoxymethylbenzimidazole as a non-leaving ligand (trans-[Pt(AMBi)2Cl2]): Synthesis, antiproliferative activity, DNA interaction and molecular docking studies compared with its cis isomer (cis-[Pt(AMBi)2Cl2]). <i>Journal of Molecular Structure</i> , 2019, 1184, 512-518.	1.8	3

#	ARTICLE	IF	CITATIONS
2477	Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators. <i>Journal of Inorganic Biochemistry</i> , 2019, 195, 130-140.	1.5	23
2478	The interaction between SBA-15 derivative loaded with Ph ₃ Sn(CH ₂) ₆ OH and human melanoma A375 cell line: uptake and stem phenotype loss. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 223-234.	1.1	17
2479	A half-sandwich Ta ^V dichlorido complex containing an <i>o</i> , <i>N</i> , <i>o</i> -tridentate Schiff base ligand: synthesis, crystal structure and <i>in vitro</i> cytotoxicity. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2019, 75, 248-254.	0.2	4
2480	Platinum Polyoxoniobates Form Adducts with DNA. <i>Russian Journal of Bioorganic Chemistry</i> , 2019, 45, 641-646.	0.3	4
2481	Downregulation of long non-coding RNA B-Raf proto-oncogene-activated non-coding RNA reverses cisplatin resistance in laryngeal squamous cell carcinoma. <i>Archives of Medical Science</i> , 2021, 17, 1164-1174.	0.4	2
2482	Antitumor Activity of Cyclodextrin-based Supramolecular Platinum Prodrug <i>In vitro</i> and <i>In vivo</i> . <i>Letters in Drug Design and Discovery</i> , 2019, 16, 1296-1301.	0.4	1
2483	Comparison of responsiveness to cancer development and anti-cancer drug in three different C57BL/6N stocks. <i>Laboratory Animal Research</i> , 2019, 35, 17.	1.1	4
2484	FTIR Study of the Secondary Structure of DNA in Complexes with Platinum Coordination Compounds. <i>Journal of Physics: Conference Series</i> , 2019, 1400, 033004.	0.3	3
2485	Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs. <i>Acta Pharmaceutica</i> , 2019, 69, 461-482.	0.9	45
2486	Combinational delivery therapies of nucleic acids for cancer treatment. , 2019, , 257-291.		0
2487	Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy. <i>Life Sciences</i> , 2019, 239, 117060.	2.0	24
2488	Metal complexes driven from Schiff bases and semicarbazones for biomedical and allied applications: a review. <i>Materials Today Chemistry</i> , 2019, 14, 100195.	1.7	166
2489	trans Effect of Amino-Chloro-Platinum Complexes and the Reaction of Cisplatin with Guanine: A Theoretical Study. <i>Asian Journal of Chemistry</i> , 2019, 31, 1683-1687.	0.1	0
2490	Ruthenium(II) and palladium(II) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies. <i>Dalton Transactions</i> , 2019, 48, 15869-15887.	1.6	8
2491	Coordinative unsaturated Cu ^I entities are crucial intermediates governing cell internalization of copper. A combined experimental ESI-MS and DFT study. <i>Metallomics</i> , 2019, 11, 1800-1804.	1.0	12
2493	Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment. <i>Clinical Cancer Research</i> , 2019, 25, 7243-7255.	3.2	57
2494	Two telomerase-targeting Pt(II) complexes of jatrorrhizine and berberine derivatives induce apoptosis in human bladder tumor cells. <i>Dalton Transactions</i> , 2019, 48, 15247-15254.	1.6	40
2495	Copper(II) complexes with tridentate Schiff base-like ligands: solid state and solution structures and anticancer activity. <i>Dalton Transactions</i> , 2019, 48, 15220-15230.	1.6	22

#	ARTICLE	IF	CITATIONS
2496	Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells. <i>Cancers</i> , 2019, 11, 1866.	1.7	35
2497	Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates. <i>Inorganic Chemistry</i> , 2019, 58, 16676-16688.	1.9	13
2498	Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease. <i>Cancers</i> , 2019, 11, 1887.	1.7	28
2499	Polyamine-Based Pt(IV) Prodrugs as Substrates for Polyamine Transporters Preferentially Accumulate in Cancer Metastases as DNA and Polyamine Metabolism Dual-Targeted Antimetastatic Agents. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11324-11334.	2.9	26
2500	Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair. <i>Anti-Cancer Drugs</i> , 2019, 30, 774-783.	0.7	0
2501	N-Acetylcysteine Protects against the Anxiogenic Response to Cisplatin in Rats. <i>Biomolecules</i> , 2019, 9, 892.	1.8	18
2502	Repurposed Drugs Trials for Ovarian Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 149-152.	1.0	3
2503	Nanocarrier-based targeted pulmonary delivery: novel approaches for effective lung cancer treatment. , 2019, , 129-161.		4
2504	Dual-ligand functionalized carbon nanodots as green fluorescent nanosensors for cellular dual receptor-mediated targeted imaging. <i>Analyst, The</i> , 2019, 144, 6729-6735.	1.7	14
2505	Kinetic analysis of the accumulation of a half-sandwich organo-osmium pro-drug in cancer cells. <i>Metallomics</i> , 2019, 11, 1648-1656.	1.0	9
2506	Novel synthesis of platinum complexes and their intracellular delivery to tumor cells by means of magnetic nanoparticles. <i>Nanoscale</i> , 2019, 11, 23482-23497.	2.8	33
2507	Screening of molecular targets and construction of a ceRNA network for oxaliplatin resistance in colorectal cancer. <i>RSC Advances</i> , 2019, 9, 31413-31424.	1.7	2
2508	Ultrasensitive detection of uric acid in serum of patients with gout by a new assay based on Pt@Ag nanoflowers. <i>RSC Advances</i> , 2019, 9, 36578-36585.	1.7	20
2509	Mice with a Sertoli cell-specific knockout of the Ctr1 gene exhibit a reduced sensitivity to cisplatin-induced testicular germ cell apoptosis. <i>Toxicology Research</i> , 2019, 8, 972-978.	0.9	5
2510	PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 1092-1103.	2.3	38
2511	Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. <i>Neuro-Oncology</i> , 2019, 21, 252-263.	0.6	21
2512	Novel lysosome-targeted cyclometalated Iridium(III) anticancer complexes containing imine-N-heterocyclic carbene ligands: Synthesis, spectroscopic properties and biological activity. <i>Dyes and Pigments</i> , 2019, 161, 119-129.	2.0	36
2513	Metal-Organic Framework Mediated Multifunctional Nanoplatforms for Cancer Therapy. <i>Advanced Therapeutics</i> , 2019, 2, 1800100.	1.6	30

#	ARTICLE	IF	CITATIONS
2514	Synthesis, X-ray structure and in vitro cytotoxicity of trans-diammineplatinum(II) complexes of selenones, trans-[Pt(NH ₃) ₂ (selenone) ₂](NO ₃) ₂ . <i>Polyhedron</i> , 2019, 158, 234-240.	1.0	8
2515	Mitochondrial division inhibitor-1 potentiates cisplatin-induced apoptosis via the mitochondrial death pathway in cholangiocarcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 109-118.	2.5	38
2516	Design and Application of Cisplatin-Loaded Magnetic Nanoparticle Clusters for Smart Chemotherapy. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 1864-1875.	4.0	49
2517	Biological and catalytic evaluation of Ru(II)â€œmethylene complexes of Schiff base ligands: Impact of ligand appended moiety on photoâ€œinduced DNA and protein cleavage, cytotoxicity and Câ€œH activation. <i>Applied Organometallic Chemistry</i> , 2019, 33, e4756.	1.7	18
2518	Toxicity study of DE-EDCP as a potential drug for cancer therapy: Toxicity profile of DE-EDCP. <i>Human and Experimental Toxicology</i> , 2019, 38, 466-481.	1.1	1
2519	Exploring the Cytotoxicity, Uptake, Cellular Response, and Proteomics of Mono- and Dinuclear DNA Light-Switch Complexes. <i>Journal of the American Chemical Society</i> , 2019, 141, 2925-2937.	6.6	53
2520	Synthesis of new ultrasonic-assisted palladium oxide nanoparticles: an in vitro evaluation on cytotoxicity and DNA/BSA binding properties. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 4238-4250.	2.0	22
2521	Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. <i>JAMA Oncology</i> , 2019, 5, 318.	3.4	116
2522	Platinum(II) complexes of pyridineâ€œamine ligands with phenol substituents: isotactic supramolecular polymers. <i>Canadian Journal of Chemistry</i> , 2019, 97, 238-243.	0.6	6
2523	Validation and Applications of Proteinâ€œLigand Docking Approaches Improved for Metalloligands with Multiple Vacant Sites. <i>Inorganic Chemistry</i> , 2019, 58, 294-306.	1.9	35
2524	Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy. <i>ACS Nano</i> , 2019, 13, 357-370.	7.3	204
2525	Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C ^N -chelated ligands. <i>Journal of Inorganic Biochemistry</i> , 2019, 191, 1-7.	1.5	26
2526	PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers. <i>Annual Review of Cancer Biology</i> , 2019, 3, 131-150.	2.3	63
2527	Platinum(II) Complexes with 1,10â€œPhenanthroline and Hydrophilic Alkoxyacetate Ligands as Potential Antitumor Agents. <i>Chemistry and Biodiversity</i> , 2019, 16, e1800373.	1.0	7
2528	Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2. <i>Cell Chemical Biology</i> , 2019, 26, 85-97.e4.	2.5	38
2529	New Oxidovanadium(IV) Coordination Complex Containing 2-Methylnitrilotriacetate Ligands Induces Cell Cycle Arrest and Autophagy in Human Pancreatic Ductal Adenocarcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2019, 20, 261.	1.8	20
2530	UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells. <i>Journal of Oncology</i> , 2019, 2019, 1-15.	0.6	38
2531	Genistein Prevents Development of Spontaneous Ovarian Cancer and Inhibits Tumor Growth in Hen Model. <i>Cancer Prevention Research</i> , 2019, 12, 135-146.	0.7	36

#	ARTICLE	IF	CITATIONS
2532	Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?. <i>Chemical Reviews</i> , 2019, 119, 1058-1137.	23.0	463
2533	Transport of the Ruthenium Complex [Ru(GA)(dppe) ₂]PF ₆ into Triple-Negative Breast Cancer Cells Is Facilitated by Transferrin Receptors. <i>Molecular Pharmaceutics</i> , 2019, 16, 1167-1183.	2.3	36
2534	The prognostic value of excision repair cross-complementation group one enzyme expression in locally advanced cervical carcinoma patients treated with cisplatin-based treatment: a meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 35-41.	1.2	3
2535	Binding of platinum derivative, oxaliplatin to deoxyribonucleic acid: structural insight into antitumor action. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 3838-3847.	2.0	11
2536	η ² -Ketoiminato Iridium(III) Organometallic Complexes: Selective Cytotoxicity towards Colorectal Cancer Cells HCT116 <i>p53</i> . <i>Chemistry - A European Journal</i> , 2019, 25, 495-500.	1.7	10
2537	Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy. <i>Stem Cells</i> , 2019, 37, 42-53.	1.4	15
2538	Platinum iodido complexes: A comprehensive overview of anticancer activity and mechanisms of action. <i>Coordination Chemistry Reviews</i> , 2019, 380, 103-135.	9.5	43
2539	A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53. <i>Cancer Letters</i> , 2019, 440-441, 145-155.	3.2	28
2540	Enhanced release of palladium and platinum from catalytic converter materials exposed to ammonia and chloride bearing solutions. <i>Environmental Sciences: Processes and Impacts</i> , 2019, 21, 133-144.	1.7	7
2541	Lysosome-targeted Cyclometalated Iridium (III) Anticancer Complexes Bearing Phosphine-Sulfonate Ligands. <i>Applied Organometallic Chemistry</i> , 2019, 33, e4746.	1.7	12
2542	Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. <i>Acta Biomaterialia</i> , 2019, 84, 367-377.	4.1	101
2543	Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2523-2536.	3.2	20
2544	Studies on combination of oxaliplatin and dendrosomal nanocurcumin on proliferation, apoptosis induction, and long non-coding RNA expression in ovarian cancer cells. <i>Cell Biology and Toxicology</i> , 2019, 35, 247-266.	2.4	30
2545	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
2546	pH and thermo dual stimulus-responsive liposome nanoparticles for targeted delivery of platinum-acridine hybrid agent. <i>Life Sciences</i> , 2019, 217, 41-48.	2.0	18
2547	Design, synthesis and characterization of tin-based cancer chemotherapy drug entity: <i>In vitro</i> DNA binding, cleavage, induction of cancer cell apoptosis by triggering DNA damage-mediated p53 phosphorylation and molecular docking. <i>Applied Organometallic Chemistry</i> , 2019, 33, e4651.	1.7	21
2548	Nucleus-enriched Ruthenium Polypyridine Complex Acts as a Potent Inhibitor to Suppress Triple-negative Breast Cancer Metastasis <i>In vivo</i> . <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 21-30.	1.9	20
2549	Synthesis and crystal structures of phenylalanine ester-introduced palladium(II) and platinum(II) complexes and their cytotoxicities. <i>Research on Chemical Intermediates</i> , 2019, 45, 3-12.	1.3	4

#	ARTICLE	IF	CITATIONS
2550	Identification of a Novel Zebrafish Mutant Line that Develops Testicular Germ Cell Tumors. <i>Zebrafish</i> , 2019, 16, 15-28.	0.5	2
2551	Synthesis, spectroscopic characterization and in vitro cytotoxic as well as docking studies of cis-diammine platinum(II) complexes of thiones. <i>Inorganica Chimica Acta</i> , 2019, 484, 347-351.	1.2	5
2552	A conveniently synthesized Pt (IV) conjugated alginate nanoparticle with ligand self-shielded property for targeting treatment of hepatic carcinoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 15, 153-163.	1.7	12
2553	Evaluation of (E^3 - <i>p</i> -cymene) ruthenium diclofenac complex as anticancer chemotherapeutic agent: interaction with biomolecules, cytotoxicity assays. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 3905-3913.	2.0	10
2554	Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/ β 2-catenin/CBP signaling. <i>Clinical Cancer Research</i> , 2019, 25, 1022-1035.	3.2	36
2555	Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. <i>Pharmacogenomics Journal</i> , 2019, 19, 15-24.	0.9	5
2556	In vitro antitumor activity of water-soluble copper(I) complexes with diimine and monodentate phosphine ligands. <i>Arabian Journal of Chemistry</i> , 2020, 13, 998-1010.	2.3	16
2557	Docking Approach to Predict Inhibition Activity of New Pt(II) Complexes Against Kinase Protein and Human DNA: Full Characterization, HF-FC Modeling and Genotoxicity. <i>Journal of Inorganic and Organometallic Polymers and Materials</i> , 2020, 30, 907-922.	1.9	11
2558	Cisplatin, rather than oxaliplatin, increases paracellular permeability of LLC-PK1 cells via activating protein kinase C. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 111-116.	1.1	2
2559	A novel cyclopalladated ferrocene derivative: Synthesis, single crystal structure and evaluation of in vitro antitumor activity. <i>Journal of Molecular Structure</i> , 2020, 1200, 127077.	1.8	7
2560	Synthesis, characterization, DNA/BSA interactions and in vitro cytotoxicity study of palladium(II) complexes of hispolon derivatives. <i>Journal of Inorganic Biochemistry</i> , 2020, 202, 110857.	1.5	40
2561	Antitumor activity of organoruthenium complexes with chelate aromatic ligands, derived from 1,10-phenanthroline: Synthesis and biological activity. <i>Journal of Inorganic Biochemistry</i> , 2020, 202, 110869.	1.5	18
2562	Vitamin E protects against cisplatin-induced genotoxicity in human lymphocytes. <i>Toxicology in Vitro</i> , 2020, 62, 104672.	1.1	19
2563	Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines. <i>Nutrition and Cancer</i> , 2020, 72, 352-363.	0.9	13
2564	Cisplatin-induced alteration on membrane composition of A549 cells revealed by ToF-SIMS. <i>Surface and Interface Analysis</i> , 2020, 52, 256-263.	0.8	9
2565	Heterobinuclear copper(II)-platinum(II) complexes with oxindolimine ligands: Interactions with DNA, and inhibition of kinase and alkaline phosphatase proteins. <i>Journal of Inorganic Biochemistry</i> , 2020, 203, 110863.	1.5	4
2566	Platinum(II)-oxalato complexes of seliciclib (CYC202) derivatives show different cellular effects and lesser adverse effects in mouse lymphoma model than cisplatin. <i>Journal of Biological Inorganic Chemistry</i> , 2020, 25, 67-73.	1.1	2
2567	Rationalization of the Superior Anticancer Activity of Phenanthriplatin: An In-Depth Computational Exploration. <i>Chemistry - A European Journal</i> , 2020, 26, 259-268.	1.7	17

#	ARTICLE	IF	CITATIONS
2568	Nâ€Heterocyclic Carbene Platinum Complexes: A Big Step Forward for Effective Antitumor Compounds. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 10-20.	1.0	46
2569	Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with an L-alanyl-based ligand. <i>Journal of Inorganic Biochemistry</i> , 2020, 203, 110868.	1.5	11
2570	Synthesis, characterization, apoptosis, ROS, autophagy and western blotting studies of cyclometalated iridium(III) complexes. <i>Inorganic Chemistry Communication</i> , 2020, 111, 107594.	1.8	2
2571	HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair. <i>Thoracic Cancer</i> , 2020, 11, 3071-3085.	0.8	23
2572	Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer Cells. <i>Pharmacology</i> , 2020, 105, 209-224.	0.9	3
2573	Cisplatin-induced threshold shift in the CBA/CaJ, C57BL/6J, BALB/cJ mouse models of hearing loss. <i>Hearing Research</i> , 2020, 387, 107878.	0.9	17
2574	¹ H NMR-Based Metabolic Profiles Delineate the Anticancer Effect of Vitamin C and Oxaliplatin on Hepatocellular Carcinoma Cells. <i>Journal of Proteome Research</i> , 2020, 19, 781-793.	1.8	11
2575	Photoactive metal complexes that bind DNA and other biomolecules as cell probes, therapeutics, and theranostics. <i>Chemical Communications</i> , 2020, 56, 1464-1480.	2.2	32
2576	Ovarian cancerâ€associated mesothelial cells induce acquired platinumâ€resistance in peritoneal metastasis <i>via</i> the FN1/Akt signaling pathway. <i>International Journal of Cancer</i> , 2020, 146, 2268-2280.	2.3	41
2577	Molecular mechanism of C-phycoerythrin induced apoptosis in LNCaP cells. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115272.	1.4	15
2578	Designing of novel zinc(<sc>ii</sc>) Schiff base complexes having acyl hydrazone linkage: study of phosphatase and anti-cancer activities. <i>Dalton Transactions</i> , 2020, 49, 1232-1240.	1.6	57
2579	Cu(<sc>ii</sc>) phenanthrolineâ€phenazine complexes dysregulate mitochondrial function and stimulate apoptosis. <i>Metallomics</i> , 2020, 12, 65-78.	1.0	24
2580	Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy. <i>ACS Omega</i> , 2020, 5, 726-734.	1.6	23
2581	Design, synthesis and biological evaluation of naphthalenebenzimidazole platinum (II) complexes as potential antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 188, 112033.	2.6	15
2582	A nanobiosensor for the simple detection of small molecules using non-crosslinking aggregation of gold nanoparticles with G-quadruplexes. <i>Analytical Methods</i> , 2020, 12, 230-238.	1.3	5
2583	Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms. <i>Inorganic Chemistry Frontiers</i> , 2020, 7, 678-688.	3.0	34
2584	Palladium release from catalytic converter materials induced by road de-icer components chloride and ferrocyanide. <i>Chemosphere</i> , 2020, 245, 125578.	4.2	9
2585	Organic Cation Transporters in Health and Disease. <i>Pharmacological Reviews</i> , 2020, 72, 253-319.	7.1	180

#	ARTICLE	IF	CITATIONS
2586	Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. <i>Food and Chemical Toxicology</i> , 2020, 136, 111079.	1.8	100
2587	The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer. <i>Biomaterials</i> , 2020, 232, 119751.	5.7	26
2588	A novel molecularly imprinted polymer decorated by CQDs@HBNNS nanocomposite and UiO-66-NH ₂ for ultra-selective electrochemical sensing of Oxaliplatin in biological samples. <i>Sensors and Actuators B: Chemical</i> , 2020, 307, 127614.	4.0	53
2589	Glucose-modification of cisplatin to facilitate cellular uptake, mitigate toxicity to normal cells, and improve anti-cancer effect in cancer cells. <i>Journal of Molecular Structure</i> , 2020, 1203, 127361.	1.8	3
2590	Exploring the Reactivity and Biological Effects of Heteroleptic Nâ€Heterocyclic Carbene Gold(I)â€Alkynyl Complexes. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 1040-1051.	1.0	26
2591	Genipin increases oxaliplatin-induced cell death through autophagy in gastric cancer. <i>Journal of Cancer</i> , 2020, 11, 460-467.	1.2	16
2592	Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. <i>Cancer Letters</i> , 2020, 473, 74-89.	3.2	63
2593	â€œDual Layerâ€•Self-Sorting with Cucurbiturils. <i>Journal of the American Chemical Society</i> , 2020, 142, 867-873.	6.6	16
2594	DNA-templated quantum dots and their applications in biosensors, bioimaging, and therapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 9-17.	2.9	30
2595	Structure-Based Design of Novel Biphenyl Amide Antagonists of Human Transient Receptor Potential Cation Channel Subfamily M Member 8 Channels with Potential Implications in the Treatment of Sensory Neuropathies. <i>ACS Chemical Neuroscience</i> , 2020, 11, 268-290.	1.7	13
2596	DOTA-Branched Organic Frameworks as Giant and Potent Metal Chelators. <i>Journal of the American Chemical Society</i> , 2020, 142, 198-206.	6.6	45
2597	The Fluorine Effect in Zwitterionic Half-Sandwich Iridium(III) Anticancer Complexes. <i>Inorganic Chemistry</i> , 2020, 59, 748-758.	1.9	24
2598	Rational design of anticancer platinum(IV) prodrugs. <i>Advances in Inorganic Chemistry</i> , 2020, 75, 149-182.	0.4	16
2599	Harnessing an Artificial Intelligence Platform to Dynamically Individualize Combination Therapy for Treating Colorectal Carcinoma in a Rat Model. <i>Advanced Therapeutics</i> , 2020, 3, 1900127.	1.6	7
2600	Inhibition of miR-574-5p suppresses cell growth and metastasis and enhances chemosensitivity by targeting RNA binding protein QKI in cervical cancer cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 951-966.	1.4	9
2601	Platinum Derivatives Effects on Anticancer Immune Response. <i>Biomolecules</i> , 2020, 10, 13.	1.8	55
2602	Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy. <i>Medicine (United States)</i> , 2020, 99, e22637.	0.4	4
2603	<p>Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 427-444.	0.4	0

#	ARTICLE	IF	CITATIONS
2604	Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7379.	1.8	6
2605	Induction of Redox-Mediated Cell Death in ER-Positive and ER-Negative Breast Cancer Cells by a Copper(II)-Phenolate Complex: An In Vitro and In Silico Study. <i>Molecules</i> , 2020, 25, 4504.	1.7	8
2606	Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6928.	1.8	40
2607	Proof of Phosphate Diester Binding Ability of Cytotoxic DNA-Binding Complexes. <i>Inorganic Chemistry</i> , 2020, 59, 14615-14619.	1.9	7
2608	Synthesis of Amino Acid Schiff Base Nickel (II) Complexes as Potential Anticancer Drugs In Vitro. <i>Bioinorganic Chemistry and Applications</i> , 2020, 2020, 1-15.	1.8	17
2609	Autophagy-Associated lncRNAs: Promising Targets for Neurological Disease Diagnosis and Therapy. <i>Neural Plasticity</i> , 2020, 2020, 1-13.	1.0	23
2610	Potent half-sandwich Ru(II) N ^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112763.	2.6	20
2611	Near-Infrared Light Irradiation Induced Mild Hyperthermia Enhances Glutathione Depletion and DNA Interstrand Cross-Link Formation for Efficient Chemotherapy. <i>ACS Nano</i> , 2020, 14, 14831-14845.	7.3	67
2612	Synthesis and structure of a new thiazoline-based palladium(II) complex that promotes cytotoxicity and apoptosis of human promyelocytic leukemia HL-60 cells. <i>Scientific Reports</i> , 2020, 10, 16745.	1.6	18
2613	Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7613.	1.8	17
2614	Tuning excited state of bipyridyl platinum(II) complexes with bio-active flavonolate ligand: Structures, photoreactivity, and DFT calculations. <i>Inorganica Chimica Acta</i> , 2020, 513, 119952.	1.2	0
2615	Encapsulation of a Ru(II)-p-cymene complex of the antibacterial drug trimethoprim into a polydiacetylene-phospholipid assembly to enhance its in vitro anticancer and antibacterial activities. <i>New Journal of Chemistry</i> , 2020, 44, 20047-20059.	1.4	9
2616	Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: A review. <i>Polyhedron</i> , 2020, 192, 114827.	1.0	26
2617	Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma. <i>Neurosurgery</i> , 2021, 88, 428-436.	0.6	7
2618	Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(III) dithiocarbamates. <i>Chemical Science</i> , 2020, 11, 10465-10482.	3.7	37
2619	Potent cyclometallated Pd(II) antitumor complexes bearing β -amino acids: synthesis, structural characterization, DNA/BSA binding, cytotoxicity and molecular dynamics simulation. <i>Dalton Transactions</i> , 2020, 49, 14891-14907.	1.6	14
2620	Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin. <i>Frontiers in Oncology</i> , 2020, 10, 1744.	1.3	14
2621	Synthesis and in vitro antitumor activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127527.	1.0	7

#	ARTICLE	IF	CITATIONS
2622	New copper complexes inducing bimodal death through apoptosis and autophagy in A549 cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2020, 213, 111260.	1.5	31
2623	Further Approaches in the Design of Antitumor Agents with Response to Cell Resistance: Looking toward Aza Crown Ether-dtc Complexes. <i>Inorganic Chemistry</i> , 2020, 59, 15120-15134.	1.9	7
2624	Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 907-925.	1.5	3
2625	Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(π -carbazole-based hydrazone complexes. <i>Dalton Transactions</i> , 2020, 49, 11385-11395.	1.6	138
2626	Peripherally administered cisplatin activates a parvocellular neuronal subtype expressing arginine vasopressin and enhanced green fluorescent protein in the paraventricular nucleus of a transgenic rat. <i>Journal of Physiological Sciences</i> , 2020, 70, 35.	0.9	4
2627	Biological properties of a benzothiazole-based mononuclear platinum(II) complex as a potential anticancer agent. <i>Journal of Coordination Chemistry</i> , 2020, 73, 1817-1832.	0.8	8
2628	Mechanisms underlying the cytotoxic activity of syn/anti-isomers of dinuclear Au(I) NHC complexes. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112576.	2.6	13
2629	Physicochemical profile of Os (III) complexes with pyrazine derivatives: From solution behavior to DNA binding studies and biological assay. <i>Journal of Molecular Liquids</i> , 2020, 316, 113804.	2.3	3
2630	In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17535-17542.	3.3	15
2631	In Vitro Study of Synergic Effect of Cisplatin and Low Molecular Weight Heparin on Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 549412.	1.3	5
2632	GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates. <i>Cell Metabolism</i> , 2020, 32, 938-950.e6.	7.2	70
2633	Gold(I) and Silver(I) Complexes with 2-Anilinopyridine-Based Heterocycles as Multitarget Drugs against Colon Cancer. <i>Inorganic Chemistry</i> , 2020, 59, 17732-17745.	1.9	13
2634	ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer. <i>Antioxidants</i> , 2020, 9, 1137.	2.2	14
2635	Photoactivatable diazido Pt(IV) anticancer complex can bind to and oxidize all four nucleosides. <i>Dalton Transactions</i> , 2020, 49, 17157-17163.	1.6	7
2636	Biological functions and theranostic potential of HMGB family members in human cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097085.	1.4	28
2637	A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery. <i>Cancers</i> , 2020, 12, 3482.	1.7	6
2638	Circadian Clock Protein PERIOD2 Suppresses the PI3K/Akt Pathway and Promotes Cisplatin Sensitivity in Ovarian Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 11897-11908.	0.9	16
2639	Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands. <i>Frontiers in Chemistry</i> , 2020, 8, 587207.	1.8	22

#	ARTICLE	IF	CITATIONS
2640	Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 559596.	1.3	9
2641	Mass spectrometry imaging and monitoring of in vivo glutathione-triggered cisplatin release from nanoparticles in the kidneys. <i>Nanoscale Advances</i> , 2020, 2, 5857-5865.	2.2	5
2642	Molecular targeted therapy: novel therapeutic approach for head and neck cancer. <i>Therapeutic Delivery</i> , 2020, 11, 637-651.	1.2	4
2643	Modification of multiwalled carbon nanotubes with a ruthenium drug candidate—indazolium[tetrachlorobis(1 <i>H</i> -indazole)ruthenate(<i>iii</i>)] (KP1019). <i>Dalton Transactions</i> , 2020, 49, 16791-16800.	1.6	3
2644	Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action. <i>Molecules</i> , 2020, 25, 5167.	1.7	29
2645	Self-Assembled Pt(II) Metallosupramolecular Tubular Cage as Dual Warhead Antibacterial Agent in Water. <i>Inorganic Chemistry</i> , 2020, 59, 12690-12699.	1.9	37
2646	BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity. <i>Inorganic Chemistry</i> , 2020, 59, 11823-11833.	1.9	42
2647	Cisplatin binding to β -lactoglobulin: a structural study. <i>Dalton Transactions</i> , 2020, 49, 12450-12457.	1.6	6
2648	Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis. <i>Redox Biology</i> , 2020, 36, 101677.	3.9	40
2649	Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes. <i>Molecules</i> , 2020, 25, 3492.	1.7	36
2650	Nucleobase Pair—Metal Dimer/Dinuclear Metal Cation Interaction: A Theoretical Study. <i>ACS Omega</i> , 2020, 5, 18808-18817.	1.6	0
2651	Synthesis of Pt(II) complexes of the type [Pt(1,10-phenanthroline)(SArFn) ₂] (SArFn = 6H ₃ -3,4-F ₂); <i>Trends in Biochemistry and Biophysics</i> , 2020, 211, 111206.	1.5	15
2652	A recombinant platform to characterize the role of transmembrane protein hTMEM205 in Pt(ii)-drug resistance and extrusion. <i>Metallomics</i> , 2020, 12, 1542-1554.	1.0	2
2653	Delivery of Platinum(IV) Prodrugs via Bi ₂ Te ₃ Nanoparticles for Photothermal—Chemotherapy and Photothermal/Photoacoustic Imaging. <i>Molecular Pharmaceutics</i> , 2020, 17, 3403-3411.	2.3	15
2654	D-Pinitol treatment induced the apoptosis in human leukemia MOLT-4 cells by improved apoptotic signaling pathway. <i>Saudi Journal of Biological Sciences</i> , 2020, 27, 2134-2138.	1.8	5
2655	Metallo components exhibiting significant anticancer and antibacterial properties: a novel sandwich-type like polymeric structure. <i>Scientific Reports</i> , 2020, 10, 12472.	1.6	9
2656	Polyphosphate Functions <i>In Vivo</i> as an Iron Chelator and Fenton Reaction Inhibitor. <i>MBio</i> , 2020, 11, .	1.8	36
2657	DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. <i>Cancers</i> , 2020, 12, 2098.	1.7	57

#	ARTICLE	IF	CITATIONS
2658	Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues. <i>Inorganic Chemistry</i> , 2020, 59, 11676-11687.	1.9	31
2659	Synthesis and Antitumor Activity Evaluation of Cyclometalated <i>trans</i> -Indazole Ruthenium(II) and Iridium(III) Complexes. <i>ChemPlusChem</i> , 2020, 85, 1800-1812.	1.3	15
2660	Novel nickel(II), palladium(II), and platinum(II) complexes having a pyrrolyl-iminophosphine (PNN) pincer: Synthesis, crystal structures, and cytotoxic activity. <i>Journal of Inorganic Biochemistry</i> , 2020, 205, 111015.	1.5	18
2661	Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1390.	3.4	115
2662	Surface-Enhanced Raman Scattering Detection of Nucleic Acids Exhibiting Sterically Accessible Guanines Using Ruthenium-Polypyridyl Reagents. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 7218-7223.	2.1	5
2663	Efficacy and Safety of Human Serum Albumin-cisplatin Complex in U87MG Xenograft Mouse Models. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7932.	1.8	14
2664	Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. <i>Cell Death and Disease</i> , 2020, 11, 942.	2.7	10
2665	Thermodynamic Insights by Microscale Thermophoresis into Translesion DNA Synthesis Catalyzed by DNA Polymerases Across a Lesion of Antitumor Platinum-acridine Complex. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7806.	1.8	1
2666	Visualization of uracils created by APOBEC3A using UdgX shows colocalization with RPA at stalled replication forks. <i>Nucleic Acids Research</i> , 2020, 48, e118-e118.	6.5	19
2667	One-pot synthesis of acid-degradable polyphosphazene prodrugs for efficient tumor chemotherapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 10540-10548.	2.9	20
2668	The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress. <i>Cell Death Discovery</i> , 2020, 6, 110.	2.0	11
2669	<i>In vitro</i> reactions of a cyanocobalamin-cisplatin conjugate with nucleoside monophosphates. <i>Rapid Communications in Mass Spectrometry</i> , 2020, 34, e8945.	0.7	1
2670	Albumin-Based Carriers for Systemic Delivery to Tackle Cancer. <i>Healthy Ageing and Longevity</i> , 2020, , 247-270.	0.2	2
2671	Probing drug delivery and mechanisms of action in 3D spheroid cells by quantitative analysis. <i>Analyst</i> , 2020, 145, 7687-7694.	1.7	0
2672	Cisplatin ototoxicity and role of antioxidant on its prevention. <i>Hearing, Balance and Communication</i> , 2020, 18, 234-241.	0.1	4
2673	The Synergistic Anticancer Effect of Dual Drug- (Cisplatin/Epigallocatechin Gallate) Loaded Gelatin Nanoparticles for Lung Cancer Treatment. <i>Journal of Nanomaterials</i> , 2020, 2020, 1-15.	1.5	15
2674	Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 43444-43455.	4.0	33
2675	Stronger Cytotoxicity for Cancer Cells Than for Fast Proliferating Human Stem Cells by Rationally Designed Dinuclear Complexes. <i>Inorganic Chemistry</i> , 2020, 59, 14464-14477.	1.9	7

#	ARTICLE	IF	CITATIONS
2676	Induction of immunogenic cell death in cancer cells by a photoactivated platinum(^{iv}) prodrug. <i>Inorganic Chemistry Frontiers</i> , 2020, 7, 4150-4159.	3.0	40
2677	Parameter control and property analysis in the preparation of platinum iodide nanocolloids through the electrical spark discharge method. <i>RSC Advances</i> , 2020, 10, 30169-30175.	1.7	5
2678	Inhibition of Dengue Virus Serotype 2 in Vero Cells with [Cu(2,4,5-triphenyl-1H-imidazole) ₂ (H ₂ O) ₂].Cl ₂ . <i>Gastroenterology Insights</i> , 2020, 12, 8744.	0.7	3
2679	Advances in Gold Nanoparticle-Based Combined Cancer Therapy. <i>Nanomaterials</i> , 2020, 10, 1671.	1.9	60
2680	Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(ⁱⁱ) complexes. <i>Dalton Transactions</i> , 2020, 49, 14009-14016.	1.6	10
2681	METTL3 potentiates resistance to cisplatin through m ⁶ A modification of TFAP2C in seminoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 11366-11380.	1.6	42
2682	Development of novel ruthenium(ⁱⁱ)-arene complexes displaying potent anticancer effects in glioblastoma cells. <i>Dalton Transactions</i> , 2020, 49, 13294-13310.	1.6	14
2683	Illuminating Platinum Transportation while Maximizing Therapeutic Efficacy by Gold Nanoclusters <i>via</i> Simultaneous Near-Infrared-I/II Imaging and Glutathione Scavenging. <i>ACS Nano</i> , 2020, 14, 13536-13547.	7.3	181
2684	A coassembled peptide hydrogel boosts the radiosensitization of cisplatin. <i>Chemical Communications</i> , 2020, 56, 13017-13020.	2.2	11
2685	Hydrated electrons induce the formation of interstrand cross-links in DNA modified by cisplatin adducts. <i>Journal of Radiation Research</i> , 2020, 61, 343-351.	0.8	2
2686	A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 350.	1.8	12
2687	Photoactivated Nanosheets Accelerate Nucleus Access of Cisplatin for Drug-Resistant Cancer Therapy. <i>Advanced Functional Materials</i> , 2020, 30, 2001546.	7.8	36
2688	mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. <i>Nature Communications</i> , 2020, 11, 4684.	5.8	87
2689	Encapsulation of Nedaplatin in Novel PEGylated Liposomes Increases Its Cytotoxicity and Genotoxicity against A549 and U2OS Human Cancer Cells. <i>Pharmaceutics</i> , 2020, 12, 863.	2.0	35
2690	Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors. <i>ACS Nano</i> , 2020, 14, 13343-13366.	7.3	91
2691	A mixed-valence diruthenium(ii,iii) complex endowed with high stability: from experimental evidence to theoretical interpretation. <i>Dalton Transactions</i> , 2020, 49, 14520-14527.	1.6	25
2692	Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. <i>Cancers</i> , 2020, 12, 2398.	1.7	9
2693	Phosphorescent Iridium(III) Complexes for Anticancer Applications. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 3978-3986.	1.0	35

#	ARTICLE	IF	CITATIONS
2694	Radiation therapy combined with intracerebral convection-enhanced delivery of cisplatin or carboplatin for treatment of the F98 rat glioma. <i>Journal of Neuro-Oncology</i> , 2020, 149, 193-208.	1.4	12
2695	Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. <i>Nature Communications</i> , 2020, 11, 4124.	5.8	20
2696	Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. <i>BMC Medicine</i> , 2020, 18, 236.	2.3	33
2697	The history of organoplatinum chemistry in Iran: 40-year research. <i>Journal of the Iranian Chemical Society</i> , 2020, 17, 2683-2715.	1.2	7
2698	Inducing endoplasmic reticulum stress in cancer cells using graphene oxide-based nanoparticles. <i>Nanoscale Advances</i> , 2020, 2, 4887-4894.	2.2	16
2699	The Impact of [C16Pyr][Amp] on the Aggressiveness in Breast and Prostate Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9584.	1.8	4
2700	Inhibition of Type IV Secretion Activity and Growth of <i>Helicobacter pylori</i> by Cisplatin and Other Platinum Complexes. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 602958.	1.8	11
2701	Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction. <i>Cells</i> , 2020, 9, 2643.	1.8	63
2702	REVIEW: Biomedical applications of Schiff base metal complexes. <i>Journal of Coordination Chemistry</i> , 2020, 73, 3109-3149.	0.8	134
2703	Inhibition of Drp1 Sensitizes Cancer Cells to Cisplatin-Induced Apoptosis through Transcriptional Inhibition of c-FLIP Expression. <i>Molecules</i> , 2020, 25, 5793.	1.7	8
2704	Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts. <i>Metallomics</i> , 2020, 12, 1834-1840.	1.0	15
2705	Synthesis, physicochemical, thermal, and XRD/HSA interactions of mixed [Cu(Bipy)(Dipn)](X) ₂ complexes: DNA binding and molecular docking evaluation. <i>Journal of Coordination Chemistry</i> , 2020, 73, 3236-3248.	0.8	15
2706	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e116-e131.	1.8	30
2707	Vinpocetine reduces cisplatin-induced acute kidney injury through inhibition of NF- κ B pathway and activation of Nrf2/ARE pathway in rats. <i>International Urology and Nephrology</i> , 2020, 52, 1389-1401.	0.6	14
2708	Cytotoxic dimeric half-sandwich Ru(II), Os(II) and Ir(III) complexes containing the 4,4'-biphenyl-based bridging ligands. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5785.	1.7	10
2709	Novel phosphine sulphide gold(III) complexes: topoisomerase I inhibitors and antiproliferative agents. <i>Dalton Transactions</i> , 2020, 49, 7852-7861.	1.6	9
2710	Recent advances in anticancer ruthenium Schiff base complexes. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5687.	1.7	49
2711	Development of highly potent Arene-Ru(II)-ninhydrin complexes for inhibition of cancer cell growth. <i>Inorganica Chimica Acta</i> , 2020, 508, 119641.	1.2	8

#	ARTICLE	IF	CITATIONS
2712	Supramolecular combination chemotherapy: a pH-responsive co-encapsulation drug delivery system. <i>Chemical Science</i> , 2020, 11, 6275-6282.	3.7	58
2713	Organelle-targeting metal anticancer agents. <i>Advances in Inorganic Chemistry</i> , 2020, 75, 287-337.	0.4	10
2714	Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies. <i>Advances in Medical Sciences</i> , 2020, 65, 265-285.	0.9	29
2715	Modified pyrazole platinum(II) complex can circumvent albumin and glutathione: Synthesis, structure and cytotoxic activity. <i>Bioorganic Chemistry</i> , 2020, 100, 103936.	2.0	11
2716	Ligand-centred redox activation of inert organoiridium anticancer catalysts. <i>Chemical Science</i> , 2020, 11, 5466-5480.	3.7	35
2717	Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity. <i>Cells</i> , 2020, 9, 1322.	1.8	15
2718	Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1129-1140.	1.1	2
2719	Monitoring cell endocytosis of liposomes by real-time electrical impedance spectroscopy. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 6371-6380.	1.9	6
2720	Unexpected Thymine Oxidation and Collision-Induced Thymine-Pt-guanine Cross-Linking on 5â€²-TpG and 5â€²-GpT by a Photoactivatable Diazido Pt(IV) Anticancer Complex. <i>Inorganic Chemistry</i> , 2020, 59, 8468-8480.	1.9	10
2721	Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(IV) prodrugs with prolonged circulation time in blood. <i>Dalton Transactions</i> , 2020, 49, 8107-8113.	1.6	10
2722	MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 516.	1.1	12
2723	Synthesis and characterization of novel naphthalene-derivatized tridentate ligands and their net neutral rhenium tricarbonyl complexes and cytotoxic effects on non-small cell lung cancer cells of interest. <i>Polyhedron</i> , 2020, 187, 114652.	1.0	8
2724	A Pt(IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance. <i>Bioorganic Chemistry</i> , 2020, 101, 104011.	2.0	8
2725	Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo. <i>Journal of Controlled Release</i> , 2020, 326, 25-37.	4.8	32
2726	Lighting up metallohelices: from DNA binders to chemotherapy and photodynamic therapy. <i>Chemical Communications</i> , 2020, 56, 7537-7548.	2.2	14
2729	<i>Pituranthos chloranthus</i> Oil as an Antioxidant-Based Adjuvant Therapy against Cisplatin-Induced Nephrotoxicity. <i>Journal of Toxicology</i> , 2020, 2020, 1-8.	1.4	5
2730	Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma. <i>International Immunopharmacology</i> , 2020, 86, 106694.	1.7	18
2731	Synthesis, Spectral Characterization and Pharmacological Evaluation of Ni(II) Complexes of 6-Nitro-benzothiazole Incorporated Azo Dyes. <i>Journal of Inorganic and Organometallic Polymers and Materials</i> , 2020, 30, 3781-3796.	1.9	9

#	ARTICLE	IF	CITATIONS
2732	Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression. <i>Anticancer Research</i> , 2020, 40, 3203-3208.	0.5	1
2733	Generation of Stable cisPt Resistant Lung Adenocarcinoma Cells. <i>Pharmaceuticals</i> , 2020, 13, 109.	1.7	8
2734	Platinum(II) Complexes Bearing Triphenylphosphine and Chelating Oximes: Antiproliferative Effect and Biological Profile in Resistant Cells. <i>ChemMedChem</i> , 2020, 15, 1464-1472.	1.6	11
2735	Platinum-AIEgen coordination complex for imaging-guided annihilation of cisplatin-resistant cancer cells. <i>Chemical Communications</i> , 2020, 56, 7785-7788.	2.2	13
2736	Lycopene protects against central and peripheral neuropathy by inhibiting oxaliplatin-induced ATF-6 pathway, apoptosis, inflammation and oxidative stress in brains and sciatic tissues of rats. <i>NeuroToxicology</i> , 2020, 80, 29-40.	1.4	45
2737	Biotinylated platinum(II) metallacage towards targeted cancer theranostics. <i>Chemical Communications</i> , 2020, 56, 8460-8463.	2.2	25
2738	Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2384-2403.	5.7	23
2739	Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 29024-29036.	4.0	19
2740	Pharmacophore conjugation strategy for multi-targeting metal-based anticancer complexes. <i>Advances in Inorganic Chemistry</i> , 2020, , 257-285.	0.4	3
2741	The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. <i>Cell and Bioscience</i> , 2020, 10, 35.	2.1	57
2742	Appended Aromatic Moieties Determine the Cytotoxicity of Neutral Cyclometalated Platinum(II) Complexes Derived from 2-(2-Pyridyl)benzimidazole. <i>Inorganic Chemistry</i> , 2020, 59, 4961-4971.	1.9	28
2743	Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion. <i>Journal of Controlled Release</i> , 2020, 322, 13-30.	4.8	25
2744	Comparison of the Effect of Platinum (IV) Complexes on Spheroids and Monolayer Culture of HeLa Cells. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 168, 583-588.	0.3	1
2745	Construction of redox-responsive tumor targeted cisplatin nano-delivery system for effective cancer chemotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119190.	2.6	26
2746	Multiparametric analysis of the effectiveness of cisplatin on cutaneous squamous carcinoma cells Using two different types of adjuvants. <i>PLoS ONE</i> , 2020, 15, e0230022.	1.1	4
2747	Antiproliferative Activity of Gold(I) N-Heterocyclic Carbene and Triphenylphosphine Complexes with Ibuprofen Derivatives as Effective Enzyme Inhibitors. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5618.	1.7	7
2748	Development of a Pre-assembled Through-Bond Energy Transfer (TBET) Fluorescent Probe for Ratiometric Sensing of Anticancer Platinum(II) Complexes. <i>Chemistry - an Asian Journal</i> , 2020, 15, 1449-1455.	1.7	9
2749	Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(IV) prodrugs. <i>Chemical Science</i> , 2020, 11, 3829-3835.	3.7	58

#	ARTICLE	IF	CITATIONS
2750	<i>Corydalis saxicola</i> Alkaloids Attenuate Cisplatin-Induced Neuropathic Pain by Reducing Loss of IENF and Blocking TRPV1 Activation. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 407-428.	1.5	24
2751	Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. <i>Science Advances</i> , 2020, 6, eaay9789.	4.7	139
2752	The Rational Design and Biological Mechanisms of Nanoradiosensitizers. <i>Nanomaterials</i> , 2020, 10, 504.	1.9	25
2753	Imaging and therapeutic applications of Zn(II)-cryptolepine-curcumin molecular probes in cell apoptosis detection and photodynamic therapy. <i>Chemical Communications</i> , 2020, 56, 3999-4002.	2.2	44
2754	Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. <i>Science Advances</i> , 2020, 6, eaaz4204.	4.7	136
2755	Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines. <i>Cancers</i> , 2020, 12, 577.	1.7	7
2756	Allyl palladium complexes bearing carbohydrate-based N-heterocyclic carbenes: Anticancer agents for selective and potent <i>in vitro</i> cytotoxicity. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5876.	1.7	30
2757	Rac1b: An emerging therapeutic target for chemoresistance in colorectal cancer. , 2020, , 153-171.		1
2758	The importance of indole and azaindole scaffold in the development of antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112506.	2.6	94
2759	Cyclometallated gold(III) complexes against colon cancer. X-ray structure of [Au(C,NPhenylpyridine)(OAc) ₂]. <i>Journal of Organometallic Chemistry</i> , 2020, 920, 121340.	0.8	8
2760	Synthesis, crystal structure, antiproliferative activity, DNA binding and density functional theory calculations of 3-(pyridin-2-yl)-8-tert-butylcoumarin and its copper(II) complex. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5875.	1.7	5
2761	Exploiting Cancer's Tactics to Make Cancer a Manageable Chronic Disease. <i>Cancers</i> , 2020, 12, 1649.	1.7	3
2762	Interaction and Reactivity of Cisplatin Physisorbed on Graphene Oxide Nano-Prototypes. <i>Nanomaterials</i> , 2020, 10, 1074.	1.9	7
2763	Cocktail polyprodrug nanoparticles concurrently release cisplatin and peroxy-nitrite-generating nitric oxide in cisplatin-resistant cancers. <i>Chemical Engineering Journal</i> , 2020, 402, 126125.	6.6	65
2764	Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 4793-4810.	3.3	18
2765	Blue moon ensemble simulation of aquation free energy profiles applied to mono and bifunctional platinum anticancer drugs. <i>Journal of Computational Chemistry</i> , 2020, 41, 1973-1984.	1.5	7
2766	Fabrication of oxidized bacterial cellulose by nitrogen dioxide in chloroform/cyclohexane as a highly loaded drug carrier for sustained release of cisplatin. <i>Carbohydrate Polymers</i> , 2020, 248, 116745.	5.1	26
2767	In vitro and in vivo anti-proliferative activity and ultrastructure investigations of a copper(II) complex toward human lung cancer cell NCI-H460. <i>Journal of Inorganic Biochemistry</i> , 2020, 210, 111166.	1.5	10

#	ARTICLE	IF	CITATIONS
2768	Structural Control of Boronic Acid Ligands Enhances Intratumoral Targeting of Sialic Acid To Eradicate Cancer Stem-like Cells. <i>ACS Applied Bio Materials</i> , 2020, 3, 5030-5039.	2.3	18
2769	Redox-sensitive polyglutamic acid-platinum(IV) prodrug grafted nanoconjugates for efficient delivery of cisplatin into breast tumor. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102252.	1.7	7
2770	Systematic functional identification of cancer multi-drug resistance genes. <i>Genome Biology</i> , 2020, 21, 27.	3.8	26
2771	Short-Term Diet Restriction but Not Alternate Day Fasting Prevents Cisplatin-Induced Nephrotoxicity in Mice. <i>Biomedicines</i> , 2020, 8, 23.	1.4	7
2772	Synthesis and anticancer activities of thiosemicarbazones derivatives of thiochromanones and related scaffolds. <i>Medicinal Chemistry Research</i> , 2020, 29, 630-642.	1.1	8
2773	The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 937.	1.8	86
2774	Inhibition of thioredoxin reductase 1 correlates with platinum-based chemotherapeutic induced tissue injury. <i>Biochemical Pharmacology</i> , 2020, 175, 113873.	2.0	16
2775	Metallocomplexâ€“Peptide Interactions Studied by Ultrahigh Resolution Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 594-601.	1.2	4
2776	Ternary Co(II), Ni(II) and Cu(II) complexes containing dipyrrophenazine and saccharin: Structures, reactivity, binding interactions with biomolecules and DNA damage activity. <i>Inorganica Chimica Acta</i> , 2020, 506, 119532.	1.2	16
2777	Pharmacokinetics and tissue distribution in rats of a novel anticancer platinum compound LLC-1903. <i>Xenobiotica</i> , 2020, 50, 980-987.	0.5	1
2778	Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets. <i>Metallomics</i> , 2020, 12, 547-561.	1.0	22
2779	Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1242.	1.8	75
2780	Biomedical applications of metal organic polygons and polyhedra (MOPs). <i>Coordination Chemistry Reviews</i> , 2020, 410, 213181.	9.5	58
2781	RBP EIF2S2 Promotes Tumorigenesis and Progression by Regulating MYC-Mediated Inhibition via FHIT-Related Enhancers. <i>Molecular Therapy</i> , 2020, 28, 1105-1118.	3.7	37
2782	Chemoresistant ovarian cancer enhances its migration abilities by increasing store-operated Ca ²⁺ entry-mediated turnover of focal adhesions. <i>Journal of Biomedical Science</i> , 2020, 27, 36.	2.6	26
2783	Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 861-874.	1.2	15
2784	Tumorâ€“Oriented Telomeraseâ€“Terminated Nanoplatform as Versatile Strategy for Multidrug Resistance Reversal in Cancer Treatment. <i>Advanced Healthcare Materials</i> , 2020, 9, e1901739.	3.9	12
2785	CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells. <i>Molecular Carcinogenesis</i> , 2020, 59, 512-519.	1.3	19

#	ARTICLE	IF	CITATIONS
2786	Modulating Effect of Gum Arabic on Cisplatin-induced Testicular Damage in Albino Wister Rats. <i>Revista Brasileira De Farmacognosia</i> , 2020, 30, 90-98.	0.6	9
2787	Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 150, 1-13.	2.0	21
2788	Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells. <i>Molecular Oncology</i> , 2020, 14, 686-703.	2.1	5
2789	Systemic Evaluation on the Pharmacokinetics of Platinum-Based Anticancer Drugs From Animal to Cell Level: Based on Total Platinum and Intact Drugs. <i>Frontiers in Pharmacology</i> , 2019, 10, 1485.	1.6	19
2790	Medicinal inorganic chemistry: New perspectives and targets for the periodic table. <i>Advances in Inorganic Chemistry</i> , 2020, 75, 57-86.	0.4	7
2791	Niacin-ligated platinum(Pt^{IV})–ruthenium(Ru^{II}) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity <i>in vivo</i> . <i>Chemical Communications</i> , 2020, 56, 3069-3072.	2.2	22
2792	Oxamuplatin: a cytotoxic Pt^{II} complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer. <i>Dalton Transactions</i> , 2020, 49, 2547-2558.	1.6	13
2793	Mangostin attenuates stemness and enhances cisplatin-induced cell death in cervical cancer stem-like cells through induction of mitochondrial-mediated apoptosis. <i>Journal of Cellular Physiology</i> , 2020, 235, 5590-5601.	2.0	18
2794	Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 996-1005.	0.9	37
2795	The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. <i>Scientific Reports</i> , 2020, 10, 1063.	1.6	66
2796	Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines. <i>PLoS ONE</i> , 2020, 15, e0228331.	1.1	7
2797	A BODIPY-based fluorescent sensor for the detection of Pt^{2+} and Pt drugs. <i>Chemical Communications</i> , 2020, 56, 2695-2698.	2.2	34
2798	Rhodium(I) Complex-Based Polymeric Nanomicelles in Water Exhibiting Coexistent Near-Infrared Phosphorescence Imaging and Anticancer Activity in Vivo. <i>Journal of the American Chemical Society</i> , 2020, 142, 2709-2714.	6.6	32
2799	Biological Evaluation of Azo- and Imino-Based Carboxylate Triphenyltin(IV) Compounds. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 930-941.	1.0	7
2800	Fluorescent zwitterionic Iridium(III) complexes containing sulfonate groups: synthesis, biological activity and tracking in live cells. <i>Dyes and Pigments</i> , 2020, 176, 108220.	2.0	4
2801	Antioxidant and anti-apoptotic effects of vitexilactone on cisplatin-induced nephrotoxicity in rats. <i>Biotechnic and Histochemistry</i> , 2020, 95, 381-388.	0.7	11
2802	N-Heterocyclic Carbene Platinum Complexes: A Big Step Forward for Effective Antitumor Compounds. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 2-2.	1.0	0
2803	Protein binding studies with human serum albumin, molecular docking and <i>in vitro</i> cytotoxicity studies using HeLa cervical carcinoma cells of Cu^{II} / Zn^{II} complexes containing a carbohydrazone ligand. <i>Dalton Transactions</i> , 2020, 49, 2947-2965.	1.6	33

#	ARTICLE	IF	CITATIONS
2804	Synthesis and characterisation of a novel mono functionalisable Pt(IV) oxaliplatin-type complex and its peptide conjugate. <i>Inorganica Chimica Acta</i> , 2020, 505, 119492.	1.2	8
2805	Synthesis and in vitro cytotoxicity studies of Pd(II) and Pt(II) acetamide complexes: Molecular structures of trans-[PdCl ₂ (bzmta) ₂].DMF (bzmta=2-acetylamino-6-methylbenzothiazole) and cis-[PtCl ₂ (bzta) ₂].2DMF (bzta=2-acetylamino-6-methylbenzothiazole). <i>Polyhedron</i> , 2020, 185, 114591.	1.0	4
2806	Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy. <i>Molecules</i> , 2020, 25, 1994.	1.7	9
2807	Efficient tailoring of platinum nanoparticles supported on multiwalled carbon nanotubes for cancer therapy. <i>Nanomedicine</i> , 2020, 15, 793-808.	1.7	19
2808	Links between cancer metabolism and cisplatin resistance. <i>International Review of Cell and Molecular Biology</i> , 2020, 354, 107-164.	1.6	48
2809	Targeting DNA Repair in Ovarian Cancer Treatment Resistance. <i>Clinical Oncology</i> , 2020, 32, 518-526.	0.6	18
2810	Lysosome-targeted chemotherapeutics: Anticancer mechanism of N-heterocyclic carbene iridium(III) complex. <i>Journal of Inorganic Biochemistry</i> , 2020, 207, 111063.	1.5	17
2811	Synthesis and Structure of Arene Ru(II) N ⁺ O-Chelating Complexes: <i>In Vitro</i> Cytotoxicity and Cancer Cell Death Mechanism. <i>Organometallics</i> , 2020, 39, 1366-1375.	1.1	137
2812	Progesterone-Calcitriol Combination Enhanced Cytotoxicity of Cisplatin in Ovarian and Endometrial Cancer Cells In Vitro. <i>Biomedicines</i> , 2020, 8, 73.	1.4	5
2813	Role of Transient Anions in Chemoradiation Therapy: Base Modifications, Cross-Links, and Cluster Damages Induced to Cisplatin-DNA Complexes by 20 eV Electrons. <i>Journal of Physical Chemistry B</i> , 2020, 124, 3315-3325.	1.2	8
2814	Proteomic analysis of the <i>S. cerevisiae</i> response to the anticancer ruthenium complex KP1019. <i>Metallomics</i> , 2020, 12, 876-890.	1.0	9
2815	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. <i>Cancers</i> , 2020, 12, 1013.	1.7	17
2816	Nuclease and anticancer activity of antioxidant conjugated terpyridine metal complexes. <i>Inorganica Chimica Acta</i> , 2020, 507, 119596.	1.2	13
2817	The first structurally characterized sulfonamide derivatized Zn(II)-dipicolylamine complexes with eight membered chelate rings. <i>Synthetic and structural studies. Journal of Molecular Structure</i> , 2020, 1216, 128310.	1.8	1
2818	Long-term causes of death among pediatric patients with cancer. <i>Cancer</i> , 2020, 126, 3102-3113.	2.0	23
2819	Metal-based nanocontainers for drug delivery in tumor therapy. , 2020, , 195-215.		3
2820	Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine. , 2020, , 371-404.		6
2821	Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance. <i>Bioorganic Chemistry</i> , 2020, 99, 103768.	2.0	11

#	ARTICLE	IF	CITATIONS
2822	Metalloproteomic Approaches for Matching Metals to Proteins: The Power of Inductively Coupled Plasma Mass Spectrometry (ICP-MS). <i>Chemistry Letters</i> , 2020, 49, 697-704.	0.7	13
2823	Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus. <i>Cancers</i> , 2020, 12, 809.	1.7	7
2824	Modulation of the Autophagy-Lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. <i>Molecules</i> , 2020, 25, 1580.	1.7	12
2825	A DNA-based nanocarrier for efficient cancer therapy. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 330-339.	2.4	20
2826	Polypyridyl-Based Copper Phenanthrene Complexes: Combining Stability with Enhanced DNA Recognition. <i>Chemistry - A European Journal</i> , 2021, 27, 971-983.	1.7	17
2827	Intracellular RNA and nuclear DNA-dual-targeted tumor therapy via upconversion nanoplateforms with UCL/MR dual-mode bioimaging. <i>Chemical Engineering Journal</i> , 2021, 405, 126606.	6.6	14
2828	Synthesis of bis[benzyl- λ -N ϵ 2- λ -hydrazinocarbodithioato λ -N ϵ 2, S]nickel(II) complex as a novel lead molecule for cancer treatment. <i>Applied Organometallic Chemistry</i> , 2021, 35, .	1.7	4
2829	Miconazole induces protective autophagy in bladder cancer cells. <i>Environmental Toxicology</i> , 2021, 36, 185-193.	2.1	10
2830	Activatable Mitochondria-Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 1403-1410.	7.2	81
2831	Gas-blasting nanocapsules to accelerate carboplatin lysosome release and nucleus delivery for prostate cancer treatment. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 192-202.	4.3	5
2832	Activatable Mitochondria-Targeting Organoarsenic Prodrugs for Bioenergetic Cancer Therapy. <i>Angewandte Chemie</i> , 2021, 133, 1423-1430.	1.6	7
2833	High-pressure homogenization and tailoring of size-tunable <i>Ganoderma lucidum</i> spore oil nanosystem for enhanced anticancer therapy. <i>Chemical Engineering Journal</i> , 2021, 406, 127125.	6.6	10
2834	Photoacoustic imaging-guided chemo-photothermal combinational therapy based on emissive Pt(II) metallacycle-loaded biomimic melanin dots. <i>Science China Chemistry</i> , 2021, 64, 134-142.	4.2	19
2835	Cu (II) and Co (II/III) complexes of N,O-chelated Schiff base ligands: DNA interaction, protein binding, cytotoxicity, cell death mechanism and reactive oxygen species generation studies. <i>Applied Organometallic Chemistry</i> , 2021, 35, .	1.7	11
2836	Luminescent ruthenium(II)-para-cymene complexes of aryl substituted imidazo-1,10-phenanthroline as anticancer agents and the effect of remote substituents on cytotoxic activities. <i>Inorganica Chimica Acta</i> , 2021, 515, 120066.	1.2	15
2837	Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells. <i>Journal of Controlled Release</i> , 2021, 329, 833-846.	4.8	13
2838	RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target. <i>Medicinal Research Reviews</i> , 2021, 41, 586-615.	5.0	6
2839	Octahedral Copper(II) Carboxylates with 1,10-Phenanthroline: Synthesis, Structural Characterization, DNA-Binding and Anti-Fungal Properties. <i>Journal of Chemical Crystallography</i> , 2021, 51, 418-431.	0.5	3

#	ARTICLE	IF	CITATIONS
2840	The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells. <i>Journal of Biological Inorganic Chemistry</i> , 2021, 26, 43-55.	1.1	19
2841	DNA interactive and selective anticancer activity studies of copper(II) complexes decorated water-soluble porphyrin. <i>Applied Organometallic Chemistry</i> , 2021, 35, e6094.	1.7	1
2842	Multinuclear biologically active Ru, Rh, Os and Ir arene complexes. <i>Coordination Chemistry Reviews</i> , 2021, 431, 213690.	9.5	24
2843	A review on homo multinuclear anticancer Metallotherapeutics. <i>Inorganica Chimica Acta</i> , 2021, 517, 120184.	1.2	6
2844	Peptide-based nanomaterials for gene therapy. <i>Nanoscale Advances</i> , 2021, 3, 302-310.	2.2	12
2845	The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 443-450.	0.5	19
2846	Biopolymer Immune Implants™ Sequential Activation of Innate and Adaptive Immunity for Colorectal Cancer Postoperative Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2004559.	11.1	60
2847	Identification of cytotoxic copper(II) complexes with phenanthroline and quinoline, quinoxaline or quinazoline-derived mixed ligands. <i>Polyhedron</i> , 2021, 194, 114886.	1.0	10
2848	Polyphenol-cisplatin complexation forming core-shell nanoparticles with improved tumor accumulation and dual-responsive drug release for enhanced cancer chemotherapy. <i>Journal of Controlled Release</i> , 2021, 330, 992-1003.	4.8	24
2849	Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. <i>International Journal of Cancer</i> , 2021, 148, 1219-1232.	2.3	13
2850	Organotin(IV) complexes derived from 1,4-naphthalenedicarboxylic acid: synthesis, structure, in vitro cytostatic activity. <i>Journal of Organometallic Chemistry</i> , 2021, 935, 121654.	0.8	12
2851	A Cisplatin-Selective Fluorescent Probe for Real-Time Monitoring of Mitochondrial Platinum Accumulation in Living Cells. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 9264-9269.	7.2	13
2852	Structure-Based Drug Design of Phenazopyridine Derivatives as Inhibitors of Rev1 Interactions in Translesion Synthesis. <i>ChemMedChem</i> , 2021, 16, 1126-1132.	1.6	5
2853	Promising novel therapies for relapsed and refractory testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 53-69.	1.1	4
2854	A Cisplatin-Selective Fluorescent Probe for Real-Time Monitoring of Mitochondrial Platinum Accumulation in Living Cells. <i>Angewandte Chemie</i> , 2021, 133, 9350-9355.	1.6	3
2855	Unveiling the interaction profile of cisplatin with gold-supported magnesia film. <i>Applied Surface Science</i> , 2021, 540, 148365.	3.1	8
2856	Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators. <i>Cellular Signalling</i> , 2021, 78, 109871.	1.7	82
2857	8-Hydroxyquinoline platinum(II) loaded nanostructured lipid carriers: synthesis, physicochemical characterization and evaluation of antitumor activity. <i>New Journal of Chemistry</i> , 2021, 45, 821-830.	1.4	3

#	ARTICLE	IF	CITATIONS
2858	Cancer cell-targeted cisplatin prodrug delivery <i>in vivo</i> via metabolic labeling and bioorthogonal click reaction. <i>Biomaterials Science</i> , 2021, 9, 1301-1312.	2.6	11
2859	¹ H and ¹⁹⁵ Pt NMR prediction for inclusion compounds formed by cisplatin and oxidized carbon nanostructures. <i>RSC Advances</i> , 2021, 11, 599-611.	1.7	4
2860	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188459.	3.3	5
2861	Pregnane X receptor (PXR) protects against cisplatin-induced acute kidney injury in mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 165996.	1.8	15
2862	The rediscovery of platinum-based cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 37-50.	12.8	452
2863	Pd(II) and Pt(II) complexes with N-(1,3-benzothiazol-2-yl)acetamide ligands, spectroscopic characterization, DFT computational and <i>in-vitro</i> cytotoxicity studies. <i>Materials Today: Proceedings</i> , 2021, 43, 977-985.	0.9	6
2864	Antitumor activity of tridentate pincer and related metal complexes. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 5254-5273.	1.5	13
2865	New triorganotin(<i>iv</i>) compounds with aromatic carboxylate ligands: synthesis and evaluation of the pro-apoptotic mechanism. <i>RSC Advances</i> , 2021, 11, 4499-4514.	1.7	10
2866	A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms. <i>Mutagenesis</i> , 2021, 36, 75-86.	1.0	19
2867	A Review of Phosphate and Borate Sol-Gel Glasses for Biomedical Applications. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000055.	1.7	23
2868	Unexpected solution behaviour of ester-functionalized half-sandwich Ru(ii) and Ir(iii) complexes. <i>Dalton Transactions</i> , 2021, 50, 8017-8028.	1.6	3
2869	Design, physico-chemical characterization and <i>in vitro</i> biological activity of organogold(<i>iii</i>) glycoconjugates. <i>Dalton Transactions</i> , 2021, 50, 8963-8979.	1.6	7
2870	Development of Anticancer Activity of the Pt(II) Complex with <i>N</i> -Heterocyclic Amine: Its <i>In Vitro</i> Pharmacokinetics with Thiol and Thio-Ethers, DNA and BSA Binding, and Cell Cycle Arrest. <i>ACS Applied Bio Materials</i> , 2021, 4, 853-868.	2.3	10
2871	An overview of polymeric nanomicelles in clinical trials and on the market. <i>Chinese Chemical Letters</i> , 2021, 32, 243-257.	4.8	69
2872	The Role of HIPEC in the Treatment of Ovarian Cancer. , 2021, , 209-216.		0
2873	An unexpected in-solution instability of diiodido analogue of picoplatin complicates its biological characterization. <i>Dalton Transactions</i> , 2021, 50, 6071-6075.	1.6	4
2874	Fighting against drug-resistant tumors by the inhibition of ¹³ C-glutamyl transferase with supramolecular platinum prodrug nano-assemblies. <i>Journal of Materials Chemistry B</i> , 2021, 9, 4587-4595.	2.9	10
2875	<i>C. tropicalis</i> promotes chemotherapy resistance in colon cancer through increasing lactate production to regulate the mismatch repair system. <i>International Journal of Biological Sciences</i> , 2021, 17, 2756-2769.	2.6	21

#	ARTICLE	IF	CITATIONS
2876	Novel polyamide amidine anthraquinone platinum(II) complexes: cytotoxicity, cellular accumulation, and fluorescence distributions in 2D and 3D cell culture models. <i>Journal of Biological Inorganic Chemistry</i> , 2021, 26, 217-233.	1.1	2
2877	Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3-10.	0.5	9
2878	High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 87-99.	0.4	2
2879	Synthesis and evaluation of the anticancer activity of [Pt(diimine)(<i>N,N</i> -dibutyl- <i>N,N</i> - ϵ^2 -acylthiourea)] ⁺ complexes. <i>Dalton Transactions</i> , 2021, 50, 11742-11762.	1.6	10
2880	Targeting protein-protein interactions in the DNA damage response pathways for cancer chemotherapy. <i>RSC Chemical Biology</i> , 2021, 2, 1167-1195.	2.0	14
2881	Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin. <i>Journal of Biological Chemistry</i> , 2021, 296, 100633.	1.6	33
2882	Design and recognition of cucurbituril-secured platinum-bound oligopeptides. <i>Chemical Science</i> , 2021, 12, 9962-9968.	3.7	10
2883	Synthesis, characterization, crystal structure, DNA and human serum albumin interactions, as well as antiproliferative activity of a Cu(II) complex containing a Schiff base ligand formed in situ from the Cu(II)-induced cyclization of 1,5-bis(salicylidene)thiocarbohydrazide. <i>Applied Organometallic Chemistry</i> , 2021, 35, e6152.	1.7	11
2884	Antitumor Activity of Small Activating RNAs Induced PAWR Gene Activation in Human Bladder Cancer Cells. <i>International Journal of Medical Sciences</i> , 2021, 18, 3039-3049.	1.1	5
2885	Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 83-98.	4.3	28
2886	4-Hydroxyhalcone effects on cisplatin-induced genotoxicity model. <i>Toxicology Research</i> , 2021, 10, 11-17.	0.9	6
2887	Bone tumor-targeted delivery of theranostic ^{195m} Pt-bisphosphonate complexes promotes killing of metastatic tumor cells. <i>Materials Today Bio</i> , 2021, 9, 100088.	2.6	12
2888	The Medicinal Chemistry of Metal-Containing Anticancer drugs. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2889	Molecular Delivery of Cytotoxic Agents via Integrin Activation. <i>Cancers</i> , 2021, 13, 299.	1.7	5
2890	Interaction of Platinum-based Drugs with Proteins: An Overview of Representative Crystallographic Studies. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 6-27.	1.0	14
2891	An intramolecular photoswitch can significantly promote photoactivation of Pt(<i>iv</i>) prodrugs. <i>Chemical Science</i> , 2021, 12, 6536-6542.	3.7	31
2892	X-ray absorption spectroscopy of exemplary platinum porphyrin and corrole derivatives: metal- versus ligand-centered oxidation. <i>RSC Advances</i> , 2021, 11, 32269-32274.	1.7	3
2893	Manganese-deposited iron oxide promotes tumor-responsive ferroptosis that synergizes the apoptosis of cisplatin. <i>Theranostics</i> , 2021, 11, 5418-5429.	4.6	57

#	ARTICLE	IF	CITATIONS
2894	LincRNA-p21 Inhibits Cisplatin-Induced Apoptosis of Human Renal Proximal Tubular Epithelial Cells by Sponging miR-449a. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 495-501.	0.9	3
2895	Identification of potent anticancer copper(II) complexes containing tripodal bis[2-ethyl-di(3,5-dialkyl-1H-pyrazol-1-yl)]amine moiety. <i>Dalton Transactions</i> , 2021, 50, 11521-11534.	1.6	7
2896	A doxorubicin-platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells. <i>RSC Advances</i> , 2021, 11, 4818-4828.	1.7	15
2897	Roles of RAD18 in DNA replication and post-replication repair (PRR). , 2021, , 275-292.		0
2898	Phenalenyl based platinum anticancer compounds with superior efficacy: design, synthesis, characterization, and interaction with nuclear DNA. <i>New Journal of Chemistry</i> , 2021, 45, 10524-10533.	1.4	1
2899	Mitochondria-targeted cyclometalated rhodium(III) complexes: synthesis, characterization and anticancer research. <i>Dalton Transactions</i> , 2021, 50, 9068-9075.	1.6	15
2900	Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy. <i>Medical Oncology</i> , 2021, 38, 6.	1.2	11
2901	An oxidation responsive nano-radiosensitizer increases radiotherapy efficacy by remodeling tumor vasculature. <i>Biomaterials Science</i> , 2021, 9, 6308-6324.	2.6	15
2902	Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance. <i>Journal of Materials Chemistry B</i> , 2021, 9, 5173-5194.	2.9	42
2903	Ruthenium and iron metallodrugs: new inorganic and organometallic complexes as prospective anticancer agents. , 2021, , 223-276.		4
2904	Platinum(IV)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light. <i>Dalton Transactions</i> , 2021, 50, 10593-10607.	1.6	5
2905	Stable W/O/W multiple nanoemulsion encapsulating natural tocotrienols and caffeic acid with cisplatin synergistically treated cancer cell lines (A549 and HEP G2) and reduced toxicity on normal cell line (HEK 293). <i>Materials Science and Engineering C</i> , 2021, 121, 111808.	3.8	19
2906	Synthesis, characterization and anticancer activity of Fe(II) and Fe(III) complexes containing N-(8-quinolyl)salicylalimine Schiff base ligands. <i>Journal of Biological Inorganic Chemistry</i> , 2021, 26, 327-339.	1.1	19
2907	Novel Oxovanadium Complex VO(hntdtsc)(NPIP): Anticancer Activity and Mechanism of Action on HeLa Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 608218.	1.6	5
2908	History and emerging trends in chemotherapy for gastric cancer. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 446-456.	1.2	25
2909	Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. <i>ESMO Open</i> , 2021, 6, 100034.	2.0	0
2910	The safety of current pharmacotherapeutic strategies for osteosarcoma. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 427-438.	1.0	11
2911	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021, 13, 946.	1.7	31

#	ARTICLE	IF	CITATIONS
2912	Elucidating the Roles of Fenton Reactants in Drug-Treated Cells by Using a Selective Rhodamine-Thiophenol Fluorogenic Sensor. <i>Analysis & Sensing</i> , 2021, 1, 90-94.	1.1	1
2913	Disruption of the Microtubule Network and Inhibition of VEGFR2 Phosphorylation by Cytotoxic N,O-Coordinated Pt(II) and Ru(II) Complexes of Trimethoxy Aniline-Based Schiff Bases. <i>Inorganic Chemistry</i> , 2021, 60, 3418-3430.	1.9	17
2914	Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines. <i>Molecules</i> , 2021, 26, 1056.	1.7	19
2915	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. <i>Scientific Reports</i> , 2021, 11, 3176.	1.6	17
2916	Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612451.	1.8	17
2917	MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy. <i>Reproductive Sciences</i> , 2021, 28, 2036-2049.	1.1	9
2918	Mechanisms of resistance to chemotherapy in non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2021, 44, 146-164.	2.7	62
2919	Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 610097.	1.8	9
2920	Recent advances in cancer photo-theranostics: the synergistic combination of transition metal complexes and gold nanostructures. <i>SN Applied Sciences</i> , 2021, 3, 1.	1.5	6
2921	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1882.	1.8	13
2923	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. <i>Cells</i> , 2021, 10, 517.	1.8	20
2924	SIRT1 and gynecological malignancies (Review). <i>Oncology Reports</i> , 2021, 45, .	1.2	10
2925	Could Cisplatin Loading on Biosynthesized Silver Nanoparticles Improve Its Therapeutic Efficacy on Human Prostate Cancer Cell Line and Reduce Its In Vivo Nephrotoxic Effects?. <i>Biological Trace Element Research</i> , 2022, 200, 582-590.	1.9	9
2926	Recent Advances and Trends in Chemical CPP-Drug Conjugation Techniques. <i>Molecules</i> , 2021, 26, 1591.	1.7	13
2927	A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodruge for enhanced breast cancer therapy. <i>Journal of Controlled Release</i> , 2021, 331, 460-471.	4.8	21
2928	PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 584-592.	0.9	11
2929	Nanocarrier-delivered small interfering RNA for chemoresistant ovarian cancer therapy. <i>Wiley Interdisciplinary Reviews RNA</i> , 2021, 12, e1648.	3.2	8
2930	1,3-Diazepine: A privileged scaffold in medicinal chemistry. <i>Medicinal Research Reviews</i> , 2021, 41, 2247-2315.	5.0	16

#	ARTICLE	IF	CITATIONS
2931	Structural elucidation, theoretical investigation, biological screening and molecular docking studies of metal(II) complexes of NN donor ligand derived from 4-(2-aminopyridin-3-methylene)aminobenzoic acid. <i>BioMetals</i> , 2021, 34, 529-556.	1.8	14
2932	Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 41.	1.3	14
2933	Using a High Quantum Yield Fluorescent Probe with Two-Photon Excitation to Detect Cisplatin in Biological Systems. <i>ACS Sensors</i> , 2021, 6, 1400-1406.	4.0	5
2934	Recent advances in amino acid-metal coordinated nanomaterials for biomedical applications. <i>Chinese Journal of Chemical Engineering</i> , 2021, 38, 30-42.	1.7	7
2935	Design, Synthesis and Pharmacological Evaluation of Three Novel Dehydroabietyl Piperazine Dithiocarbamate Ruthenium (II) Polypyridyl Complexes as Potential Antitumor Agents: DNA Damage, Cell Cycle Arrest and Apoptosis Induction. <i>Molecules</i> , 2021, 26, 1453.	1.7	14
2936	Anticancer effect of sodium metavanadate on murine breast cancer both in vitro and in vivo. <i>BioMetals</i> , 2021, 34, 557-571.	1.8	1
2937	Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine. <i>Science Advances</i> , 2021, 7, .	4.7	50
2938	Synthesis, structures and anticancer potentials of five platinum(II) complexes with benzothiazole-benzopyran targeting mitochondria. <i>Polyhedron</i> , 2021, 196, 115004.	1.0	6
2939	Overcoming Radiation Resistance by Iron-Platinum Metal Alloy Nanoparticles in Human Copper Transport 1-Overexpressing Cancer Cells via Mitochondrial Disturbance. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2071-2085.	3.3	12
2940	Synthesis and Antitumor Activity of (3-Hydroxyacrylate-O, $\text{O}^{\ominus 2}$) Diammineplatinum(II). <i>Pharmaceutical Fronts</i> , 2021, 03, e13-e17.	0.4	1
2941	Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2793.	1.8	13
2942	PER2 Circadian Oscillation Sensitizes Esophageal Cancer Cells to Chemotherapy. <i>Biology</i> , 2021, 10, 266.	1.3	7
2943	Arene Ruthenium(II) Complexes Bearing the $\text{P}^{\ominus}\text{-P}$ or $\text{P}^{\ominus}\text{-P},\text{S}$ Ph ₂ P(CH ₂) ₃ SPh Ligand. <i>Molecules</i> , 2021, 26, 1860.	1.7	2
2944	Host-guest nanosized coordination complexes based on Ag-isonicotinic acid-H ₂ O and Ni-4,4'-bipyridine-aminobenzoic acid-H ₂ O as potentially active anticancer and antimicrobial agents. <i>Applied Organometallic Chemistry</i> , 2021, 35, e6235.		3
2945	One-Pot Synthesis-Biocompatible Copper-Triptide Complex as a Nanocatalytic Medicine to Enhance Chemodynamic Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1394-1402.	2.6	19
2946	Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4163-4178.	2.9	18
2947	Hypoxia Active Platinum(IV) Prodrugs of Orotic Acid Selective to Liver Cancer Cells. <i>Inorganic Chemistry</i> , 2021, 60, 4342-4346.	1.9	9
2948	Synthesis, Characterization and Antiproliferative Evaluation of Pt(II) and Pd(II) Complexes with a Thiazine-Pyridine Derivative Ligand. <i>Pharmaceuticals</i> , 2021, 14, 395.	1.7	6

#	ARTICLE	IF	CITATIONS
2949	Anticancer Half-Sandwich Rhodium(III) Complexes. <i>Inorganics</i> , 2021, 9, 26.	1.2	24
2950	Photoinduced charge-separated molecular probe for ultrasensitive spectrum analysis and rapid colorimetric detection of platinum ions. <i>Analytica Chimica Acta</i> , 2021, 1153, 338278.	2.6	3
2951	Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. <i>Circulation Research</i> , 2021, 128, 1040-1061.	2.0	59
2952	A novel palladium (II) complex with a ferrocene-based ligand: Synthesis, X-ray crystallography and in vitro anticancer activity study. <i>Inorganic Chemistry Communication</i> , 2021, 126, 108448.	1.8	5
2953	Nanomedicines for combating multidrug resistance of cancer. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1715.	3.3	14
2954	Interfaces between cellular responses to DNA damage and cancer immunotherapy. <i>Genes and Development</i> , 2021, 35, 602-618.	2.7	61
2955	Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity. <i>Inorganica Chimica Acta</i> , 2021, 518, 120220.	1.2	4
2957	From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. <i>Cancers</i> , 2021, 13, 2024.	1.7	5
2958	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. <i>Translational Oncology</i> , 2021, 14, 101025.	1.7	12
2959	New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells. <i>ChemMedChem</i> , 2021, 16, 1956-1966.	1.6	14
2960	Dinuclear half-sandwich Ir(III) complexes containing 4,4'-methylenedianiline-based ligands: Synthesis, characterization, cytotoxicity. <i>Journal of Organometallic Chemistry</i> , 2021, 938, 121748.	0.8	2
2961	DNA-Targeted Metallodrugs: An Untapped Source of Artificial Gene Editing Technology. <i>ChemBioChem</i> , 2021, 22, 2184-2205.	1.3	18
2962	Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?. <i>Molecules</i> , 2021, 26, 2601.	1.7	63
2963	Cancer Therapy-Associated Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1291-1305.	1.1	66
2964	Anti-metastasis and anti-proliferation effect of mitochondria-accumulating ruthenium(II) complexes via redox homeostasis disturbance and energy depletion. <i>Journal of Inorganic Biochemistry</i> , 2021, 217, 111380.	1.5	17
2965	Cyanidin-3-O-glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells. <i>Journal of Food Science</i> , 2021, 86, 2700-2712.	1.5	22
2966	Pt(IV) Prodrugs Designed to Embed in Nanotubes of a Polysaccharide for Drug Delivery. <i>ACS Applied Bio Materials</i> , 2021, 4, 4841-4848.	2.3	5
2967	The alterations of microbiota and pathological conditions in the gut of patients with colorectal cancer undergoing chemotherapy. <i>Anaerobe</i> , 2021, 68, 102361.	1.0	15

#	ARTICLE	IF	CITATIONS
2968	Alternative redox forms of ASNA-1 separate insulin signaling from tail-anchored protein targeting and cisplatin resistance in <i>C. elegans</i> . <i>Scientific Reports</i> , 2021, 11, 8678.	1.6	5
2969	Platinum(II) <i>N</i> -heterocyclic carbene complexes arrest metastatic tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
2970	MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1773-1791.	1.3	7
2971	Platinum Complexes in Colorectal Cancer and Other Solid Tumors. <i>Cancers</i> , 2021, 13, 2073.	1.7	38
2972	Maloplatin-B, a Cisplatin-Based BODIPY-Tagged Mito-Specific "Chemo-PDT" Agent Active in Red Light. <i>Inorganic Chemistry</i> , 2021, 60, 6410-6420.	1.9	16
2973	Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5111.	1.8	18
2974	Platinum (II)-coordinated <i>Portulaca oleracea</i> polysaccharides as metal-drug based polymers for anticancer study. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 201, 111628.	2.5	8
2975	Genomic Characterization of Cisplatin Response Uncovers Priming of Cisplatin-Induced Genes in a Resistant Cell Line. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5814.	1.8	8
2976	Horizontal Transfer of miR-643 from Cisplatin-Resistant Cells Confers Chemoresistance to Recipient Drug-Sensitive Cells by Targeting APOL6. <i>Cells</i> , 2021, 10, 1341.	1.8	8
2977	Cis-Palladium(II) complex incorporating 3-(2-pyridyl)-5-methyl-1,2,4-triazole: structure and cytotoxic activity. <i>Chemical Papers</i> , 2021, 75, 4899-4906.	1.0	4
2978	An Oligonucleotide-Distortion-Responsive Organic Transistor for Platinum-Drug-Induced DNA Damage Detection. <i>Advanced Materials</i> , 2021, 33, e2100489.	11.1	10
2979	Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies. <i>Molecules</i> , 2021, 26, 3157.	1.7	23
2980	Redox-Resetting of cisplatin-resistant ovarian cancer cells by cisplatin-encapsulated nanostructured lipid carriers. <i>Nanomedicine</i> , 2021, 16, 979-995.	1.7	5
2981	Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time. <i>Inorganic Chemistry</i> , 2021, 60, 7974-7990.	1.9	16
2982	THz Detection of Biomolecules in Aqueous Environments: Status and Perspectives for Analysis Under Physiological Conditions and Clinical use. <i>Journal of Infrared, Millimeter, and Terahertz Waves</i> , 2021, 42, 607-646.	1.2	10
2983	A novel ferrocene-palladium metal complex: synthesis, single crystal structure, in vitro cytotoxicity study and molecular docking. <i>Journal of Molecular Structure</i> , 2021, 1232, 130021.	1.8	10
2984	Potential Therapeutic Targets for Cisplatin-Induced Kidney Injury: Lessons from Other Models of AKI and Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1559-1567.	3.0	37
2985	Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 640392.	1.3	31

#	ARTICLE	IF	CITATIONS
2986	MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638537.	1.3	17
2987	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. <i>Translational Oncology</i> , 2021, 14, 101056.	1.7	17
2988	Circadian Rhythm of NER and ATR Pathways. <i>Biomolecules</i> , 2021, 11, 715.	1.8	11
2989	MiR-3168, miR-6125, and miR-4718 as potential predictors of cisplatin-induced nephrotoxicity in patients with head and neck cancer. <i>BMC Cancer</i> , 2021, 21, 575.	1.1	14
2990	A Homotypic Membrane-Camouflaged Biomimetic Nanoplatform with Gold Nanocrystals for Synergistic Photothermal/Starvation/Immunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 23469-23480.	4.0	28
2991	Diverse and unexpected outcomes from oxidation of the platinum(II) anticancer agent [Pt{(p-BrC6F4)NCH2CH2NEt2}Cl(py)] by hydrogen peroxide. <i>Journal of Inorganic Biochemistry</i> , 2021, 218, 111360.	1.5	2
2992	Comparative study of cytotoxic activities, DNA binding and molecular docking interactions of anticancer agent epirubicin and its novel copper complex. <i>Journal of Molecular Structure</i> , 2021, 1232, 130072.	1.8	8
2993	Dual-target platinum(IV) complexes exhibit antiproliferative activity through DNA damage and induce ER-stress-mediated apoptosis in A549 cells. <i>Bioorganic Chemistry</i> , 2021, 110, 104741.	2.0	7
2994	Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability. <i>Journal of Nanoscience and Nanotechnology</i> , 2021, 21, 2760-2777.	0.9	0
2995	Pressure-Enriched Chemistry of Pt: Prediction and Synthesis of Dense Sodium Platinides. <i>Journal of Physical Chemistry C</i> , 2021, 125, 11791-11798.	1.5	1
2996	Harnessing Genomic Stress for Antitumor Immunity. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1128-1150.	2.5	5
2997	Nanodelivery of natural isothiocyanates as a cancer therapeutic. <i>Free Radical Biology and Medicine</i> , 2021, 167, 125-140.	1.3	19
2998	Luminescent AIE Dots for Anticancer Photodynamic Therapy. <i>Frontiers in Chemistry</i> , 2021, 9, 672917.	1.8	19
2999	A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma. <i>ELife</i> , 2021, 10, .	2.8	14
3000	The Permeation Mechanism of Cisplatin Through a Dioleoylphosphocholine Bilayer**. <i>ChemPhysChem</i> , 2021, 22, 1251-1261.	1.0	7
3001	The Role of Tumour Metabolism in Cisplatin Resistance. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 691795.	1.6	36
3002	Is the cytotoxic activity of phenanthriplatin dependent on the specific size of the phenanthridine ligand I ϵ system?. <i>Journal of Inorganic Biochemistry</i> , 2021, 219, 111447.	1.5	9
3003	Rhodium Complexes Targeting DNA Mismatches as a Basis for New Therapeutics in Cancers Deficient in Mismatch Repair. <i>Biochemistry</i> , 2021, 60, 2055-2063.	1.2	12

#	ARTICLE	IF	CITATIONS
3005	FXYP6 Regulates Chemosensitivity by Mediating the Expression of Na ⁺ /K ⁺ -ATPase $\hat{1}$ and Affecting Cell Autophagy and Apoptosis in Colorectal Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-15.	0.9	11
3007	Acidity-responsive phosphorescent metal complexes for cancer imaging and theranostic applications. <i>Journal of Organometallic Chemistry</i> , 2021, 943, 121821.	0.8	2
3008	The DNA binding properties of 9-aminoacridine carboxamide Pt complexes. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 40, 116191.	1.4	6
3010	Anticancer Activity, DNA Binding, and Photodynamic Properties of a N ³ C ⁴ N-Coordinated Pt(II) Complex. <i>Inorganic Chemistry</i> , 2021, 60, 10350-10360.	1.9	16
3011	Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 87-97.	2.0	22
3012	The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. <i>Biochemical Pharmacology</i> , 2021, 188, 114542.	2.0	12
3013	Selective cytotoxicity of cyclometalated gold(III) complexes on Caco-2 cells is mediated by G2/M cell cycle arrest. <i>Metallomics</i> , 2021, 13, .	1.0	6
3014	Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance. <i>Clinical Epigenetics</i> , 2021, 13, 122.	1.8	7
3015	Nitric Oxide Synthase Potentiates the Resistance of Cancer Cell Lines to Anticancer Chemotherapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1397-1406.	0.9	4
3016	Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. <i>MedComm</i> , 2021, 2, 315-340.	3.1	99
3018	Intercalation Ability of Novel Monofunctional Platinum Anticancer Drugs: A Key Step in Their Biological Action. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4391-4399.	2.5	9
3019	Mortalin/glucose-regulated protein 75 promotes the cisplatin-resistance of gastric cancer via regulating anti-oxidation/apoptosis and metabolic reprogramming. <i>Cell Death Discovery</i> , 2021, 7, 140.	2.0	8
3020	Biodistribution and efficacy of the anticancer drug, oxaliplatin palmitate acetate, in mice. <i>International Journal of Pharmaceutics</i> , 2021, 604, 120740.	2.6	3
3021	PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair. <i>Cancers</i> , 2021, 13, 3604.	1.7	6
3022	Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8271.	1.8	44
3023	Plasma-activated medium induces apoptosis in chemotherapy-resistant ovarian cancer cells: High selectivity and synergy with carboplatin. <i>Plasma Processes and Polymers</i> , 2021, 18, 2100074.	1.6	21
3024	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.	1.6	20
3025	Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents. <i>Coordination Chemistry Reviews</i> , 2021, 439, 213890.	9.5	44

#	ARTICLE	IF	CITATIONS
3026	Synthesis, characterization, and miRNA-mediated PI3K suppressing activity of novel cisplatin-derived complexes of selenones. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103245.	2.3	4
3027	Cisplatin release from inclusion complex formed by oxidized carbon nanotube: A DFT study. <i>Chemical Physics Letters</i> , 2021, 774, 138619.	1.2	3
3028	Synergistic effects of silver nanoparticles and cisplatin in combating inflammation and hyperplasia of airway stents. <i>Bioactive Materials</i> , 2022, 9, 266-280.	8.6	13
3029	Disulfide bond based cascade reduction-responsive Pt(IV) nanoassemblies for improved anti-tumor efficiency and biosafety. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 203, 111766.	2.5	17
3030	A metal-free salalen ligand with anti-tumor and synergistic activity in resistant leukemia and solid tumor cells via mitochondrial pathway. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2591-2607.	1.2	6
3031	A novel water-soluble platinum(II) complex with the amino acid deoxyalliin: synthesis, crystal structure, theoretical studies and investigations about its antibacterial activity. <i>Journal of Molecular Structure</i> , 2021, 1236, 130316.	1.8	2
3032	Low-Energy Electron Damage to Condensed-Phase DNA and Its Constituents. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7879.	1.8	27
3033	Nanopore Sequencing Accurately Identifies the Cisplatin Adduct on DNA. <i>ACS Sensors</i> , 2021, 6, 3082-3092.	4.0	14
3034	<i>PRPS2</i> Enhances Resistance to Cisplatin via Facilitating Exosomes-mediated Macrophage M2 Polarization in Non-small Cell Lung Cancer. <i>Immunological Investigations</i> , 2022, 51, 1423-1436.	1.0	10
3035	Diatom-like silica-protein nanocomposites for sustained drug delivery of ruthenium polypyridyl complexes. <i>Journal of Inorganic Biochemistry</i> , 2021, 221, 111489.	1.5	9
3036	Cisplatin Resistance in Epstein-Barr-Virus-Associated Gastric Carcinoma Acquired through ATM Methylation. <i>Cancers</i> , 2021, 13, 4252.	1.7	1
3037	Transcriptomics Profiling Identifies Cisplatin-Inducible Death Receptor 5 Antisense Long Non-coding RNA as a Modulator of Proliferation and Metastasis in HeLa Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 688855.	1.8	5
3038	Cisplatin's potential for type 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1. <i>Computers in Biology and Medicine</i> , 2021, 135, 104640.	3.9	6
3039	Thermodynamic Genome-Scale Metabolic Modeling of Metallo-drug Resistance in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4130.	1.7	5
3040	SIRT3-mediated mitochondrial unfolded protein response weakens breast cancer sensitivity to cisplatin. <i>Genes and Genomics</i> , 2021, 43, 1433-1444.	0.5	9
3041	Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy. <i>Biomaterials</i> , 2021, 275, 120970.	5.7	52
3042	Novel iron(III) complexes based on 2-hydrazinylpyrimidine derivative: Synthesis, characterization and preliminary evaluation of antitumor activity. <i>Journal of Molecular Structure</i> , 2021, 1238, 130417.	1.8	2
3043	Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1478-1495.	0.9	11

#	ARTICLE	IF	CITATIONS
3044	Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines. <i>Molecules</i> , 2021, 26, 4740.	1.7	8
3045	In Vitro Nephrotoxicity Studies of Established and Experimental Platinum-Based Compounds. <i>Biomedicines</i> , 2021, 9, 1033.	1.4	4
3046	Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120788.	2.6	20
3047	Towards Imaging Pt Chemoresistance Using Gd(III)â€Pt(II) Theranostic MR Contrast Agents. <i>ChemMedChem</i> , 2021, , .	1.6	2
3048	Beyond Single-Cell Analysis of Metallodrugs by ICP-MS: Targeting Cellular Substructures. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9468.	1.8	9
3049	Mitochondriaâ€specific nanocatalysts for chemotherapyâ€augmented sequential chemoreactive tumor therapy. <i>Exploration</i> , 2021, 1, 50-60.	5.4	76
3050	PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 5491-5505.	0.4	25
3051	Logicâ€Gated Proximity Aptasensing for Cellâ€Surface Realâ€Time Monitoring of Apoptosis. <i>Angewandte Chemie</i> , 2021, 133, 21026-21032.	1.6	4
3052	Antitumor Effect of Organometallic Half-Sandwich Ru(II)â€Arene Complexes Bearing a Glutathione <i>S</i> -Transferase Inhibitor. <i>Inorganic Chemistry</i> , 2021, 60, 13051-13061.	1.9	15
3053	Antitumour activity of coordination polymer nanoparticles. <i>Coordination Chemistry Reviews</i> , 2021, 441, 213977.	9.5	24
3054	<i>In vitro</i> DNA binding, pBR322 cleavage and molecular docking studies of 1,2-diaminobenzene, dichloro glycolyl glycinate tin(IV) and zirconium(IV) complexes. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 11484-11494.	2.0	1
3055	The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Chemotherapy</i> , 2021, 66, 124-133.	0.8	12
3056	The Role of Low-Energy Electron Interactions in cis-Pt(CO) ₂ Br ₂ Fragmentation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8984.	1.8	5
3057	Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. <i>Seminars in Cancer Biology</i> , 2021, 77, 144-166.	4.3	50
3058	Implications of inhibition of Rev1 interaction with Y family DNA polymerases for cisplatin chemotherapy. <i>Genes and Development</i> , 2021, 35, 1256-1270.	2.7	6
3059	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. <i>Cell Death and Disease</i> , 2021, 12, 789.	2.7	4
3060	DNA-interacting properties of two analogous square-planar cis-chlorido complexes: copper versus palladium. <i>Journal of Biological Inorganic Chemistry</i> , 2021, 26, 727-740.	1.1	7
3061	Synthesis, Characterization, and Anticancer Activity of Benzothiazole Aniline Derivatives and Their Platinum (II) Complexes as New Chemotherapy Agents. <i>Pharmaceutics</i> , 2021, 14, 832.	1.7	12

#	ARTICLE	IF	CITATIONS
3062	Letâ€“7i miRNA and platinum loaded nanoâ€“graphene oxide platform for detection/reversion of drug resistance and synergetic chemicalâ€“photothermal inhibition of cancer cell. Chinese Chemical Letters, 2022, 33, 767-772.	4.8	23
3063	Logicâ€“Gated Proximity Aptasensing for Cellâ€“Surface Realâ€“Time Monitoring of Apoptosis. Angewandte Chemie - International Edition, 2021, 60, 20858-20864.	7.2	38
3064	Synthesis and characterization of silver(I) complexes bearing phenanthroline derivatives as ligands: Cytotoxicity and DNA interaction evaluation. Inorganic Chemistry Communication, 2021, 131, 108757.	1.8	6
3065	Missingâ€“Linkerâ€“Assisted Artesunate Delivery by Metalâ€“Organic Frameworks for Synergistic Cancer Treatment. Angewandte Chemie, 0, , .	1.6	2
3066	Cr(V)â€“Cr(III) in-situ transition promotes ROS generation to achieve efficient cancer therapy. Biomaterials, 2021, 276, 120991.	5.7	18
3067	Metallo drugs as Anticancer Chemotherapeutics and Diagnostic Agents: A Critical Patent Review (2010-2020). Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, .	0.8	5
3068	EGR1-CCL2 Feedback Loop Maintains Epithelial-Mesenchymal Transition of Cisplatin-Resistant Gastric Cancer Cells and Promotes Tumor Angiogenesis. Digestive Diseases and Sciences, 2022, 67, 3702-3713.	1.1	7
3069	Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. Molecular Therapy, 2021, 29, 2723-2736.	3.7	85
3070	Determinants of Homologous Recombination Deficiency in Pancreatic Cancer. Cancers, 2021, 13, 4716.	1.7	9
3071	Synthesis and investigation of in vitro cytotoxic activities and thermal stability of novel pyridine derivative platinum (II) complexes vis a vis DFT studies. Polyhedron, 2021, 210, 115492.	1.0	3
3072	Missingâ€“Linkerâ€“Assisted Artesunate Delivery by Metalâ€“Organic Frameworks for Synergistic Cancer Treatment. Angewandte Chemie - International Edition, 2021, 60, 26254-26259.	7.2	28
3073	Mutual Prodrugs of 5â€“Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs. ChemMedChem, 2021, 16, 3496-3512.	1.6	26
3074	Circadian clock, carcinogenesis, chronochemotherapy connections. Journal of Biological Chemistry, 2021, 297, 101068.	1.6	35
3075	Analytical methods for the quantification of cisplatin, carboplatin, and oxaliplatin in various matrices over the last two decades. Current Pharmaceutical Analysis, 2021, 18, .	0.3	2
3076	Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 5911-5925.	0.8	9
3077	N-Heterocyclic Carbene Iron Complexes as Anticancer Agents: In Vitro and In Vivo Biological Studies. Molecules, 2021, 26, 5535.	1.7	5
3078	DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. Frontiers in Oncology, 2021, 11, 708294.	1.3	15
3079	Ionic liquids application for wastewater treatment and biofuel production: A mini review. Journal of Molecular Liquids, 2021, 337, 116421.	2.3	23

#	ARTICLE	IF	CITATIONS
3080	Mechanisms of drug resistance in ovarian cancer. <i>Journal of Education, Health and Sport</i> , 2021, 11, 362-367.	0.0	0
3081	Synthesis and anticancer activity of Pt(0) olefin complexes bearing 1,3,5-triaza-7-phosphaadamantane and λ^5 -heterocyclic carbene ligands. <i>Applied Organometallic Chemistry</i> , 2021, 35, e6438.	1.7	3
3082	Engineering Metal Nanoclusters for Targeted Therapeutics: From Targeting Strategies to Therapeutic Applications. <i>Advanced Functional Materials</i> , 2021, 31, 2105662.	7.8	47
3083	Co(II) complexes of curcumin and a ferrocene-based curcuminoid: a study on photo-induced antitumor activity. <i>Journal of Biological Inorganic Chemistry</i> , 2021, 26, 881-893.	1.1	3
3084	Homologous recombination deficiency and glycolysis-related pathway in adjuvant chemotherapy for triple-negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e513.	1.7	0
3085	Magnetic hyperthermia mediated by <i>Escherichia coli</i> for targeted cancer therapy. <i>Journal of the Taiwan Institute of Chemical Engineers</i> , 2021, 126, 29-35.	2.7	4
3086	Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2527-2538.	1.9	6
3087	Synthesis, characterization of ruthenium(II), nickel(II), palladium(II), and platinum(II) triphenylphosphine-based complexes bearing an ONS-donor chelating agent: Interaction with biomolecules, antioxidant, in vitro cytotoxic, apoptotic activity and cell cycle analysis. <i>Journal of Inorganic Biochemistry</i> , 2021, 223, 111549.	1.5	44
3088	A 2-(benzothiazol-2-yl)-phenolato platinum(II) complex as potential photosensitizer for combating bacterial infections in lung cancer chemotherapy. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113600.	2.6	14
3089	Therapeutic agent-based infinite coordination polymer nanomedicines for tumor therapy. <i>Coordination Chemistry Reviews</i> , 2021, 445, 214059.	9.5	23
3090	A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. <i>Journal of Controlled Release</i> , 2021, 338, 358-366.	4.8	18
3091	Density functional study of trans,trans,trans-[Pt(N3)2(OH)2(Py)2] on molecular structure and vibrational spectroscopy. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 261, 120022.	2.0	3
3092	Chemodynamic therapy agents Cu(II) complexes of quinoline derivatives induced ER stress and mitochondria-mediated apoptosis in SK-OV-3 cells. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113636.	2.6	24
3093	Design, synthesis, ligand's scaffold variation and structure elucidation of Cu(II) complexes; In vitro DNA binding, morphological studies and their anticancer activity. <i>Polyhedron</i> , 2021, 209, 115450.	1.0	6
3094	Endothelial peroxynitrite causes disturbance of neuronal oscillations by targeting caspase-1 in the arcuate nucleus. <i>Redox Biology</i> , 2021, 47, 102147.	3.9	6
3095	Synthesis and biological evaluation of zwitterionic half-sandwich Rhodium(III) and Ruthenium(II) organometallic complexes. <i>Bioorganic Chemistry</i> , 2021, 116, 105311.	2.0	8
3096	Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells. <i>Cancer Letters</i> , 2021, 520, 267-280.	3.2	7
3097	Homo and heterobimetallic palladium and platinum complexes bearing λ^5 -diphosphane bridges involved in biological studies. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113651.	2.6	6

#	ARTICLE	IF	CITATIONS
3098	Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113793.	2.6	23
3099	Anticancer activity and cell death mechanism of Pt(II) complexes: Their in vitro bio-transformation to Pt(II)-DNA adduct formation and BSA binding study by spectroscopic method. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 262, 120096.	2.0	9
3100	What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives. <i>Coordination Chemistry Reviews</i> , 2021, 449, 214210.	9.5	65
3101	Near-infrared II emissive metal clusters: From atom physics to biomedicine. <i>Coordination Chemistry Reviews</i> , 2021, 448, 214184.	9.5	37
3102	Artificial nanocage-based 3D framework platforms: From construction design to biomedical applications. <i>Chemical Engineering Journal</i> , 2021, 426, 131891.	6.6	5
3103	Acid-responsive endosomolytic polymeric nanoparticles with amplification of intracellular oxidative stress for prodrug delivery and activation. <i>Biomaterials Science</i> , 2021, 9, 4613-4629.	2.6	10
3104	Multifunctional Pt(<i>iv</i>) prodrug candidates featuring the carboplatin core and deferoxamine. <i>Dalton Transactions</i> , 2021, 50, 8167-8178.	1.6	9
3105	Copper(<i>ii</i>) complexes with tridentate halogen-substituted Schiff base ligands: synthesis, crystal structures and investigating the effect of halogenation, leaving groups and ligand flexibility on antiproliferative activities. <i>Dalton Transactions</i> , 2021, 50, 3990-4007.	1.6	28
3106	Fluorescent palladium(<i>ii</i>) and platinum(<i>ii</i>) NHC/1,2,3-triazole complexes: antiproliferative activity and selectivity against cancer cells. <i>Dalton Transactions</i> , 2021, 50, 2158-2166.	1.6	9
3107	Cisplatin- ϵ -conjugated gold nanoparticles-based drug delivery system for targeting hepatic tumors. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22722.	1.4	29
3108	Supramolecular self-associating amphiphiles (SSAs) as nanoscale enhancers of cisplatin anticancer activity. <i>RSC Advances</i> , 2021, 11, 14213-14217.	1.7	13
3109	FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 753.	1.8	13
3110	Functional Platinum(II) Complexes with Four-Photon Absorption Activity, Lysosome Specificity, and Precise Cancer Therapy. <i>Inorganic Chemistry</i> , 2021, 60, 2362-2371.	1.9	19
3111	Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(<i>iv</i>) anticancer prodrugs. <i>Dalton Transactions</i> , 2021, 50, 13737-13747.	1.6	14
3112	Engineering nanomedicine for glutathione depletion-augmented cancer therapy. <i>Chemical Society Reviews</i> , 2021, 50, 6013-6041.	18.7	342
3113	Nanoscale Metal-Organic Layers Detect Mitochondrial Dysregulation and Chemoresistance via Ratiometric Sensing of Glutathione and pH. <i>Journal of the American Chemical Society</i> , 2021, 143, 1284-1289.	6.6	38
3114	Synthesis, structural characterization, protein binding, DNA cleavage and anticancer activity of fluorophore labelled copper(<i>ii</i>) complexes based on 1,8-naphthalimide conjugates. <i>New Journal of Chemistry</i> , 2021, 45, 16319-16332.	1.4	9
3115	Mustards-Derived Terpyridine-Platinum Complexes as Anticancer Agents: DNA Alkylation vs Coordination. <i>Inorganic Chemistry</i> , 2021, 60, 2414-2424.	1.9	26

#	ARTICLE	IF	CITATIONS
3116	Rational design of a lysosome-targeting and near-infrared absorbing Ru(^{II})-BODIPY conjugate for photodynamic therapy. <i>Chemical Communications</i> , 2021, 57, 1790-1793.	2.2	33
3117	Anticancer Gold ^I -Heterocyclic Carbene Complexes: A Comparative in vitro and ex vivo Study. <i>ChemMedChem</i> , 2017, 12, 1429-1435.	1.6	52
3118	Targeting the AKT Pathway in Ovarian Cancer. , 2011, , 73-94.		3
3119	Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. , 2009, , 83-88.		4
3120	Genotoxicity of the Residues of Anticancer Drugs: A Hazard for Aquatic Environment. , 2020, , 403-420.		1
3121	Cancer Stem Cells and Chemoresistance: Strategies to Overcome Therapeutic Resistance. , 2015, , 477-518.		2
3122	Ovarian Cancer Chemoresistance. , 2011, , 2674-2676.		4
3123	Size-related cytotoxicological aspects of polyvinylpyrrolidone-capped platinum nanoparticles. <i>Food and Chemical Toxicology</i> , 2017, 105, 337-346.	1.8	24
3124	Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review. <i>International Journal of Pharmaceutics</i> , 2020, 583, 119385.	2.6	15
3125	Evaluation of photochemotherapeutic potential of a few oxo-bridged dimeric Fe(III) compounds having Salen-type ligands. <i>Polyhedron</i> , 2020, 186, 114614.	1.0	9
3126	Ruthenium, Osmium and Iridium in the Fight Against Cancer. <i>2-Oxoglutarate-Dependent Oxygenases</i> , 2019, , 31-61.	0.8	3
3127	Recent Advances in Anticancer Copper Compounds. <i>2-Oxoglutarate-Dependent Oxygenases</i> , 2019, , 91-119.	0.8	19
3128	Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs. <i>2-Oxoglutarate-Dependent Oxygenases</i> , 2019, , 308-347.	0.8	14
3129	Influence of substituents on DNA and protein binding of cyclometalated Ir(^{III}) complexes and anticancer activity. <i>Dalton Transactions</i> , 2017, 46, 8572-8585.	1.6	35
3130	Gd(^{III})-Pt(^{IV}) theranostic contrast agents for tandem MR imaging and chemotherapy. <i>Chemical Science</i> , 2020, 11, 2524-2530.	3.7	28
3131	Platinum pathway. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 563-564.	0.7	39
3133	Synthesis and molecular structure of biologically significant bis(1,3-dimesityl-4,5-naphthoquinoimidazol-2-ylidene)gold(I) complexes with chloride and dichloridoaurate counter-ions. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2019, 75, 462-468.	0.2	1
3134	Chlorella sorokiniana Extract Prevents Cisplatin-Induced Myelotoxicity In Vitro and In Vivo. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-14.	1.9	7

#	ARTICLE	IF	CITATIONS
3135	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. <i>Journal of Clinical Investigation</i> , 2019, 129, 2431-2445.	3.9	28
3136	Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. <i>Journal of Clinical Investigation</i> , 2009, 119, 1974-1985.	3.9	56
3137	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 517-25.	3.9	462
3138	Germacrone Reduces Cisplatin-Induced Toxicity of Renal Proximal Tubular Cells & via Inhibition of Organic Cation Transporter. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1693-1698.	0.6	11
3139	Histological Changes in Kidney and Liver of Rats Due to Gold (III) Compound [Au(en)Cl ₂]Cl. <i>PLoS ONE</i> , 2012, 7, e51889.	1.1	17
3140	Two 4N Cell-Cycle Arrests Contribute to Cisplatin-Resistance. <i>PLoS ONE</i> , 2013, 8, e59848.	1.1	21
3141	Rad5 Template Switch Pathway of DNA Damage Tolerance Determines Synergism between Cisplatin and NSC109268 in <i>Saccharomyces cerevisiae</i> . <i>PLoS ONE</i> , 2013, 8, e77666.	1.1	1
3142	Potentiating Effect of UVA Irradiation on Anticancer Activity of Carboplatin Derivatives Involving 7-Azaindoles. <i>PLoS ONE</i> , 2015, 10, e0123595.	1.1	12
3143	Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2016, 11, e0162925.	1.1	63
3144	Platinum(II) Iodido Complexes of 7-Azaindoles with Significant Antiproliferative Effects: An Old Story Revisited with Unexpected Outcomes. <i>PLoS ONE</i> , 2016, 11, e0165062.	1.1	18
3145	The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy. <i>PLoS ONE</i> , 2017, 12, e0178221.	1.1	13
3146	The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells. <i>PLoS ONE</i> , 2017, 12, e0179203.	1.1	28
3147	Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. <i>PLoS ONE</i> , 2020, 15, e0244383.	1.1	15
3148	<i>Dictyostelium discoideum</i> as a pharmacological model system to study the mechanisms of medicinal drugs and natural products. <i>International Journal of Developmental Biology</i> , 2019, 63, 541-550.	0.3	17
3149	Flavored Guilu Erxian decoction inhibits the injury of human bone marrow mesenchymal stem cells induced by cisplatin. <i>Cellular and Molecular Biology</i> , 2018, 64, 58-64.	0.3	7
3150	Investigating the Apoptosis Ability of Ethylenediamine 8-Hydroxyquinolinato Palladium (II) Complex. <i>Advanced Pharmaceutical Bulletin</i> , 2016, 6, 449-453.	0.6	21
3151	The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R663-R685.	1.6	57
3152	PT (II) AND PD (II) COMPLEXES INFLUENCE ON SPHEROIDS GROWTH OF BREAST CANCER CELLS. <i>Biotechnologia Acta</i> , 2017, 10, 61-67.	0.3	4

#	ARTICLE	IF	CITATIONS
3153	Perspectives and Potential Applications of Ruthenium-Based Nanocarriers for Cancer Therapy. <i>Journal of Pharmaceutics and Drug Development</i> , 2014, 1, .	0.1	3
3154	Cooperation and interplay between base and nucleotide excision repair pathways: From DNA lesions to proteins. <i>Genetics and Molecular Biology</i> , 2020, 43, e20190104.	0.6	47
3155	Phospho- β -Np63 \pm /Rpn13-dependent regulation of LKB1 degradation modulates autophagy in cancer cells. <i>Aging</i> , 2010, 2, 959-968.	1.4	28
3156	Distinct effects of epirubicin, cisplatin and cyclophosphamide on ovarian somatic cells of prepuberal ovaries. <i>Aging</i> , 2019, 11, 10532-10556.	1.4	5
3157	Enhancer-bound Nrf2 licenses HIF-1 \pm transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells. <i>Aging</i> , 2021, 13, 364-375.	1.4	14
3158	Novel strategies to target chemoresistant triple-negative breast cancer. <i>Genes and Cancer</i> , 2020, 11, 95-105.	0.6	3
3159	Radio-frequency plasma polymerized biodegradable carrier for <i>in vivo</i> release of cis-platinum. <i>Oncotarget</i> , 2016, 7, 58121-58132.	0.8	8
3160	Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in <i>BRCA1</i> -associated triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 68662-68673.	0.8	13
3161	Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells. <i>Oncotarget</i> , 2016, 7, 71841-71855.	0.8	19
3162	14-3-3 β attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells. <i>Oncotarget</i> , 2013, 4, 2045-2056.	0.8	14
3163	Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin. <i>Oncotarget</i> , 2017, 8, 19156-19171.	0.8	11
3164	Tumor-associated NADH oxidase (tNOX)-NAD ⁺ -sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells. <i>Oncotarget</i> , 2017, 8, 15338-15348.	0.8	16
3165	Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity. <i>Oncotarget</i> , 2017, 8, 50845-50863.	0.8	9
3166	Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs. <i>Oncotarget</i> , 2017, 8, 30933-30955.	0.8	4
3167	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	0.8	13
3168	The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2017, 8, 44312-44325.	0.8	76
3169	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. <i>Oncotarget</i> , 2017, 8, 72544-72563.	0.8	60
3170	Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. <i>Oncotarget</i> , 2017, 8, 103710-103730.	0.8	24

#	ARTICLE	IF	CITATIONS
3171	Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. <i>Oncotarget</i> , 2014, 5, 7776-7787.	0.8	24
3172	Organic cation transporter 3 mediates cisplatin and copper cross-resistance in hepatoma cells. <i>Oncotarget</i> , 2018, 9, 743-754.	0.8	16
3173	The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models. <i>Oncotarget</i> , 2018, 9, 14524-14538.	0.8	49
3174	Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. <i>Oncotarget</i> , 2018, 9, 24707-24717.	0.8	14
3175	Subcellular localization of FANCD2 is associated with survival in ovarian carcinoma. <i>Oncotarget</i> , 2020, 11, 775-783.	0.8	5
3176	Enhanced nucleotide excision repair capacity in lung cancer cells by preconditioning with DNA-damaging agents. <i>Oncotarget</i> , 2015, 6, 22575-22586.	0.8	21
3177	Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling. <i>Oncotarget</i> , 2016, 7, 33055-33068.	0.8	60
3178	Magnetic resonance imaging-guided and targeted theranostics of colorectal cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 307-327.	1.4	18
3179	Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. <i>Current Medicinal Chemistry</i> , 2017, 24, 1586-1606.	1.2	89
3180	Transition Metal-Based Prodrugs for Anticancer Drug Delivery. <i>Current Medicinal Chemistry</i> , 2020, 26, 7476-7519.	1.2	11
3181	Cisplatin Toxicology: The Role of Pro-inflammatory Cytokines and GABA Transporters in Cochlear Spiral Ganglion. <i>Current Pharmaceutical Design</i> , 2020, 25, 4820-4826.	0.9	9
3182	Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. <i>Current Pharmaceutical Design</i> , 2020, 26, 932-945.	0.9	15
3183	Engineered Inorganic Nanoparticles for Drug Delivery Applications. <i>Current Drug Metabolism</i> , 2013, 14, 518-530.	0.7	58
3184	Synthesis, Structural Characterization, Molecular Modeling and DNA Binding Ability of CoII, NiII, CuII, ZnII, PdII and CdII Complexes of Benzocycloheptenone Thiosemicarbazone Ligand. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019, 19, 1068-1079.	1.1	16
3185	Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics. <i>Current Drug Delivery</i> , 2020, 17, 558-576.	0.8	31
3186	Novel Selenosemicarbazone Metal Complexes Exert Anti-tumor Effect via Alternative, Caspase-independent Necroptotic Cell Death. <i>Medicinal Chemistry</i> , 2014, 10, 759-771.	0.7	24
3187	Platinum Compounds: A Hope for Future Cancer Chemotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 296-306.	0.9	172
3188	Metal Complexes of Natural Product Like-compounds with Antitumor Activity. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 48-65.	0.9	15

#	ARTICLE	IF	CITATIONS
3189	Antitumor Potential of Berberine and Cinnamic Acid against Solid Ehrlich Carcinoma in Mice. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 356-364.	0.9	24
3190	Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1243-1252.	0.9	4
3191	Three Pt-Pt Complexes with Donor-acceptor Feature: Anticancer Activity, DNA Binding Studies and Molecular Docking Simulation. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1762-1774.	0.9	4
3192	Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer. <i>Anticancer Research</i> , 2016, 36, 6005-6010.	0.5	10
3193	Complex of Platinum(II) with Tris(2-carboxyethyl)phosphine Induces Apoptosis in Canine Lymphoma/Leukemia Cell Lines. <i>Anticancer Research</i> , 2017, 37, 539-546.	0.5	5
3194	Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein. <i>Anticancer Research</i> , 2018, 38, 1993-2000.	0.5	24
3195	ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 507-513.	0.5	19
3196	Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 343-350.	0.5	13
3197	Potential Application for Tissue Engineering in Natural Rubber Latex. <i>Nippon Gomu Kyokaishi</i> , 2018, 91, 331-336.	0.0	2
3199	miRNA Expression Signatures of Therapy Response in Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 63.	1.7	8
3200	Overexpression of ABCC2 and NF- κ B/p53 with Reduction in Cisplatin and 4OH-Tamoxifen Sensitivity in MCF-7 Breast Cancer Cells: The Influence of TNF- α . <i>Pharmaceutical Sciences</i> , 2020, 26, 150-158.	0.1	2
3202	Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin. <i>World Journal of Gastroenterology</i> , 2014, 20, 8229.	1.4	24
3203	The role of pyruvate kinase M2 in anticancer therapeutic treatments (Review). <i>Oncology Letters</i> , 2019, 18, 5663-5672.	0.8	22
3204	Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway. <i>Oncology Letters</i> , 2020, 19, 323-333.	0.8	78
3205	Apurinic endonuclease 1 promotes the cisplatin resistance of lung cancer cells by inducing Parkin-mediated mitophagy. <i>Oncology Reports</i> , 2019, 42, 2245-2254.	1.2	15
3206	Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. <i>Journal of Thoracic Disease</i> , 2015, 7, 400-6.	0.6	22
3207	Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. <i>Journal of Gastrointestinal Oncology</i> , 2011, 2, 27-33.	0.6	51
3208	Current and future systemic treatment options in metastatic pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 280-95.	0.6	33

#	ARTICLE	IF	CITATIONS
3209	Cytotoxic and antitumour studies of acetoacetanilide N(4)-methyl(phenyl)thiosemicarbazone and its transition Metal Complexes. Indian Journal of Pharmaceutical Sciences, 2015, 77, 655.	1.0	7
3210	Protective Effect of on Cisplatin-induced Oxidative Renal Damage in Rats. Pharmacognosy Magazine, 2018, 13, S807-S816.	0.3	4
3211	Protective effect of Withania coagulans fruit extract on cisplatin-induced nephrotoxicity in rats. Pharmacognosy Research (discontinued), 2017, 9, 354.	0.3	13
3212	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 1086-1097.	1.3	59
3213	Use of Cucurbit [6] Uril as a Modifier in the Electrochemical Determination of Antitumor Platinum (II) Complex: $[PtCl_2(Dimethylamine)_2] \cdot 2H_2O$. Application to Biological Samples. American Journal of Analytical Chemistry, 2013, 04, 314-322.	0.3	4
3214	Current Status for Oral Platinum (IV) Anticancer Drug Development. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2018, 07, 231-247.	0.3	15
3215	In Vitro Investigation of DNA Damage Induced by the DNA Cross-Linking Agents Oxaliplatin and Satraplatin in Lymphocytes of Colorectal Cancer Patients. Journal of Cancer Therapy, 2012, 03, 78-89.	0.1	5
3216	Evaluation of Cisplatin-Loaded Polymeric Micelles and Hybrid Nanoparticles Containing Poly(Ethylene Terephthalate) and Bovine Serum Albumin. Journal of Applied Polymer Science, 2019, 143, 47057.	0.2	4
3217	Synthesis, crystal structure and in vitro anticancer studies of two bis(8-quinolinolato-N,O)-platinum(II) complexes. European Journal of Chemistry, 2019, 10, 37-44.	0.3	2
3218	Delay of the Blink Reflex in Patients Receiving Platinum-Analogue Chemotherapy. Annals of Rehabilitation Medicine, 2016, 40, 66.	0.6	3
3219	Antiprogesterins in Ovarian Cancer. , 0, , .		3
3220	Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials. Biochemical Compounds, 2016, 4, 1.	0.7	18
3221	Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1209-1215.	0.5	23
3222	Short Low Concentration Cisplatin Treatment Leads to an Epithelial Mesenchymal Transition-like Response in DU145 Prostate Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1025-1028.	0.5	15
3223	Advances in drug delivery system for platinum agents based combination therapy. Cancer Biology and Medicine, 2015, 12, 362-74.	1.4	36
3224	The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model. ELife, 2020, 9, .	2.8	17
3225	Phospholipase A ₂ from krait Bungarus fasciatus venom induces human cancer cell death in vitro. PeerJ, 2019, 7, e8055.	0.9	16
3226	Modular synthesis of antimalarial quinoline-based PGM metallarectangles. Dalton Transactions, 2021, 50, 15274-15286.	1.6	5

#	ARTICLE	IF	CITATIONS
3227	Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatin and Eribulin. <i>In Vivo</i> , 2021, 35, 3107-3110.	0.6	4
3228	An erythrocyte-delivered photoactivatable oxaliplatin nanoprodug for enhanced antitumor efficacy and immune response. <i>Chemical Science</i> , 2021, 12, 14353-14362.	3.7	15
3229	Multifunctional carbon dots with near-infrared absorption and emission for targeted delivery of anticancer drugs, tumor tissue imaging and chemo/photothermal synergistic therapy. <i>Nanoscale Advances</i> , 2021, 3, 6869-6875.	2.2	12
3230	Synthesis and Development of Platinum-Based Anticancer Drugs. <i>Indian Institute of Metals Series</i> , 2021, , 643-740.	0.2	0
3231	Nucleophilic substitution of chloride from the [Pt(chlorido)(NNN)/(NCN)] ⁺ , <i>Results in Chemistry</i> , 2021, 3, 100218.	0.9	0
3232	The Dark Side of Platinum Based Cytostatic Drugs: From Detection to Removal. <i>Processes</i> , 2021, 9, 1873.	1.3	10
3233	A Click Chemistry Approach to Targeted DNA Crosslinking with <i>cis</i> -Platinum(II)-Modified Triplex-Forming Oligonucleotides. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	16
3234	XANES spectroscopy for the clinician. <i>Comptes Rendus Chimie</i> , 2022, 25, 189-208.	0.2	6
3235	Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein. <i>Frontiers in Oncology</i> , 2021, 11, 752127.	1.3	9
3236	Developing a Novel Indium(III) Agent Based on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer by Multitargeting the Tumor Microenvironment Components. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14587-14602.	2.9	15
3237	A Click Chemistry Approach to Targeted DNA Crosslinking with <i>cis</i> -Platinum(II) Modified Triplex Forming Oligonucleotides. <i>Angewandte Chemie</i> , 0, , .	1.6	0
3238	Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 764119.	1.3	20
3239	Processing and Bypass of a Site-Specific DNA Adduct of the Cytotoxic Platinum-“Acridinylthiourea Conjugate by Polymerases Involved in DNA Repair: Biochemical and Thermodynamic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10838.	1.8	0
3240	Research progress of azido-containing Pt(IV) antitumor compounds. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113927.	2.6	17
3241	Converting an Almost Noncytotoxic Ru(II) Complex with Photolabile Ligands into a Highly Efficient PACT Agent. <i>Particle and Particle Systems Characterization</i> , 2021, 38, 2100193.	1.2	0
3242	The gold complex auranofin: new perspectives for cancer therapy. <i>Discover Oncology</i> , 2021, 12, 42.	0.8	48
3243	SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/ β -catenin pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10684-10697.	1.6	7
3244	Synthesis, Characterization and Biological Studies of Organoselenium trans-Palladium(II) Complexes. <i>Medicinal Chemistry</i> , 2021, 17, 1007-1022.	0.7	1

#	ARTICLE	IF	CITATIONS
3245	Platinum Drugs in Children with Cancer. , 2009, , 365-371.		1
3246	Pharmacogenetics of Lung Cancer. , 2010, , 87-106.		0
3247	PKC and Resistance to Chemotherapeutic Agents. , 2010, , 409-429.		2
3248	Cellular Inorganic Chemistry Concepts and Examples. , 2010, , 1-33.		0
3249	Chapter 8. Non-Covalent Polynuclear Platinum Compounds as Polyamine Analogs. RSC Drug Discovery Series, 2011, , 191-204.	0.2	2
3250	The Synthesis of Platinum(II) Intercalators. , 2011, , 69-100.		0
3251	Molecular Mechanism of Cisplatin Resistance in Head and Neck Cancers. Practica Otologica, 2011, 104, 161-170.	0.0	0
3254	Traditional Chinese Medicine Active Ingredient-Metal Based Anticancer Agents. , 0, , .		1
3255	Geochemistry and Biochemistry: Insights into the Fate and Transport of Pt-Based Chemotherapy Drugs. , 2013, , 19-29.		0
3256	A Zinc(II) Phthalocyanine Conjugated with an Oxaliplatin Derivative for Dual Chemo- and Photodynamic Therapy. Springer Theses, 2013, , 35-48.	0.0	0
3257	Overexpression of DNA Polymerase Î¶ Affects Cisplatin Resistance in Ovarian Cancer: An Immunohistochemical Study. The Showa University Journal of Medical Sciences, 2013, 25, 109-118.	0.1	0
3258	Biomolecular Interactions of Platinum Complexes. Monographs in Supramolecular Chemistry, 2013, , 260-299.	0.2	3
3259	NUCLEOTIDE EXCISION REPAIR (NER). , 2013, , 26-38.		0
3260	Platinum Resistance: The Role of Molecular, Genetic and Epigenetic Factors. Journal of Medical Sciences (Faisalabad, Pakistan), 2013, 13, 160-168.	0.0	0
3261	Emerging Potential of Nanoparticles for the Treatment of Solid Tumors and Metastasis. , 2013, , 1-28.		0
3263	CHAPTER 15. Platinum. 2-Oxoglutarate-Dependent Oxygenases, 2014, , 429-460.	0.8	3
3264	Ovarian Cancer Chemoresistance. , 2014, , 1-6.		0
3266	PARP Inhibitor Resistanceâ€”What Is Beyond BRCA1 or BRCA2 Restoration?. Cancer Drug Discovery and Development, 2015, , 453-471.	0.2	0

#	ARTICLE	IF	CITATIONS
3268	Ovarian Cancer Chemoresistance. , 2017, , 3264-3268.		0
3269	HEMATOLOGICAL TOXICITY IN RATS; THERAPEUTIC PROPERTIES OF ANDROGRAPHIS PANICULATA ON OXALIPLATIN INDUCED. The Professional Medical Journal, 2017, 24, 342-346.	0.0	0
3271	MECHANISM OF APOPTOSIS INHIBITION TO SQUAMOUS CELL CARCINOMA OF ORAL CANCER IN CISPLATIN TREATMENT. Folia Medica Indonesiana, 2017, 53, 1.	0.1	1
3272	Indikation von CRS und HIPEC bei peritonealen Metastasen von Ovarialkarzinomen. , 2018, , 213-221.		0
3273	Harnessing Chemoselective Imine Ligation for Tethering Bioactive Molecules to Platinum(IV) Prodrugs. Springer Theses, 2018, , 33-53.	0.0	1
3275	Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents. Springer Theses, 2018, , 103-130.	0.0	0
3277	Determining the amount of platinum from hair, urine and blood samples with graphite furnace atomic absorption spectrometer with graphite furnace at patients with chemotherapy. , 2018, , .		0
3278	Enhancing the Therapeutic Potential of Platinum-based Anticancer Agents by Incorporating Clinically Approved Drugs as Ligands. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 1-30.	0.8	1
3279	An Initial Demonstration of Polyester Monomer Coordination Properties: Synthesis and Biological Activity of Metal Complexes Derived from a New Nanosized Diol. Letters in Organic Chemistry, 2019, 16, 235-244.	0.2	4
3280	THE EFFECT OF ALLOGENEIC MESENCHYMAL STEM CELL TRANSPLANTATION ON THE ACTIVITY OF MITOCHONDRIAL SUCCINATE DEHYDROGENASE IN THE LIVER OF RECIPIENT ANIMALS. Ukrainian Journal of Veterinary Sciences, 2019, 10, 1-2.	0.1	0
3281	p28GANK overexpression is associated with chemotherapy resistance and poor prognosis in ovarian cancer. Oncology Letters, 2020, 19, 505-512.	0.8	1
3282	Antioxidant Supplementation with N-Acetylcysteine as a Protection Against Cisplatin-Induced Motor Impairment in Rats. Serbian Journal of Experimental and Clinical Research, 2020, .	0.2	0
3283	Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion. Biochemical Journal, 2020, 477, 937-951.	1.7	1
3284	Synthesis, characterization, and biological activity of new mixed ammine/amine platinum(IV) complexes. Applied Organometallic Chemistry, 2020, 34, e5680.	1.7	1
3285	Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer. PeerJ, 2020, 8, e9234.	0.9	11
3286	Palmijihwang-tang Alleviates Cisplatin-induced Nephrotoxicity through Inhibiting ROS Production and p53 Activation. Journal of Physiology & Pathology in Korean Medicine, 2020, 34, 170-176.	0.2	0
3288	Structure elucidation, <i>in vitro</i> binding studies and ROS-dependent anti-cancer activity of Cu(II) and Zn(II) phthaloylglycinate(phen) complexes against MDA-MB-231 cells. Metallomics, 2021, 13, .	1.0	8
3289	The prognostic value of excision repair cross-complementing Group 1 expression in nasopharyngeal cancer patients. Journal of Research in Medical Sciences, 2020, 25, 34.	0.4	0

#	ARTICLE	IF	CITATIONS
3290	Frontiers of metal-coordinating drug design. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 497-511.	2.5	28
3291	Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury. <i>Kidney360</i> , 2021, 2, 205-214.	0.9	4
3294	A quinolone derivative-based organoplatinum(II) metallacycle supramolecular self-delivery nanocarrier for combined cancer therapy. <i>Supramolecular Chemistry</i> , 2020, 32, 597-604.	1.5	3
3295	Photoactive metallodrugs. , 2021, , .		0
3296	Principles of small moleculeâ€“DNA recognition. , 2022, , 191-286.		1
3297	Exploring coordination preferences and biological applications of pyridyl-based organochalcogen (Se, Te) ligands. <i>Coordination Chemistry Reviews</i> , 2022, 450, 214254.	9.5	29
3298	Synthesis and characterization of a mononuclear nickel(II) complex with N,O-donor ligand: Its DNA/HSA protein binding properties and tumor suppressive function. <i>Journal of Molecular Structure</i> , 2022, 1250, 131687.	1.8	4
3300	Optimized Structure Investigation of Platinum Complex (VI) using DFT. <i>Journal of Engineering and Applied Sciences</i> , 2019, 14, 9936-9945.	0.2	0
3301	Construction of Well-Defined Discrete Metallacycles and Their Biological Applications. , 2020, , 1045-1071.		0
3302	Crystal structures of chlorido[dihydroxybis(1-iminoethoxy)]arsanido- Pt^{III} $\langle i \rangle \text{N} \langle /i \rangle$, $\langle i \rangle \text{As} \langle /i \rangle$, $\langle i \rangle \text{N} \langle /i \rangle \hat{\text{e}}^2$]platinum(II) and of a polymorph of chlorido[dihydroxybis(1-iminopropoxy)]arsanido- Pt^{III} $\langle i \rangle \text{N} \langle /i \rangle$, $\langle i \rangle \text{As} \langle /i \rangle$, $\langle i \rangle \text{N} \langle /i \rangle \hat{\text{e}}^2$]platinum(II). <i>Acta Crystallographica Section E: Crystallographic Communications</i> , 2020, 76, 180-185.	0.2	0
3303	DNA Binding Potency and Antimicrobial Analysis of New Indole and Pyrazolone Based Transition Metal(II) Complexes. <i>Asian Journal of Chemistry</i> , 2020, 32, 1903-1908.	0.1	1
3304	Antitumor Activity of Novel Azoles on Ehrlich Ascites Carcinoma Cells in Mice. <i>Archives in Neurology & Neuroscience</i> , 2020, 7, .	0.1	1
3306	Interaction of Copper Trafficking Proteins with the Platinum Anticancer Drug Kiteplatin. <i>ChemMedChem</i> , 2022, 17, .	1.6	3
3307	Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin. <i>ACS Nano</i> , 2021, 15, 18541-18556.	7.3	17
3308	Structural, thermal, electronic, vibrational, magnetic, and cytotoxic properties of chloro(glycinato-N,O)(1,10-phenanthroline-N, $\text{N} \hat{\text{e}}^2$)â€“copper(II) trihydrate coordination complex. <i>Journal of Inorganic Biochemistry</i> , 2022, 226, 111658.	1.5	9
3309	Assessment of antiproliferative activity of new halfâ€“sandwich arene Ru (II) furylbenzhydrazone complexes. <i>Applied Organometallic Chemistry</i> , 2022, 36, e6512.	1.7	8
3310	Anticancer activity and biomolecular interaction of Pt(II) complexes: Their synthesis, characterisation and DFT study. <i>Applied Organometallic Chemistry</i> , 2022, 36, e6506.	1.7	8
3311	Combined chemotherapy of platinum and fluorouracil promotes T cell–mediated antitumor immunity. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 53, 29-35.	0.9	1

#	ARTICLE	IF	CITATIONS
3313	Anticancer Activity Assessment and DNA Binding Properties of Two Binuclear Platinum (II) Complexes using Spectroscopic and Molecular Simulation Approaches. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 2066-2073.	0.9	1
3314	Metal-organic Nanopharmaceuticals. <i>Pharmaceutical Nanotechnology</i> , 2020, 8, 163-190.	0.6	2
3315	The molecular genetics of breast cancer and targeted therapy. <i>Biologics: Targets and Therapy</i> , 2007, 1, 241-58.	3.0	18
3316	Differential DNA damage responses in p53 proficient and deficient cells: cisplatin-induced nuclear import of XPA is independent of ATR checkpoint in p53-deficient lung cancer cells. <i>International Journal of Biochemistry and Molecular Biology</i> , 2011, 2, 138-145.	0.1	17
3317	Molecular genetics of testicular germ cell tumors. <i>American Journal of Cancer Research</i> , 2012, 2, 153-67.	1.4	31
3318	Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 418-31.	1.0	16
3320	Understanding and improving platinum anticancer drugs--phenanthriplatin. <i>Anticancer Research</i> , 2014, 34, 471-6.	0.5	224
3321	Primary culture of trigeminal satellite glial cells: a cell-based platform to study morphology and function of peripheral glia. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2014, 6, 1-12.	0.8	19
3322	Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3803-10.	0.5	40
3323	Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 20565-72.	1.3	61
3325	Arsenic Trioxide Induces Apoptosis via Specific Signaling Pathways in HT-29 Colon Cancer Cells. <i>Journal of Cancer Science & Therapy</i> , 2017, 9, 298-306.	1.7	11
3328	A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. <i>American Journal of Cancer Research</i> , 2019, 9, 699-713.	1.4	7
3329	It's About Time: Advances in Understanding the Circadian Regulation of DNA Damage and Repair in Carcinogenesis and Cancer Treatment Outcomes. <i>Yale Journal of Biology and Medicine</i> , 2019, 92, 305-316.	0.2	16
3330	Cisplatin-Based Chemotherapy of Human Cancers. <i>Journal of Cancer Science & Therapy</i> , 2019, 11, .	1.7	24
3331	T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 473-490.	1.4	11
3333	Epigenetics and precision medicine in prostate cancer. , 2022, , 69-108.		0
3334	Polydopamine Nanoparticles Containing a Cisplatin Analog for Anticancer Treatment and Diagnostics. <i>ACS Applied Nano Materials</i> , 2021, 4, 14126-14135.	2.4	2
3335	A Colorectal Cancer 3D Bioprinting Workflow as a Platform for Disease Modeling and Chemotherapeutic Screening. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 755563.	2.0	17

#	ARTICLE	IF	CITATIONS
3336	An NIR Discrete Metallacycle Constructed from Perylene Bisimide and Tetraphenylethylene Fluorophores for Imaging-Guided Cancer Radio-Chemotherapy. <i>Advanced Materials</i> , 2022, 34, e2106388.	11.1	79
3337	Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 91.	0.8	6
3338	16-Electron Half-Sandwich Rhodium(III), Iridium(III), and Ruthenium(II) Complexes as Lysosome-Targeted Anticancer Agents. <i>Organometallics</i> , 2021, 40, 3999-4010.	1.1	7
3339	Exploring Anticancer Activities and Structure-Activity Relationships of Binuclear Oxidovanadium(IV) Complexes. <i>ACS Applied Bio Materials</i> , 2021, 4, 8571-8583.	2.3	7
3340	Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation. <i>Inorganic Chemistry</i> , 2021, 60, 18379-18394.	1.9	6
3341	Cisplatin-Induced Bradycardia: A Silent Risk Observed in Two Different Clinical Cases. <i>Cureus</i> , 2021, 13, e19769.	0.2	2
3342	Transition metal complexes of triazole-based bioactive ligands: synthesis, spectral characterization, antimicrobial, anticancer and molecular docking studies. <i>Research on Chemical Intermediates</i> , 2022, 48, 703-729.	1.3	38
3343	Antitumor Effects of Ir(III)-Indazole Complexes for Triple Negative Breast Cancer. <i>Inorganic Chemistry</i> , 2021, 60, 17593-17607.	1.9	23
3344	Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 784602.	2.0	14
3345	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	1.1	5
3346	Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e054004.	0.8	1
3347	Effects of cisplatin on mitochondrial function and autophagy-related proteins in skeletal muscle of rats. <i>BMB Reports</i> , 2021, 54, 575-580.	1.1	4
3348	Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. <i>European Journal of Cancer</i> , 2022, 160, 189-205.	1.3	9
3349	Electron Delocalization in Spectroelectrochemically and Computationally Characterized [Pt(<i>p</i> -BrC ₆ F ₄)NCH ₂ C(Cl)NEt ₂ Cl(py)] ⁺ Formed by Electrochemical Oxidation of [Pt(^{II}){(<i>p</i> -BrC ₆ F ₄)NCH ₂ C(Cl)NEt ₂ Cl(py)}. <i>Inorganic Chemistry</i> , 2021, 60, 18899-18911.	1.9	1
3350	Platinum binding preferences dominate the binding of novel polyamide amidine anthraquinone platinum(^{II}) complexes to DNA. <i>Dalton Transactions</i> , 2021, 50, 17945-17952.	1.6	2
3351	Synthesis, Characterization, Crystal Structure, DNA and HSA Interactions, and Anticancer Activity of a Mononuclear Cu(II) Complex with a Schiff Base Ligand Containing a Thiadiazoline Moiety. <i>ACS Omega</i> , 2022, 7, 2881-2896.	1.6	35
3352	Influence of ligand lipophilicity in Pt(II) complexes on their antiproliferative and apoptotic activities in tumour cell lines. <i>Journal of Inorganic Biochemistry</i> , 2022, 227, 111688.	1.5	8
3353	Investigation of nucleic acid damage induced by a novel ruthenium anti-cancer drug using multiple analytical techniques: Sequence specificity and damage kinetics. <i>International Journal of Biological Macromolecules</i> , 2022, 198, 68-76.	3.6	5

#	ARTICLE	IF	CITATIONS
3354	Platinum(IV) complexes as inhibitors of CD47-SIRP α axis for chemoimmunotherapy of cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 229, 114047.	2.6	19
3355	2-Aminoethoxydiphenyl borate ameliorates functional and structural abnormalities in cisplatin-induced peripheral neuropathy. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 70, 126909.	1.5	5
3356	Protective effect of nutritional supplementation of zinc-sulfate against cisplatin-induced spermatogonial and testicular dysfunctions in adult male Sprague-Dawley rats. <i>Endocrine and Metabolic Science</i> , 2022, 6, 100116.	0.7	6
3358	Combinatorial nanococktails via self-assembling lipid prodrugs for synergistically overcoming drug resistance and effective cancer therapy. <i>Biomaterials Research</i> , 2022, 26, 3.	3.2	10
3359	trans-Dichloro(triphenylarsino)(N,N-dialkylamino)platinum(II) Complexes: In Search of New Scaffolds to Circumvent Cisplatin Resistance. <i>Molecules</i> , 2022, 27, 644.	1.7	5
3360	Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	1
3361	Gallium (III) Complexes in Cancer Chemotherapy. <i>European Journal of Inorganic Chemistry</i> , 2022, 2022, .	1.0	20
3362	Nanocarrier System for Increasing the Therapeutic Efficacy of Oxaliplatin. <i>Current Cancer Drug Targets</i> , 2022, 22, 361-372.	0.8	2
3363	Evaluation of the anticancer activities with various ligand substituents in Co(ii/iii)-picolyl phenolate derivatives: synthesis, characterization, DFT, DNA cleavage, and molecular docking studies. <i>Dalton Transactions</i> , 2022, 51, 2346-2363.	1.6	3
3364	Chemotherapy Side-Effects: Not All DNA Damage Is Equal. <i>Cancers</i> , 2022, 14, 627.	1.7	88
3365	Fighting metallodrug resistance through alteration of drug metabolism and blockage of autophagic flux by mitochondria-targeting AIEgens. <i>Chemical Science</i> , 2022, 13, 1428-1439.	3.7	14
3366	Gold (III) Derivatives in Colon Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 724.	1.8	22
3367	Application Potential of Plant-Derived Medicines in Prevention and Treatment of Platinum-Induced Peripheral Neurotoxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 792331.	1.6	3
3368	A simple synthetic entryway into (<i>N</i> -heterocyclic carbene)gold σ -steroidyl complexes and their anticancer activity. <i>Applied Organometallic Chemistry</i> , 0, , .	1.7	10
3369	DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds. <i>Frontiers in Oncology</i> , 2021, 11, 749178.	1.3	2
3370	Pt(<i>iv</i>) antitumor prodrugs: dogmas, paradigms, and realities. <i>Dalton Transactions</i> , 2022, 51, 2121-2134.	1.6	40
3371	Detailed structural and spectroscopic elucidation of ferrocenium coupled N-heterocyclic carbene gold(i) complexes. <i>Dalton Transactions</i> , 2022, 51, 1533-1541.	1.6	0
3372	Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. <i>Cell Death Discovery</i> , 2022, 8, 12.	2.0	18

#	ARTICLE	IF	CITATIONS
3373	BODIPY-Tagged Platinum(II) Curcumin Complexes for Endoplasmic Reticulum-Targeted Red Light PDT. <i>Inorganic Chemistry</i> , 2022, 61, 1335-1348.	1.9	15
3374	Osmium(ν) nitride triggers mitochondria-induced oncosis and apoptosis. <i>Chemical Communications</i> , 2022, 58, 2468-2471.	2.2	5
3375	Double hydrophilic copolymers – synthetic approaches, architectural variety, and current application fields. <i>Chemical Society Reviews</i> , 2022, 51, 995-1044.	18.7	20
3376	Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901). <i>Oncologist</i> , 2022, 27, e116-e125.	1.9	6
3377	Cisplatin~cyclooxygenase inhibitor conjugates, free and immobilised in mesoporous silica SBA-15, prove highly potent against triple-negative MDA-MB-468 breast cancer cell line. <i>Dalton Transactions</i> , 2022, 51, 857-869.	1.6	7
3378	Fluorescent ABC~Triblock Polymer Nanocarrier for Cisplatin Delivery to Cancer Cells. <i>Chemistry - an Asian Journal</i> , 2022, 17, .	1.7	6
3379	Effect of cashew (<i>Anacardium occidentale</i> L.) nut~supplemented diet on steroidogenic enzymes, hormonal and oxidative imbalances, and sperm parameters in cisplatin~induced reproductive toxicity in male rats. <i>Journal of Food Biochemistry</i> , 2022, 46, e14100.	1.2	3
3380	Insights into cisplatin-induced neurotoxicity and mitochondrial dysfunction in <i>Caenorhabditis elegans</i> . <i>DMM Disease Models and Mechanisms</i> , 2022, , .	1.2	3
3381	Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. <i>Scientific Reports</i> , 2022, 12, 1658.	1.6	4
3382	A Proteomic Platform Enables to Test for AML Normalization In Vitro. <i>Frontiers in Chemistry</i> , 2022, 10, 826346.	1.8	3
3383	Palladium(II) complexes: Structure, development and cytotoxicity from cisplatin analogues to chelating ligands with N stereocenters. <i>Inorganica Chimica Acta</i> , 2022, 534, 120797.	1.2	2
3384	Synthesis and Contemporary Applications of Platinum Group Metals Complexes with Acyclic Diaminocarbene Ligands (Review). <i>Russian Journal of Inorganic Chemistry</i> , 2022, 67, 48-90.	0.3	16
3385	Characterization and Antitumor Activity of Furazano[3,4-g]pteridine-2,4(1H,3H)-dione. <i>Heterocycles</i> , 2022, 104, .	0.4	1
3386	Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities. , 2022, 10, e003833.		10
3387	Oxidative DNA Damage and Cisplatin Neurotoxicity Is Exacerbated by Inhibition of OGG1 Glycosylase Activity and APE1 Endonuclease Activity in Sensory Neurons. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1909.	1.8	3
3388	Core-shell structured nanoparticles for photodynamic therapy-based cancer treatment and related imaging. <i>Coordination Chemistry Reviews</i> , 2022, 458, 214427.	9.5	30
3389	Effects of cisplatin on mitochondrial function and autophagy-related proteins in skeletal muscle of rats. <i>BMB Reports</i> , 2021, 54, 575-580.	1.1	0
3390	Induction of Apoptosis in Sgc-7901 Cells by Iridium(III) Complexes Via Endoplasmic Reticulum Stress-Mitochondrial Dysfunction Pathway. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
3391	Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machinery: pitfalls and progress. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 117, e210403.	0.8	1
3392	Quantum Chemical Studies of the Electronic Structures of Anti-Tumor Agents: Au(III) (L = Porphine,) Tj ETQq1 1 0.784314 rgBT /Over	0.4	0
3393	Synthesis and anticancer activity of two highly water-soluble and ionic Pt(IV) complexes as prodrugs for Pt(II) anticancer drugs. <i>RSC Medicinal Chemistry</i> , 2022, 13, 594-598.	1.7	2
3394	Metal complexes as chemotherapeutic agents. , 2022, , .		0
3395	Gold(III) Heteroleptic Complexes with Sns-Thiosemicarbazonate Ligands as Cytotoxic Agents: Experimental and Computational Insights into the Mechanism of Action. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3396	Investigation of the influence of chirality and halogen atoms on the anticancer activity of enantiopure palladium(II) complexes derived from chiral amino-alcohol Schiff bases and 2-picolyamine. <i>New Journal of Chemistry</i> , 2022, 46, 6470-6483.	1.4	12
3397	Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machinery: pitfalls and progress. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	0.8	0
3398	Recent advances in noble metal complex based photodynamic therapy. <i>Chemical Science</i> , 2022, 13, 5085-5106.	3.7	62
3399	Metallodrugs in cancer nanomedicine. <i>Chemical Society Reviews</i> , 2022, 51, 2544-2582.	18.7	70
3400	Mechanisms of chemotherapy resistance in ovarian cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, , .	0.9	17
3401	The Dual Therapeutic Effect of Metformin Nuclei Based Drugs Modified with One of Tulbaghia Violacea Extract Compounds. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3402	Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer via a multi-mechanism. <i>Dalton Transactions</i> , 2022, 51, 5257-5270.	1.6	4
3404	Intravenous Administration of Cisplatin with Magnesium Sulfate Supplement May Prevent Kidney Toxicity in Rats: The Role of Gender and Magnesium Sulfate Dose. <i>International Journal of Nephrology</i> , 2022, 2022, 1-12.	0.7	1
3405	Synthesis, structural characterization and evaluation of anticancer activity of polymeric silver(I) complexes based on niflumic acid/naproxen and picoline derivatives. <i>Journal of Coordination Chemistry</i> , 2022, 75, 178-196.	0.8	6
3406	Use of chemotherapy to treat hepatocellular carcinoma. <i>BioScience Trends</i> , 2022, 16, 31-45.	1.1	35
3407	Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. <i>Science Advances</i> , 2022, 8, eabm1831.	4.7	59
3408	Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death. <i>ACS Nano</i> , 2022, 16, 3647-3663.	7.3	92
3409	Conception and Evaluation of Fluorescent Phosphine-Gold Complexes: From Synthesis to <i>in vivo</i> Investigations. <i>ChemMedChem</i> , 2022, , .	1.6	3

#	ARTICLE	IF	CITATIONS
3410	Photoâ€Reduction with NIR Light of Nucleusâ€Targeting Pt^{IV} Nanoparticles for Combined Tumorâ€Targeted Chemotherapy and Photodynamic Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	93
3411	Enhancing Circulation and Tumor Accumulation of Carboplatin via an Erythrocyteâ€Anchored Prodrug Strategy. <i>Angewandte Chemie</i> , 0, , .	1.6	3
3412	Diorganotin(IV) complexes based on tridentate ONO ligands as potential anticancer agents. <i>Journal of Inorganic Biochemistry</i> , 2022, 232, 111808.	1.5	15
3413	Enhancing Circulation and Tumor Accumulation of Carboplatin via an Erythrocyteâ€Anchored Prodrug Strategy. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	17
3414	Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse. <i>Scientific Reports</i> , 2022, 12, 5453.	1.6	2
3415	<i>Fusobacterium nucleatum</i> and cancer. <i>Periodontology 2000</i> , 2022, 89, 166-180.	6.3	37
3416	A risk model of gene signatures for predicting platinum response and survival in ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, 39.	1.3	12
3417	Photoâ€Reduktion mit NIRâ€Licht von Zellkern akkumulierenden Pt ^{IV} â€Nanopartikeln fÃ¼r eine kombinierte Tumor ausgerichtete Chemotherapie und Photodynamische Immuntherapie. <i>Angewandte Chemie</i> , 0, , .	1.6	4
3418	Protein-Based Delivery Systems for Anticancer Metallodrugs: Structure and Biological Activity of the Oxaliplatin/Î²-Lactoglobulin Adduct. <i>Pharmaceuticals</i> , 2022, 15, 425.	1.7	5
3419	Copper(II) Complexes of Halogenated Quinoline Schiff Base Derivatives Enabled Cancer Therapy through Glutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5134-5148.	2.9	32
3420	Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 232, 114205.	2.6	66
3421	Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 127, 105772.	0.8	7
3422	A New Strategy to Fight Metallodrug Resistance: Mitochondriaâ€Relevant Treatment through Mitophagy to Inhibit Metabolic Adaptations of Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	16
3423	Photon counting micro-CT for imaging Cisplatin. , 2022, , .		0
3424	A New Strategy to Fight Metallodrug Resistance: Mitochondriaâ€Relevant Treatment through Mitophagy to Inhibit Metabolic Adaptations of Cancer Cells. <i>Angewandte Chemie</i> , 0, , .	1.6	2
3425	Icaritin Inhibits Migration and Invasion of Human Ovarian Cancer Cells via the Akt/mTOR Signaling Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 843489.	1.3	3
3426	Indenyl and Allyl Palladate Complexes Bearing<i>N</i>â€Heterocyclic Carbene Ligands: an Easily Accessible Class of New Anticancer Drug Candidates. <i>European Journal of Inorganic Chemistry</i> , 2022, 2022, .	1.0	13
3427	Advantageous Reactivity of Unstable Metal Complexes: Potential Applications of Metal-Based Anticancer Drugs for Intratumoral Injections. <i>Pharmaceutics</i> , 2022, 14, 790.	2.0	15

#	ARTICLE	IF	CITATIONS
3428	Structure-activity relations of Pd(II) and Pt(II) thiosemicarbazone complexes on different human glioblastoma cell lines. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2022, 648, .	0.6	1
3429	Platinum-based Cancer Chemotherapeutics: Recent Trends and Future Perspectives. <i>Current Chinese Science</i> , 2022, 2, 275-293.	0.2	2
3430	Cisplatin – A more Efficient Drug in Combination with Radionuclides?. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, 325-332.	0.3	4
3431	Quantum chemical studies of the electronic structures of anti-tumor agents: Au(III) (L=terpyridine, Tj ETQq1 1 0.784314 rgBT /Over	1.1	1
3432	siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin. <i>Gene</i> , 2022, 821, 146333.	1.0	6
3433	Gold(III) heteroleptic complexes with SNS-thiosemicarbazone ligands as cytotoxic agents: Experimental and computational insights into the mechanism of action. <i>Polyhedron</i> , 2022, 219, 115767.	1.0	0
3434	New Pt(II) diiodido complexes containing bidentate 1,3,4-thiadiazole-based ligands: Synthesis, characterization, cytotoxicity. <i>Inorganica Chimica Acta</i> , 2022, 536, 120891.	1.2	5
3435	Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy. <i>Coordination Chemistry Reviews</i> , 2022, 460, 214462.	9.5	23
3436	Heterobimetallic complexes containing organometallic acylhydrazone ligands as potential inhibitors of human carbonic anhydrases. <i>Journal of Inorganic Biochemistry</i> , 2022, 232, 111814.	1.5	2
3437	Conventional Chemotherapy Nephrotoxicity. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 402-414.e1.	0.6	18
3438	How can the cisplatin analogs with different amine act on DNA during cancer treatment theoretically?. <i>Journal of Molecular Modeling</i> , 2022, 28, 2.	0.8	7
3439	LGCMDs: Predicting miRNA-Drug Sensitivity based on Light Graph Convolution Network. , 2021, , .		2
3440	Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids. <i>Nucleic Acids Research</i> , 2022, 50, e28-e28.	6.5	8
3441	Stress Granules in the Anti-Cancer Medications Mechanism of Action: A Systematic Scoping Review. <i>Frontiers in Oncology</i> , 2021, 11, 797549.	1.3	3
3442	Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions. <i>Frontiers in Oncology</i> , 2021, 11, 772604.	1.3	1
3443	Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 770663.	1.6	13
3444	siRNA-Based Carrier-Free System for Synergistic Chemo/Chemodynamic/RNAi Therapy of Drug-Resistant Tumors. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 361-372.	4.0	13
3445	Discovery and characterization of potent Androgen Receptor 1 inhibitors for cancer treatment. <i>Clinical and Translational Medicine</i> , 2021, 11, e627.	1.7	7

#	ARTICLE	IF	CITATIONS
3446	Engineering Supramolecular Nanomedicine for Targeted Near Infrared-triggered Mitochondrial Dysfunction to Potentiate Cisplatin for Efficient Chemophototherapy. <i>ACS Nano</i> , 2022, 16, 1421-1435.	7.3	36
3448	Self-assembled ruthenium and osmium nanosystems display potent anticancer profile by interfering with metabolic activity. <i>Inorganic Chemistry Frontiers</i> , 0, , .	3.0	1
3449	Automatic identification of drug sensitivity of cancer cell with novel regression-based ensemble convolution neural network model. <i>Soft Computing</i> , 2022, 26, 5399-5408.	2.1	5
3450	Pure DNA scaffolded drug delivery systems for cancer therapy. <i>Biomaterials</i> , 2022, 285, 121532.	5.7	9
3451	Challenges and opportunities in the development of metal-based anticancer theranostic agents. <i>Bioscience Reports</i> , 2022, 42, .	1.1	13
3453	Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis. <i>Breast</i> , 2022, 64, 7-18.	0.9	13
3454	Cisplatin resistance-related multi-omics differences and the establishment of machine learning models. <i>Journal of Translational Medicine</i> , 2022, 20, 171.	1.8	18
3455	A Theranostic Nanocomplex Combining with Magnetic Hyperthermia for Enhanced Accumulation and Efficacy of pH-Triggering Polymeric Cisplatin(IV) Prodrugs. <i>Pharmaceutics</i> , 2022, 15, 480.	1.7	7
3456	Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. <i>Science China Technological Sciences</i> , 2022, 65, 1011-1028.	2.0	7
3457	Thalidomide-based Pt(IV) prodrugs designed to exert synergistic effect of immunomodulation and chemotherapy. <i>Journal of Inorganic Biochemistry</i> , 2022, 232, 111842.	1.5	3
3484	Dithiocarbazate ^{Fe(III)} , ^{Co(III)} , ^{Ni(II)} , and ^{Zn(II)} Complexes: Design, Synthesis, Structure, and Anticancer Evaluation. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6677-6689.	2.9	17
3485	Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. <i>Cell Death and Disease</i> , 2022, 13, 398.	2.7	20
3486	A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 786-798.	1.9	3
3487	TMT-based proteomics analysis of the cerebral cortex of TauT knockout rats. <i>Proteome Science</i> , 2022, 20, 6.	0.7	1
3490	Effect of bionanocomposites on human health. , 2022, , 479-498.		0
3491	Analysis of Changes in the Structure of DNA when Interacting with Platinum Coordination Compounds by IR Spectroscopy. <i>Biophysics (Russian Federation)</i> , 2022, 67, 15-21.	0.2	2
3492	Adsorption of 2-(pyridin-2-yl)benzothiazoles with terminal thioacetate groups on the gold surface and their complexation with copper(ii) chloride. <i>Russian Chemical Bulletin</i> , 2022, 71, 260-266.	0.4	0
3493	Gold(III)-P-chirogenic complex induces mitochondrial dysfunction in triple-negative breast cancer. <i>IScience</i> , 2022, 25, 104340.	1.9	14

#	ARTICLE	IF	CITATIONS
3494	Selenium and Platinum Compounds in Cancer Therapy: Potentiality of their Progeny as Future Chemotherapeutics. <i>Current Chemical Biology</i> , 2022, 16, 1-11.	0.2	3
3495	Prognostic Factors for the Therapeutic Performance of Cisplatin in Head and Neck Malignancies. <i>Frontiers in Oncology</i> , 2022, 12, 778380.	1.3	1
3496	Evaluation of DNA/BSA interaction and in vitro cell cytotoxicity of μ_2 -oxido bridged divanadium(V) complexes containing ONO donor ligands. <i>Journal of Inorganic Biochemistry</i> , 2022, 233, 111852.	1.5	16
3497	Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapy. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 67, 116814.	1.4	6
3498	Dithiocarbamate based oxidomethoxido vanadium(V) and mixed-ligand oxidovanadium(IV) complexes: Study of solution behavior, DNA binding, and anticancer activity. <i>Journal of Inorganic Biochemistry</i> , 2022, 233, 111844.	1.5	14
3499	Recent Advances in Synthesis and Medicinal Evaluation of 1,2-Benzothiazine Analogues. <i>Asian Journal of Organic Chemistry</i> , 2022, 11, .	1.3	6
3501	Multifunctional Nanoplatforms as a Novel Effective Approach in Photodynamic Therapy and Chemotherapy, to Overcome Multidrug Resistance in Cancer. <i>Pharmaceutics</i> , 2022, 14, 1075.	2.0	10
3502	<i>In vivo</i> stealthified molecularly imprinted polymer nanogels incorporated with gold nanoparticles for radiation therapy. <i>Journal of Materials Chemistry B</i> , 2022, 10, 6784-6791.	2.9	12
3503	Anticancer alkylating agents. , 2022, , 393-505.		0
3504	The Combination of a Novel GLUT1 Inhibitor and Cisplatin Synergistically Inhibits Breast Cancer Cell Growth By Enhancing the DNA Damaging Effect and Modulating the Akt/mTOR and MAPK Signaling Pathways. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	10
3505	DNA and BSA Interaction Studies and Antileukemic Evaluation of Polyaromatic Thiosemicarbazones and Their Copper Complexes. <i>Compounds</i> , 2022, 2, 144-162.	1.0	4
3506	Preparation of novel Rh (III) half-sandwich complexes bearing 5-phenyl-2-(pyridin-2-yl)-1,2-dihydro-3H-pyrazol-3-one ligands, and their anti-cancer properties. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3507	Stability of half-sandwich Os(II) complex with indomethacin-functionalized ligand in the presence of carboxypeptidase A. <i>Dalton Transactions</i> , 0, , .	1.6	1
3508	The Therapeutical Effects of Damage-Specific Stress Induced Exosomes on the Cisplatin Nephrotoxicity in Vivo. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3509	Anticancer half-sandwich Ir(III) complex and its interaction with various biomolecules and their mixtures – a case study with ascorbic acid. <i>Inorganic Chemistry Frontiers</i> , 2022, 9, 3758-3770.	3.0	11
3510	Choline Kinase Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells. <i>Pharmaceutics</i> , 2022, 14, 1143.	2.0	0
3511	Effectiveness of the Sanyin Formula Plus Chemotherapy on Survival in Women With Triple-Negative Breast Cancer: A Randomized Controlled Trial. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3512	SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth. <i>Clinical and Experimental Pharmacology and Physiology</i> , 0, , .	0.9	1

#	ARTICLE	IF	CITATIONS
3513	Characterization of [Ru(bpy) ₂ (diamine)] ²⁺ complexes and their DNA binding and cleavage, BSA interaction, cytotoxic, and anticancer mechanistic properties. <i>Polyhedron</i> , 2022, 223, 115925.	1.0	1
3514	The Rationale for Laser-Induced Thermal Therapy (LITT) and Intratumoral Cisplatin Approach for Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5934.	1.8	3
3515	Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
3516	DNA Damage Repair Proteins, HSP27, and Phosphorylated-HSP90 α as Predictive/Prognostic Biomarkers of Platinum-based Cancer Chemotherapy: An Exploratory Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 425-434.	0.6	1
3517	Balancing the interplay between ligand ejection and therapeutic window light absorption in ruthenium polypyridyl complexes. <i>Dalton Transactions</i> , 0, , .	1.6	1
3518	Ruthenium complexes for photoactivated dual activity: Drug delivery and singlet oxygen generation. <i>Advances in Inorganic Chemistry</i> , 2022, , .	0.4	1
3519	Stereoselective synthesis of oxime containing Pd(II) compounds: Highly effective, selective and stereo-regulated cytotoxicity against carcinogenic PC-3 cells. <i>Dalton Transactions</i> , 0, , .	1.6	3
3520	High drug loading polymer micelle@ZIF-8 hybrid core-shell nanoparticles through donor-receptor coordination interaction for pH/H ₂ O ₂ -responsive drug release. <i>Frontiers of Materials Science</i> , 2022, 16, .	1.1	4
3521	Formation of Iridium(III) and Rhodium(III) Amine, Imine, and Amido Complexes Based on Pyridine-Amine Ligands: Structural Diversity Arising from Reaction Conditions, Substituent Variation, and Metal Centers. <i>Inorganic Chemistry</i> , 2022, 61, 10051-10065.	1.9	8
3522	Novel Nickel(II), Palladium(II), and Platinum(II) Complexes with O,S Bidendate Cinnamic Acid Ester Derivatives: An In Vitro Cytotoxic Comparison to Ruthenium(II) and Osmium(II) Analogues. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6669.	1.8	6
3523	PDSM-LGCN: Prediction of drug sensitivity associated microRNAs via light graph convolution neural network. <i>Methods</i> , 2022, 205, 106-113.	1.9	3
3524	Natural Polyphenols-Platinum Nanocomplexes Stimulate Immune System for Combination Cancer Therapy. <i>Nano Letters</i> , 2022, 22, 5615-5625.	4.5	21
3525	Current Developments of N-Heterocyclic Carbene Au(I)/Au(III) Complexes toward Cancer Treatment. <i>Biomedicines</i> , 2022, 10, 1417.	1.4	11
3526	Interaction of organoruthenium(II)-polypyridyl complexes with DNA and BSA. <i>BioMetals</i> , 2022, 35, 813-829.	1.8	1
3527	The role of gut microbiota in the development of colorectal cancer: a review. <i>International Journal of Colorectal Disease</i> , 2022, 37, 1509-1523.	1.0	14
3528	Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
3529	A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking. <i>International Journal of Pharmaceutics</i> , 2022, 622, 121897.	2.6	3
3530	Biotin-Targeted Au(I) Radiosensitizer for Cancer Synergistic Therapy by Intervening with Redox Homeostasis and Inducing Ferroptosis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8401-8415.	2.9	14

#	ARTICLE	IF	CITATIONS
3531	The Synthesis, Characterization, Molecular Docking and In Vitro Antitumor Activity of Benzothiazole Aniline (BTA) Conjugated Metal-Salen Complexes as Non-Platinum Chemotherapeutic Agents. <i>Pharmaceuticals</i> , 2022, 15, 751.	1.7	7
3532	Anticancer performance of Ir(III)-based anticancer agents in the treatment of cisplatin resistant cancer cells. <i>ChemMedChem</i> , 0, , .	1.6	0
3533	DNA interaction and BSA binding of O-vanillin-based new Schiff base Co(III) and Ni(II) complexes: Theoretical, experimental, antibacterial and anticancer studies. <i>Polyhedron</i> , 2022, 223, 115987.	1.0	10
3534	Water soluble transition metal [Ni(II), Cu(II) and Zn(II)] complexes of N-phthaloylglycinate bis(1,2-diaminocyclohexane). DNA binding, pBR322 cleavage and cytotoxicity. <i>Dalton Transactions</i> , 2022, 51, 11713-11729.	1.6	12
3535	DNA binding, DNA cleavage, cellular uptake, cytotoxicity, and apoptosis-inducing ability of a binuclear schiff base copper(II) complex. <i>New Journal of Chemistry</i> , 0, , .	1.4	1
3536	Nitroreductase-Induced Bioorthogonal Ligation for Prodrug Activation: A Traceless Strategy for Cancer-Specific Imaging and Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3537	Degradable polyprodrugs: design and therapeutic efficiency. <i>Chemical Society Reviews</i> , 2022, 51, 6652-6703.	18.7	28
3538	Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7081.	1.8	9
3539	Pro-Inflammatory Signalling Promotes Cisplatin-Induced Toxicity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7227.	1.8	25
3540	Carbon Nanotubes in Tumor-Targeted Chemotherapeutic Formulations: A Review of Opportunities and Challenges. <i>ACS Applied Nano Materials</i> , 2022, 5, 8649-8679.	2.4	6
3541	Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7241.	1.8	17
3542	Is antitumor Pt(IV) complex containing two axial lonidamine ligands a true dual- or multi-action prodrug?. <i>Metallomics</i> , 2022, 14, .	1.0	6
3543	PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. <i>Oncolmmunology</i> , 2022, 11, .	2.1	25
3544	Construction of miRNA-lncRNA-mRNA co-expression network affecting EMT-mediated cisplatin resistance in ovarian cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4530-4547.	1.6	6
3546	Induction of apoptosis in SGC-7901 cells by iridium(III) complexes via endoplasmic reticulum stress-mitochondrial dysfunction pathway. <i>Journal of Biological Inorganic Chemistry</i> , 2022, 27, 455-469.	1.1	4
3547	The dual therapeutic effect of metformin nucleic acid-based drugs modified with one of <i>Tulbaghia violacea</i> extract compounds. <i>Applied Organometallic Chemistry</i> , 2022, 36, .	1.7	6
3548	5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3549	Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies. <i>Current Oncology</i> , 2022, 29, 4768-4778.	0.9	14

#	ARTICLE	IF	CITATIONS
3550	Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. <i>Nano Today</i> , 2022, 45, 101532.	6.2	46
3551	Cellular landscaping of cisplatin resistance in cervical cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113345.	2.5	22
3552	Combination of light and Ru(II) polypyridyl complexes: Recent advances in the development of new anticancer drugs. <i>Coordination Chemistry Reviews</i> , 2022, 469, 214656.	9.5	43
3553	<i>In vitro</i> and <i>in vivo</i> antitumor studies of potential anticancer agents of platinum(II) complexes of dicyclopentadiene and dithiocarbamates. <i>Metallomics</i> , 2022, 14, .	1.0	6
3554	Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells. <i>Materials</i> , 2022, 15, 5028.	1.3	3
3555	Introduction of Fluorine into Antitumor-Active Dinuclear Platinum(II) Complexes Leads to Modulation of <i>In Vivo</i> Antitumor Activity in Mice. <i>Inorganic Chemistry</i> , 2022, 61, 12155-12164.	1.9	2
3556	Nanotechnology-integrated ferroptosis inducers: a sharp sword against tumor drug resistance. <i>Journal of Materials Chemistry B</i> , 2022, 10, 7671-7693.	2.9	9
3557	Casiopeinas [®] third generation, with indomethacin: synthesis, characterization, DFT studies, antiproliferative activity, and nanoencapsulation. <i>RSC Advances</i> , 2022, 12, 21662-21673.	1.7	2
3558	Platinum anticancer drugs: Targeting and delivery. , 2022, , .		0
3559	Heterodinuclear Ru ^{II} -Pt Complexes Bridged with 2,3-Bis(pyridyl)pyrazinyl Ligands: Studies on Kinetics, Deoxyribonucleic Acid/Bovine Serum Albumin Binding and Cleavage, <i>In Vitro</i> Cytotoxicity, and <i>In Vivo</i> Toxicity on Zebrafish Embryo Activities. <i>ACS Omega</i> , 2022, 7, 26226-26245.	1.6	11
3560	Synthesis, structure, and anticancer studies of Cu (II) and Ni (II) complexes based on (5-chlorosalicylaldehyde)-4-aminoantipyrine Schiff base. <i>Applied Organometallic Chemistry</i> , 2022, 36, .	1.7	2
3561	Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy. <i>Materials Today Advances</i> , 2022, 15, 100276.	2.5	4
3562	Nucleic Acid Aptamers Increase the Anticancer Efficiency and Reduce the Toxicity of Cisplatin-Arabinogalactan Conjugates <i>In Vivo</i> . <i>Nucleic Acid Therapeutics</i> , 2022, 32, 497-506.	2.0	3
3563	Simultaneous Photoactivation of cGAS ⁺ STING Pathway and Pyroptosis by Platinum(II) Triphenylamine Complexes for Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	35
3564	Unique enantiopure camphor-based neutral arene ⁺ ruthenium(II) complexes: DNA/BSA binding, kinetic and cytotoxic studies. <i>Journal of Coordination Chemistry</i> , 2022, 75, 1636-1655.	0.8	1
3565	The Cancer Stem Cell Potency of Group ¹⁰ Azadiphosphine Metal Complexes. <i>European Journal of Inorganic Chemistry</i> , 0, , .	1.0	1
3566	Chitosan-stabilized platinum nanoparticles induce apoptotic cell death in breast cancer cells. <i>Applied Nanoscience (Switzerland)</i> , 0, , .	1.6	2
3567	Plant-Derived Bioactive Compounds in Colorectal Cancer: Insights from Combined Regimens with Conventional Chemotherapy to Overcome Drug-Resistance. <i>Biomedicines</i> , 2022, 10, 1948.	1.4	14

#	ARTICLE	IF	CITATIONS
3568	Simultaneous Photoactivation of cGAS β STING Pathway and Pyroptosis by Platinum(II) Triphenylamine Complexes for Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	3
3569	GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	1
3570	Time-Dependent Studies of Oxaliplatin and Other Nucleolar Stress-Inducing Pt(II) Derivatives. <i>ACS Chemical Biology</i> , 2022, 17, 2262-2271.	1.6	7
3571	In-silico pharmacology against cancer of a novel phytosterol Dendrosterone isolated from plant <i>Dendrobium ochreatum</i> . <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 4, 100149.	0.5	1
3572	Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways. <i>Phytomedicine</i> , 2022, 105, 154383.	2.3	15
3573	Thiosemicarbazone N-Heterocyclic Cu(II) complexes inducing nuclei DNA and mitochondria damage in hepatocellular carcinoma cells. <i>Journal of Inorganic Biochemistry</i> , 2022, 236, 111964.	1.5	1
3574	Theoretical investigation on hydrolysis mechanism of cis-platin analogous Pt(II)/Pd(II) complex by DFT calculation and molecular docking approach for their interaction with DNA & HSA. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 117, 108314.	1.3	5
3575	Reactions of Ru(III)-drugs KP1019 and KP418 with guanine, 2 β -deoxyguanosine and guanosine: a DFT study. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	0
3576	Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11261.	1.8	8
3577	A sulfhydryl blocking reagent BT-4 sensitizes cisplatin-based micelle prodrugs for efficient treatment of breast cancer. <i>International Journal of Pharmaceutics</i> , 2022, 626, 122187.	2.6	1
3578	A split β -lactamase sensor for the detection of DNA modification by cisplatin and ruthenium-based chemotherapeutic drugs. <i>Journal of Inorganic Biochemistry</i> , 2022, 236, 111986.	1.5	1
3579	Successes and failures of immunotherapy for gastric cancer. <i>Drug Discovery Today</i> , 2022, 27, 103343.	3.2	3
3580	Nitroreductase-induced bioorthogonal ligation for prodrug activation: A traceless strategy for cancer-specific imaging and therapy. <i>Bioorganic Chemistry</i> , 2022, 129, 106167.	2.0	0
3581	Anticancer application of ferrocene appended configuration-regulated half-sandwich iridium(III) pyridine complexes. <i>Journal of Inorganic Biochemistry</i> , 2022, 237, 112010.	1.5	7
3582	The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114680.	2.6	20
3583	Novel zinc(II)-curcumin molecular probes bearing berberine and jatrorrhizine derivatives as potential mitochondria-targeting anti-neoplastic drugs. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114736.	2.6	6
3584	Anticancer Application of Ferrocene Appended Configuration-Regulated Half-Sandwich Iridium(III) Pyridine Complexes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3585	In-Silico Pharmacology Against Cancer of a Novel Phytosterol Dendrosterone Isolated from Plant <i>Dendrobium Ochreatum</i> . <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
3586	Reversal of cisplatin chemotherapy resistance by glutathione-resistant copper-based nanomedicine via cuproptosis. <i>Journal of Materials Chemistry B</i> , 2022, 10, 6296-6306.	2.9	52
3587	Advances in the design of photoactivated platinum anticancer complexes. <i>Advances in Inorganic Chemistry</i> , 2022, , 95-127.	0.4	1
3588	Recent advances in luminescent metallacycles/metallacages for biomedical imaging and cancer therapy. <i>Dalton Transactions</i> , 2022, 51, 16428-16438.	1.6	15
3589	Lysosome-targeted cyclometalated iridium(III) complexes: JMJD inhibition, dual induction of apoptosis, and autophagy. <i>Metallomics</i> , 2022, 14, .	1.0	5
3590	<i>Metallomics and metalloproteomics.</i> , 2022, , .		0
3591	Microneedle patch with spongy coating to co-load multiple drugs to treat multidrug-resistant melanoma. <i>Biomaterials Science</i> , 2022, 10, 6282-6290.	2.6	1
3592	Recent Advances of Metal-Based Anticancer Agents and Their In Vivo Potential Against Various Types of Malignancies. , 2022, , 1-28.		0
3593	Copper complexes with quinolone appended 1,8-naphthalimide conjugates: structural characterization, DNA and protein binding and cytotoxicity studies. <i>New Journal of Chemistry</i> , 2022, 46, 16801-16812.	1.4	4
3594	<i>Cancer therapies inducing DNA damage.</i> , 2022, , 205-225.		0
3595	Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs. <i>Dalton Transactions</i> , 2022, 51, 12512-12523.	1.6	8
3596	Antitumor effects of new glycoconjugated Pt agents dual-targeting GLUT1 and Pgp proteins. <i>Dalton Transactions</i> , 2022, 51, 16082-16092.	1.6	2
3597	A hydrazine-bridged dinuclear ruthenium complex: Structural properties and biological activity. <i>Journal of Molecular Structure</i> , 2023, 1272, 134228.	1.8	2
3598	Targeting the Unwindosome by Mebendazole Is a Vulnerability of Chemoresistant Hepatoblastoma. <i>Cancers</i> , 2022, 14, 4196.	1.7	3
3599	Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state. <i>ELife</i> , 0, 11, .	2.8	3
3600	Potent Chlorambucil-Platinum(IV) Prodrugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10471.	1.8	11
3601	Inorganic Nanoflowers Synthetic Strategies and Physicochemical Properties for Biomedical Applications: A Review. <i>Pharmaceutics</i> , 2022, 14, 1887.	2.0	5
3603	Transition Metal Complexes with Tridentate Schiff Bases (O and N) Derived from Salicylaldehyde: An Analysis of Their Potential Anticancer Activity. <i>ChemMedChem</i> , 2022, 17, .	1.6	16
3604	Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy. <i>Cancer Research Communications</i> , 2022, 2, 1266-1281.	0.7	3

#	ARTICLE	IF	CITATIONS
3605	A theoretical characterization of mechanisms of action of osmium(III)-based drug Os-KP418: hydrolysis and its binding with guanine. <i>Structural Chemistry</i> , 0, , .	1.0	0
3606	Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery. <i>Cancers</i> , 2022, 14, 4655.	1.7	4
3607	Microâ€Nanocarriers Based Drug Delivery Technology for Bloodâ€Brain Barrier Crossing and Brain Tumor Targeting Therapy. <i>Small</i> , 2022, 18, .	5.2	23
3608	The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 15, 817-825.	0.4	0
3609	Platinum(IV) Complexes of the 1,3,5-Triamino Analogue of the Biomolecule Cis-Inositol Designed as Innovative Antineoplastic Drug Candidates. <i>Pharmaceutics</i> , 2022, 14, 2057.	2.0	3
3610	Ruthenium-Locked Helical Chirality: A Barrier of Inversion and Formation of an Asymmetric Macrocyclic. <i>Inorganic Chemistry</i> , 2022, 61, 16045-16054.	1.9	2
3611	Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-11.	1.1	0
3612	Blood Components as Carriers for Smallâ€Molecule Platinum Anticancer Drugs. <i>ChemMedChem</i> , 2022, 17, .	1.6	1
3613	Colon cancer and colorectal cancer: Prevention and treatment by potential natural products. <i>Chemico-Biological Interactions</i> , 2022, 368, 110170.	1.7	52
3614	Prevention of cisplatin-induced nephrotoxicity by kidney-targeted siRNA delivery. <i>International Journal of Pharmaceutics</i> , 2022, 628, 122268.	2.6	3
3615	The therapeutical effects of damage-specific stress induced exosomes on the cisplatin nephrotoxicity IN VIVO. <i>Molecular and Cellular Probes</i> , 2022, 66, 101861.	0.9	2
3616	Selectively inhibiting malignant melanoma migration and invasion in an engineered skin model using actin-targeting dinuclear Ru ^{II} -complexes. <i>RSC Medicinal Chemistry</i> , 2023, 14, 65-73.	1.7	1
3617	<i>In vitro</i> studies on the selective cytotoxic effect of luminescent Ru(^{II})- <i>p</i> -cymene complexes of imidazo-pyridine and imidazo quinoline ligands. <i>Dalton Transactions</i> , 2022, 51, 17263-17276.	1.6	9
3618	Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines. <i>Nanomaterials</i> , 2022, 12, 3767.	1.9	9
3619	Synthesis and Characterization of New Ruthenium (II) Complexes of Stoichiometry [Ru(<i>p</i> -Cymene)Cl ₂ L] and Their Cytotoxicity against HeLa-Type Cancer Cells. <i>Molecules</i> , 2022, 27, 7264.	1.7	1
3620	C9orf16 represents the aberrant genetic programs and drives the progression of PDAC. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
3621	Characterization of Ferroptosis-Related Molecular Subtypes with Immune Infiltrations in Neuropathic Pain. <i>Journal of Pain Research</i> , 0, Volume 15, 3327-3348.	0.8	1
3622	Tumor microenvironment and redox dual stimuli-responsive polymeric nanoparticles for the effective cisplatin-based cancer chemotherapy. <i>Nanotechnology</i> , 2023, 34, 035101.	1.3	1

#	ARTICLE	IF	CITATIONS
3623	Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates. <i>Molecules</i> , 2022, 27, 7120.	1.7	7
3624	Schiff base complexes, cancer cell lines, and anticancer evaluation: a review. <i>Journal of Coordination Chemistry</i> , 2022, 75, 2018-2038.	0.8	5
3625	A spotlight on alkaloid nanoformulations for the treatment of lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
3626	Metallo-Drugs in Cancer Therapy: Past, Present and Future. <i>Molecules</i> , 2022, 27, 6485.	1.7	47
3627	Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?. <i>Cancers</i> , 2022, 14, 4960.	1.7	9
3628	The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia. <i>Pharmaceutics</i> , 2022, 14, 2184.	2.0	0
3629	An experimental and theoretical approach of coordination compounds derived from meso-tetra(thiophen-2-yl)porphyrin: DNA interactions and cytotoxicity. <i>Inorganic Chemistry Communication</i> , 2023, 147, 110135.	1.8	0
3630	Kidney Cyst Lining Epithelial Cells Are Resistant to Low-Dose Cisplatin-Induced DNA Damage in a Preclinical Model of Autosomal Dominant Polycystic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12547.	1.8	0
3631	Pt(IV)-Deferasirox Prodrug Combats DNA Damage Repair by Regulating RNA N ⁶ -Methyladenosine Methylation. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 14692-14700.	2.9	11
3632	Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin-induced apoptosis in epithelial ovarian cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	2
3633	Trilobatin, an Active Dihydrochalcone from <i>Lithocarpus polystachyus</i> , Prevents Cisplatin-Induced Nephrotoxicity via Mitogen-Activated Protein Kinase Pathway-Mediated Apoptosis in Mice. <i>ACS Omega</i> , 2022, 7, 37401-37409.	1.6	2
3634	miR766-3p and miR124-3p Dictate Drug Resistance and Clinical Outcome in HNSCC. <i>Cancers</i> , 2022, 14, 5273.	1.7	3
3635	The anticancer impacts of N, S donor pyrazole based ligand and its Co(III) and Cu(II) complexes on breast cancer cells. <i>Transition Metal Chemistry</i> , 2022, 47, 311-320.	0.7	1
3636	Genome-wide CRISPR Screen Reveal Targets of Chiral Gold(I) Anticancer Compound in Mammalian Cells. <i>ACS Omega</i> , 2022, 7, 39197-39205.	1.6	2
3637	Planispine A Sensitized Cancer Cells to Cisplatin by Inhibiting the Fanconi Anemia Pathway. <i>Molecules</i> , 2022, 27, 7288.	1.7	1
3638	Competitive binding studies of the nucleosomal histone targeting drug, [Ru(η -6-p-cymene)Cl ₂ (pta)] (RAPTA-C), with oligonucleotide-peptide mixtures.. <i>Journal of Inorganic Biochemistry</i> , 2023, 238, 112043.	1.5	1
3639	A review on the chemistry of novel platinum chelates based on azo-azomethine ligands. <i>Reviews in Inorganic Chemistry</i> , 2022, .	1.8	0
3640	Albumin-templated platinum (II) sulfide nanodots for size-dependent cancer theranostics. <i>Acta Biomaterialia</i> , 2023, 155, 564-574.	4.1	7

#	ARTICLE	IF	CITATIONS
3641	Engineering biosafe Cisplatin loaded Nanostructured Lipid Carrier: Optimization, Synthesis, Pharmacokinetics and Biodistribution. <i>Journal of Microencapsulation</i> , 0, , 1-44.	1.2	0
3642	Unraveling and Overcoming Platinum Drug-Resistant Cancer Tumors with DNA Nanostructures. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	17
3643	Effect of cisplatin on oral ulcer-induced nociception in rats. <i>Archives of Oral Biology</i> , 2022, 144, 105572.	0.8	1
3644	Cisplatin-induced changes in calcitonin gene-related peptide or TNF- α release in rat dorsal root ganglia in vitro model of neurotoxicity are not reverted by rosiglitazone. <i>NeuroToxicology</i> , 2022, 93, 211-221.	1.4	2
3645	Tailoring carrier-free nanocombo of small-molecule prodrug for combinational cancer therapy. <i>Journal of Controlled Release</i> , 2022, 352, 256-275.	4.8	13
3646	Emerging platinum(0) nanotherapeutics for efficient cancer therapy. <i>Journal of Controlled Release</i> , 2022, 352, 276-287.	4.8	5
3647	Synthesis, characterization and biological evaluation of two cyclometalated iridium(III) complexes containing a glutathione S-transferase inhibitor. <i>Journal of Inorganic Biochemistry</i> , 2023, 238, 112050.	1.5	5
3648	Glucose starvation impairs NER and γ -H2AX after UVB irradiation. <i>Toxicology in Vitro</i> , 2023, 86, 105503.	1.1	0
3650	Inhibition of DNA synthesis and cancer therapies. <i>The Enzymes</i> , 2022, , 11-21.	0.7	1
3651	Redox-Triggered Nanomedicine via Lymphatic Delivery: Inhibition of Melanoma Growth by Ferroptosis Enhancement and a Pt(IV)-Prodrug Chemoimmunotherapy Approach. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	2
3652	Metal complexes of Heena TM (2-hydroxy-1,4-naphthoquinone): Synthesis, Characterization and anticancer activity. <i>Inorganica Chimica Acta</i> , 2023, 546, 121290.	1.2	5
3653	Silver nanoparticles potentiate antitumor and oxidant actions of cisplatin via the stimulation of TRPM2 channel in glioblastoma tumor cells. <i>Chemico-Biological Interactions</i> , 2023, 369, 110261.	1.7	6
3654	Oxaliplatin disrupts nucleolar function through biophysical disintegration. <i>Cell Reports</i> , 2022, 41, 111629.	2.9	13
3655	Protective Effect of Natural Antioxidants on Reducing Cisplatin-Induced Nephrotoxicity. <i>Disease Markers</i> , 2022, 2022, 1-17.	0.6	6
3656	Integrative Metallomics Studies of Toxic Metal(loid) Substances at the Blood Plasma-Red Blood Cell-Organ/Tumor Nexus. <i>Inorganics</i> , 2022, 10, 200.	1.2	9
3657	Quantum Chemical Investigation on Hydrolysis of Orally Active Organometallic Ruthenium(II) and Osmium(II) Anticancer Drugs and Their Interaction with Histidine. <i>Journal of Physical Chemistry B</i> , 2022, 126, 9516-9527.	1.2	2
3658	Arene Variation of Highly Cytotoxic Tridentate Naphthoquinone-Based Ruthenium(II) Complexes and In-Depth In Vitro Studies. <i>Pharmaceutics</i> , 2022, 14, 2466.	2.0	8
3659	Evaluation of Cisplatin-Induced Pathology in the Larval Zebrafish Lateral Line. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14302.	1.8	2

#	ARTICLE	IF	CITATIONS
3660	The first evidence of antibiofilm action of <i>Proteus mirabilis</i> with tetra-cationic porphyrins containing cisplatin by antimicrobial photodynamic therapy. <i>Microbial Pathogenesis</i> , 2023, 174, 105859.	1.3	3
3662	Direct targeting of sEH with alisol B alleviated the apoptosis, inflammation, and oxidative stress in cisplatin-induced acute kidney injury. <i>International Journal of Biological Sciences</i> , 2023, 19, 294-310.	2.6	19
3663	Designing a multitarget In(<sc>iii</sc>) compound to overcome the resistance of lung cancer cells to cisplatin. <i>Dalton Transactions</i> , 2023, 52, 269-280.	1.6	2
3664	A novel manganese dioxide-based drug delivery strategy <i>via in situ</i> coating $\hat{3}$ -polyglutamic acid/cisplatin for intelligent anticancer therapy. <i>Journal of Materials Chemistry B</i> , 2023, 11, 667-674.	2.9	3
3665	Hybrid protein-polymer nanoparticles based on P(NVCL-co-DMAEMA) loaded with cisplatin as a potential anti-cancer agent. <i>Journal of Drug Delivery Science and Technology</i> , 2023, 79, 103995.	1.4	2
3666	Cancer cell membrane biomimetic mesoporous silica nanotheranostics for enhanced Ferroptosis-mediated immuogenic cell death on Gastric cancer. <i>Chemical Engineering Journal</i> , 2023, 455, 140868.	6.6	10
3667	Pt(IV) prodrug initiated microparticles from microfluidics for tumor chemo-, photothermal and photodynamic combination therapy. <i>Bioactive Materials</i> , 2023, 24, 185-196.	8.6	12
3668	Nanocarriers for platinum drug delivery. , 2023, 2, 77-89.		12
3669	NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. <i>Biomarkers in Medicine</i> , 0, , .	0.6	0
3670	MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going. <i>Cancers</i> , 2022, 14, 5731.	1.7	1
3671	Sisplatin ve Timokinon Kombinasyonunun MCF-7 HÄ¼crelerindeki Antiproliferatif Etkisinin DeÄYerlendirilmesi. <i>Biological Diversity and Conservation</i> , 0, , .	0.3	0
3672	Beta-Caryophyllene Enhances the Anti-Tumor Activity of Cisplatin in Lung Cancer Cell Lines through Regulating Cell Cycle and Apoptosis Signaling Molecules. <i>Molecules</i> , 2022, 27, 8354.	1.7	11
3673	A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance. <i>Nature Communications</i> , 2022, 13, .	5.8	22
3674	Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14511.	1.8	6
3675	Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer. <i>Cancers</i> , 2022, 14, 5894.	1.7	3
3676	Chemistry towards Biologyâ€™Instruct: Snapshot. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14815.	1.8	2
3677	Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
3678	Enriching Chemical Space of Bioactive Scaffolds by New Ring Systems: Benzazocines and Their Metal Complexes as Potential Anticancer Drugs. <i>Inorganic Chemistry</i> , 2022, 61, 20445-20460.	1.9	6

#	ARTICLE	IF	CITATIONS
3679	Anticancer Activity, Reduction Mechanism and G-Quadruplex DNA Binding of a Redox-Activated Platinum(IV)â€“Salphen Complex. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15579.	1.8	4
3680	Genomewide m6A Mapping Uncovers Dynamic Changes in the m6A Epitranscriptome of Cisplatin-Treated Apoptotic HeLa Cells. <i>Cells</i> , 2022, 11, 3905.	1.8	4
3681	Combination Treatment of Withalongolide a Triacetate with Cisplatin Induces Apoptosis by Targeting Translational Initiation, Migration, and Epithelial to Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. <i>Nutrients</i> , 2022, 14, 5398.	1.7	0
3682	New Au(III)- and Fe(III)-based complexes of bio-pharmacological interest: DFT and in silico studies. <i>Theoretical Chemistry Accounts</i> , 2023, 142, .	0.5	0
3683	Substitution reactions of <i>cis</i> -platinum(II) complexes containing bidentate <i>N,N</i> -donor pyridinecarboxamide ligands with different substituents. <i>Journal of Coordination Chemistry</i> , 2022, 75, 2557-2573.	0.8	3
3684	Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3685	Synthetic beidellite clay as nanocarrier for delivery of antitumor oxindolimine-metal complexes. <i>Journal of Inorganic Biochemistry</i> , 2023, 240, 112099.	1.5	0
3687	Synthesis, structural and spectral characteristics of novel <i>n</i> , <i>Î</i> -chelate complexes of Pd(II) and Pt(II) with <i>N</i> -allylthioureas and their influence on the growth of spheroids cells MCF-7 and GGT activity. <i>Polyhedron</i> , 2022, , 116272.	1.0	0
3688	Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15410.	1.8	21
3689	Cisplatin Toxicity Is Mediated by Direct Binding to Toll-Like Receptor 4 through a Mechanism That Is Distinct from Metal Allergens. <i>Molecular Pharmacology</i> , 2023, 103, 158-165.	1.0	1
3690	Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand. <i>Cancers</i> , 2023, 15, 107.	1.7	4
3691	Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 573-591.	2.3	4
3692	IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway. <i>Biological and Pharmaceutical Bulletin</i> , 2023, 46, 26-34.	0.6	1
3693	Platinum(terpyridine) complexes with <i>N</i> -heterocyclic carbene co-ligands: high antiproliferative activity and low toxicity <i>in vivo</i> . <i>Dalton Transactions</i> , 2023, 52, 1388-1392.	1.6	2
3694	DNA radiosensitization by terpyridine-platinum: damages induced by the 5 and 10 eV transient anions. <i>Nanoscale</i> , 0, , .	2.8	1
3695	An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies. <i>Inorganica Chimica Acta</i> , 2023, 548, 121388.	1.2	8
3696	Cisplatin Binding to Human Serum Transferrin: A Crystallographic Study. <i>Inorganic Chemistry</i> , 2023, 62, 675-678.	1.9	2
3697	Exploring Michaelisâ€“Menten Kinetics and the Inhibition of Catalysis in a Synthetic Mimic of Catechol Oxidase: An Experiment for the Inorganic Chemistry or Biochemistry Laboratory. <i>Journal of Chemical Education</i> , 2023, 100, 893-899.	1.1	2

#	ARTICLE	IF	CITATIONS
3698	Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches. <i>Molecular Omics</i> , 0, , .	1.4	5
3699	(Salen)osmium(VI) nitrides catalyzed glutathione depletion in chemotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 108153.	4.8	0
3700	Copper(II) complex enhanced chemodynamic therapy through GSH depletion and autophagy flow blockade. <i>Dalton Transactions</i> , 2023, 52, 3287-3294.	1.6	5
3701	Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic Signatures. <i>Cells</i> , 2023, 12, 266.	1.8	0
3702	Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH. <i>Prostate</i> , 2023, 83, 470-486.	1.2	6
3703	Chiral metallic anticancer drugs: A brief-review. <i>European Journal of Chemistry</i> , 2022, 13, 483-490.	0.3	1
3704	Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer. <i>Acta Biomaterialia</i> , 2023, 158, 560-570.	4.1	3
3705	The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH ₃ COO)Cl ₂ (NH ₃) ₂ (OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake. <i>Bioinorganic Chemistry and Applications</i> , 2022, 2022, 1-15.	1.8	12
3706	Carbon nanotubes as nanovectors for targeted delivery of platinum based anticancer drugs. , 2023, , 205-227.		0
3707	Hepato and renoprotective activity of <i>Kappaphycus alvarezii</i> ethanolic extract in cisplatin causes hepatic and kidney harm in Albino Wistar rats. <i>Aquaculture International</i> , 2023, 31, 1925-1940.	1.1	1
3708	Chlorin e6: A Promising Photosensitizer in Photo-Based Cancer Nanomedicine. <i>ACS Applied Bio Materials</i> , 2023, 6, 349-364.	2.3	36
3709	Insight into autophagy in platinum resistance of cancer. <i>International Journal of Clinical Oncology</i> , 2023, 28, 354-362.	1.0	2
3710	New palladium(II) and platinum(II) complexes with an ONS donor azo-thioether pincer ligand: synthesis, characterization, protein binding study and <i>in vitro</i> cytotoxicity. <i>New Journal of Chemistry</i> , 2023, 47, 4931-4943.	1.4	5
3711	Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy. <i>NAR Cancer</i> , 2023, 5, .	1.6	14
3712	Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs. <i>Biological Research</i> , 2023, 56, .	1.5	5
3713	Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy. <i>Cancers</i> , 2023, 15, 666.	1.7	13
3714	Recent Advances of Metal-Based Anticancer Agents and Their In Vivo Potential Against Various Types of Malignancies. , 2023, , 917-943.		0
3715	New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells. <i>Pharmaceutics</i> , 2023, 15, 466.	2.0	7

#	ARTICLE	IF	CITATIONS
3716	Anticancer Drugs Paclitaxel, Carboplatin, Doxorubicin, and Cyclophosphamide Alter the Biophysical Characteristics of Red Blood Cells, <i>In Vitro. Biology</i> , 2023, 12, 230.	1.3	3
3717	PD-1/PD-L1 and DNA Damage Response in Cancer. <i>Cells</i> , 2023, 12, 530.	1.8	12
3718	Revelation of potential bioactive water-soluble Boc- <i>l</i> -valine and imidazole appended metal complexes {M = Co(II), Cu(II) & Zn(II)}: synthesis, characterization, ct-DNA binding, pBR322 cleavage, SOD mimetic, and cytotoxicity studies. <i>Dalton Transactions</i> , 2023, 52, 5141-5154.	1.6	1
3719	A Gourd-shaped Organometallic Coordination Cage: Synthesis and Selective Binding of Two Drug Molecules. <i>Acta Chimica Sinica</i> , 2023, 81, 217.	0.5	0
3720	Recent progress in cancer cell membrane-based nanoparticles for biomedical applications. <i>Beilstein Journal of Nanotechnology</i> , 0, 14, 262-279.	1.5	2
3721	Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	30
3722	In vitro evaluation of photon and carbon ion radiotherapy in combination with cisplatin in head and neck squamous cell carcinoma cell lines. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
3723	Versatile functionalization of pectic conjugate: From design to biomedical applications. <i>Carbohydrate Polymers</i> , 2023, 306, 120605.	5.1	2
3724	Synthesis, characterization, DFT calculations and application of some metal complexes derived from 2-(((2-(dimethylamino)ethyl)amino)(4-nitrophenyl)methyl)-3-hydroxynaphthalene-1,4-dione. <i>Inorganic Chemistry Communication</i> , 2023, 151, 110651.	1.8	0
3725	Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. <i>Advanced Drug Delivery Reviews</i> , 2023, 196, 114773.	6.6	26
3726	Synthesis and biological evaluation of cholic acid-conjugated oxaliplatin as a new prodrug for liver cancer. <i>Journal of Inorganic Biochemistry</i> , 2023, 243, 112200.	1.5	4
3727	Synthesis of Carbazole-Substituted thiosemicarbazone and its Cu(II) Complex, DNA/Protein Binding, Cytotoxic, antiproliferative activities and molecular docking studies. <i>Inorganic Chemistry Communication</i> , 2023, 152, 110711.	1.8	3
3728	Conjugated linoleic acid strengthens the apoptotic effect of cisplatin in A549 cells. <i>Prostaglandins and Other Lipid Mediators</i> , 2023, 166, 106731.	1.0	1
3729	Electrochemical detection of Oxaliplatin induced DNA damage in G-quadruplex structures. <i>Analytical Biochemistry</i> , 2023, 671, 115149.	1.1	1
3730	Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands. <i>Current Opinion in Chemical Biology</i> , 2023, 74, 102303.	2.8	11
3731	Photophysical study on DNA & BSA binding and cytotoxic behaviour of piperidine-Pt(II) complexes: Their kinetics & mechanism and molecular docking. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2023, 441, 114740.	2.0	2
3732	An overview of advancement of organoruthenium(II) complexes as prospective anticancer agents. <i>Coordination Chemistry Reviews</i> , 2023, 487, 215169.	9.5	11
3733	Platinum(II) 5-substituted-8-hydroxyquinoline coordination compounds induces mitophagy-mediated apoptosis in A549/DDP cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2023, 241, 112152.	1.5	8

#	ARTICLE	IF	CITATIONS
3734	Aquaporin Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 317-330.	0.8	7
3735	Cisplatin-Conjugated Polyurethane Capsule for Dual Drug Delivery to a Cancer Cell. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 25193-25200.	4.0	11
3736	Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy. <i>Drug Delivery</i> , 2023, 30, .	2.5	9
3739	A Non-Conventional Platinum Drug against a Non-Small Cell Lung Cancer Line. <i>Molecules</i> , 2023, 28, 1698.	1.7	0
3740	Progress of Metal-Based Anticancer Chemotherapeutic Agents in Last two Decades and their Comprehensive Biological (DNA/RNA Binding, Cleavage and Cytotoxicity Activity) Studies. <i>Chemical Record</i> , 2023, 23, .	2.9	3
3741	Controlled sequential in situ self-assembly and disassembly of a fluorogenic cisplatin prodrug for cancer theranostics. <i>Nature Communications</i> , 2023, 14, .	5.8	38
3742	Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	5
3743	A monoadduct generating Ru(^{II}) complex induces ribosome biogenesis stress and is a molecular mimic of phenanthriplatin. <i>RSC Chemical Biology</i> , 2023, 4, 344-353.	2.0	2
3744	Self-Assembly of a Linear-Dendritic Polymer Containing Cisplatin and Norcantharidin into Raspberry-like Multimicelle Clusters for the Efficient Chemotherapy of Liver Cancer. <i>ACS Applied Materials & Interfaces</i> , 0, , .	4.0	0
3745	Hetero-bimetallic transition metal-substituted Krebs-type polyoxometalate with N-chelating ligand as anticancer agents. <i>Tungsten</i> , 2023, 5, 225-234.	2.0	7
3746	Antitumor potential of platinum(II) complexes of selenium donor ligands. <i>Metallomics</i> , 2023, 15, .	1.0	0
3747	<i>In vitro</i> and <i>in vivo</i> antitumor activity of novel half-sandwich ruthenium complexes containing quinoline derivative ligands. <i>Dalton Transactions</i> , 2023, 52, 4728-4736.	1.6	4
3748	In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
3749	Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5715.	1.8	1
3750	Rethinking Biosynthesis of Aclacinomycin A. <i>Molecules</i> , 2023, 28, 2761.	1.7	1
3751	To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	26
3752	Reduktion von Platin(IV)-Prodrug Hämoglobin Nanopartikeln mit tief eindringender Ultraschallbestrahlung für eine gezielte und therapeutisch verstärkte Krebstherapie. <i>Angewandte Chemie</i> , 0, , .	1.6	0
3753	Reduction of Platinum(IV) Prodrug Hemoglobin Nanoparticles with Deeply Penetrating Ultrasound Radiation for Tumor-Targeted Therapeutically Enhanced Anticancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	14

#	ARTICLE	IF	CITATIONS
3754	Synthesis, structural characterization, DNA/HSA binding, molecular docking and anticancer studies of some D-Luciferin complexes. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104845.	2.3	2
3755	<i>In Vitro</i> and <i>In Vivo</i> Evaluation of Anti-Tumor Biological Functions of Enolase Targeted Peptide Modified Oxaliplatin-Loaded Fe ₃ O ₄ Nanoparticles Alongside with Photothermal Radiotherapy. <i>Journal of Biomedical Nanotechnology</i> , 2022, 18, 2860-2867.	0.5	1
3756	The involvement of AuroraA and p53 in oxaliplatin-resistant colon cancer cells. <i>Journal of Cellular Biochemistry</i> , 2023, 124, 619-632.	1.2	0
3757	Functional chromopeptide nanoarchitectonics: molecular design, self-assembly and biological applications. <i>Chemical Society Reviews</i> , 2023, 52, 2688-2712.	18.7	39
3758	Older but Stronger: Development of Platinum-Based Antitumor Agents and Research Advances in Tumor Immunity. <i>Inorganics</i> , 2023, 11, 145.	1.2	3
3761	The Reduction of Uromodulin, Complement Factor H, and Their Interaction Is Associated with Acute Kidney Injury to Chronic Kidney Disease Transition in a Four-Time Cisplatin-Injected Rat Model. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6636.	1.8	2
3762	Synthesis and anticancer mechanisms of nickel(II)-2-amino-8-quinolinol complexes with 2,2'-bipyridine ancillary ligands. <i>Inorganic Chemistry Communication</i> , 2023, 152, 110712.	1.8	3
3763	Cellular Functions of Deubiquitinating Enzymes in Ovarian Adenocarcinoma. <i>Genes</i> , 2023, 14, 886.	1.0	2
3764	A nanomedicine based on stoichiometric coordination of camptothecin and organoplatinum (II) for synergistic antitumor therapy. <i>Acta Biomaterialia</i> , 2023, 164, 553-562.	4.1	2
3765	Metabolic modulation of CtBP dimeric status impacts the repression of DNA damage repair genes and the platinum sensitivity of ovarian cancer. <i>International Journal of Biological Sciences</i> , 2023, 19, 2081-2096.	2.6	0
3766	Developing an Anticancer Platinum(II) Compound Based on the Uniqueness of Human Serum Albumin. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 5669-5684.	2.9	14
3779	Optimized Neural Network for Evaluation Cisplatin Role in Neoplastic Treatment. <i>Advances in Intelligent Systems and Computing</i> , 2023, , 133-146.	0.5	0
3781	DNA alkylating agents. , 2023, , 237-290.		0
3802	Dichloro Ru(II)-p-cymene-1,3,5-triaza-7-phosphaadamantane (RAPTA-C): A Case Study. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 982-996.	2.5	3
3808	Combining radiation and systemic therapy. , 2024, , 99-126.		0
3820	Application of three-dimensional cell culture technology in screening anticancer drugs. <i>Biotechnology Letters</i> , 0, , .	1.1	0
3830	Principles of Clinical Oncology and Systemic Treatments. , 2023, , 225-246.		0
3834	Nucleus-selective self-augmenting cascade nanoassemblies for targeted synergistic photo-chemo therapy of tumors. <i>Chemical Communications</i> , 0, , .	2.2	0

#	ARTICLE	IF	CITATIONS
3846	Discovery of cisplatin-binding proteins by competitive cysteinome profiling. RSC Chemical Biology, 2023, 4, 670-674.	2.0	2
3853	The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control. British Journal of Cancer, 2023, 129, 1877-1892.	2.9	1
3855	Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance. RSC Chemical Biology, 2023, 4, 1003-1013.	2.0	1
3860	TGF- β 2 in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer. , 2023, 40, .		1
3863	Unique opportunities of metal scaffolds in drug design. , 2023, , 875-899.		0
3866	Targeted gold nanoparticles as magic bullets for cancer treatment: A review. AIP Conference Proceedings, 2023, , .	0.3	0
3898	Chemotherapy-induced neuronal DNA damage: an intriguing toolbox to elucidate DNA repair mechanisms in the brain. Genome Instability & Disease, 2023, 4, 315-332.	0.5	0
3900	Cisplatin SERS Detection Based on the Binding of Sulfhydryl Groups. , 2023, , .		0
3920	Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer. Molecular Biology Reports, 2024, 51, .	1.0	0
3927	Emergence of metal-based anticancer therapeutics: A promising perspective. , 2024, , 411-450.		0
3939	Importance of porous coordination polymers as nanocarriers in therapeutics. , 2024, , 341-367.		0
3948	The Molecular Classification of Ovarian Cancer and Implication for Treatment. , 2023, , 285-315.		0